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Abstract 
 
The signal transducer and activator of transcription (STAT) proteins are a family of 
transcription factors which transduce extracellular signals from cytokines, growth factors and 
G-proteins to the nucleus. STATs become activated by phosphorylation and translocate to the 
the nucleus where they bind to specific target promoters. STAT1 has previously been shown 
to have a role in inducing apoptosis in the myocardium following ischaemia/reperfusion 
injury (I/R), however the role of STAT3 in myocardial apoptosis is less clear. Here it is 
shown that STAT3 is phosphorylated in cardiac cells both in vito and in vivo in response to 
I/R injury and plays a protective role by reducing the levels of apoptosis. Several modulators 
of STAT3 activity were found to be upregulated following I/R, including JAK2, SOCS3 and 
GRIM-19. STAT3 was also found to be important in regulating DNA damage and repair 
through altered activity of DNA damage response proteins. Administration of the antioxidant 
tempol in vivo, reduced infarct size in a rat model of I/R injury and this was accompanied by 
a reduction in STAT1 and STAT3 phosphorylation. Increasing STAT1 phosphorylation with 
IFN-•  treatment abolished  the protective effect of tempol, suggesting that inhibition of 
STAT1 phosphorylation  may be a key protective effect of tempol infusion. Affymetrix 
microarray analysis of  hearts  from the in  vivo  I/R model identified  several novel gene 
expression changes  and uncovered transcriptional reduction in large numbers of genes 
involved in mitochondrial respiration and transport. In addition, this approach identified 
several possible new regulators of cardiac protection mediated by tempol and the urocortin 
hormones.     
 
The mitogen activated protein kinase (MAPK) family is involved in sensing cellular stress 
and play key roles in I/R injury and inflammation. MAPK activity is balanced by MAPK 
phosphatases (MKPs) such as MKP-1 and the role of MKP-1 in modulating the immune 
response was investigated. Mice deficient in MKP-1 were more susceptible to endotoxic 
shock and had elevated levels of serum cytokines. MKP-1 was found to be upregulated 
following toll-like recptor (TLR) stimulation and this was dependent on the signaling 
adaptors MyD88 and Trif. Macrophages deficient in MKP-1 had increased phosphorylation 
of p38 MAPK and JNK following TLR stimulation and secreted elevated amounts of the pro-
inflammatory cytokines TNF-•, IL-12 and the anti-inflammatory cytokine IL-10. The 
temporal control and regulation of cytokine production in response to TLR stimulation was 
dissected using pharmacological inhibition of MAPKs. MKP-1 was not found to contribute to 
T cell differentiation but did have a role to play in the adaptive immune response as MKP-1- 
deficient mice failed to recover from an experimental model of multiple sclerosis.  
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis is dedicated to my parents  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
 
Acknowledgements 
 
First and foremost I would like to thank my parents who throughout my life always told me I 
could be whatever I wanted to and for their constant love and support. All those years of 
encouragement really paid off!  
 
I would like to thank Prof. David Latchman for giving me the opportunity to work in his lab 
and letting me have the freedom to pursue my scientific interests. My appreciation goes to 
Paul Townsend for his support and insight over the last few years and also to Steph and 
Dicko. Thanks to the Bogue foundation for providing me with a fellowship to travel to Yale 
and to Richard Flavell for giving me the opportunity to work in his lab there. Special thanks 
to Hongbo Chi for really looking after me at Yale and for all he taught me there. 
 
The journey over the last few years would have been far less fun and interesting without all 
the wonderful people who have been part of MMBU, both past and present.  Jimmy, Mattia, 
Naushaad, Dan, Charis, Emma, because of you guys I got to a rare thing; spend each day 
working with friends rather than colleagues. My thanks aswell to our tireless lab manager 
John, who keeps the whole thing together. 
 
Finally I would like to thank Sam for her love and support, you make it all worthwhile.  
 
Is tú 
grá mo chroí. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Declaration: The work described in this thesis was carried out by the author unless 
otherwise stated 6 
 
Publications in the course of this work: 
 
Barry SP, Lawrence KM, Townsend PA, Soond SM, McCormick J, Hubank M, Eaton S, Sivarajah 
A, Knight RA, Thiemermann C, Latchman D and Stephanou A. Gene expression profiling reveals 
novel targets of urocortin mediated cardioprotection and free radical inhibition.  Physiological 
Genomics, 2009; Accepted subject to revision. 
Barry SP, Townsend PA, McCormick J, Knight RA, Scarabelli TM, Latchman DS and Stephanou A. 
Genetic Manipulation of STAT3 Sensitizes Cells to Oxidative Stress. Biochem Biophys Res Commun
Soond SM, 
. 
2009, 385:324-9. 
Barry SP, Melino G, Knight RA, Latchman DS and Stephanou AS. p73-mediated 
transcriptional activity is negatively regulated by polo-like kinase 1. Cell Cycle 2008, 7(9):1214-23
 
. 
Soond SM, Townsend PA, Barry SP, Knight RA, Latchman DS and Stephanou A. ERK and the F-
box protein betaTRCP target STAT1 for degradation. J Biol Chem 2008, 283(23):
 
16077-83. 
Barry SP, Jayasinghe SN, Latchman DS and Stephanou A. Gene expression studies on bio-
electrosprayed primary cardiac myocytes. Biotechnology Journal 2008, 3(4):
 
530-5. 
Barry SP,  Davidson SM and  Townsend PA. Molecular regulation of cardiac  hypertrophy. 
International Journal of Biochemistry and Cell Biology 2008, 40(10):2023-39
 
. 
Barry SP
 
, Jayasinghe SN, Latchman DS and Stephanou A. Bio-elecrospring primary neonatal cardiac 
myocytes. Bioprocessing Journal 2007, 6(1):5-8. 
Barry SP
 
, Townsend PA, Latchman DS and Stephanou A. Role of the JAK-STAT pathway in 
myocardial injury. Trends in Molecular Medicine 2007, 13(2):82-89. 
McCormick J
*, Barry 
*
 
, Sivarajah A, Stefanutti G, Townsend PA, Lawrence KM, Eaton S, Knight 
RA, Thiemermann C, Latchman DS, Stephanou A. Free radical scavenging inhibits STAT 
phosphorylation following in vivo ischaemia/reperfusion injury.  FASEB J.  2006, 20(12):2115-7 
*Joint first author. 
Chi H, Barry SP, Roth R, Wu J, Jones EA, Bennett AM
 
 
and Flavell RA. Dynamic regulation of pro- 
and anti-inflammatory cytokines by MKP-1 in innate immune responses. Proc Natl Acad Sci U S A 
2006,103(7):2274-9. 
Townsend PA, Craig MS, Davidson SM, McCormick J, Barry S
   
 et al. STAT1 facilitates the ATM 
activated checkpoint pathway following DNA damage. Journal of Cell Science 2005, 118:1629-39.  7 
 
 
 
Table of Contents 
Abstract  3 
Dedication  4 
Acknowledgements  5 
Publications in the course of this work  6 
Table of contents  7 
List of figures  12 
List of Tables  16 
Abbreviations  17 
Chapter 1: Introduction  20 
1.1 Myocardial Infarction    21 
1.2 Ischaemia/Reperfusion Injury    22 
     1.2.1 Mechanisms of I/R Induced Cell Death  24 
     1.2.2 Caspases  24 
1.2.3 Bcl-2 Proteins    27 
1.2.4 Inhibitors of Apoptosis (IAPs)  28 
1.2.5 Evidence for Apoptosis Mediated Cell Death During I/R Injury   29 
1.2.6 The Mitochondrial Permeability Transition Pore  31 
1.2.7 Reactive Oxygen Species (ROS) in Myocardial Cell Death  32 
1.2.8 Ca2+ Overload and Contracture  34 
1.3 The JAK/STAT Pathway     35 
1.3.1 JAK/STAT Family Members     35 
1.3.2 STAT Activation    36 
1.3.3 STAT Nuclear Import     39 
1.3.4 STAT Nuclear Export    40 
1.3.5 STAT Serine Phosphorylation     41 
1.3.6 STAT Dephosphorylation  43 
1.3.7 Negative Regulation of STATs by SOCS  44 
1.3.8 Inhibition of STAT DNA Binding by PIAS  47 
1.3.9 Inhibition of STAT3 Nuclear Translocation by GRIM-19  47 
1.3.10 Non-Transcriptional Regulation of Gene Expression by STATs  48 
1.4 The JAK/STAT Pathway and Cardiac Injury  50 
1.4.1  JAK/STAT Signalling– A Key Player in Apoptosis   50 
1.4.2 STATs as Mediators of Myocardial Cell Death  51 
1.4.3 JAK/STAT Pathway in Ischaemic Preconditioning   52 
1.4.4 Role of STAT1 and 3 in Hypertrophy and Angiogenesis     53 
1.5 Urocortins  56 
1.5.1 The Urocortin Family   56 
1.5.2 Urocortins and Heart Failure  56 
1.5.3 Urocortins and Ischaemia  57 
1.6 Mitochondrial Transport  58 8 
 
1.6.1 Import into the Mitochondria  58 
1.6.2 The TOM Complex  58 
1.6.3 The TIM22/TIM23 Complex  60 
1.6.4The SAM Complex  61 
1.7 The DNA Damage Response  61 
1.7.1 Double Strand Breaks  61 
         1.7.2 Initiation of the DNA Damage Response: ATM and H2AX  61 
1.7.3 Amplification of the DNA Damage Response: MDC1  64 
1.8 The Innate Immune System   65 
1.8.1 Inflammation     65 
1.8.2 Toll-Like Receptors (TLR)   66 
1.8.3 TLR Adaptors  67 
1.9 The Adaptive Immune System   69 
1.9.1 Antigen Presentation   69 
1.9.2 CD8 Cells   69 
1.9.3 CD4 Cells and Th1/Th2/Th17 Differentiation    69 
1.10 Cytokines     71 
1.10.1 TNF     71 
1.10.2 IL-10     73 
1.10.3 IL-12   73 
1.11 MAPK Signalling in the Innate Immune System     73 
1.11.1 Upstream Signals     73 
1.11.2 p38 MAPK   75 
1.11.3 c-Jun N-terminal Kinase (JNK)   76 
1.11.4 Extracellular Regulated Kinase (ERK)   77 
1.11.5 MAPK Phosphatase -1 (MKP-1)     77 
1.12 Inflammatory Diseases     79 
1.12.1 Multiple Sclerosis    79 
1.12.2 Inflammatory Bowel Disease (IBD)    80 
   
Chapter 2: Materials and Methods  82 
2.1 Reagents  83 
2.2 Animals   83 
2.3 In Vivo Procedures    84 
2.3.1 Myocardial Ischaemia and Reperfusion in the Rat   84 
2.3.2 Endotoxic shock    85 
2.3.3 Listeria Infection   85 
2.3.4 Experimental Autoimmune Encephalomyelitis (EAE)   85 
2.3.5 Dextran Sulphate Sodium (DSS) Induced Colitis     86 
2.3.6 Middle Cerebral Artery Occlusion (MCAO)    86 
2.4 Cell Culture   86 
2.4.1 Freezing and Recovery of Cell Lines     86 
2.4.2 Preparation of Neonatal Rat Ventricular Cardiac Myocytes    87 
 9 
 
2.4.3 Hypoxia/Reoxygenation of Neonatal Rat Ventricular Cardiac Myocytes    87 
 
2.4.4 Isolation of Bone Marrow Derived Macrophages       87 
2.4.5 Isolation of Bone Marrow Derived Dendritic Cells    88 
2.4.6 T Cell Isolation from Mouse Spleen and Lymph Node    88 
2.4.7 T cell Differentiation    89 
2.4.8 Preparation of High Titre Adenoviral Stocks  89 
2.5 Analysis of Protein Levels   90 
2.5.1 Western Blotting   90 
2.5.2 ELISA    90 
2.5.3 Immunohistochemistry    91 
2.5.4 Intracellular staining    91 
2.5.6 Determination of tissue malondialdehyde concentration    91 
2.5.7 Nuclear Extract    92 
2.5.8 Electromobility Shift Assay (EMSA)    92 
2.6 Gene Expression Analysis     93 
2.6.1 RNA Extraction    93 
2.6.2 cDNA Synthesis    94 
2.6.3 Quantitative Real Time PCR (qPCR)    94 
2.6.4  Luciferase Promoter Assay   95 
2.7 Affymetrix Microarray Analysis     95 
2.7.1 cDNA Preparation    95 
2.7.2 Preparation of Biotinylated cRNA Target by In Vitro Transcription    96 
2.7.3 Target cRNA Fragmentation and Hybridisation    96 
2.7.4 Fluidics Protocol for Microarray Staining     97 
2.7.5 Microarray Data Analysis    97 
2.7.6 Ingenuity Pathway Analysis  98 
2.8 Propagation and Purification of Plasmid DNA     98 
2.8.1 Preparation of Competent JM109    98 
2.8.2 Transformation of JM109    99 
2.8.3 Large Scale plasmid DNA Extraction from E.Coli    99 
2.8.4 DNA Restriction Digest and Agarose Gel Electrophoresis    100 
2.8.5 DNA Transfection    100 
2.9 Cell Death Measurements   100 
2.9.1 TdT mediated dUTP nick end labeling (TUNEL)    100 
2.9.2 Exclusion of Trypan Blue    101 
2.9.3 Annexin V Staining   101 
2.9.4 Quantification of Infarct Size in the Heart    102 
2.9.5 Statistical Analysis  102 
   
Chapter 3: Role of STAT1 and STAT3 in I/R Injury  103 
 3.1 Aims  104 
3.2 Overexpression of STAT3 Protects Cardiac Myocytes from Hypoxia/Reoxygenation    105 
3.3 Adenoviral Delivery of Dominant Negative STAT3 Increases I/R mediated Cell Death in  108 
 10 
 
Cardiac Myocytes   
3.4 Deletion of STAT3 Sensitises Cells to Oxidative Stress and I/R Injury   113 
 
3.5 STAT3 becomes Phosphorylated and Transcriptionally Active Following 
Ischaemia/Reperfusion in vitro 
 
116 
3.6 Oxidative stress induces STAT3 serine phosphorylation through an ERK-dependent      
pathway  
124 
 
3.7 Activation of STAT1 and STAT3 following in vivo ischaemia/reperfusion injury  126 
3.8 Increased Expression of STAT3 Target Genes Following in vivo I/R injury   131 
                3.9 I/R injury in the brain induces distinct kinetics of STAT activity  132 
3.10 Reperfusion Induced Myocardial STAT Tyrosine Phosphorylation is Mediated by ROS   134 
3.11 Increased 
  139  Phosphorylation Following IFN-γ Treatment Increases Infarct  Size and 
Reduces the Protective Effect of Tempol 
3.12 Discussion  142 
   
Chapter 4: Investigating Gene Expression Changes in Myocardial Infarction using Microarray  
Analysis 
147 
4.1 Aims  148 
4.2 Drug Infusion, Gene Array Procedure and Quality Control  149 
4.3 Parameters for Differential Expression  153 
4.4 Gene Ontology Analysis of Genes Differentially Expressed by I/R Injury  155 
4.5 Differential Expression mediated by Tempol Infusion During I/R  163 
4.6 Differential Expression mediated by Ucn1 and Ucn2 Infusion During I/R  166 
4.7 Validation of Microarray Data by qPCR  171 
4.8 Activation of a STAT3 Transcriptional Programme Following I/R Injury   173 
4.9 IL-17 Regulation in I/R injury   179 
4.10 Differential Regulation of MAPKs and MKP-1 during I/R Injury  182 
4.11 Uracil Metabolism is Altered by I/R Injury  184 
4.12 Reduced Expression of Mitochondrial Translation Genes Following I/R Injury   186 
4.13 Reduced Expression of Mitochondrial and Respiratory Chain Genes Following I/R Injury   187 
4.14 Reduced Expression of Mitochondrial Import Machinery Genes Following I/R Injury  190 
4.15 Cardioprotective Genes Induced by Ucn1 and Ucn2  193 
4.16 Discussion  197 
 
  Chapter 5: Regulation of the DNA Damage Response by STAT3  203 
5.1 Aims  204 
5.2 STAT3-/- MEFs Repair DNA Less Efficiently That Wild Type Cells  204 
5.3 STAT3-/- MEFs Show Reduced Activity of the ATM/H2AX Pathway  207 
5.4 STAT3 Facilitates DNA Damage Mediated Upregulation of MDC1   210 
5.5 Discussion  214 
 
   
 11 
 
 
  Chapter 6: Regulation of the MAPK Pathway in Inflammation  220 
6.1 Aims  221 
6.2 MKP-1 Deficient Mice have Elevated Cytokine Production, are Hyperresponsive to        
Endotoxic Shock and are Less Susceptible to Listeria Monocytogenes Infection in vivo    221 
6.3 MKP-1 Negatively Regulates p38 MAPK, JNK and AP-1 Activity and iNOS expression  226 
6.4 TLR Mediated MKP-1 Expression Proceeds Through TRIF and MyD88  229 
6.5 Regulation of IL-10 by MKP-1  232 
6.6 Dynamic Regulation of TNF-α is Mediated Through IL-10 in MKP-1-/- -Macrophages  238 
6.7 MKP-1 Activity Promotes IL-12 Expression  244 
 
6.8 MKP-1 Deficiency has no Effect on the Outcome of DSS Induced Coilitis  249 
6.9 MKP-1 Deficiency Impairs Recovery from Experimental Autoimmune Encephalomyelitis  250 
6.10 Loss of MKP-1 does not Effect T Cell Differentiation  252 
6.11 Discussion  257 
   
 
Chapter 7: General Discussion and Future Work  263 
Appenndix 1  272 
Appenndix 2  273 
Appenndix 3A - Microarray: IR Vs Sham  273 
Appenndix 3B - Microarray: Tempol Vs IR  293 
Appenndix 3C - Microarray: Ucn1 Vs IR  295 
Appenndix 3D - Microarray: Ucn2 Vs IR  297 
References  300 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   12 
 
                                                             List of Figures 
 
Figure 1.1  -  Lethal reperfusion injury increases myocardial infarct size  23 
Figure 1.2  -  The three main pathways of apoptosis  26 
Figure 1.3  -  Model of STAT protein structure   36 
Figure 1.4  -  Outline of the JAK/STAT pathway  37 
Figure 1.5  -  JAK usage by cytokines  38 
Figure 1.6 -  STAT1 conformations  39 
Figure 1.7  -  STAT import/export cycle  41 
Figure 1.8  -  Inhibition of STAT signaling by SOCS  46 
Figure 1.9  -  Roles of the JAK/STAT pathway in cardiac pathology  55 
Figure 1.10  -  The mitochondrial import Machinery  59 
Figure 1.11  -  Schematic of the DNA damage response  63 
Figure 1.12  -  TLRs and their cognate ligands  66 
Figure 1.13  -  Signalling pathways initiated by TLR stimulation  68 
Figure 1.14  -  Outline of T-helper cell differentiation  71 
Figure 1.15  -  The MAPK signaling cascade  74 
Figure  3.1  -  Murine STAT3 is transcriptionally active in neonatal rat ventricular myocytes  105 
Figure  3.2  -  Transfection of STAT3 into cardiac myocytes confers protection from  
ischaemia/reperfusion injury                                                                                         
107 
Figure  3.3  -  Adenoviral transduction of cardiac myocytes  110 
Figure  3.4  -  Dominant negative STAT3 increases I/R induced cell death in cardiac myocytes  111 
Figure  3.5  -  STAT3 Protects Cardiac Myocytes From Oxidative Stress  112 
Figure  3.6  -  STAT3-/- MEFs are highly sensitive to I/R damage  114 
Figure  3.7  -  STAT3-/- MEFs undergo enhanced cell death following oxidative stress  115 
Figure  3.8  -  Activation of STAT3 and STAT1 following I/R Injury  117 
Figure  3.9  -  Testing qPCR efficiency  119 
Figure  3.10  - Characterisation of STAT3 dependent gene expression in cardiac myocytes  120 
 
     13 
 
   
Figure  3.11  - STAT3 mRNA expression is decreased and STAT3-dependent gene expression   is  
increased by I/R injury 
122 
Figure  3.12  -  STAT3 dependent luciferase reporter activity is enhanced by I/R injury  123 
Figure  3.13  -  STAT3 serine 727 phosphorylation is ERK1/2 dependent  125 
Figure  3.14  -  Parameters of the in vivo ischaemia/reperfusion model  127 
Figure  3.15  -  Reperfusion activates the DNA damage and apoptotic pathways  128 
Figure  3.16  -  Time course of STAT1 and STAT3 activation following I/R injury  130 
Figure  3.17  -  Expression of STAT3 target genes are increased following I/R injury in viv  131 
Figure  3.18  -  STAT activation following cerebral I/R injury  133 
Figure  3.19  -  Infusion of tempol inhibits ROS production and loweres infarct size  135 
Figure  3.20  -  Tempol infusion reduces JAK/STAT activation and increases GRIM-19  137 
Figure  3.21  - Immunohistochemical Staining of STAT Phosphorylation Following Tempol   Infusion  138 
Figure  3.22  - Effect of I/R and drug infusion on blood pressure, heart rate and pressure rate index  140 
Figure  3.23  - IFN-• induced STAT1 increases infarct size and abrogates the protective effect of 
tempol.  
141 
Figure  4.1  -  GCRMA normalisation, probe intensity and RNA degradation plots  152 
Figure  4.2  -  Volcano plots and numbers of differentially expressed genes  154 
Figure  4.3  -  Manual Gene Ontology analysis of genes differentially expressed by I/R  compared to 
sham 
156 
Figure  4.4  -  Ingenuity analysis of genes differentially expressed by I/R  158 
Figure  4.5  -  Ingenuity network analysis of genes differentially expressed during I/R  160 
Figure  4.6  -   Gene Ontology analysis of genes differentially expressed by tempol when compared to 
saline infusion during I/R 
164 
Figure  4.7  -   Ingenuity functional and network analysis of genes differentially expressed by between 
tempol and I/R 
165 
Figure  4.8  -  Manual GO analysis of genes differentially expressed by Ucn1 and Ucn2 when  
                        compared to saline infusion during I/R 
168   14 
 
 
Figure  4.9  -  Ingenuity analysis of genes differentially expressed by Ucn1 and Ucn2 infusion        
compared to saline infusion during I/R 
 
169 
  
  Figure  4.10  -  Network analysis of the Ucn1 and Ucn2 groups  170 
Figure  4.11  - Comparison of fold changes obtained by three separate normalisation methods    
compared with qPCR 
172 
Figure  4.12  -  The IL-6/STAT3/SOCS3 axis is induced by I/R and enhanced by Ucn1  176 
Figure  4.13  -  Regulation of the Nitric Oxide pathway by I/R injury  178 
Figure  4.14  -  The IL-17 axis is regulated by I/R injury  181 
Figure  4.15  -  MAPK activity during I/R injury  183 
Figure  4.16  -  dUTPase levels are reduced by I/R and partially restored by tempol  185 
Figure  4.17  -  I/R injury represses the expression of mitochondrial transport genes  192 
Figure  4.18  -  Tim23 and Tim44 are repressed in an ex vivo model of I/R injury  193 
 
Figure  4.19  -  Tempol and Ucn1 upregulate XIAP expression  194 
Figure  4.20  -  Ucn1 and Ucn2 inhibit free radical formation following I/R injury  196 
Figure 5.1  -  Rate of HCR in MEF cells with a dose response of UV irradiation  206 
Figure 5.2  -  STAT3-/- MEFs have reduced capacity to repair damaged DNA  207 
Figure 5.3  -  STAT3 increases the rate of DNA repair  208 
Figure 5.4  -  Phosphorylation of ATM and H2AX are reduced in STAT3-/- MEFs  210 
Figure 5.5  -  Phosphorylation of Chk1 but not p53 is reduced in STAT3-/- MEFs  211 
Figure 5.6  -  DNA damage mediated increase in MDC1 expression is compromised in STAT3-/-   
MEFs 
213 
Figure 5.7  -  STAT3 regulates the MDC1 promoter  215 
Figure 6.1  -  MKP-1 genotyping  222 
Figure 6.2  -  MKP-1-/- mice show enhanced cytokine production following LPS challenge  222 
Figure 6.3  -  Flow cytometry analysis of myeloid cells markers in MKP-1+/+ and MKP-1-/- mice  220 
Figure 6.4  -  MKP-1-/- mice are hyperresponsive to endotoxic shock in vivo  224 
Figure 6.5  -  MKP-1-/- mice are less susceptible to Listeria infection  225 15 
 
Figure 6.6  -  Prolonged MAPK activity in MKP-1-/- BMDM in response to LPS  226 
Figure 6.7  -  Increased AP-1 DNA binding activity in MKP-1-/- BMDM  228 
Figure 6.8  -  MKP-1 Expression can be Stimulated Through both the MyD88 Dependent and  
Independent Pathways 
230 
Figure 6.9  -  MKP-1 upregulation by LPS is dependent on MAPKs and NF-•B   232 
Figure 6.10  -  LPS induced MKP-1 expression in dendritic cells  233 
Figure 6.11  -  MKP-1 inhibits TLR induced IL-10 expression and has gene dosage effects  234 
Figure 6.12  -  Temporal regulation of IL-10 by MKP-1  236 
Figure 6.13  -  MKP-1 inhibition of IL-10 is controlled through MAPK  237 
Figure 6.14  -  Temporal regulation of TNF-• in MKP-1 deficient cells  239 
Figure 6.15  -  TNF-• expression in MKP-1-/- macrophages is controlled through IL-10 upregulation  241 
Figure 6.16  -  Increased IL-10 in MKP-1-/- macrophages leads to overproduction of Bcl-3 through 
increased STAT3 activation 
243 
Figure 6.17  -  IL-12p40 expression is repressed in MKP-1-/- mice following TLR stimulation  245 
Figure 6.18  -  Time course of IL-12 expression in MKP-1-/- mice  246 
Figure 6.19  -  Effect of MAPK inhibition on IL-12p40 levels  247 
Figure 6.20  -  Reduced IL-10 expression in MKP-1-/- macrophages may not be responsible for the 
increased levels of IL-12 
248 
Figure 6.21  -  Loss of MKP-1 does not affect outcome of DSS induced colitis  250 
Figure 6.22  -  MKP-1 null mice show impaired recovery from EAE  251 
Figure 6.23  -   Flow Cytometry analysis of lymphoid cell Markers in MKP-1+/+ and MKP-1  -/- mice  252 
Figure 6.24  -  MKP-1 does not affect IL-10 expression from Th2 cells or IFN-• expression from Th1 
cells 
255 
Figure 6.25  -  MKP-1 expression in activated T cells  256 
Figure 6.26  -  Model of MKP-1 mediated temporal regulation of cytokine production in TLR signaling  260 
   
 
 
 
 16 
 
 
List of Tables 
 
 
Table 1.1 - List of kinases which have been shown to phosphorylate STAT3 at ser727  43 
Table 4.1  - Quality control statistics for microarrays  150 
Table 4.2 - Top 20 differentially expressed genes between I/R and Sham  156 
Table 4.3 - Top 20 differentially expressed genes between tempol and I/R   164 
Table 4.4 - Top 20 differentially expressed genes between Ucn1, Ucn2 and  I/R.   167 
Table 4.5 - Genes differentially regulated by I/R previously been shown to be targets of 
STAT3  174 
Table 4.6 - Mitochondrial respiratory complex genes differentially expressed during I/R 
injury.   188 
Table 4.7 - Mitochondrial import genes are differentially regulated during I/R injury  191 
Table 6.1 - EAE clinical score measurement  251 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
 
 
                                            Abbreviations 
 
7-AAD  7-amino-actinomycin 
AIF  Apoptosis inducing factor 
AP-1  Activator protein-1 
APAF1  Apoptotic protease activating factor 1 
ARE  AU rich element 
ASK1  Apoptosis signal-regulating kinase 1 
ATF  Activating transcription factor 
ATM  Ataxia-telangiectasia mutated gene 
ATP  Adenosine-5'-triphosphate 
Bcl-2  B-Cell lymphoma 
BMDC  Bone marrow derived dendritic cells 
BMDM  Bone marrow derived macrophages 
BRCA1  Breast cancer, type 1, included 
cAMP  Cyclic adeonosine monophosphate 
Cdk  Cell division kinase 
Chk  Cell cycle checkpoint kinase 1 
COX  Cyclooxygenase 
CT-1   Cardiotrophin 1 
DC  Dendritic cell 
DDR  DNA damage response 
DIABLO  Direct IAP binding protein with low PI 
DMEM  Dulbecco’s modified eagles medium 
DMSO  Dimethylsulfoxide 
DSB  Double strand break 
DUSP  Dual specificity phosphate 
EAE  Experimental autoimmune encephalomyelitis 
EGF  Epidermal growth factor 
ELK-1  E-26-like protein 1 
ERK  Extracellular regulated kinase 
FADD  FAS associated death domain 
FBS  Foetal Bovine Serum 
GAS  IFN-γ activated sequence 
GFP  Green fluorescent protein 
gp130   glycoprotein 130 
GRIM19   Gene associated with retinoid and interferon induced mortality 19 
GTP  Guanosine-5'-triphosphate 
H2AX  Histone 2AX 
I/R  Ischamia/Reperfusion 
IBD  Inflammatory bowel disease 
IFN  Interferon 
IKK  IκB kinase 
IMS  Inner mitochondrial space 
iNOS  Inducible nitric oxide synthase 18 
 
IRAK  Interleukin-1 receptor-associated kinase 
IRF  Interferon regulatory factor 
IκB  Inhibitor of Nf-κB 
JAK  Janus activated kinase 
JNK  c-Jun N-terminal kinase 
LIF  Leukaemia inhibitory factor 
LPS  Lipopolysacharide 
MAL  MyD88 adapter-like 
MAPK  Mitogen activated protein kinase 
MCC1  Mediator of DNA damage checkpoint protein 1 
MDA  Malondialdehyde 
MEF  Mouse embryonic fibroblast 
MEK/MKK  MAPK or ERK kinase/MAPK kinase 
MEKK/MKKK  MEK kinase/MAPK kinase kinase 
MHC  Major histocompatibility complex 
MI  Myocardial infarction 
MK2  MAPK activated protein kinase 2 
MKP  MAPK phosphatase 
MLK1  Mixed lineage kinase-1 
MNK1  MAPK interacting kinase-1 
MOI  Multiplicity of Infection 
MOMP  Mitocondrial outer membrane potential 
Mre11  meiotic recombination 11 
MRN   Mre11/Rad50/Nbs1 
MS   Multiple Sclerosis 
MSK1  Mitogen and stress activated protein kinase 
mTOR  Mammalian target of rapamycin 
MyD88  Myeloid differentiation factor 88 
Nbs1   Nijmegen breakage syndrome 1 
Nemo  Nf-κB essential modifier 
NFAT  Nuclear factor of activated T cells 
NF-κB  Nuclear factor kappa B 
Nlk  Nemo-like kinase 
NOS  Nitric oxide synthase 
NRVM  Neonatal rat ventricular cardiac myocytes 
OSM  Oncostatin M 
PIAS  Protein inhibitor of activated STAT 
PKC  Protein kinase C 
PMN  Polymorphonuclear cell 
Rad50   Homolog of yeast radiation 50 
ROS  Reactive oxygen species 
RSK  Ribosomal S6 kinase 
RT  Room temperature 
SAM  Sorting and assembly machinery 
Skp2  S-phase kinase-associated protein 2 
Smac  Second mitochondrial derived activator of caspases 19 
 
SOCS  Supressor of cytokine signalling 
SOD  Superoxide dismutase 
Sp1  Specificity protein 1 
STAT  Signal transducer and activator of transcription 
STEMI  ST-elevated myocardial infarction 
TAK1  TGF-β activating kinase 1 
TBK1  TRAF family member-associated NF-kappa B activator (TANK)-binding kinase 1 
TBK1  TANK binding kinase 1 
TCR  T cell receptor 
TdT  Terminal tranferase 
TFAF6  TNF receptor-associated factor 6  
TGF  Transforming growth factor 
TIM  Translocase of inner mitochondrial membrane 
TIR  translocated intimin receptor 
TIRAP  Toll-interleukin 1 receptor (TIR) domain-containing adapter protein 
TIRAP   TIR domain-containing adaptor protein 
TLR  Toll-like receptor 
TNF  Tumor necrosis factor 
TNFR1  TNF receptor 1 
TOM  Translocase of outer mitochondrial membrane 
Tpl2  Tumor progression locus 1 
TRAF6  TNF receptor-associated factor 6 
TRIF  Toll/IL-1 receptor (TIR) domain-containing adaptor 
TRIF  TIR domain containing adaptor inducing IFN-β 
TUNEL  TdT-mediated mediated dUTP nick end labeling 
Tyk  Protein-tyrosine kinase 2 
UV  Ultraviolet 
VDAC  Voltage dependent anion channel 
XIAP  X-linked inhibitor of apoptosis 
γIR  Gamma irradiation 
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1.1 Myocardial Infarction 
 
Coronary heart disease (CHD) is one of the leading causes of mortality and morbidity in the 
world, displaying an aetiology that is both varied and complex. The latest World Health 
Organisation (WHO) estimates suggest that 7.6 million people die annually from CHD, 
which represents 13% of all global deaths. In patients with CHD, coronary vessel occlusion 
occurs following rupture of an atherosclerotic plaque, a lesion consisting of a lipid-rich core 
surrounded by a fibrotic cap (Hannson and Libby, 2006). Atherosclerotic plaque growth is 
increased by hypercholesterolemia which leads to the accumulation of oxidised modified 
low-density lipoprotein (oxLDL) in arterial walls, this causes endothelial cell dysfunction, 
upregulation of inflammatory mediators and leukocyte recruitment, all contributing to plaque 
growth (Stambler et al., 1988).  Macrophage accumulation inside the plaque generates 
proteolytic and thrombogenic mediators which ultimately lead to plaque rupture (Aikawa and 
Libby, 2004). 
 
Plaque rupture results in pro-thrombotic conditions inside the vessel, resulting in a rapid 
thrombotic occlusion; this can cause severely restricted blood flow to the heart, depriving 
myocardial tissue of oxygen and nutrients which is known as ischaemia. Ischaemic heart 
damage directly results in cardiac myocyte cell death and the subsequent formation of an area 
of dead tissue known as an infarct, this process in therefore referred to  as myocardial 
infarction (MI). The INTERHEART study published in 2004 has suggested that over 90% of 
myocardial infarctions are attributed to modifiable risk factors such  as hypertension, 
smoking, obesity, dyslipidemia and diabetes (Yusuf et al., 2004). Once myocardial infarction 
is diagnosed, patients are separated into two categories based on EGG measurements; ST 
elevation MI (STEMI) or non- ST elevation MI (NSTEMI). NSTEMI presents in a similar 
fashion to unstable angina and is normally treated medically with drugs such as aspirin and 
heparin (Braunwald, 2003). Patients presenting with STEMI are treated with percutaneous 
coronary intervention (PCI) which involves an angioplasty and insertion of a stent or through 
the use of thrombolytic drugs (Sanchez et al., 2005, Shah, 2007). Fibrinolytic drugs such as 
tissue plasminogen activator (tPA) and streptokinase currently represent the optimal 
treatment for improving survival after STEMI (Kaul et al., 2004). Even given the current 
treatments, it is estimated that one third of people suffering from MI will die within the first 
year after the primary event (Rosamond et al., 2008). In addition many of the survivors 22 
 
develop systolic dysfunction eventually resulting in congestive heart failure which can lead to 
further hospitalisation or mortality.  
 
 
1.2 Ischaemia/Reperfusion Injury  
 
Following MI, interventions are aimed at restoring blood flow to the previously ischaemic 
vascular bed. In a seemingly contradictory process however, restoration of blood flow, while 
obviously being essential to restore cardiac function, can actually result in enhanced levels of 
myocardial damage and increased infarct size  (Eefting, 2004). This phenomenon of 
reperfusion-induced damage, known as ischaemia/reperfusion (I/R) injury was first described 
in 1960 and is caused by exacerbated death of cardiac myocytes which were viable until 
immediately before reperfusion (Jennings et al., 1960). Despite successful medical 
reperfusion following ischaemia, the incidence of cardiac failure after reperfusion stands at 
25% and mortality rates at almost 10% which can be attributed to I/R injury (Keeley et al., 
2003) and myocardial I/R thus represents an important target for therapeutic intervention. 
The publication of the AMISTAD (Acute Myocardial Infarction Study of Adenosine) study, 
demonstrated for the first time that a drug could reduce infarct size in a multi-centre trial 
(Mahaffey  et al., 1999), however translation of positive pre-clinical results from other 
potential therapies has been disappointing (Bolli et al., 2004). 
 
I/R injury encompasses several types of myocardial dysfunction, including myocardial 
stunning, no-reflow ischaemia, reperfusion induced arrhythmias and lethal reperfusion injury 
(Yellon and Hausenloy, 2007). Myocardial stunning, also called post-ischaemic left-
ventricular  dysfunction, is manifested by mechanical dysfunction after ischaemia, even 
though blood flow has been restored and there is no evidence of cellular necrosis 
(Heyndrickx et al., 1975). The time taken to recover contractile performance varies but 
damage to the heart is reversible and patients usually recover after several weeks (Barnes and 
Khan, 2003). No-reflow ischaemia occurs when the microvasculature is obstructed after 
ischaemia, pathologically this manifests as tissue compression, endothelial swelling, myocyte 
oedema and neutrophil infiltration, all resulting in an inability to fully perfuse a previously 
ischaemic area (Kloner et al., 1980). No-reflow occurs after the myocytes are already dead 
and is associated with reduced left ventricular function, ventricular arrhythmia and cardiac 
rupture; patients diagnosed with no-reflow therefore have a poor prognosis (Ito et al., 1996). 23 
 
Reperfusion induced arrhythmias are caused by dysregulated 
+
 
 release from the sarcoplasmic 
reticulum and are potentially life threatening (Prunier et al., 2008). 
Lethal reperfusion injury is the most damaging form of I/R injury and since its discovery it 
has been highly debated as to whether lethal reperfusion independently contributes to cardiac 
myocyte cell death or merely exacerbates cell death due to the ischaemic episode (Kloner, 
1993). However, the numerous studies in animal models which show that  therapeutic 
intervention before the onset of reperfusion reduces infarct size strongly support a role for 
lethal reperfusion mediated cell death and current thinking posits that lethal reperfusion 
injury accounts for up to 50% of the final infarct size (Piper et al., 1998, Yallon and 
Hausenloy, 2007). Fig 1.1 depicts the reduction in infarct size that can be achieved by 
preventing lethal reperfusion injury. 
 
 
 
Fig 1.1.   Lethal reperfusion injury increases myocardial infarct size. Hearts are stained with 
triphenyl tetrazolium chloride (TTC), infarcted tissue appears white and viable tissue is stained red. 
On the left, infarct size is shown as a percentage of the area at risk. Following ischaemia, successful 
reperfusion substantially lowers infarct  size;  however lethal reperfusion injury diminishes the 
magnitude of reduction. Preventing lethal reperfusion injury through cardioprotective intervention at 
the time of reperfusion further reduces the infarct size (Taken from Yellon and Hausenloy, 2007). 
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1.2.1 Mechanisms of I/R Induced Cell Death 
 
During I/R injury, cell death can occur through apoptosis, necrosis and autophagy. Necrosis 
is uncontrolled cellular destruction; necrotic cells rapidly loose membrane integrity and 
release their contents into the extracellular space. Among the proteins released from necrotic 
cells are danger associated molecular patterns (DAMPs) such as high mobility group protein 
B1, uric acid, heat shock proteins (HSPs)  and genomic DNA which are recognised by 
receptors on dendritic cells and lead to the mounting of an inflammatory response (Scaffidi et 
al., 2002, Shi et al., 2003, Muruve et al., 2008). Apoptosis on the other hand is a form of 
controlled cellular suicide, distinct from necrosis which does not lead to activation of the 
immune system. During apoptosis, cells become rounded, retract from neighbouring cells, 
undergo nuclear fragmentation and membrane blebbing and eventually are engulfed by 
phagocytes (Taylor et al., 2008). Apoptosis is initiated and controlled through a precisely 
ordered signalling cascade that contains multiple checks and balances; at the same time that 
apoptosis is initiated, an anti-apoptotic programme is also induced. The significance of this is 
that apoptosis is not irreversible, activation of the apoptotic cascade does not guarantee cell 
death and thus apoptosis is a highly regulated fluidic process. Autophagy involves formation 
of autophagosomes which degrade and recycle proteins and organelles allowing them to be 
reused in order to maintain metabolic function. Autophagy has been shown to occur in the 
myocardium during I/R injury, however the study of autophagy in this context is still at an 
early stage and it is not yet fully understood how it contributes to cell survival following 
reperfusion (Yan et al., 2005, Gustafsson and Gottlieb, 2008). 
 
 
1.2.2 Caspases 
 
Apoptosis is regulated by an ordered signalling cascade which converges on a family of 
cysteine proteases called caspases which are responsible for controlling the organised cellular 
destruction. Caspases are present in the cell as inactive precursors and are activated following 
cleavage; caspase activation can occur through three main routes which are depicted in Fig 
1.2. Apoptogenic mediators such as granzyme B released from cytotoxic T cells can induce 
apoptosis in target cells by directly activating caspase-3, this is a common form of cell death 
in virally infected cells which display viral epitopes on their MHC for recognition by 
cytotoxic T cells (Darmon et al., 1995). The extrinsic pathway on the other hand involves 
recognition of extracellular ligands such as FasL and TNF-• by the corresponding death 25 
 
receptors such as Fas or TNFR1; these directly activate caspase-8 though binding the adapter 
protein Fas associated death domain (FADD) (Srinivasula et al., 1996). The intrinsic pathway 
involves regulation of the Bcl-2 family of proteins, ultimately resulting in activation of the 
pore forming Bax and Bak which cause mitochondrial membrane opening and release of 
apoptogenic mediators such as cytochrome c (Rosse et al., 1998). The function of cytochrome 
c in healthy cells is to shuttle electrons from complex III to complex IV in the mitochondrial 
respiratory chain. During apoptosis however, cytochrome c is released from the mitochondria 
and translocates to the cytosol where it binds to apoptotic converting protease-activating 
factor (APAF-1) and dATP in a heptameric protein complex called the apoptosome which is 
responsible for caspase-9 activation (Li et al., 1997). In a series of cleavage events, 
downstream caspases are further activated in a precise order, eventually resulting in 
activation of the effector caspases, caspase-3, caspase-6 and caspase-7 (Slee et al., 1999). 
Together these caspases are responsible for cleavage of a host of cellular substrates which 
result in demolition of the cell. For example, cleavage of cytoskeletal proteins such as actin, 
myosin and filamin lead to dissolution of the actin cytoskeleton network and contribute to the 
rounding, retraction and membrane blebbing of cells characteristic of apoptosis (Taylor et al., 
2008). Cleavage of the inhibitor of caspase activated DNase II (ICAD) allows activation of 
the CAD endonuclease and subsequent DNA degradation and chromatin condensation (Enari 
et al., 1998).  
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Fig 1.2. The three main pathways of apoptosis. The extrinsic pathway (1) is mediated through 
extracellular ligands such as FasL and TNF-•, these bind to death receptors such as FAS and TNF-R 
and induce caspase-8 activity via the adaptor protein FADD. Caspase-8 can directly activate casapase-
3 and caspase-7 and can cleave BID to tBID which directly induces BAX and BAK activity. The 
intrinsic pathway (2) is controlled by the Bcl-2 family, BAX and BAK activity are held in check by 
anti-apoptotic Bcl-2 proteins, this is antagonized by BH3-only proteins. BAX and BAK 
oligomerization and insertion into the mitochondrial membrane promote the release of cytochrome c 
into the cytosol where it binds to APAF-1 and Capase-9 in the apoptosome. The apoptosome can 
directly activate caspase-3 and caspase-7 which in turn cases downstream activation of the other 
caspases. Apoptosis can also be induced directly by the grannzyme B pathway (3), cytotoxic T cells 
release grannzyme B through the pore forming perforin which directly activates caspase-3 and tBID. 
Taken from Taylor et al., 2008. 
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1.2.3 Bcl-2 Proteins 
 
The intrinsic pathway of apoptosis is co-ordinately regulated by the Bcl-2 family of proteins. 
Bcl-2, the founder member of this family was first identified as an oncogene at the breakpoint 
of the t[14:18] chromosomal translocation found in B-cell follicular lymphoma (Bakhshi et 
al., 1985). Subsequently it was found that transduction of Bcl-2 into B cells could rescue 
them from cell death, clearly identifying Bcl-2 as an anti-apoptotic protein (Vaux et al., 
1998). The Bcl-2 family are normally grouped into three categories; pro-apoptotic (Bax, Bak 
and Bok), anti-apoptotic (Bcl-2, Bcl-, Mcl-1, Bcl-W, Bcl-2A1 and Bcl-B) and BH3-only 
proteins, which are homologous only in their BH3 domain (Bik, Hrk, Bim, Bad, Bid, Puma, 
Noxa and Bmf). BAX and BAK are a focal point for apoptotic induction by the intrinsic 
pathway; they are kept inactive through direct binding and inhibition by the anti-apoptotic 
Bcl-2 proteins, the BH-3 only proteins disrupt this interaction and allow BAX and BAK to 
oligomerize and exert their pro-apoptotic effect on the mitochondria (Taylor et al., 2008). 
Other BH3 only proteins such as BIM, PUMA and tBID can directly activate BAK and BAX; 
p53 has also been shown to be capable of directly activating BAX in the cytosol (Chipuk et 
al., 2004, Ming et al., 2006, Terrones et al., 2008). Generation of BAX/BAK double 
knockout mice has shown that BAX and BAK are essential for stress induced apoptosis; a 
high proportion of the double knockouts die during embryogenesis and neonates have various 
defects, including elevated numbers of lymphocytes and myeloid cells (Lindsten et al., 2000, 
Rathmell et al., 2002). The intrinsic and extrinsic pathways are not entirely separate and in 
certain circumstances can intersect. For example, caspase-8 cleaves BID to generate a 
truncated C-terminal fragment called tBID, tBID activity triggers BAX oligomerisation and 
translocation to the mitochondria while BCL-
 
 is responsible for inhibiting this BAX-tBID 
interaction (Roucou et al., 2002).  
BAX and BAK oligomerisation appears to be essential for inducing mitochondrial outer 
membrane permeabilisation (MOMP). This may occur through direct pore forming activity of 
BAK and BAX, although the precise nature of this mechanism remains controversial (Chipuk 
et al., 2006). MOMP allows the diffusion to the cytosol of apoptogenic proteins such as 
cytochrome c, Smac/DIABLO, apoptosis-inducing factor (AIF), Tim8a, and endonuclease G, 
which normally reside in the intermembrane space between the inner and the outer membrane 
of the mitochondria (Arnoult et al, 2003, 2005). Although BAX and BAK are constitutively 
expressed, they only induce MOMP following apoptotic stimuli, a process which is 28 
 
dependent on their oligomerization and stable insertion into the outer membrane (Chipuk and 
Green, 2008).  
 
The most favoured model for BAX and BAK activation suggests that they require both direct 
activation by BH3-only proteins and repression of anti-apoptotic Bcl-2 proteins by additional 
BH3-only members (Kuwana et al., 2005). Recently, Green and colleagues have proposed 
what they call the innocent bystander scenario where they suggest that control of the intrinsic 
pathway of apoptosis rests solely with Bcl-2 family mediated MOMP and lacks any input in 
terms of signalling mechanisms from within the mitochondria themselves (Chipuk et al., 
2006). Importantly, Bcl-2 proteins are controlled both transcriptionally and post-
translationally, allowing multiple levels of regulation of the apoptotic process. The BH3-only 
proteins NOXA and PUMA are trascriptionally regulated by p53, BIM is induced by 
FOXO3A and STAT3 upregulates Bcl- and BIM (Oda et al., 2000, Nakano et al., 2001, 
Catlett-Falcone et al., 1999, Epling-Burnette et al., 2001). Examples of post-translational 
control include BAD and BIM; BAD is normally sequestered in the cytosol by 14-3-3 and 
dephosphorylation of BAD following growth factor withdrawal allows it to interact with Bcl- 
(Zhou et al., 2000) 
 
, BIM can be phosphorylated by ERK which targets it for ubiquitin 
mediated proteasomal degradation (Ley et al., 2003). 
 
1.2.4 Inhibitors of Apoptosis (IAPs) 
 
The intrinsic pathway of apoptosis is antagonised by the inhibitor of apoptosis (IAP) family 
of proteins including X-linked IAP (XIAP), IAP1 and IAP2 which block cytochrome c 
induced apoptosis by inhibiting caspase activity. XIAP is a major constituent of native 
apoptosomes where it binds to and inhibits caspase-3, caspase-7 and caspase-9 (Deveraux et 
al., 1997, Hill et al., 2004). XIAP is an E3 ubiquitin ligase and cells from mice deficient in 
XIAP or harbouring a XIAP protein without the ring finger domain have be shown to have 
elevated caspase-3 activity, demonstrating that this ubiquitin ligase activity is essential for 
inhibition of caspases (Schile et al., 2008). Following treatment with  or TNF-•, XIAP-
deficient MEFs show elevated levels of ROS due to reduced expression of anti-oxidant genes 
such as superoxide dismutase 1 (SOD1), SOD2, haem oxygenase 1 (HO-1) and glutathione 
peroxidise (Gpx-1) (Resch et al., 2008). This was associated with prolonged activation of 
JNK and increased susceptibility to apoptosis, suggesting that XIAP may have functions in 29 
 
addition to caspase inhibition. XIAP deficient mice however were found to be similar to wild 
type mice in the ability to induce apoptosis and this was attributed to elevated levels of IAP1 
and IAP2 which may compensate for loss of XIAP (Harlin et al., 2001). IAPs themselves are 
regulated by Smac/DIABLO and HtrA2/Omi which are released from the mitochondria to the 
cytosol and bind directly to IAPs, thereby relieving their inhibitory effect on caspases (Du et 
al., 2000, Verhagen et al., 2000, Suzuki et al., 2001), Smac/DIABLO achieves this by both 
blocking caspase-IAP association and also by repressing IAP ubiquitin ligase activity, thus 
promoting increased caspase activity (Ekert et al., 2001, Creagh et al., 2004).  
 
 
 
1.2.5 Evidence for Apoptosis Mediated Cell Death During I/R Injury 
 
Although the precise contribution of apoptosis to I/R induced cell death is controversial, 
several studies have provided compelling evidence for a fundamental role of apoptosis in 
cardiac pathology following I/R injury  (Eefting, 2004).  In caspase 8 transgenic mice, a 
cardiac myocyte apoptotic rate of 0.2% was sufficient to induce cardiac dysfunction and heart 
failure by six months, while in human patients, rates of cardiac myocyte apoptosis of the 
order of 0.1-0.25% have been associated with end stage dilated cardiomyopathy (Wencker et 
al., 2003, Zorc et al., 2003).  Several early studies measured levels apoptosis in autopsy 
samples from patients with acute myocardial infarction and compared them to samples from 
patients who died of non-cardiac related disease. Saraste et al., detected apoptosis by both 
DNA laddering and TUNEL assay and found levels of 0.04% apoptosis in the central infarct 
area and higher rates of 0.8% in the border area around the infarct compared to 0.005% in the 
non-infarcted region or control hearts (Saraste et al., 1997). A similar study from Anversa’s 
group identified an average of 12% apoptotic cells in the border region and 1% in control 
samples (Olivetti et al., 1996). Even higher rates of apoptosis (26%) were noted by Abbate et 
al., who used the TUNEL assay (TdT-mediated mediated dUTP nick end labeling) in 
combination with cleaved caspase-3 immunostaining (Abbate et al., 2002). While these 
studies report differing levels of apoptosis, presumably due to heterogeneity  in patient 
samples, confounding medical treatment in each patient and the fact that the findings 
represent a level of apoptosis at a fixed time point rather than the cumulative loss of cardiac 
myocytes, they nonetheless demonstrate that MI is associated with elevated levels of 
apoptosis in human patients. Even a small loss of cells from the heart could have a profound 
impact on myocardial function and contractility. For example, an apoptotic rate of 0.1% 30 
 
would be expected to result in a ~37% loss in cardiac myocyte number over a year given that 
myocytes have a limited ability to replenish themselves (Mani, 2008). Thus a greater 
understanding of MI mediated apoptosis is essential for preserving cardiac integrity following 
MI.  
 
Further support for the relevance of apoptosis in I/R injury comes from studies which show 
that administration of pharmacological inhibitors of caspases-3, -8 and -9 during ischaemia 
and at the onset of reperfusion all significantly lower infarct size in ex vivo and in vivo 
models of I/R injury (Yaoita et al., 1998, Holly et al., 1999, Mocanu et al., 2000, Huang et 
al., 2000). In studies of human cardiomyopathy, the cleaved forms of caspases -3, -8 and -9 
have been detected as well as the release of cytochrome c (Narula et al., 1999, Scheubel et al., 
2002). In culture, cardiac myocytes exposed to simulated I/R, hypoxia and oxidative stress 
show caspase activation, PARP cleavage, cytochrome C release and BAD/BAX 
mitochondrial translocation (Cook et al., 1999, Kang, 2000). Other studies demonstrate that 
genetic manipulation of components of the apoptotic machinery can greatly influence I/R 
injury. Transgenic overexpression of Bcl-2 leads to reduced apoptosis, improved left 
ventricular ejection fraction and decreased infarct size after left coronary ligation (Brocherion 
et al., 2000). Likewise, following I/R injury, Bax-deficient mice have reduced apoptotic 
indexes and superior cardiac function compared to wild type controls (Hochhauser et al., 
2003). Deletion of the p53 target gene PUMA has also been shown to reduce infarct sizes by 
50% (Toth et al., 2006). In addition, modulation of the extrinsic pathway has also provided 
supporting evidence. Adenoviral administration of FasL induces apoptosis in the myocardium 
of adult rats and Fas-deficient mice suffer significantly less apoptosis after MI, resulting in 
reduced infarct sizes (Lee et al., 2002).  
 
Although it is clear that the entire cellular machinery of apoptosis is present in cardiac 
myocytes, apoptotic regulation in these terminally differentiated cells is distinct from that of 
other dividing cell types. Since loss of myocytes is so detrimental to the heart, the threshold 
for apoptosis is elevated in cardiac myocytes compared to other cell types. One of the ways 
this is achieved is through reduced availability of components of the intrinsic pathway. 
Sanchis et al. found that treating cardiac myocytes with staurosporine caused the release of 
cytochrome c into the cytosol but did not lead to caspase-3 activation or DNA fragmentation 
(Sanchis et al., 2003). They attributed this finding to the lack of Apaf-1 expression in cardiac 
myocytes and showed that transfecting cardiac myocytes with Apaf-1 restored sensitivity to 31 
 
staurosporine induced cell death. Likewise, Potts et al., found that cardiac myocytes were 
resistant to apoptosis induced by micro-injection of cytochrome c (Potts et al., 2005). In 
contrast to Sanchis et al., their study detected Apaf-1 expression but found that it was greatly 
reduced in comparison to other cell types. In support of these findings it has also been shown 
that cytosolic cytochrome c and caspase-9 activity was present in the absence of caspase-3 
activity and apoptosis in failing human hearts (Scheubel et al., 2002). In addition, the 
expression of several caspases, Bcl-2 and Bax have been shown to be repressed postnatally 
which was associated with reduced caspase-3 activity and DNA fragmentation following 
ischaemia (Bahi et al., 2006). These studies demonstrate that although apoptosis certainly 
takes place in cardiac myocytes, it may be more tightly controlled and limited expression of 
Apaf-1 and caspases may thus serve as a break on apoptosis where a higher critical threshold 
must be reached before initiating irreversible cell death signals. 
 
 
1.2.6 The Mitochondrial Permeability Transition Pore 
 
The proton gradient which is required for energy production in the cell is maintained by the 
inner  membrane of the mitochondria. Mitochondrial membrane potential is controlled 
through the mitochondrial permeability transition pore (MPTP). This is a large non-specific 
pore spanning both the inner and outer mitochondrial membranes which is formed through 
the association of the voltage-dependent anion channel (VDAC),  the adenine nuclear 
translocase (ANT) and cyclophillin D (Clerk et al, 2003, Baines, 2007). The MPTP is 
+, 
redox, voltage and pH sensitive and remains closed during ischaemia due to the low pH 
within the cell. In the first few minutes of reperfusion however, the pore opens due to a 
restoration of pH, increases in 
+  levels, free radical production and inhibition of ATP 
synthesis (Griffiths and Halestrap, 1995, Kim et al., 2006). MPTP opening is associated with 
increases in mitochondrial volume and permeability which can ultimately lead to a reduction 
in membrane potential (••) and inhibition of ATP synthesis, causing  defects in energy 
production needed to sustain heart muscle contraction (Baines, 2007). Sustained opening of 
the pore leads to a collapse in the proton gradient and electrical potential across the inner 
membrane and this in turn causes oxidative phosphorylation uncoupling. Under the force of 
osmotic pressure, the matrix begins to swell and while the inner mitochondrial membrane can 
undergo cristae remodelling to adapt to the expansion, the outer membrane is unable to do so 
and eventually ruptures (Gustafsson and Gottlieb, 2008). This allows the release of pro-32 
 
apoptotic mediators such as cytochrome c, AIF and endonuclease G into the cytosol which 
may further the apoptotic process (Yang and Cortopassi, 1998). This is supported by studies 
which show that pharmacological inhibition of MPTP opening with cyclosporine, sangliferin 
A or preconditioning reduce infarct size in rodents by 50%, suggesting that high levels of 
MPTP opening is a detrimental event during I/R injury (Hausenloy et al., 2003, Javadov et 
al., 2003). In agreement with this, gene targeted mice deficient in cyclophilin D, an essential 
component of the MPTP, were resistant to mitochondrial permeability transition and had a 
40% reduction in infarct size following I/R injury (Baines et al., 2005, Nakagawa et al., 
2005). This has recently been confirmed in humans where a small clinical study showed that 
a single intravenous bolus of cyclosporine in patients with acute ST-elevation myocardial 
infarction undergoing primary PCI reduced biochemical markers of cardiac dysfunction and 
decreased infarct size by 20% (Piot et al., 2008). It must be noted however that MPTP may 
actually be dispensable for activation of apoptosis via the mitochondrial pathway since 
cyclophinin D deficient cells were found to respond normally to apoptotic stimuli (Baines et 
al., 2005). 
 
 
1.2.7 Reactive Oxygen Species (ROS) in Myocardial Cell Death 
 
Another mechanism whereby reperfusion induces cell death in the myocardium is through the 
generation of ROS. ROS consist of hydrogen peroxide (), the superoxide anion (
-) and the 
hydroxyl radical (·OH) amongst others. ROS can cause cellular damage in several ways, 
including DNA strand breaks, lipid peroxidation and reduction of protein sulfhydryl bonds 
(Goswami et al., 2007). In addition, ROS can induce apoptosis directly via peroxidation of 
cardiolipin which disrupts the cytochome c–cardiolipin interaction, thereby releasing 
cytochrome c into the cytosol where it induces apoptosome formation (Shidoji et al., 1999). 
Under normal cellular conditions in the myocardium, 95% of oxygen is reduced to  via the 
mitochondrial electron transport chain. However the remaining 5% of oxygen is reduced via 
the univalent pathway in which free radicals are produced, namely the superoxide anion (
-) 
and its protonated form ·, these are in turn converted by superoxide dismutase (SOD) into  
which is toxic at high concentrations.  is further reduced to  via catalase or glutathione 
peroxidase, therefore the toxic superoxide radical can be safely metabolised to water (Becker, 
2004). During ischaemia however, the increasing concentration of  can lead to the generation 
of the damaging hydroxyl radical (·OH) via the fenton reaction (Mao et al., 1993). Oxidative 33 
 
stress thus occurs when excess ROS generation cannot be adequately removed by 
antioxidants.  
 
Zweier et al., measured free radical production using paramagnetic resonance spectroscopy in 
isolated Langendorf perfused rabbit hearts and found generation of free radicals during 
ischaemia was accompanied by a further burst within 10 seconds of reperfusion (Zweier et 
al., 1987). This finding was recapitulated in cardiac myocyte culture using the fluorescent 
oxidant probe 2’,7’-dichlorofluorescin diacetate which is converted to the fluorescent probe 
DCF by oxidation. Using DCF, Vanden-Hoek et al. demonstrated that ROS are produced in 
cultured cardiac myocytes during ischaemia and similarly to the isolated heart model, this 
was followed by a dramatic burst of ROS generation during reperfusion which reached a peak 
after 5 min (Vanden-Hoek et al., 1997).  
 
The generation of ROS during ischaemia can be abolished by pharmacological inhibitors of 
mitochondrial electron transport, and several studies suggest that complex III is the main site 
of ROS generation during ischaemia (Chen et al., 2003, Becker at al., 1999). Intriguingly. 
these same inhibitors appear to have little effect on the ROS burst which occurs following 
reperfusion, suggesting that ROS production occurs through distinct mechanisms in 
ischaemia and reperfusion (Becker, 2004). Further ROS production occurs through a 
mechanism known as ROS induced ROS release. In this phenomenon, initial ROS production 
leads to the opening of the MPTP and decreased ••
 
 followed by disruption and redox reduction 
of the electron transport chain, this increases the rate of electron transfer to molecular oxygen 
accompanied by a concomitant increase in superoxide production. (Zorov et al., 2000). 
Treatment of cardiac myocytes with bongkrekic acid, an inhibitor of MPTP opening, 
inhibited this second burst of ROS from the mitochondria (Zorov et al., 2000).  The 
contribution of ROS to myocardial damage during I/R injury is highlighted in studies of 
transgenic mice overexpressing SOD1 or SOD2, both of which have reduced infarct size 
following I/R injury (Chen et al., 1996, Chen et al., 1998). Infusion of membrane permeable 
free radical scavengers such as tempol have also been shown to reduce infarct size in rats and 
rabbits by up to 60% (McDonald et al., 1999). Although ROS inhibition has been shown to 
reduce infarct size in animal models, clinical trials of antioxidant therapies such as SOD, 
vitamin E and •-carotene have all proved disappointing (Flaherty et al., 1994, Rapola et al., 
1997). 34 
 
While ROS production can be highly toxic and damaging to cellular structures, they also play 
a role in cell signaling. A pertinent example of this is the finding that the cardioprotection 
afforded by ischaemic preconditioning (brief periods of repeated ischaemia before the onset 
of reperfusion) is lost in the presence of anti-oxidants and preconditioning can be mimicked 
by pro-oxidants both in vitro and in vivo (Vanden-Hoek et al., 2000, Tang et al., 2002). 
Therefore ROS production in cardiac myocytes can have both detrimental and beneficial 
effects during I/R injury.  
 
 
1.2.8 
+
 
 Overload and Contracture 
In addition to apoptosis and ROS production, myocardial damage can occur via 
hypercontracture following reperfusion. During ischaemia, the lack of oxygen leads to 
lowered production of ATP, increased lactic acid accumulation and a lowering of the pH. In 
order to try to restore the pH balance, myocytes utilise the Na
+/H
+ exchanger to remove 
excess protons, however this has the ancillary effect of increasing the intracellular Na
+ 
concentration (Wang et al., 2000). Normally excess Na
+ is pumped out of the cell using the 
Na
+/K
+-ATPase, however since ATP levels are depleted in ischaemic cells, the Na
+/K
+-
ATPase cannot work at full capacity. This causes the sarcolemmal Na
+/
+ exchanger to operate 
in the reverse mode, pumping out high levels of 
+ into the cytosol, eventually resulting in 
calcium overload (Allen and Xiao, 2003). In addition to this 
+ overloaded state, the contractile 
machinery of the myocyte is directly compromised due to the low ATP levels and the 
myocyte will appear in a state of contracture which causes a shortening and stiffening of the 
myocardium (Hohl et al., 1982). Once ATP production has been resumed upon reperfusion, 
the contractile machinery is reactivated, however this often occurs faster than restoration of 
normal cytosolic Ca
+  levels and can cause uncontrolled 
+  dependent contraction, rapid 
oscillations in 
+
 
 transport from the sarcoplasmic reticulum and eventually hypercontracture 
(Gustafsson and Gottlieb, 2008).  In this hypercontracted state, myocytes are prone to 
mechanical damage which can contribute to the spread of necrosis.  
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1.3 The JAK/STAT Pathway 
 
 
1.3.1 JAK/STAT Family Members 
 
While research into the underlying molecular mechanisms of MI remains challenging, there 
is great potential to uncover candidate targets for novel therapeutic intervention through 
elucidation of the precise signalling cascades that control cell fate following cardiac damage.  
One of the pathways which has recently come to the fore as instrumental in determining cell 
fate is the JAK-STAT pathway. This pathway may represent a significant emerging target for 
therapeutic intervention in cardiac disease and thus  it is of great interest to uncover the 
regulatory mechanisms involved in JAK/STAT signalling during I/R injury.  
 
The JAK/STAT pathway is an evolutionary conserved signalling network involved in a wide 
range of distinct cellular process, including inflammation, apoptosis, cell cycle control and 
development. JAKs are cytosolic tyrosine kinases which are associated with the intracellular 
domain of membrane bound receptors, whose function is to transduce signals from 
extracellular ligands such as cytokines, growth factors and hormones to the nucleus in order 
to orchestrate the appropriate cellular response (O’Shea et al., 2002). There are four family 
members; JAK1, 2, 3 and Tyk2, all of which show different receptor affinities, they all 
however transduce their signal through recruitment of STAT transcription factors (Levy and 
Darnell, 2002). The STAT family consists of seven members; STAT1, 2, 3, 4, 5a, 5b and 6, 
and although they are structurally similar proteins, they are functionally heterogeneous (Levy 
and Daenell, 2002). STATs possess a series of conserved structural domains; the N-terminal 
domain (NTD) is involved in reciprocal STAT interactions and is loosely tethered to the rest 
of the STAT protein, the coiled coil (CC) domain contains consensus sites for nuclear 
transport, the DNA binding domain (DBD) binds to conserved regulatory sequences in the 
promoters of target genes, the src homology 2 (SH2) domain controls receptor binding and 
the C-terminal domain (CTD) contains the phosphorylation sites necessary for STAT 
activation (Fig 1.3). The work presented here focuses on STAT1 and STAT3, as there is 
currently little data to suggest a prominent role for any other members of the STAT family in 
I/R injury and therefore they will not be discussed further. 
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Fig 1.3 Model of STAT protein structure (for reference STAT3 is shown) consisting of an N-terminal 
domain (NTD), a coiled coil domain (CC), a DNA binding domain (DBD), a linker domain, a Src 
homology 2 domain (SH2) and a C-terminal transactivation domain  (CTD). STATs can be 
phosphorylated at distinct residues which control their activation and DNA binding, shown here are 
the tyrosine 705 and serine 727 phosphorylation sites in STAT3. 
 
 
 
1.3.2 STAT Activation 
 
A large array of cytokines and growth factors utilize the JAK/STAT network to transduce 
their cognate signal to the nucleus, for example IL-6, IL-10, cardiotrophin 1 (CT-1) and G-
CSF induce STAT3 activity,  while interferons (IFN) utilize predominantly STAT1 and 
STAT2. Ligand binding to the extracellular domain of JAK associated cytokine receptors 
induces receptor dimerisation and JAK autophosphorylation. JAKs then transphosphorylate 
the cytoplasmic domain of the cytokine receptor and create  a docking site for the SH2 
domain of STATs (Levy and Darnell, 2002). Once STATs bind to the intracellular receptor 
chain, they are phosphorylated by JAKs at distinct tyrosine residues, causing the bound 
STATs to be released from the receptor  and translocate to the nucleus  where they bind 
specific sequences such as the IFN-• activated sequence (GAS) in the promoters of target 
genes (Fig 1.4) (Levy and Darnell, 2002). Once bound to DNA, the NTD is responsible for 
recruiting RNA Pol II and co-factors such as the histone acetyl transferase p300 (Hou et al., 
2008). 
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Fig 1.4. Outline of the JAK/STAT3 Pathway. Members of the JAK tyrosine kinases are recruited to 
cytokine receptors, growth factor receptors or G-protein  coupled receptors. They induce tyrosine 
phosphorylation of STAT3 which causes it to translocate to the nucleus. In addition, STAT3 can be 
phosphorylated by non-receptor tyrosine kinases and serine kinases. Transport into the nucleus is 
controlled by importins and once in the nucleus, active STAT3 binds to target sequences such as the 
IFN-• activated sequence (GAS), this is aided by histone acetyl transferases such as p300. 
Dephosphorylation allows STAT3 to dissociate from DNA and return to the cytosol. Activation of 
STAT3 is antagonised SOCS3 and nuclear translocation is blocked by GRIM-19. In the nucleus PIAS 
blocks STAT3 binding to DNA. 
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There are currently around 36 known cytokine receptor combinations that respond to 38 
cytokines which utilize distinct combinations of JAKs and STATs (Murray, 2007). The 
selective use of receptor combinations outlined in Fig 1.5 allow a certain specificity for 
signaling but it is currently unknown precisely how cytokines exert differing responses 
utilizing the same JAK and STAT combinations.  The JAK/STAT pathway can also be 
stimulated by G-protein coupled receptors such as the angiotensin II receptor and this may be 
mediated through Rho family GTPases (Marrero et al., 1995, Pelletier et al., 2003). Another 
mode of JAK/STAT activation is via non-receptor tyrosine kinases such as Src, Fer, Abl, Etk 
and Lck which all induce STAT3 activity (Yu et al., 1995, 1997, Nelson et al., 1998, Lund et 
al., 1999, Wen et al., 1999, Priel-Halachami et al., 2000). The IL-6 family of cytokines 
comprises IL-6, IL-11, leukaemia inhibitory factor (LIF), oncostatin M (OSM), ciliary 
neurotrophic factor (CNTF), cardiotrophin-1 (CT-1) and cardiotrophin-like cytokine (CLC). 
IL-6 cytokine receptors are comprised of the signal transducer gp130 in combination with IL-
6R, IL-11R, LIF-R or OSM-R. All IL-6 cytokines potently activate STAT3 and this is 
followed by internalization and degradation of gp130 (Fischer and Hilfiker-Kleiner, 2007). 
Serum levels of IL-6, soluble gp130, LIF and CT-1 have all been shown to be elevated in 
patients suffering from heart failure and these levels correlate with the severity of left 
ventricular dysfunction, suggesting that the IL-6/STAT3 axis may have a role to play in 
myocardial cell death (Roig et al., 1998, Hirota et al., 2004, Toree-Aminone et al., 1996, 
Khan et al., 2006). 
 
 
Fig 1.5. JAK usage by cytokines. Shown are cytokines and the JAK combinations which they utilize. 
Taken from Murray, 2007. 
 39 
 
Dimerization of STATs appears to be essential for DNA binding and retention in the nucleus. 
Traditionally it was thought that inactive STATs were present as monomers and only undergo 
dimerization after phosphorylation, however accumulating evidence suggests that 
unphosphorylated STATs are present in the cytosol as dimmers or higher order multimers 
(Ndubuisi et al., 1999). Unphosphorylated STAT1 dimers are formed by reciprocal 
interactions of their N-terminal domains, coiled-coil and DNA binding domains in an anti-
parallel conformation (Fig 1.6) (Zhong et al., 2005). Phosphorylation promotes dimerization 
through the SH2 domains in a parallel confirmation which is essential for DNA binding and 
nuclear retention and these parallel and anti-parallel conformations appear to be mutually 
exclusive (Fig 1.6) (Mao et al., 2005, Wenta et al., 2008). Recently it has been shown that 
tyrosine phosphorylation of  STAT1 is dispensable for DNA binding per se, however 
phosphorylation promotes the parallel conformation which increases DNA binding activity 
by more than 200 fold (Wenta et al., 2008). 
 
  
 
 
1.3.3 STAT Nuclear Import 
 
In the last few years we have gained a much more detailed understanding as to how the 
phosphorylated STATs are transported to the nucleus. Work from Uwe Vinkemer’s group 
and others has shown that once phosphorylated, STAT dimers are transported to the nucleus 
in both an energy-dependent and an energy independent manner  (Meyer  et al., 2004). 
Importins such as importin •5  bind to phosphorylated STAT dimers and transport them 
through nuclear pore complexes with a conserved sequence in the coiled-coil domain 
essential for nuclear import (Ma et al., 2003). Conversion of RanGTP to RanGDP in the 
nucleus allows STATs to re-enter the cytosol, utilizing exportins such as chromosomal region  
Fig 1.6. STAT1 conformations. The domains are N-
terminal domain (ND), coiled:coil domain (CC), 
DNA-binding domain (DBD), linker domain (L), and 
SH2 domain (SH2). The ND is shown tied to the CC 
through a flexible tether (not to scale), and the 
residues C-terminal to the –SH2 include the  Y701, 
which is phosphorylated (red dot) when the molecule 
is activated. The C-terminal region is also flexible as 
indicated by the wavy black line. At the bottom of the 
figure are diagrams of the parallel and antiparallel 
structures supported by crystallographic results (Chen 
et al. 1998; Mao et al. 2005). Notable is the F172 
residue that is important in the antiparallel structure. 
Taken from Martens et al., 2006. 
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maintenance 1 (CRM1) (McBride et al., 2000). The CRM1 binding site in STAT1 is located 
within the DNA binding domain, suggesting that CRM1 is prohibited from binding when 
STAT1 is bound to chromatin (McBride et al., 2000).  Using protein microinjection 
techniques, Marg et al. demonstrated that unphosphorylated STAT1 could move freely 
between the cytoplasm and the nucleus (Marg et al., 2004). This occurred in the absence of 
cytokine stimulation and even when the RanGTPase active transport system was disrupted by 
depleting the cells of energy. It seems therefore that two modes of STAT nuclear transport 
exist, an energy-independent method involving unphosphorylated STATs in which direct 
interaction with nucleoporins allows constant shuffling between the cytoplasm and nucleus 
and an energy-dependent system where phosphorylated STATs need to be actively 
transported into the nucleus (Meyer and Vinkemeier, 2004). Since nuclear translocation of 
STATs is a relatively fast process (5-10 minutes), a mechanism  exists  to replenish the 
cytosolic pool of STATs to allow further ligand induced activation and prolong target gene 
transcription.  
 
 
1.3.4 STAT Nuclear Export 
 
Nuclear export is controlled by STAT dephosphorylation and inhibition of tyrosine 
phosphatases prolongs STAT1 retention in the nucleus.  The kinetics of nuclear retention 
correlate with the level of STAT-DNA binding, suggesting that STATs are protected from 
dephosphorylation while bound to DNA (Meyer et al., 2003). How then do nuclear 
phosphatases gain access to STATs? In the case of STAT1, Darnell and colleagues have 
proposed an elegant model whereby following dissociation from DNA, the N–terminal 
domains of both proteins in the dimer interact and undergo rearrangement (Zhong et al., 
2005). This forms an anti parallel structure allowing the coiled coil domain of one monomer 
to bind to the DNA binding domain of the other, thus exposing the phosphate residues to 
nuclear phosphatases (Zhong et al., 2005, Mao et al., 2005). This antiparallel configuration 
allows the two molecules to remain in association following nuclear export. Thus it seems 
that a nuclear pool of activated STATs is maintained by constant export and re-import which 
is controlled by a tightly regulated tyrosine phosphorylation-dephosphorylation cycle (Meyer 
et al., 2003). The schematic of the import/export cycle of STATs is depicted in Fig 1.7. 
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Fig 1.7. STAT import/export cycle. STAT tyrosine phosphorylation by cytokine, growth factor or 
G-protein coupled receptors induces a STAT parallel conformation and nuclear import through 
importin-•, the anti-parallel confirmation allows access to nuclear phosphatases and subsequent 
nuclear export via CRM1. Unphosphorylated STATs can also shuttle freely between the cytosol and 
nucleus. 
 
 
 
1.3.5 STAT Serine Phosphorylation 
 
As well as tyrosine phosphorylation, STAT1 and 3 can both undergo serine phosphorylation 
at position 727. While serine phosphorylation is cell and stimulus specific, it appears to be 
necessary for full transcriptional activity of STATs in many instances, for example mutating 
STAT3 at serine 727 to alanine (S727A) reduces transactivation of STAT3 responsive 
promoters (Shen et al., 2004). The transcriptional outcome of STAT serine phosphorylation 
may be determined by the target promoter itself, with different STAT target genes displaying 
varying transcriptional responses to a STAT1 serine mutant (Kovarik et al., 2001). Several 
serine kinases have been shown to be capable of phosphorylating STATs under different 
conditions. STAT3 serine kinases include ERK and PKC•  (see  table 1.1 for full list of 
STAT3 serine kinases), while STAT1 serine kinase include p38 MAPK, Ca(2+)/calmodulin-
dependent kinase (CaMK) II and PKC-• (Nair et al., 2002, Uddin et al., 2002, Ramsauer et 
al., 2002). Serine phosphorylation may serve to prime STATs for an altered transcriptional 42 
 
response once a second signal for tyrosine phosphorylation is received (Decker and Kovarik, 
2000). Furthermore, serine phosphorylation may augment transcriptional responsiveness 
through altered co-factor recruitment, for example, serine phosphorylation of STAT3 has 
been shown to influence recruitment of the co-factor p300/CBP, a histone acetyl transferase 
(HAT) which facilitates chromatin unwinding and transcription factor access to target DNA 
(Schuringa et al., 2001). Evidence for the important role for STAT serine phosphorylation in 
vivo comes from studies of mutant mice where the serine residue at position 727 is mutated to 
an alanine (S727A). STAT1 S727A mice displayed increased mortality upon Listeria 
monocytogenes  infection  and have increased resistance to LPS-induced endotoxic shock, 
however this mutation only affects a subset of STAT1 target genes (Varinou et al., 2003). In 
contrast, STAT3 S727A mice exhibited 75% perinatal lethality and are more sensitive to 
LPS-induced endotoxic shock (Shen et al., 2004, Shen et al, 2005).  
 
By having two modes of activation, tyrosine and serine phosphorylation allow tight 
regulation of STAT activity so that signals from several pathways can converge to modulate 
STAT induced gene activation. Recently Kovarik’s group demonstrated that STAT1 Y701 
phosphorylation and nuclear translocation were a prerequisite for serine phosphorylation by 
interferons (Sadzak et al., 2008). Moreover, STAT1 mutants which were unable to associate 
with chromatin were refractory for S727 phosphorylation, suggesting that STAT1 needs to be 
assembled  into chromatin-associated transcriptional complexes to become S727-
phosphorylated and fully biologically active in response to IFNs. 
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Table 1.1. List of kinases which have been shown to phosphorylate STAT3 at ser727, the stimulus 
and the cell type are also listed. 
 
 
1.3.6 STAT Dephosphorylation  
 
While there are a multitude of studies concerning the initial phosphorylation and activation of 
STATs, there  are relatively few studies concerning STAT dephosphorylation. The first 
STAT1 phosphatase identified was T cell protein tyrosine phosphatase 45 (TC45) which was 
shown to be responsible for Y701 dephosphorylation in response to IFN-• (ten Hoeve et al., 
2002). •-arrestin-1, which interacts with STAT1 serves as a platform for dephosphorylation 
by recruiting TC45 (Mo et al., 2008). •-arrestin-1-deficient mouse embryonic fibroblasts 
underwent Y701 phosphorylation as normal in response to IFN-•. However, while 
phosphorylation in wild type cells began to decline by 90 min, STAT1 remained 
phosphorylated at Y701 for up to 3 hr in the absence of •-arrestin-1 (Mo et al., 2008). 
Functionally this was manifested by an enhanced IFN-• mediated antiviral response to 
vesicular somatitis virus when •-arrestin-1 was inhibited (Mo et al., 2008).  
 
Another mode of STAT1 dephosphorylation is via Src homology region 2 domain-containing 
phosphatase 2 (SHP2) which was shown to bind to the SH2 domain of STAT1 in response to 
Kinase  Stimulus  Cell Type  Reference 
ERK  EGF  3T3  Chung et al., 1997 
JNK  UV  COS-1  Lim and Cao, 1999 
mTOR  CNFT  Neuroblastoma  Yokogami et al., 2000 
PKC•  IL-6  HepG2  Schuringa et al., 2001 
ERK  Leptin  macrophages  O’Rourke and Shepherd, 2002 
RSK  UV  lymphoblasts  Zhang et al., 2003 
Cdk5  Neuregulin  myotubes  Fu et al., 2004 
MSK1  Erythropoietin  erythroid cells  Wierenga et al., 2003 
p38 MAPK  IL-13  monocytes  Xu et al., 2003 
NLK  IL-6  HepG2  Kojima et al., 2005 
Cdk1  Nocadazole  Hela  Shi et al., 2006 44 
 
IFN-• and EGF and repress both tyrosine and serine phosphorylation in the nucleus (Wu et 
al., 2002). This association is exploited by the human cytomegalovirus which increases SHP2 
binding to STAT1, reducing STAT1 phosphorylation and thereby dampening the antiviral 
response (Davon and Barignon, 2008).  
 
Less is known about phosphatases  which target STAT3, but recently a tyrosine 
phosphopeptide screen of cells overexpressing the receptor protein tyrosine phosphatase T 
(PTPRT) identified STAT3 as a substrate (Zhang et al., 2007). RNAi mediated inhibition of 
PTPRT in MCF-7 cells significantly  increased STAT3 Y705 phosphorylation and 
overexpression of PTPRT dramatically reduced IL-6 mediated STAT3 tyrosine 
phosphorylation and nuclear translocation as well as reducing STAT3 target gene expression. 
T cell protein tyrosine phosphatase TC-PTP has also shown to be capable of 
dephosphorylating STAT3 following IL-6 treatment in 293 cells (Yammamoto et al., 2002). 
 
These studies show that in addition to the regulatory mechanisms involved in STAT 
activation there are signaling pathways which limit the duration of STAT phosphorylation. 
This is necessary to avoid any unwanted side effects of prolonged STAT activation. For 
example, dysregulated phosphorylation of STAT1 might lead to an excessive inflammatory 
response or increased levels of apoptosis. It is also necessary in allowing repeated rounds of 
STAT activation; STAT dephosphorylation allows STATs to be returned to the cytosol where 
they can once again be phosphorylated.  In the future, more detailed understanding of STAT 
dephosphorylation will add to our knowledge of the regulation of the JAK/STAT pathway. 
 
 
1.3.7 Negative Regulation of STATs by SOCS   
The suppressor of cytokine signaling (SOCS) proteins control the negative regulation of 
cytokine responses. There are seven members of the SOCS family (SOCS1-7) which are all 
induced by cytokines and therefore they form part of a negative feedback loop of cytokine 
control, in addition SOCS proteins can be induced by other agonists such as LPS, statins and 
cAMP. SOCS1 and SOCS3 are potent inhibitors of the JAK/STAT pathway, The SH2 
domain of SOCS1 and SOCS3 is necessary to facilitate binding to a site in active JAK1, 
JAK2 and Tyk2 while the SOCS kinase inhibitory region (KIR) is responsible for 
suppressing JAK kinase activity (Narazaki et al., 1998, Sasaki et al., 1999).  The SOCS SH2 45 
 
domain determines other target selectivity, for example the SH2 domain of SOCS3 binds to 
phosphorylated tyrosine residues on cytokine receptors such as Tyr757 of gp130 and Tyr800 
of IL-12, SOCS1 can bind to both the IFN-• and IFN-• receptors and both the SOCS1 and 
SOCS3 SH2 domain can bind to the Y1007 residue in the activation loop of JAK2 
(Yasukawa et al., 1999, Yohimura et al., 1997) 
 
In addition, SOCS proteins function as E3 ubiquitin ligases and therefore target proteins for 
proteasomal degradation (Yoshimura et al., 2007). This is mediated through a region in the C 
terminus known as the SOCS box which binds a complex containing elongin B/C, cullin-5 
and RING-box-2 (RBX2) which recruit E2 ubiquitin transferase, resulting in 20S mediated 
proeasomal destruction of SOCS-bound proteins (Kamura et al., 1998, Zhang et al., 1999, 
Vuong et al., 2004). Deletion of the SOCS box in SOCS1 led to enhanced levels of 
phosphorylated STAT1 and increased IFN-• responses, showing that this region in necessary 
for the full activity of SOCS1 (Zhang et al., 2001). Initial phosphorylation of JAKs appears to 
be necessary for SOCS-mediated degradation. In unstimulated cells, JAK2 was found to be 
mono-ubiquitinated whereas stimulation with IL-3 or IFN-• led to phosphorylation at Y7001, 
recruitment of SOCS1 and subsequent polyubiquitination and degradation (Ungureanu et al., 
2002). 
 
The need for correct control of JAK/STAT signaling is highlighted in studies of SOCS1-
deficient mice, these mice develop an excessive fatal IFN-• response which could be rescued 
by the administration of anti-IFN-• antibodies (Alexander et al., 1999). Lymphocytes from 
these mice exhibit accelerated apoptosis with age and SOCS1
-/-
 
 MEFs are far more sensitive 
to TNF-• mediated apoptosis that their wild type counterparts, showing that tempering of the 
IFN-•/STAT1 axis is necessary to restrain exuberant STAT1-mediated apoptosis (Naka et al., 
1998, Morita et al., 2000). 
The SOCS proteins provide a level of specificity for cytokine signaling through the 
JAK/STAT pathway. For example, STAT3 is essential for the biological effects both IL-6 
and IL-10, however IL-6 is a pro-inflammatory cytokine whereas IL-10 is anti-inflammatory. 
The differing responses appear to be controlled at the level of SOCS3; IL-6 and IL-10 both 
upregulate SOCS3, however SOCS3 selectively dampens IL-6 signalling by binding to the 
IL-6R subunit gp130 without having any effect on IL-10 signalling. IL-6 therefore induces 
transient STAT3 activation while IL-10 promotes prolonged STAT3 activity; this is 46 
 
evidenced by the prolonged STAT3 phosphorylation seen in SOCS3 deficient cells following 
IL-6 treatment (Lang et al., 2003). Prolonged STAT3 activation is therefore instrumental in 
the anti-inflammatory response and leads to suppression of pro-inflammatory cytokine 
production by toll-like receptors (Fig 1.8). Moreover, IL-6 treatment of macrophages 
deficient in SOCS3 or harboring mutation of the SOCS3 binding site on gp130 produces an 
anti-inflammatory response, clearly showing that the duration of STAT3 activity determines 
the differing biological responses to IL-6 and IL-10 (Yasukawa et al., 2003). This was 
confirmed by studies demonstrating an anti-inflammatory response using modified leptin and 
erythropoietin receptors which could activate STAT3 but not bind SOCS3 (El Kasmi et al., 
2006) and by using a constitutively active STAT3 which also mediates an anti-inflammatory 
response (Williams et al., 2007). Thus it seems that regulation of the duration of STAT3 
phosphorylation by SOCS3 determines the outcome of anti-inflammatory cytokine signaling.  
 
 
 
 
Fig 1.8. Inhibition of STAT signaling by SOCS3. SOCS3 expression is induced by cytokines TLR 
ligands and cAMP. SOCS3 blocks STAT3 and STAT1 activation by the IL-6 pathway but does not 
affect IL-10 signalling. SOCS3 therefore inhibits pro-inflammatory IL-6 activity while allowing anti-
inflammatory IL-10 signalling through prolonged STAT3 activation. An unknown protein or proteins 
(x) is thought to be responsible for STAT3 mediated inhibition of pro-inflammatory responses 
induced from TLRs. Taken from Yoshimura et al., 2007. 
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1.3.8 Inhibition of STAT DNA Binding by PIAS 
 
Another group of STAT regulators are the protein inhibitor of activated STAT (PIAS) family. 
PIAS3 was originally found to block STAT3 mediated DNA binding and repress STAT3 
mediated gene transcription without affecting STAT1 and likewise PIAS1 was shown to 
specifically bind to and inhibit STAT1 DNA binding (Chung et al., 1997, Liu et al, 1998). In 
a similar manner to SOCS1 deficient mice, deletion of PIAS1 also led to enhanced IFN 
antiviral responses in vivo (Liu et al., 2004). Proteins which interfere with this PIAS-STAT 
interaction can in turn enhance STAT mediated transcription, for example the proto-oncogene 
Gf1-1 (growth factor independence-1) was found to antagonize the STAT3-PIAS3 interaction 
and overcome  PIAS3 mediated repression of STAT3 target genes (Rodel et al., 2000). 
Interestingly, PIAS1 binding to STAT1 was shown to be inhibited when STAT1 was 
methylated by protein arginine methyl-transferase PRMT1, demonstrating post-translational 
control of STATs in addition to phosphorylation (Mowen et al., 2000).  
 
PIAS proteins have been shown to function as E3-type small ubiquitin-like modifier (SUMO) 
ligases and STAT1 was found to be SUMOylated at Lys703 by PIAS1 and PIAS3 
(Ungureanu et al., 2003). Lys703 SUMOylation appears to be dependent upon prior ser727 
phosphorylation by p38 MAPK and ERK and mutation of the SUMO site was shown to 
enhance IFN-• responsiveness (Vanhatupa et al., 2008, Ungureanu et al., 2003). However a 
separate study found no effect on STAT1 activity following Lys703 mutation (Rogers et al., 
2003). Therefore, in addition to inhibition of JAK/STAT signaling at the receptor site, STATs 
can also be prohibited from binding DNA, demonstrating the multiple levels of control that 
are employed to regulate JAK/STAT responses. 
 
 
1.3.9 Inhibition of STAT3 Nuclear Translocation by GRIM-19 
 
GRIM-19 was originally isolated from an anti-sense mRNA screen of genes involved in 
promoting cell death in response to IFN-• plus retinoic acid and was later found to be a 
component of mitochondrial NADH:ubiquinone oxidoreductase (complex I) (Angell et al., 
2000, Fearnley et al., 2001, Murray et al, 2003). Yeast-two-hybrid screens identified STAT3 
as a GRIM-19 binding protein; this interaction does not affect the initial activation of STAT3 
nor its ability to bind DNA but appears to inhibit STAT3 nuclear translocation, forming 
aggregates with STAT3 at the peri-nuclear region (Lufei et al., 2003, Zhang et al., 2003). 48 
 
GRIM-19 represses STAT3 transcriptional activity but has no effect on other STAT proteins 
and is therefore a specific negative regulator of STAT3. GRIM-19 was shown to suppress 
growth in Src transformed cells which have constitutive STAT3 activity, inhibit cellular 
transformation induced by constitutively  active STAT3 and substantially reduce tumor 
volume in xenografts from STAT3 overexpressing cells (Lufei et al., 2003, Kalakonda et al., 
2007). Therefore GRIM-19 represents a novel inhibitor of STAT3 activity and may have 
important roles in limiting the oncogenic potential of STAT3 in cancer. 
 
 
1.3.10 Non-Transcriptional Regulation of Gene Expression by STATs 
 
Recently RNAi screens in Drosophila  have found interactions between the JAK/STAT 
pathway and chromatin regulators. Shi et al. conducted a genetic screen for modifiers of the 
oncogenic allele of the Drosophila JAK homolog Hop known as tumorous lethal (
-1). They 
identified several chromatin modifying genes such as the non-histone chromosomal  protein 
heterochromatin 1 (HP-1), the histone methyl transferase Su(var)3-9 and the histone 
deacetylase Rpd3 and found that crossing flies deficient in either of these genes with 
-1 flies 
resulted in increased numbers of melanoic tumors (Shi et al., 2006). Moreover, these genes 
are essential components of heterochromatin and over-activity of Hop/JAK was found to 
block heterochromatin-mediated silencing of genes which are not normally regulated by the 
JAK/STAT pathway (Shi et al., 2006). Increasing heterochromatic gene silence via a HP-1 
transgenic completely abolished 
-1
 
  tumorigenicity, suggesting that heterochromatic gene 
silencing is necessary for constitutive JAK mediated tumorigenesis. The Drosophila STAT 
homolog STAT92E was found to bind to HP-1 only when STAT92E was unphosphorylated, 
this association was present in the nucleus where it was responsible for stabalised HP-1 
localisation and histone H3 methylation (Shi et al., 2008). STAT92E phosphorylation led to 
reduced heterchomatin localization, dissociation of HP-1 and heterochromatin destabilization 
suggesting that STAT phosphorylation may therefore regulate access to chromatin. 
Chromatin remodeling through the JAK/STAT pathway has also been shown in human cells. 
Phosphorylation of STAT1 was found to be essential for remodeling of the major 
histocompatibility complex (MHC) locus, where following IFN-• stimulation the chromatin 
carrying the entire locus loops out from chromosome 6 (Christova et al., 2007). Binding of 
STAT1 to the MHC gene engaged recruitment of the chromatin remodeling enzyme BRG1 49 
 
(BRM/SWI2-related gene 1) the ATPase component of the SWI/SNF chromatin remodeling 
complex, followed by binding of RNA polymerase II. A separate study showed that STAT1 
deficient cells expressing a STAT1 S727A mutant had reduced recruitment of the co-factor 
CBP, reduced histone H4 hyperacetylation and decreased RNA polymerase II recruitment to 
the gbp2 promoter following IFN-• stimulation (Ramsauer et al., 2007). STAT3 has likewise 
been shown to be capable  of remodeling chromatin at the p21 promoter through its 
association with BRG1 and cdk9 (Giraud et al., 2004). Taken together these studies highlight 
the emerging role of the JAK/STAT pathway in epigenetic control and demonstrate that 
STATs modulate transcriptional responses on multiple levels.   
 
Unphosphorylated STAT1 has been shown to have other direct effects on gene expression; 
using a Y701F STAT1 mutant, Stark’s group showed that STAT1 could still meditate low 
molecular mass polypeptide (LMP2) expression in the absence of tyrosine phosphorylation  
(Chatterjee-kishore et al., 2000). This was found to be due to unphosphorylated STAT1 
complexing with interferon regulatory factor 1 (IRF1) to induce LMP2 transcription. A 
micro-array study found that cells overexpressing a STAT3 Y705F mutant could up-regulate 
over a thousand transcripts when compared to STAT3 deficient cells (Yang et al., 2005). The 
mechanism of regulation appears to be distinct, since unphosphorylated STAT3 complexes 
with unphosphorylated NF-•B to drive expression of genes that do not respond directly to 
phosphorylated STAT3 (Yang et al., 2007). These studies did not examine epigenetic 
regulation which might be partial responsible for some of the effects, neither was the level of 
serine phosphorylation addressed in this studies. Another question is whether gene expression 
through non-phosphorylated STATs is driven by anti-parallel dimmers. These questions 
notwithstanding, it is intriguing that STAT1 and STAT3 when not tyrosine phosphorylated 
are still capable of mediating gene expression and greatly adds to the complexity of 
JAK/STAT signalling. 
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1.4 The JAK/STAT Pathway and Cardiac Injury 
 
1.4.1  JAK/STAT Signalling– A Key Player in Apoptosis 
 
Both STAT1 and 3 have been shown to play direct roles in controlling cell fate. Darnell’s 
group initially demonstrated that STAT3 could function as an oncogene, was responsible for 
v-Src mediated cellular transformation and could induce tumors in nude mice (Bromberg et 
al., 1998 1999). When STAT3 was deleted specifically from T cells, IL-6 could no longer 
induce  proliferation  nor protect these cells from apoptosis  (Takeda et al., 1998). Clear 
evidence for the anti-apoptotic activity of STAT3 came from a host of studies demonstrating 
that constitutive activation of STAT3 was responsible for apoptotic resistance in tumor cells 
from myeloma, melanoma, mycosis fungoides, head and neck, prostate, ovarian and breast 
cancers. (Catlett-Falcone et al., 1999, Niu et al., 1999, Nielsen et al., 1999, Grandis et al., 
2000, Gao et al., 2001, Garcia et al., 2001, Burke et al., 2001). There has been a lot of recent 
interest in the development of novel inhibitors of STAT3 as possible cancer therapeutics, 
which have been shown to induce apoptosis in cancer cells and slow cancer growth in vivo 
(Leong et al., 2003, Nam et al., 2005, Turkson et al., 2005). Fibroblasts transformed with a 
constitutively active form of STAT3 were resistant to serum withdrawal and UV-induced 
apoptosis and showed cell cycle dysregulation (Shen et al., 2001). These  studies clearly 
established STAT3 as an anti-apoptotic transcription factor and identified several STAT3 
target genes responsible for this effect, including Bcl-2, Bcl-
 
, FLIP, Mcl-1 and survivin as 
well as inhibition of caspase expression (Shen et al., 2001, Epling-Burnette et al., 2001). 
Recently STAT3 has also been shown to inhibit p53 expression, providing another means 
whereby STAT3 controls growth arrest and apoptosis (Niu et al., 2005). 
Although STAT3 is generally thought to be an anti-apoptotic transcription factor, it has been 
shown to be pro-apoptotic under certain circumstances. One notable example of pro-apoptotic 
STAT3 activity is in the involuting mammary gland. STAT3 is highly activated during 
normal mammary gland involution and specific deletion of STAT3 in mammary tissue was 
found to delay involution due to reduced apoptosis (Chapman et al., 1999). One mechanism 
of STAT3-mediated apoptosis during involution is through upregulated IGFBP-5 (Insulin 
growth factor [IGF] binding protein-5) which sequesters the pro-survival factor IGF-1 to 
casein micelles (Chapman et al., 1999). During  involution, activity of the anti-apoptotic 
kinase Akt is normally downregulated, however Akt downregulation fails to occur in STAT3-51 
 
deficient mammary glands (Abell et al., 2005). This was accompanied by reduced expression 
of the phosphoinositide-3-OH- kinase (PI(3)K) subunits p50• and p55• but with no change in 
the p85 subunits, therefore STAT3 promotes a switch in PI(3)K subunit usage which results 
in inhibition of Akt activity and instigation of apoptosis (Abell et al., 2005). This 
phenomenon has also been demonstrated in SOCS3-deficient MEFs, where STAT3 activity is 
greatly prolonged. LIF treatment of SOCS3
-/- 
 
MEFs resulted in STAT3 dependent apoptosis 
which was accompanied by increased p50• and p55• PI(3)K subunit expression and reduced 
Akt activity (Lu et al., 2006). Likewise, SOCS3-deficient mammary glands undergo elevated 
levels of apoptosis during involution, accompanied by elevated STAT3 activity (Sutherland 
et al., 2006, Robinson et al., 2007). Leptin has also been shown to induce apoptosis in 
mammary cells in a STAT3 dependent manner (Motta et al., 2007). The STAT3 target gene 
CCAAT/enhancer binding protein delta (C/EBP•) has been shown to be important in 
transducing a pro-apoptotic STAT3 signal; deletion of C/EBP• in the mammary gland 
delayed involution due to failed induction of several pro-apoptotic mediators, including 
BAX, IGFBP-5 and clusterin (Thangaraju et al., 2005). Apoptosis and involution does 
eventually occur in the STAT3 deficient mice, possibly through a p53 dependent mechanism 
(Matthews and Clarke, 2005). These studies show that STAT3 is capable of promoting 
apoptosis in certain settings and therefore adds to the complexity of STAT signaling during 
apoptosis.  
Early studies on STAT1 mediated apoptosis revealed that STAT1 could induce cell death 
through upregulation of caspase 1 (Chin et al., 1997). STAT1 null cells are resistant to TNF 
induced apoptosis due to defective constitutive expression of caspases 1, 2 and 3, while other 
pro-apoptotic target genes include Fas, FasL, p21 and p53  (Levy and Darnell, 2002). 
Furthermore, following DNA damage, STAT1 acts as a cofactor for p53 and modulates the 
cell-cycle checkpoint response through an ATM-Chk2 pathway  (Townsend et al., 2004, 
2005).  STAT1 can also induce apoptosis through inhibition of the antiapoptotic NF-•B 
pathway. TNF promotes STAT1 binding to the TRADD/TNF receptor complex, this inhibits 
TRADD binding to TRAF2 and RIP and subsequent NF-•B activation (Wang et al., 2000). 
Recently, acetylated STAT1 has been shown to bind to the p65 subunit of NF-•B and inhibit 
NF-•B dependent transcription of anti-apoptotic genes (Kramer et al., 2006). Interestingly in 
fibroblasts,  increased expression of STAT3 inhibited the proapoptotic effects of STAT1, 
suggesting that STAT1 and 3 can act antagonistically to one another to control cell fate (Shen 
et al., 2001). 52 
 
1.4.2 STATs as Mediators of Myocardial Cell Death 
 
STAT1 activity is upregulated in cardiac myocytes following simulated I/R and exacerbates 
cardiac damage through induction of pro-apoptotic STAT1 effectors, such as caspase1, Fas 
and FasL (Stephanou et al., 2000). Support for the role of STAT1 as a pro-apoptotic factor in 
the myocardium comes from studies which show that inhibition of STAT1 activity during I/R 
results in significant cardioprotection. For example, both infusion and oral administration of 
the green tea polyphenol extract epigallocatechin-3-gallate reduced infarct size and caspase 
activity  following I/R in a STAT1 dependent manner (Townsend et al., 2004).  A pro-
apoptotic role has also been ascribed to STAT1 in neuronal ischaemia, STAT1 deficient mice 
show reduced neurological damage following ischaemia and this was associated with reduced 
caspase 3 activity and reduced neuronal cell death (Takagi et al., 2002).  Many of the 
propapototic effects of STAT1 are attributable to the C-terminal domain, with 
phosphorylation at serine 727 being indispensable for I/R induced apoptosis and Fas/FasL 
expression  (Stephanou et al., 2002). Interestingly, S727 phosphorylation of STAT1 is 
necessary for PKC• induced apoptosis following DNA damage (DeVries et al., 2004). The 
proapoptotic effects of STAT1 can be blocked by p38 MAPK inhibition, suggesting cross-
talk between the JAK-STAT pathway and the MAP kinase pathway during I/R injury 
(Stephanou et al., 2001). There is far less data concerning the role of STAT3 in I/R injury in 
the myocardium but some studies have suggested that STAT3 may have cytoprotective roles 
in the heart. STAT3 overexpression  protected mice from doxorubicin induced 
cardiomyopathy and transfection of STAT3 into cardiac myocytes abrogated the proapoptotic 
effects of STAT1 following I/R injury (Negoro et al., 2000, Stephanou et al., 2004). 
 
 
 
1.4.3 JAK/STAT Pathway in Ischaemic Preconditioning 
 
Preconditioning (PC) refers to the administration of transient sublethal episodes of ischaemia 
before a prolonged I/R injury, which renders the heart less susceptible to the deleterious 
effects of I/R mediated damage. PC can reduce infarct size by up to 80%, providing a very 
efficacious adjunctive therapy where reperfusion injury is unavoidable (Xuan et al., 2003). 
PC can be divided into two separate phases, an early phase which occurs immediately after 
reperfusion and lasts for up to 2 hr and a late phase which is sustained for up to 72 hr. Several 
studies from Roberto Bolli’s group and others have recently uncovered the obligatory role of 
the JAK/STAT pathway in mediating the cardioprotective effects of late PC through iNOS 53 
 
and COX-2 induction. Adenoviral mediated gene transfer of iNOS confers a protective effect 
equivalent to that of PC and inhibition of COX-2 abrogates iNOS dependent cardioprotection 
(Xuan et al., 2003, Li et al., 2003). In a mouse model of late PC, JAK1, JAK2, STAT1 and 
STAT3 but not any other members of the JAK/STAT pathway were phosphorylated (Xuan et 
al., 2001). PC induces STAT1 and STAT3 tyrosine phosphorylation through JAK1/2 and 
serine phosphorylation by a PKC•-Raf-MEK-ERK pathway, both of which appear  to be 
necessary for full transcriptional activation of PC associated genes (Xuan et al., 2003, 2005). 
Upregulation of COX-2 by PC was abrogated by  the JAK2 inhibitor AG490 and  PC-
mediated cardioprotection is completely abolished in cardiac specific STAT3
-/-
 
  mice, 
providing clear evidence for a fundamental role for STAT3 in control of cell survival by PC 
(Xuan et al., 2001, Smith et al., 2004). Interestingly, IL-6 may be a major cytokine involved 
in this process, since late PC affords no cardioprotection in IL-6 deficient mice (Dawn et al., 
2004). NF-•B activity is also necessary for late PC and may act synergistically with the 
JAK/STAT pathway to upregulate iNOS (Yuan et al., 1990). 
STAT3 also seems to serve as a focal point for TNF-• mediated preconditioning, since 
STAT3 inhibition abolishes TNF-• induced cardioprotection, data which is suggestive of a 
crosstalk between the TNF-•-NF-•B -STAT pathways (Lecour et al., 2005, Smith, 2002). 
STAT3 also plays a role in early PC, inhibition of STAT3 activity with the JAK2 inhibitor 
AG490 was found to abrogate the infarct sparing effects of PC through increased apoptosis 
associated with reduced expression of Bcl-2 and increased expression of Bax (Hattori et al., 
2001). These studies therefore place the JAK/STAT pathway at the centre of this exciting 
cardioprotective intervention and further research into its precise molecular control may serve 
to refine the process and contribute to its development as an established therapy for I/R 
injury. 
 
 
1.4.4 Role of STAT1 and 3 in Hypertrophy and Angiogenesis 
 
Since cardiac myocytes are a terminally differentiated cell type, myocyte death can have a 
severe effect on cardiac output, as these cells cannot be efficiently replaced. As a result of 
this imbalance, the heart seeks to compensate for the reduced cardiac output through a 
process called hypertrophy, in which cardiac myocytes enlarge and increase metabolic output 
to compensate for the increased workload now required from a fewer number of cells (Frey et 
al., 2004). Hypertrophy is initially compensatory and reduces wall stress and oxygen 54 
 
consumption, which serves to maintain normal cardiac output, however if biomechanical 
stress remains chronic due to hypertension or myocardial infarction, over time chamber 
dilation and remodelling ensues and cardiac function declines which may ultimately lead to 
heart failure (Frey et al., 2004). Progression to heart failure is determined by a fine balance 
between compensatory hypertrophy and cardiac myocyte apoptosis.    
Acute pressure overload and mechanical stress have been shown to activate JAK1, JAK2, 
TYK2, STAT1, 2 and 3, while members of the IL-6 family of cytokines (including CT-1, LIF 
and IL-6 itself)  which utilize the JAK/STAT pathway have come to the fore as potent 
mediators of hypertrophy (Pan et al., 1999). IL-6 family cytokine receptors consist of a ligand 
binding receptor and a common non ligand binding transducer, gp130. Binding of IL-6 
family cytokines induces homo or heterodimerisation of gp130 which subsequently activates 
JAK/STAT and Ras-ERK1/2 pathways. Constitutive activation of gp130 in a transgenic line 
overexpressing IL-6 and the IL-6R potently induced hypertrophy and gp130 has also been 
shown to promote hypertrophy in human cardiac cells (Horota et al., 1995, Ancey et al., 
2003). Mice where gp130 has been knocked out in the myocardium have normal cardiac 
structure and function.  However these mice fail to develop compensatory hypertrophy 
following acute pressure overload and instead develop dilated cardiomyopathy (Hirota et al., 
1999). After seven days of pressure overload, 90% of the gp130
-/-
 mice died
 
Transgenic mice which overexpress STAT3 in the myocardium show signs of hypertrophy by 
12 weeks of age, their hearts display enlarged left ventricles, increased cardiac myocyte cell 
width and expression of the hypertrophic genes • myosin heavy chain (•-MHC) and ANF 
(Kunisada  et al., 2000). gp130-induced hypertrophy is tightly controlled by a negative 
feedback loop where STAT3 activity induced by hypertrophy is temporally limited though 
upregulation of SOCS3, a potent negative regulator of JAKs which allows tight regulation of 
hypertrophy programme (Yasukawa  et al., 2001). These studies show that IL-6 family 
cytokines may prevent heart failure through inhibition of apoptosis and induction of 
due to extensive 
myocyte apoptosis, suggesting that gp130 is critical in the transition from compensatory 
hypertrophy to heart failure. gp130 transduces its signal mainly through induction of STAT3, 
indeed gp130 deficient mice failed to induce STAT3 in response to pressure overload which 
may account for the increased levels of apoptosis. Inhibition of STAT3 abolishes gp130 
mediated hypertrophy and inhibits LIF dependent induction of the hypertrophic genes c-fos 
and atrial natriuretic factor (ANF) (Kunisada et al., 1998).  55 
 
compensatory hypertrophy, mediated through gp130 and STAT3. Interestingly, it has been 
reported that patients with end stage dilated cardiomyopathy have enhanced STAT3 protein 
expression and tyrosine phosphorylation (Podewski et al., 2003). A schematic of the known 
roles of STAT1 and STAT3 in cardiac pathology is outline in Fig 1.9. 
 
 
Fig 1.9. Outlined roles of the JAK/STAT pathway in cardiac pathology. In the heart, I/R injury, 
mechanical stress and inflammation lead to the  activation of JAKs and MAPKs which mediate 
tyrosine and serine phosphorylation of STAT1 and STAT3. STAT1 upregulates genes involved in 
apoptosis such as capase-1, FAS and p53. STAT3 transactivates cardioprotective genes, hypertrophic 
genes and genes involved in angiogenesis. 
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1.5 Urocortins 
 
1.5.1 The Urocortin Family 
 
Urocortins are 40 amino acid peptide members of the corticotrophin-releasing factor (CRF) 
family. Urocortins are widely expressed in the heart, CNS, gut, skeletal muscle, skin and 
immune system and have roles in inflammation, gut motility, appetite, neuronal activity and 
the cardiovascular system (Latchman, 2002). There are three members; urocortin I (Ucn1), 
urocortin 2 (stresscopin related peptide, SRP) and urocortin 3 (stresscopin, SCP). The actions 
of urocortins are mediated through two G-protein coupled receptors, CRF-R1 and CRF-R2; 
Ucn1 binds both receptors while Ucn2 and Ucn3 only bind to CRF-R2 (Boonprasert et al., 
2008).  
 
 
1.5.2 Urocortins and Heart Failure 
 
Cardiac expression of Ucn1 is increased during hypoxia and hypertrophy and circulating 
Ucn1 levels are elevated in patients suffering from heart failure (Ng et al., 2004). Ucn1 
infusion in humans leads to elevated ACHT and cortisol levels and the effects of Ucn1 on the 
cardiovascular system include vasodilatation, increased blood flow, elevated heart rate and 
positive chronotropic and ionotrophic effects (Parkes et al., 1997). Ucn1 administration has 
beneficial effects in experimental heart failure, including increased cardiac output, reduced 
peripheral resistance and decreased circulating levels of the vasoconstricting hormones 
angiotensin II, vasopressin and endothelin-1 (Rademaker et al., 2002). Ucn1 also lowers 
mean arterial pressure and circulating levels of ANP and BNP and continuous infusion 
significantly delays the onset of heart failure (Rademaker et al., 2005, 2007). Ucn2 and Ucn3 
also have beneficial cardiovascular activity. Ucn2 increases contractility in rabbit ventricular 
myocytes and reduces diastolic pressure and increases left ventricular ejection fraction and 
cardiac output in a mouse heart failure model, effects which were absent in CRF-R1 deficient 
mice (Bale et al., 2004). Likewise, Ucn3 increases cardiac output and peripheral resistance in 
ovine heart failure (Yang et al., 2006, Rademaker et al., 2005). Blocking CRF-R2 in an ovine 
heart failure model lead to increased arterial blood pressure and peripheral resistance as well 
as increased rennin and aldosterone levels, suggesting that endogenous urocortins serve a 
beneficial purpose during heart failure (Rademaker et al., 2005). 57 
 
1.5.3 Urocortins and Ischaemia 
 
As well as having roles in heart failure, urocortins have been shown to be beneficial in I/R 
injury. Our group has previously shown that Ucn1 could protect cultured cardiac myocytes 
from I/R injury in vitro and reduce infarct size and enhance cardiac function ex vivo (Brar et 
al., 2000, Scarabelli et al., 2002). Importantly, Ucn1 can protect the heart when added just 
prior to reperfusion, making it attractive as a possible therapeutic (Schulman et al., 2002). 
Ucn1 reduced CPK release, decreased the numbers of cleaved caspase-3 positive cells and 
helped maintain the reserves of high energy phosphates during I/R injury ex vivo (Scarabelli 
et al., 2002). Ucn1 is hypotensive in vivo, however, administering urocortin during 
experimental I/R in vivo reduces infarction size, lowers MAP and reduces incidences of 
ventricular tachycardia and fibrillation (Schulman et al., 2002, Liu et al., 2005). In agreement 
with a protective role for urocortins in the myocardium, deletion of the urocortin receptor 
CRF-R2 leads to increased susceptibility to I/R injury (Brar et al., 2004). Treatment of 
cardiac myocytes with urocortins leads to activation of the MEK1/2-ERK1/2 and PI(3)K-Akt 
pathways, both of which appear to be necessary for fully fledged cardioprotection by 
urocortins (Chanalaris et al., 2003, Brar et al.,  2002).  Interestingly, protein synthesis is 
required for cardioprotection by urocortins, suggesting that proteins downstream of ERK1/2 
and Akt mediate cardioprotection (Lawrence et al., 2002.)  Several of these downstream 
mediators have recently been identified. Ucn1  upregulates the expression of the Kir 6.1 
potassium channel subunit and inhibition of K(ATP) channels abrogates urocortin’s 
protective effect, urocortin also downregulates the calcium-insensitive phospholipase A2 
enzyme (Lawrence et al
 
., 2002, 2003). Mitochondrial translocation of PKC• also appears to 
be necessary for Ucn-I mediated cardioprotection, co-administration of a PKC• translocation 
inhibitor abrogated the ability of urocortin to maintain mitochondrial membrane integrity and 
protect from apoptosis during I/R (Lawrence et al., 2004, 2005).  
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1.6 Mitochondrial Transport 
 
1.6.1 Import into the Mitochondria 
 
In the heart, mitochondria account for almost 40% of total cardiac myocyte volume and are 
responsible for generating over 90% of the cell’s energy (Mcleod et al., 2003). Almost 99% 
of all mitochondrial proteins are synthesised in the cytosol and need to be transported to the 
mitochondria to maintain mitochondrial biogenesis. Up to 10-15% of all nuclear genes in 
eukaryotes code for mitochondrial proteins and these proteins must be translocated into the 
mitochondria and inserted into one of four compartments;  the outer membrane, 
intermembrane space (IMS), inner membrane or matrix (Neupert and Herrmann., 2007, 
Yamano et al., 2007). The majority of mitochondrial proteins contain an N-terminal 
presequence which is recognised by components of the mitochondrial import machinery 
(Yamano et al., 2007). The presequence is recognised by the translocase of outer 
mitochondrial membrane (TOM) complex which inserts proteins into the intermembrane 
space or passes the polypeptides to the translocase of inner mitochondrial membrane (TIM) 
complex for insertion into the matrix (Wiedemann et al., 2007). Once mitochondrial 
precursor polypeptides have been correctly imported, the pre-sequence is cleaved by 
mitochondrial processing peptidease (MPP), generating the mature protein that  is 
subsequently folded into its correct confirmation.  
 
1.6.2 The TOM Complex 
 
The TOM complex is responsible for transport of almost all mitochondrial proteins and 
consists of seven separate subunits. The receptor component of the TOM complex is 
comprised of Tom70, Tom20 and Tom22 (Fig 1.10). Tom70 and Tom20 can bind separate 
motifs but also have certain overlapping functions (Endo and Kohda, 2002). The N-terminal 
of Tom20 is anchored to the outer membrane, allowing the cytosolic C-terminal domain of 
the receptor to bind to pre-sequence containing proteins (Yamano et al., 2007). Tom70 on the 
other hand recognises proteins containing an internal targeting sequence which are destined 
for the inner membrane.  Tom22 connects Tom20 to the translocation pore and cooperates 
with Tom20 in pre-sequence binding (Neupert and Herrmann, 2007). The main pore forming 
subunit of the TOM complex is Tom40 and is associated with the stabilising proteins Tom5, 
Tom6 and Tom7 (Fig 1.10) (Kato and Mihara, 2008).  
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Ott et al. recently showed that the TOM complex is obligatory for Bax insertion into the 
mitochondrial outer membrane (Ott et al., 2007). By using a temperature sensitive Tom40 
mutant yeast strain or by pre-incubating isolated mitochondria with antibodies against Tom20 
or Tom22 they showed decreased release of cytochrome c into the cytosol in response to 
tBid/Bax treatment. Moreover, they were able to demonstrate using immunoprecipitation that 
Tom40 interacts directly with Bax in a transitory manner. Bellot et. al demonstrated that 
Tom22 also interacts with Bax in a transient manner and confirmed that inhibition of Tom22 
leads to a reduction in Bax dependent apoptosis (Bellot et al., 2007). Thus it seems that the 
TOM complex is essential for Bax mediated apoptosis and therefore the TOM complex may 
play an important role in controlling cell fate. 
 
 
 
Fig 1.10 .The mitochondrial import Machinery. Components of the TOM, TIM and SAM 
complexes are shown. Arrows indicate the directional flow of proteins to their designated 
mitochondrial compartments. Stars indicate proteins that have been show to be essential for yeast 
viability. PAM – protein import motor, MPP - mitochondrial processing peptidease, IMP - inner 
membrane peptidase. Taken from Dolezal et al., 2006. 
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1.6.3 The TIM22/TIM23 Complex 
 
Once proteins have passed through the TOM complex they are passed to one of two inner 
membrane transport machines known as the TIM22 and TIM23 complexes. Proteins destined 
for the matrix, and many which are destined for the IMS are  transported by the TIM23 
translocase, while proteins destined for the inner membrane are routed by the TIM22 
complex (Fig 1.10) (Koechler, 2004). The TIM23 complex is composed of the pore forming 
Tim23 channel, the Tim17 regulatory subunit and Tim50. Mitochondrial polypeptides first 
bind to Tim50 which in turn passes them to Tim23; Tim50 regulates the opening and closing 
of the channel and Tim17 helps to determine whether the substrates are inserted into the inner 
membrane or transported to the matrix (Meinecke et al., 2006, Chakinska et al., 2005). Tim44 
on the inner membrane binds to mitochondrial HSP70 (mtHSP70) and recruits it to the 
TIM23 complex where it binds to the incoming unfolded proteins (Moro et al., 2002). The 
energy needed to transport proteins is provided by ATP hydrolysis which causes mtHSP70 to 
dissociate from Tim44 and bind to the incoming protein; successive rounds of mtHSP70 
binding enable complete translocation of the precursor protein (Liu et al., 2003). 
 
The TIM22 complex is composed of the inner membrane proteins Tim22, Tim54 and Tim18 
and is responsible for import of members of the solute carrier family and a number of small 
Tim proteins destined for integration into the inner membrane (Jensen and Dunn, 2002). 
Unlike the TIM23 complex, the TIM22 machinery does not require ATP, instead the motor 
energy is provided solely by inner membrane electrical potential (Dolezal et al., 2006). 
Transport through the TIM22 complex is aided by a family of so-called tiny-Tim proteins 
which guide hydrophobic precursors across the intermembrane space and include Tim8, 
Tim9, Tim10, Tim12 (Koehler, 2004). The tiny-Tims have varying substrate specificities; for 
example, transport of Tim23 through the TIM22 complex requires Tim8 and Tim13, while 
transport of carrier proteins requires Tim9 and Tim10 (Paschen et al., 2000). The importance 
of this import pathway is underscored by the finding that mutations in Tim8 (also known as 
deafness-dystonia polypeptide 1 - DDP1) causes deafness dystonia syndrome (also known as 
Mohr-Tranebjaerg Syndrome) with symptoms including deafness, blindness and mental 
retardation (Jin et al., 1996). The mutation in Tim8 prohibits its binding to Tim13 and thus 
biogensis of Tim23 is compromised which leads to the neurodegeneration seen  in this 
condition (Paschen et al., 2000). 
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1.6.4 The SAM Complex 
 
The outer membrane of the mitochondria contains many •-barrel proteins such as the voltage-
dependent anion channel (VDAC), Tom40 and Mdm10 (mitochondrial disruption and 
morphology 10). These •-barrel proteins require a different sorting route to other 
mitochondrial proteins and this is provided by the sorting and assembly machinery (SAM) 
complex (also known as the translocase of outer membrane •-barrel proteins - TOB). The 
SAM complex is functionally coupled to the TOM complex and consists of the channel 
forming Sam50 (Tob55), the •-barrel receptor Sam35 (Tob38) and Sam37 (Tob37) (Fig 1.10) 
(Kutik et al., 2008).  Along with Tom40, Sam50 and Sam35 are the only mitochondrial outer 
membrane proteins essential for cellular viability (Milenkovich et al., 2004, Dolezal et al., 
2006). The mammalian homologs of Sam35 and Sam37 have been identified as metaxin 1 
and metaxin 2 respectively (Armstrong et al., 1999). 
 
 
 
1.7 The DNA Damage Response 
 
1.7.1 Double Strand Breaks 
 
DSBs occur naturally as a facet of normal cellular function, for example through meiosis 
mediated genome rearrangements, through physical stress during mitosis, during V(D)J 
recombination in lymphocytes and through endogenous ROS damage (Shrivastav et al.,  
2008). DSBs are also generated by external DNA damaging agents such as UV, ionizing 
radiation (IR) and cancer chemotherapeutics such as topoisomerase inhibitors. Failure to 
correctly repair DSBs can lead to chromosomal instability and cancer, therefore cells have 
developed sophisticated systems to detect DSBs and repair the damaged DNA. Once a DNA 
lesion has been induced, the DNA damage response (DDR) machinery is activated, resulting 
in cell cycle arrest via a series of DNA damage checkpoints. This allows the cell time to 
repair the lesion or alternatively when there are too many lesions to repair, initiate the 
apoptotic cascade (d’Addia di Fagagna, 2008). 
 
 
1.7.2 Initiation of the DNA Damage Response: ATM and H2AX 
 
Following the generation of DNA double strand breaks (DSBs) the MRN complex is 
recruited to the site of damage. The MRN complex is composed of Nbs1 (Nijmegen breakage 62 
 
syndrome  1), Mre11 (meiotic recombination 11) and Rad50 and is essential in sensing 
damaged DNA (Hopfner et al., 2002). Mre11 possesses both exo- and endonuclease activities 
which participate in unwinding the DNA, in addition Mre11 binds both Rad50 and Nbs1 and 
holds them together in a complex (Rupnik et al., 2008). Rad50 is responsible for holding the 
broken ends of the chromosome together and Nbs1 regulates binding of several downstream 
DNA repair proteins (Rubnik et al., 2008). While the broken DNA ends are being held in 
place, a signalling cascade is initiated to recruit other members of the DDR to the required 
area. (Fig 1.11). Once the MRN complex is attached to the broken DNA, Nbs1 binds the 
PI3K-related serine/threonine kinase ataxia-telangiectasia mutated  (ATM) (Uziel et al., 
2003). This has recently been shown to be achieved through the generation of ssDNA oligos 
by the exonuclease activity of Mre11 which act as a signal for ATM recruitment and 
activation (Jazayeri et al., 2008). ATM is inactive in normal cells, residing as a dimer in a 
mulimeric complex and upon recruitment by Nbs1, ATM undergoes auto-phosphorylation on 
serine 1981, leading to dimer dissociation and ATM activation (Bakkenist and Kastan, 2003). 
ATM phosphorylates a plethora of targets which participate in the DDR including H2AX, 
Chk2, p53, BRCA1, SMC1, Artemis and Nbs1, ATM activation therefore causes cell cycle 
arrest at the G1/S, intra-S and G2/M checkpoints and facilitates DNA repair (Lee and Paull, 
2007). Mutations in the ATM gene cause the inherited disorder Ataxia-telangiectasia (A-T) 
which is characterized by cerebellar ataxia, immunodeficiency and increased risk of cancer 
(Savitsky et al., 1995).  
 
The key step in the ATM signal transduction cascade appears to be phosphorylation of the 
histone protein H2AX at serine 139. •H2AX (the phosphorylated form of H2AX) recruits 
additional ATM monomers, resulting in a positive feedback loop and this amplification leads 
to a spread of •H2AX over a several hundred kilobase region around the site of the double 
stranded DNA break (Burma et al., 2001). This event generates a molecular beacon which 
recruits the entire downstream apparatus of the DDR (Fig 1.11). Cells from H2AX deficient 
mice show genomic instability and radiation-induced chromosomal aberrations, underscoring 
the central role of H2AX in the signalling and repair of DSBs (Celeste et al., 2002). Recently, 
H2AX has been shown to be regulated by post-translational modifications other than 
phosphorylation. Ikura et al. showed that ionizing radiation lead to H2AX acetylation by the 
histone acetyl transferase Tip60, this was followed by ubiquitination of H2AX by Ubc13 and 
subsequent release of H2AX from damaged chromatin (Ikura et al, 2007). H2AX 
phosphorylation may also influence chemoresistance; radiosensitive tumors were shown to 63 
 
retain •H2AX activity for longer than radioresistant tumors and a peptide mimicking the 
carboxy terminaly tail of H2AX increased cell death in irradiated radioresistant tumor cells 
(Tanega et al., 2004). In addition to its role in the DDR, H2AX is also involved in apoptosis. 
UVA irradiation leads to phosphorylation of H2AX by JNK and this was found to be 
essential for DNA fragmentation mediated by caspase-activated DNase (CAD) (Lu et al., 
2006). H2AX deficient cells have also been shown to have a greater sensitivity to the 
topoisomerase II inhibitor etoposide (Dona et al., 2008) 
 
 
Fig 1.11. Schematic of the DNA damage response. (A) Following DNA damage, the MRN complex 
is recruited to the site of the DSB, PARP1 attaches ADP-ribose units to chromatin-bound proteins. (B) 
The MRN complex binds to the broken DNA and holds the ends together, NBS1  interacts with 
•H2AX and Mre11 which signals further recruitment of the MRN complex. Autophosphorylation of 
ATM leads to activation of downstream components of the DDR pathway. (C) MDC1 is recruited by 
•H2AX, MDC1 then recruits repair proteins such as BRCA1 and its binding partner CtIP are recruited 
to the broken ends and begin the repair process. (D) Model of the role of the MRN complex in 
activation of ATM. Taken from Rupnik et al., 2008. 
 
 
   64 
 
 
DNA is repaired in two ways; non homologous end joining (NHEJ) and homologous 
recombination (HR). Breaks produced by collapsed replication forks are primarily repaired 
by HR whereas NHEJ repairs breaks when the homologous sister chromatid cannot be 
located due to condensed chromatin (Shrivastav et al., 2008). NHEJ proceeds in a stepwise 
manner, the broken DNA end is processed by the MRN complex followed by binding of 
Ku70 and Ku80. Next the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is 
recruited to the DSB and undergoes autophosphorylation and in turn phosphorylates DNA 
Ligase IV which completes the repair (Adachi et al., 2001). H2AX has been shown to 
modulate  both the HR and nonhomologous end joining NHEJ  pathways of DSB repair 
(Bassing et al., 2002). 
 
Single stranded breaks are formed by replicative stress and UV radiation and result in a 
distinct signaling cascade; single-stranded DNA-binding protein replication protein (RPA) 
binds the area around the ssDNA break and recruits ATM and Rad3-related protein (ATR) 
(Abraham, 2001). ATR in turn activates a separate signal transduction pathway from ATM, 
however this will not be discussed in detail here since the results presented all deal with 
double stranded breaks.
 
 
 
1.7.3 Amplification of the DNA Damage Response: MDC1 
 
Once the DNA damage signal is initiated it needs to be amplified; this is achieved through the 
mediator of DNA damage checkpoint protein 1 (MDC1). Within minutes of DNA damage 
MDC1 is recruited by •H2AX and becomes phosphorylated in an ATM/Chk2 dependent 
manner (Goldberg et al., 2003). MDC1 is central in recruiting the DNA repair factors 53BP1 
and BRCA1 as well as further recruitment of the MRN complex to the DSB site (Stewart et 
al., 2003). Reduced expression of MDC1 is associated with decreased apoptosis and defective 
intra-S phase and G2/M checkpoints due to reduced Chk1 phosphorylation (Lou Z et al., 
2003, Stewart et al., 2003). Silencing of MDC1 had no effect on •IR mediated activation of 
ATM or •H2AX, however reduced MDC1 levels lead to a more rapid decline in 
phosphorylation of H2AX  (Stucki et al., 2005). Thus MDC1 is dispensable for the initial 
phosphorylation of ATM and H2AX immediately following formation of a DSB, however 
MDC1 is necessary for subsequent amplification of the DDR by further recruiting ATM, 65 
 
resulting in an ATM-MDC1-H2AX positive feedback loop (Lou et al., 2006). Therefore 
MDC1-mediated ATM accumulation at DSBs induces continual phosphorylation of •H2AX 
and maintains the DDR (Stucki  et al., 2005).  MDC1
-/-
 
  mice exhibit deficiencies in 
checkpoint activation and DNA repair, ATM signalling in these mice was found to be 
defective, leading to reduced phosphorylation of Nbs1, Chk1 and Chk2 and insufficient 
activation of the DDR (Lou et al., 2006). MDC1 therefore plays a central role in the DNA 
damage response pathway by amplifying the ATM signal and orchestrating recruitment of 
repair factors to DSBs. Once MDC1 recruits a sufficient amount of ATM, Chk1 and Chk2 
become phosphorylated in an ATM dependent manner and diffuse throughout the nucleus 
spreading the DDR from the site of the break. If the DNA lesion is damaging enough, it thus 
leads to activation of the checkpoint response involving p53 and cell-division cycle 25 
(CDC25) phosphatases. Ultimately lesions that are difficult to repair or persistent will result 
in cellular senescence or apoptosis. 
 
 
1.8 The Innate Immune System 
 
 
1.8.1 Inflammation 
 
The innate immune system is the body’s first line of defense when challenged with a foreign 
object or invading pathogen. Activation of the innate immune system leads to localised 
inflammation at the site of initial contact with the invading microorganism and is 
characterised by dilation of blood vessels, cell trafficking to infected tissue and release of 
inflammatory mediators and chemoatractants. Once they cross the epithelial barrier, invading 
pathogens are recognised by resident tissue macrophages. Activated macrophages release a 
host of cytokines and chemokines which promote the recruitment of neutrophils to the site of 
infection and initially kill invading microorganisms through the release of various reactive 
oxygen and nitrogen species. This is gradually followed by further recruitment of 
macrophages which ingest invading pathogens and secrete more inflammatory mediators, all 
of which contribute to overcoming the initial infection. Mediators of the innate immune 
system also induce upregulation of co-stimulatory molecules  on dendritic cells (DCs), 
resulting in recruitment of cells of the adaptive immune system, necessary when the innate 
immune system cannot overcome the pathogenic challenge. 
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1.8.2 Toll-Like Receptors (TLR)  
 
Detection and response to microbial infection is mediated by a limited number of pattern 
recognition receptors (PRRs) expressed on DCs or macrophages which recognise conserved 
molecular products from bacteria, viruses, fungi and protazoa. This recognition by the innate 
immune system stimulates production of cytokines, type I interferons and chemokines as well 
as promoting DC maturation and ultimately recruitment of the machinery of the adaptive 
immune response (Kawai and Akira, 2005). Mammalian PRRs include a family of receptors 
termed the Toll-like receptors (TLR), so called because of their homology to the Drosophila 
Toll protein, and it is now widely accepted that TLRs are the main architects in controlling 
the innate immune response following infection. Do date, 11 mammalian TLRs have been 
characterised, all of which recognise distinct microbial PAMPs (Fig 1.12). Some TLRs are 
expressed as cell surface receptors and  recognise  structures present on the bacterial cell 
surface, for example TLR4 is a receptor for LPS, TLR2 recognises peptidoglycan and TLR5 
binds flagellin (O’Neill, 2006). Alternatively, TLRs can be expressed in the cytosol in 
endosomal vesicles; these include TLR3 which recognises double-stranded viral RNA, TLR7 
and TLR8 recognise single-stranded viral RNA and TLR9 binds to unmethylated CpG DNA 
motifs of bacteria and viruses (O’Neill, 2004). The diversity of structures to which TLRs can 
bind allows the innate immune system to mount a rapid first line of defense without the need 
to recognise species-specific antigens.  
 
 
 
 
Fig 1.12. TLRs and their cognate ligands.  Table outlining TLRs and their known ligands. On the 
right; a schematic of TLRs recognising molecular patterns associated with pathogens. Adapted from 
Yamamoto et al., 2006. 
 
   
CpG DNA TLR 9
ssRNA TLR 8
ssRNA TLR 7
Diacylated bacterial lipopeptide TLR 6
Flagellin TLR 5
Lipopolysacharide TLR 4
dsRNA (Poly I:C) TLR 3
Peptidoglycan/zymosan TLR 2
Triacylated lipoproteins  TLR 1
CpG DNA TLR 9
ssRNA TLR 8
ssRNA TLR 7
Diacylated bacterial lipopeptide TLR 6
Flagellin TLR 5
Lipopolysacharide TLR 4
dsRNA (Poly I:C) TLR 3
Peptidoglycan/zymosan TLR 2
Triacylated lipoproteins  TLR 167 
 
1.8.3 TLR Adaptors 
 
TLR signalling is propagated through a series of protein-protein interactions between adaptor 
proteins (Fig 1.3). All TLRs apart from TLR3 recruit MyD88 (myeloid differentiation 
primary response gene 88) via MAL/TIRAP (myelin and lymphocyte protein/ TIR domain-
containing adaptor protein) through TIR (translocated intimin receptor) domain interactions, 
binding of MyD88 triggers recruitment and sequential phosphorylation  IRAK4 (interleukin 1 
receptor-associated kinase 4)  and IRAK1, causing them to dissociate from the receptor 
complex and bind to TNF receptor-associated factor 6 (TRAF6) (Dunne and O’Neill, 2005). 
TRAF6 induces TAK1 (TGF-• activated kinase 1) activity and ultimately activation of the 
NF-•B and MAPK pathways, which are the main mediators of cytokine production  (Fig 
1.13). A second MyD88 independent pathway is employed by TLR3 and TLR4 which makes 
use of the adaptor protein TRIF (TIR domain containing adaptor inducing IFN-•) , TRIF 
induces TBK1 (TANK binding kinase 1) and IKK• which phosphorylate the transcription 
factor IRF3, leading to its nuclear translocation and subsequent upregulation of IFN-• (Hoebe 
et al., 2003, Sato et al., 2003). NF-•B and MAPK are also induced via the MyD88 
independent pathway, however activation is delayed, due to the requirement of secondary 
cytokine production via IRF3 (Kawai and Akira, 2005, Yammamoto et al., 2003). The picture 
has now emerged where various pathogens rapidly induce appropriate host responses through 
a limited number of receptors and adaptor molecules, promoting initial pathogenic clearance 
or activation of the adaptive immune response.  
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Fig 1.13. Signalling pathways initiated by TLR stimulation. All TLRs recruit either MyD88 and/or 
TRIF and these in turn recruit IRAK4. A series of protein-protein binding events lead to a complex of 
IRAK4, IRAK1, TRAF6, TAK1, the TAK1 binding proteins TAB1 and TAB2 and the ubiquitilating 
factors UEV1A and UBC13 which modify and activate TRAF6 and TAK1. TAK1 is a mitogen-
activated protein kinase kinase kinase and phosphorylates and MKK3, MKK6 and MKK7 leading to 
subsequent p38 and JNK activity. TAK1 also activates the IKK complex responsible for NF-•B 
activation and pro-inflammatory cytokine production such as TNF-•. In the case of TLR7, TLR8 and 
TLR9, IRAK4 recruitment also leads to TRAF3/6 mediated interferon regulatory factor (IRF) 
activation and upregulation of TNF-•, IFN-• and IFN-•. In addition MyD88 recruitment to the IFN-• 
receptor can activate p38 through mixed lineage kinase-3 (MLK3). The bridging factor MAL 
(MyD88-adaptor  protein like) is responsible for MyD88 recruitment and is regulated by BTK 
(Burton’s tyrosine kinase) and SOCS1. (Taken from O’Neill & Bowie, 2007) 
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1.9 The Adaptive Immune System 
 
 
1.9.1 Antigen Presentation 
 
In contrast to the innate immune system, the antigen-specific adaptive immune system has 
developed to recognise and destroy specific pathogens and develop a lasting immunity to 
individual organisms.  A particular microbial antigen must first be recognised by antigen 
presenting cells (APC) such as dendritic cells, macrophages or B cells, loaded on MHC 
(major histocompatibility complex) molecules and presented to T cells. APCs such as 
dendritic cells reside in the peripheral tissues where they constantly scan their surroundings 
for foreign antigens. Once they come in contact with antigen, they migrate to draining lymph 
nodes where they prime naïve T cells which bear the corresponding antigen-specific TCR (T 
cell receptor) (Randolph et al., 2005). Additional obligatory co-stimulatory signals are 
provided by the interaction of CD28 on the T cell with CD80 or CD86 on APCs (Randolph et 
al. 2005).  
 
 
1.9.2 CD8 Cells 
 
Activated T cells form two distinct classes, CD8
+ and CD4
+. CD8
+ T cells recognise antigen 
loaded on MHC class I molecules and attack predominantly virally infected cells or cells 
harboring intracellular bacteria. Activated CD8
+
 
 T cells are also known as cytotoxic T cells, 
once they recognise antigen on an infected cell they can directly induce apoptosis by 
secreting cytotoxic granules such  as perforin and granzyme or through FASL-FAS 
interactions (Bevan, 2004). Triggering the apoptotic programme has a select advantage in that 
it does not damage neighboring non-infected cells.  
 
1.9.3 CD4 Cells and Th1/Th2/Th17 Differentiation 
 
CD4
+ 
 
helper T cells (Th) recognise specific MHC class II – peptide complexes on APCs. 
Once the antigen is recognised by the naïve Th cells and the Th cell receives co-stimulation 
from APCs, they begin produce IL-2, undergo proliferation and differentiate into three main 
classes of armed effector Th cells with distinct gene expression patterns. These three Th cell 
subsets known as Th1, Th2 and Th17 perform distinct functions in the immune system.  70 
 
Th1 cells promote cell-mediated immunity and produce cytokines such as IL-2, IFN-• and 
lymphotoxin-• (LT-•)  (Murphy and Reiner, 2002). These cytokines promote CD8 T cell 
proliferation and differentiation, activate macrophages, neutrophils and natural killer (NK) 
cells and stimulate the production of opsonizing and complement-activating antibodies for 
enhanced attachment during phagocytosis  (Szabo et al., 2003). IFN-• stimulation of 
macrophages increases their production of toxic oxygen radicals, nitric oxide, and hydrolytic 
lysosomal enzymes, enabling the killing of microbes within their phagolysosomes, it also 
stimulates production of TNF-•, IL-1• and IL-12 (Angello et al., 2003).  
 
Th2 cells produce IL-4, IL-5, IL-9, IL-10 and IL-13, collectively these cytokines induce B 
cell differentiation into antibody secreting plasma cells (Mowen and Glimcher, 2004). They 
also promote antibody class switching which induces mast cell degranulation, this is critical 
in parasite killing since the majority of extracellular parasites are too large to be ingested by 
phagocytes (Mowen and Glimcher, 2004). Moreover, Th2 cells are central players in allergy 
and promote eosinophilic responses, Th2 cells can also counteract a strong Th1 response via 
production of the anti-inflammatory cytokine IL-10 (Fiorentino et al., 1991).  
 
Th17 cells are a pro-inflammatory subset associated with host defence  against infectious 
agents and auto-immune disease (Dong, 2008). Production of IL-23 stimulates the 
proliferation of Th17 cells which secrete IL-17A, IL-17F and IL-21; these cytokines then 
promote further recruitment of macrophages and neutrophils to areas of infected issue (Dong, 
2008).  IL-17 has been shown to have roles in several inflammatory diseases such as arthritis, 
colitis and multiple sclerosis (Rohn et al., 2006, Komiyama et al. 2006). 
 
The class of effector cell generated depends on the nature of the invading pathogen, for 
example, intracellular bacteria and viruses promote development of a Th1 dominated 
response, whereas allergens and extracellular parasites are strong inducers of Th2 responses. 
Differentiation into Th1, Th2 or Th17 is established during the priming phase of an immune 
reaction and depends on the cytokine profile produced by cells of the innate immune system; 
IL-12, IL-18 and IFN-• promote Th1 cell production, IL-4 and IL-25 induce a Th2 phenotype 
and TGF-•, IL-6 and IL-21 prime Th17 cells (Fig 1.14). TLR ligands can also influence 
generation of effector T cell lineages; TLR2 ligands  favour  Th2 responses and IL-10 
production, whereas TLR4, 5 and 9 promote Th1 differentiation (Schnare, 2001). 
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Fig 1.14. Outline of T-helper cell differentiation.  Naïve CD4
+
 
  T cells are activated by co-
stimulatory molecules such as CD28 and inducible T-cell co-stimulator (ICOS). Activated T cells 
differentiate down three lineages; Th1, Th2 or Th17. IL-12 stimulates Th1 cells which produce IFN-•, 
secretion of IFN-• is important in antigen presentation and cellular immunity. Th2 cells are stimulated 
by IL-4 and produce IL-4, IL-5, IL-10, and IL-13 which have roles in B cell production and allergic 
responses. TGF-• and IL-6 stimulate the production of Th17 cells which produce IL-17, IL-17F, IL-
21 and IL-22 - cytokines important in pro-inflammatory responses. Taken from Dong C, 2008.   
 
 
1.10 Cytokines 
 
 
1.10.1 TNF 
 
TNF is a potent pro-inflammatory cytokine which has many pleitrophic effects including 
leukocyte and lymphocyte activation and migration, activation of endothelial cells with 
upregulation of adhesion molecules and chemokines, recruitment of neutrophils through 
extravisation from the blood stream to the site of infection, fever the acute phase response 
and apoptosis (Bradley, 2008). TNF-• is a potent inducer of AP-1 and NF-•B transcription 
factors, which are important in cytokine, chemokine and adhesion molecule upregulation. 
 
 
 
1.10.2 IL-10 
 
The immune system has evolved multiple ways to limit the duration of the inflammatory 
response; one of the main ways this is achieved is through production of anti-inflammatory 
cytokines such as IL-10. IL-10 is produced from macrophages, DCs, B cells and CD4
+ Th2 72 
 
cells. IL-10 inhibits macrophage activation, resulting in reduced levels of TNF-•, IL-1, IL-6, 
IL-12, COX-2, iNOS and several chemokines (Couper et al., 2008). IL-10 has been shown to 
reduce antigen presentation by macrophages and DCs by abrogating MHC class II, CD80 and 
CD86 expression (Couper et al., 2008). Furthermore, IL-10 suppresses Th1 function through 
inhibition of IL-12, this in turn reduces IFN-• and LT-• secretion from Th1 cells (Haddad et 
al., 2003). The importance of IL-10 as a modifier of immune function is underscored by the 
fact that many tumors acquire an IL-10 secreting phenotype which allows them to circumvent 
cell-mediated immunity (Williams et al., 2004). Moreover, IL-10
-/- 
 
mice develop spontaneous 
intestinal inflammation when housed under specific pathogen free conditions, these mice 
remain healthy when housed under gnotobiotic conditions, suggesting that IL-10 is involved 
in regulating host responses to the intestinal flora (Sellon et al., 1998, Berg et al., 1998). IL-
10 has been shown to limit pathological inflammation in several disease models, including 
inflammatory bowel disease (IBD), septic shock, experimental autoimmune 
encephalomyelitis (EAE) and collagen-induced arthritis (Williams, 2004).  
STAT3 has been shown to be essential for IL-10 mediated anti-inflammatory effects in 
macrophages. Removal of STAT3 binding sites in the IL-10 receptor abrogated the ability of 
IL-10 to suppress LPS-mediated TNF-• production (Riley et al., 1999). The anti-
inflammatory effects of STAT3 are abrogated by cyclohexamide, suggesting that either 
STAT3 dependent target genes are required or that STAT3 titrates away cofactors from 
inflammatory gene promoters (Murray, 2005). Macrophage or endothelial cell-specific 
STAT3 knockout mice develop colitis similar to that seen in IL-10
-/-
 
 mice (Welte et al., 
2003). One candidate that has emerged as a potential mediator of IL-10 signalling is the 
STAT3 target protein Bcl-3, a member of the I•B family. Lentiviral mediated overexpression 
of Bcl-3 inhibited TNF-• production from LPS stimulated macrophages, while IL-10 could 
not suppress TNF-• production from macrophages deficient in Bcl-3 (Kuwata et al., 2003).  
Bcl-3 was shown to bind to the p50 and p52 subunits of NF-•B and enhance p50 mediated 
inhibition of TNF-• by binding to the TNF-• promoter (Kuwata et al., 2003). As discussed 
earlier, SOCS3 serves as a main regulator of STAT3 signaling and determines whether 
STAT3 induces a pro- or anti-inflammatory signal. 
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1.10.3 IL-12 
 
IL-12 is a potent pro-inflammatory cytokine secreted by several cell types. It consists of two 
subunits; p35 and p40, encoded by two unrelated genes on separate chromosomes which form 
a functional p70 heterodimer (Kang et al., 2005). IL-12 is secreted by macrophages, DCs, 
neutrophils and mast cells among others and promotes production of IFN-•, TNF-•, IL-2, IL-
8 and GM-CSF from T cells and NK cells. It increases cell mediated cytotoxicity in CD8
+ 
 
T 
cells and NK cells by increasing the formation of cytotxic granules and upregulates adhesion 
molecule expression (Kang et al., 2005). IL-12 is the main stimulator of Th1 polarisation and 
along with IFN-• antagonises Th2 differentiation. 
When IL-12 is present early during clonal expansion, it irreversibly primes CD4
+
 and CD8
+
 
 T 
cells to produce high levels of IFN-• upon restimulation (Trinchieri et al., 2003). T cells 
enhance IL-12 not only through IFN-• and IL-4 production but also through direct cell 
contact, priming DCs with a bacterial stimulus upregulates CD40 and makes them responsive 
to CD40L expressed on T cells, allowing optimal IL-12 production (Trinchieri et al., 2005). 
IL-12 is negatively regulated by several cytokines; including IL-10 and TGF-•, indeed IL-12 
may limit its own synthesis by inducing T cells to secrete IL-10 (Meyaard et al., 1996). IL-10 
has been shown to inhibit IL-12p40 transcription by inhibiting cRel recruitment to the IL-
12p40 promoter in a STAT3 dependent manner (Hoentjen et al., 2005). Overproduction of 
IL-12 can have detrimental consequences as evidenced in IL-10 deficient mice which develop 
an IL-12 mediated intestinal inflammation (Davidson et al., 1998). 
 
 
1.11 MAPK Signalling in the Innate Immune System 
 
 
1.11.1 Upstream Signals 
 
Innate immune signals received through TLRs result in the activation of two main pathways, 
the NF-•B pathway and the MAPK pathway. The MAPKs are an evolutionary conserved 
family of Thr/Tyr kinases with vast numbers of substrates and as such are involved in a wide 
range of biological processes. They are activated in response to a large variety of signals; 
including inflammatory cytokines, ischaemia, DNA damage, oxidative stress, heat shock and 
growth factors. Their function is to transduce signals from the extracellular environment to 
regulatory elements within the cell. There are three major groups of MAPKs, the c-Jun NH2-74 
 
terminal kinases (JNK), the p38 MAPKs and the extracellular signal-regulated kinases 
(ERK). MAPKs are proline-directed serine/threonine kinases and are activated by dual 
phosphorylation at a Thr-X-Tyr motif. MAPK activation is controlled by a three-tier protein 
kinase cascade, where MAPK are phosphorylated by a MAP kinase kinase 
(MEK/MKK/MAP2K), these in turn are activated by MKK kinases 
(MKKK/MEKK/MAP3K)  (Fig 1.15)  (Chang and Karin, 2001). The choice of proteins 
involved in each signalling module confers a level of adaptability and complexity to the 
control of MAPK signalling cascades. The diverse cellular stresses which produce a varied 
number of cellular responses, controlled by just a few MAPKs illustrates an underlying level 
of specificity to each signalling module. 
 
 
 
 
Fig 1.15. The MAPK signaling cascade. MAPK signaling is controlled by a cascade from 
MAP3Ks>MAP2K> MAPK. Stress, Cytokines, G-proteins, and tyrosine kinases receptors all activate 
MAP3Ks, leading to activation of the main MAPKs p38, JNK and ERK. Downstream transcription 
factors include Elk-1, AFT2, MEF2, Jun and c-Myc. Adapted from Cellsignaling.com  
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1.11.2 p38 MAPK 
 
p38 is induced by a variety of cellular stress including  LPS, heat shock, osmotic shock, 
oxidative stress and pro-inflammatory cytokines such as TNF-• and IL-1•. p38 has 4 
isoforms; p38• and p38• which share 75% homology and the more distantly related proteins 
p38• and p38•. p38• and • are ubiquitously expressed, whereas p38 • and • have limited 
tissue specificity (Saklavata, 2004). Although they share a high degree of homology, 
individual p38  isoforms have differing affinities for substrates (Ashwell, 2006).  p38 is 
activated by MKK 3, 4 and 6 and upstream MAP3Ks include TAK1, ASK1, MLK1 and 
MEKK4  (Zarubin and Han, 2005). Several targets of p38 are directly involved in the 
inflammatory response; including MAPK activated protein kinase (MK2), MNK1, ATF, 
ELK1 and NFAT (Ashwell, 2006).  
 
The use of the p38 MAPK inhibitor SB203580 has shown that p38 MAPK is necessary for 
induction of several pro-inflammatory factors, such as TNF-•, IL-1•, IL-6, iNOS and COX-2 
and that p38 can upregulate cytokine production through direct phosphorylation of 
transcription factors or through transcript stabilisation (Ashwell, 2006). Many inflammatory 
cytokines contain an AUUUA motif in a U rich region of their 3’ untranslated region known 
as AU-rich element (ARE). AREs inhibit mRNA expression at the transcriptional and 
posttranscriptional  level by targeting mRNA for deadenylation and promoting 3’-5’ 
exonuclease decay  (Dean et al., 2003).  Indeed  insertion of AREs into otherwise stable 
mRNAs results in their destabilisation and reduced protein expression (Neininger et al., 2002, 
Dean et al., 2004). Activation of p38 stabilises many mRNA transcripts containing AREs, 
including TNF-•, IL-3 IL-6, IL-8 and COX-2 (Kaminska, 2005).  The p38 target protein 
MK2 has a prominent role in transcript stabilisation as evidenced in MK2
-/-
 
 mice, which are 
unable to produce TNF-• in response to LPS, this renders them resistant to endotoxic shock 
(Kotlyarov et al., 1999). MK2 controls TNF-• expression through its ARE, since deletion of 
the ARE allows LPS induced TNF-• production in the absence of p38 and MK-2 
(Kontoyiannis et al., 1999). Tristetrapolin (TTP), a member of the zinc finger family of RNA 
binding proteins destabilises TNF-• mRNA by binding to its ARE, MK2 appears to 
phosphorylate 14-3-3 binding sites on TTP, causing it to be sequestered away from mRNA, 
thereby stabilising the TNF-• mRNA transcript (Carballo et al., 1998).  76 
 
Using pharmacological inhibition and deletion of MKKs, several studies have demonstrated a 
prominent role for p38 in the production of IL-10 and IL-12 in both leukocytes and 
lymphocytes (Yi et al., 2002, Foey et al., 1998, Lu et al., 1999). p38 activity can also effect 
cytokine translation. Poly-adenylated mRNAs form circular structures due to the 5’-cap 
binding complex binding to poly-A-binding protein and this circularisation process promotes 
translation (Saklavata, 2004). Phosphorylation of eIF-4e by the p38 inducible kinase MNK1, 
increases the interaction between the cap-binding complex and capped mRNAs, enhancing 
cytokine polysome assembly (Chang and Karin, 2001).  
 
The important role of p38 in inducing cytokine expression is borne out in animal studies 
where p38 activity has been blocked. Inhibition of p38 activity has been shown to be 
effective in reducing mortality from toxic shock in mice, improving mucosal healing in 
Crohn’s disease and ameliorating the symptoms of rheumatoid arthritis (Badger et al., 1996, 
Hommes et al., 2002). Inhibition of p38 reduced cytokine secretion from ex vivo peripheral 
blood mononuclear cells (PBMCs) and improved clinical outcome to human endotoxemia 
(Branger et al., 2002). Preliminary studies have also shown p38 inhibitors to be clinically 
beneficial in human patients with inflammatory conditions, for example p38 inhibitors are 
currently in phase II trial for rheumatoid arthritis (Pargellis and Regan, 2003). 
 
 
1.11.3 c-Jun N-terminal Kinase (JNK) 
 
JNK exists as three isoforms, JNK1, 2 and 3; JNK1 and JNK2 are widely expressed whereas 
JNK3 expression is limited to the brain, heart and testis (Weston and Davis, 2002). JNKs are 
activated by MKK4 and 7, which transduce signals from the MAP3Ks ASK1, MLK-3, TAK1 
and MEKK1-4 (Chang and Karin, 2001). Downstream targets of JNK include c-Jun, ATF2, 
AP-1, Elk1, p53 and Bcl-2 and active JNK is a potent inducer of apoptosis in response to 
several cellular insults such as UV irradiation, I/R injury, heat shock and inflammatory 
cytokines such as TNF-• (Wada and Penninger, 2004). The promoters of several cytokines 
and chemokines contain binding sites for the inflammatory transcription factor AP-1. AP-1 is 
a heterogeneous collection of dimeric transcription factors, comprising fos, jun and ATF 
subunits. JNK has been shown to phosphorylate and upregulate each of these three subunits, 
thereby enhancing AP-1 activity and cytokine production (Derijard et al., 1994). Similarly to 
p38, JNK is also involved in TNF-• translational control, overexpression of dominant 77 
 
negative JNK overcomes LPS induced depression of the translational blockade associated 
with the ARE (Swantek et al., 1997). 
 
 
1.11.4 Extracellular Regulated Kinase (ERK) 
 
ERK consists of two isofoms ERK1 (p44) and ERK2 (p42) and is activated primarily in 
response to mitogens and growth factors. These act through G-protein coupled receptors, 
which activate the small G-protein Ras, this in turn activates Raf which phosphorylates the 
MAP2Ks MEK1 and MEK2 (Shaul and Seger, 2007). ERK targets include MK1, ribosomal 
S6 kinase (RSK), c-myc, cytoplasmic phospholipase  (
 
) and the transcription factor Elk1. 
Activation of ERK promotes entry to the cell cycle, differentiation, cell migration and actin 
skeleton reorganization, and inhibition of apoptosis (Xia et al., 1995, Wada and Penninger, 
2004). ERK also has a role in mediating cytokine expression. Inhibition of ERK activity 
through deletion of its upstream activator, Tpl2 (tumor progression locus 2), showed that 
ERK is indispensable for LPS induced TNF-• production, this is achieved through enhanced 
nucleo-cytoplasmic shuffling of the TNF-• transcript, which involves targeting of the ARE 
(Dumitru et al., 2000). Pharmacological inhibition of ERK also blocks IL-10 production in 
macrophages and ERK activation promotes phosphorylation of histone H3 at the IL-10 locus 
making it more accessible to SP1 and STAT3 transcription factors (Yi et al., 2002). 
 
1.11.5 MAPK Phosphatase -1 (MKP-1) 
 
Pro-inflammatory cytokine release must be tightly controlled since dysregulated cytokine 
production can lead to severe pathologies, including inflammatory, allergic and autoimmune 
diseases such as septic shock, asthma, Crohn’s disease, rheumatoid arthritis and multiple 
sclerosis. Since MAPKs are so vital to the production of pro-inflammatory cytokines, it is not 
surprising that the body has evolved effective regulatory systems to limit the extent of MAPK 
activation following inflammatory stimuli. One way in which this is achieved is through a 
family of dual specificity phosphatases known as DUSPs or MAPK phosphatases (MKP) 
which dephosphorylate members of the MAPK family. The MKP family consists of 10 
members, all of which have different affinities to each of the 3 MAPKs. MKP-1 has been 
shown to dephosphorylate all three MAPKs with different affinities, with the order of 
preference being p38>JNK>ERK, MKP-3 is specific for ERK while MKP-5 inhibits JNK 78 
 
(Lang et al., 2006, Ashworth et al., 1996, Zhang et al., 2004). MKP-1 is a nuclear enzyme 
encoded by an immediate early gene and its transcription is induced by most stimuli which 
activate MAPKs, such as mitogens and stress signals (Sun et al., 1993). In contrast, MKP-3 
resides in the cytosol and is not induced by mitogens or stress but is induced during neuronal 
differentiation (Muda et al., 1996). 
 
MKP-1 upregulation in response to various stresses is dependent on p38 MAPK and MKP-1 
has been shown to bind to the C-terminal domain of p38 MAPK resulting in enhanced 
phosphatase activity, suggesting the existence of a negative feedback loop (Hutter et al., 
2002, Li et al., 2001). MKP-1 has also been shown to be both transcriptionally upregulated 
and phosphorylated by ERK, although the precise role of ERK mediated phosphorylation has 
not been resolved. Brondello et al. reported that ERK mediated phosphorylation of MKP-1 at 
two serine residues in its carboxy terminus stabilised MKP-1 and reduced its ubiquitin 
mediated degradation by the proteasome (Brondello et al., 1999). Lin et al. recently 
demonstrated however, that ERK mediated phosphorylation at S296 and S323 promotes 
binding of the E3 ubiquitin ligase skp2, which promotes MKP-1 ubiquitination and 
degradation (Lin and Yang et al., 2006). The use of pharmacological inhibitors of ERK has 
also produced similar conflicting data with some studies showing LPS induced MKP-1 
expression being ERK dependent while others finding no dependency whatsoever; thus the 
precise role of ERK in MKP-1 induction is still unclear (Valledor et al., 2000). 
    
MKP-1 is induced in response to peptidoglycan stimulation in RAW264.7 cells and primary 
peritoneal macrophages (Shepherd et al., 2004). The time course of induction of MKP-1 
correlated with inhibition of p38 and JNK activation. Furthermore, knockdown of MKP-1 
prolonged p38 phosphorylation and resulted in an increase in peptidoglycan induced TNF• 
secretion while overexpression had the opposite effect. Inhibition of MKP-1 in alveolar 
macrophages enhanced LPS mediated TNF-• production associated with prolonged 
activation of p38 MAPK (Zhao et al., 2005). Transfection of MKP-1 cDNA into RAW264.7 
macrophages reduced LPS induced p38, ERK and JNK phosphorylation in response to LPS 
as well as reducing production of TNF-• and IL-6 (Chen et al., 2002). These studies suggest 
that MKP-1 may have a fundamental role in control of the innate immune response. 
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1.12 Inflammatory Diseases 
 
1.12.1 Multiple Sclerosis 
 
Multiple sclerosis (MS)  is  an  inflammatory disease of the central nervous system, 
characterised  by demylenation and axonal loss, resulting in chronic multifocal sclerotic 
plaques (Compston and Coles, 2002). Myelin is secreted by oligodendrocytes and forms an 
insulating sheath around axons, facilitating axonal conductance. Loss of myelin can result in 
impaired motor, sensory and autonomic functions, all seen to varying degrees in patients 
suffering from MS (Comptston and Coles, 2002). Autoreactive anti-myelin specific T cells 
are found in the normal population but these are usually suppressed by regulatory T cells 
(Ellerman et al, 1988). In MS patients however  there is a breakdown in tolerance and 
autoreactive T cells proliferate and enter the CNS where they re-encounter the myelin antigen 
and induce activation of resident microglia (Raivich and Banati, 2004). Activated microglia 
then represent the antigen to the T cells, resulting in sustained inflammation and 
autoimmunity 
 
Experimental autoimmune encephalomyelitis (EAE) is a demyelinating autoimmune 
pathology that has many of the characteristics of MS and thus has been commonly used as an 
animal model for this disease. EAE is induced experimentally by immunizing with 
autoantigens derived from the myelin sheath, such as myelin oligodendrocyde glyccoprotein 
(MOG) or myelin basic protein (MBP). T cells become primed with these peptides in the 
periphery and migrate to the CNS where they become autoreactive, leading to autoimmune 
inflammation (El Behi et al., 2005). EAE, like MS, is characterised by distinct phases of 
pathology; preclinical stage, onset of neurological symptoms, paralysis and remission 
(Raivivh et al., 2004). 
 
The CNS has evolved multiple ways to deal with autoreactive T cells, including the dearth of 
DCs in the CNS microenvironment and production of FAS ligand to induce T cell apoptosis 
(Sabelko-Downes et al., 1999). It seems that in the inflammatory setting promoted by 
autoreactive T cells these control mechanisms are overcome leading to neuronal destruction. 
Progression of EAE is associated with infiltration of CD4
+ T cells, CD8
+ T cells and B cells, 
although the issue as to whether these cells are primed in the periphery or in situ in the CNS 
has not been fully resolved (El Behi et al., 2005). While T cell infiltration into the CNS 80 
 
parenchyma is necessary for development of EAE, infiltrating macrophages or resident 
microglia are the main effectors of pathology by causing demylenation and oligodendrocyte 
death which results in axonal deterioration (McGeachy et al., 2005). 
 
Several studies have demonstrated a role for macrophage and DC derived IL-12, TNF-•, 
IFN-• and IL-1• in promoting EAE (Leonard et al., 1995, Korner et al., 1997, Jacobs et al., 
1991, McGeachy et al., 2005). IL-12 is a potent inducer of Th1 polarisation and was 
originally thought to be critical for EAE induction. The use of an anti-IL-12 antibody 
prevented disease while IL-12 p40
-/- mice were resistant to EAE (Leonard et al., 1995, Segal 
et al., 1998). However, it has now been realised that these results may have been 
misinterpreted. IL-23 is heterodimer comprised of the p40 subunit common to IL-12 and a 
unique p19 subunit and it seems that it is IL-23 rather than IL-12 which is indispensable for 
development of EAE (Cua et al., 2003). This is borne out by the fact that unlike IL-12 p40
-/- , 
IL-12p35
-/- mice are not resistant to EAE, while in IL-23
-/- 
 
mice Th1 primed cells entered the 
CNS parenchyma but this did not lead to EAE (Cua et al., 2003, Gran et al., 2002). IL-10 has 
been demonstrated to be effective in reducing the severity of EAE, this has been shown by 
treating mice with recombinant IL-10 and intracranial injection of an IL-10 producing 
adenovirus (Bettelli et al., 2003). As would be expected on the basis of these experiments, IL-
10 deficient mice are more susceptible to EAE, whereas IL-10 T cell transgenic mice are 
resistant  (Samoilova et al., 1998, Bettelli et al., 1998). Thus,  inflammatory cytokine 
production in the periphery and in the CNS are instrumental in MS pathology and new targets 
which alter the cytokine profile and clinically influence MS progression have become of 
great interest, scientifically and medically.   
 
1.12.2 Inflammatory Bowel Disease (IBD) 
 
IBDs are chronic inflammatory diseases of the gut that present clinically as two associated 
pathologies; Crohn’s disease and ulcerative colitis. For as yet unknown reasons, the intestinal 
mucosa elicits an inflammatory response to the normally non-immunogenic intestinal flora. 
The resulting influx of neutrophils, macrophages and T cells drives intestinal inflammation, 
leading to the clinical symptoms of weight loss, diarrhea and abdominal pain (Stokkers and 
Hommes et al., 2004). TNF appears to be a main mediator in driving intestinal inflammation 
in Crohn’s disease and currently the most successful therapy in Crohn’s disease is the anti-
TNF monoclonal antibody infliximab (Stokkers and Hommes et al., 2004). A functional IL-81 
 
10 producing Th2 response appears to be necessary to suppress the effects of IBD. IL-10
-/- 
mice develop spontaneous chronic colitis and deletion of STAT3 in macrophages and 
neutrophils leads to exacerbated Th1 mediated response to bacterial antigens, resulting in 
intestinal colitis (Takeda et al., 1999). Furthermore, recombinant IL-10 has been shown to 
inhibit IBD induced by T cell transfer into RAG2 
-/-
 
 hosts, while intragastric administration of 
IL-10 secreting Lactococcus lactis ameliorated the clinical symptoms of colitis (Steodler et 
al., 2000). 
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2.1 Reagents 
 
The following TLR ligands were used: LPS from E. coli serotype O111:B4 (Sigma), 
peptidoglycan (PGN) from Staphylococcus aureus (Fluka), Poly (I-C) (Amersham Pharmacia 
Biotech), phosphorothioate-modified CpG oligonucleotide DNA 
(TCCATGACGTTCCTGACGTT, synthesized by the Keck Facility at Yale University), 
synthetic lipoprotein 
 
, flagellin and loxoribine (all from Invivogen). ELISA antibodies for 
IL-6, TNF-α, IL-12 and IL-10, the neutralizing antibody for IL-10 (JES5-2A5), and 
recombinant cytokines were from BD-Pharmingen. Inhibitors for MAPKs (SP600125, 
SB203580, U0126) and Ro106-9920 were from Calbiochem. Hydrogen peroxide and tempol 
were from Sigma. A complete list of cell lines used is presented in Appendix 1C. 
2.2 Animals 
MKP-1
-/- mice were re-derived from cryopreserved embryos obtained from Bristol-Myers 
Squibb  [153]  and were backcrossed onto C57/Black6 for at least 8 generations.  Mice 
deficient in myeloid differentiation factor 88 (MyD88) were kindly provided by Shizuo 
Akira, Osaka University, Japan [154]. Mice with a frameshift mutation in the TIR domain-
containing adaptor inducing IFN-• (TRIF) gene (  mice) were kindly provided by Bruce 
Beutler, Scripps Research Institute, La Jolla, U.S [155]. TIGER (Transgenic IL-10 GFP 
Expressing Reporter) mice were kindly provided by Dr. Sean Kim, Yale University, CT, U.S. 
All mice were used between 8 and 10 weeks of age. Sprague Dawley rats were obtained from 
UCL biological services unit at ICH. All experiments were conducted in accordance with the
 
guidelines of Institutional Animal Care and Usage Committee
  of Yale University or in 
adherence with the Home Office Guidance on the Operation of the Animals (Scientific 
Procedures) Act 1986, published by HMSO, London. Mouse geneotyping was carried out by 
digesting tail tips in digestion buffer (10mM Tris-Cl, 50mM KCl, 20mM DTT, 2% proteinase 
K, 0.1% Triton X-100, pH 9.0) at  overnight followed by heating to  for 5 min. PCR was 
carried out with 35 cycles of /45 sec, /45 sec, / 1 min.  MKP-1 genotyping was performed 
using a triple primer set consisting
  of 5'-CCAGGTACTGTGTCGGTGGTGC-3' and 5'-
CAGCGCATCGCC
 TTCTATCGCC-3' and 5'-GTCTAGGAGGATTGTGCCAGG-3'. 84 
 
2.3 In Vivo Procedures 
 
2.3.1 Myocardial Ischaemia and Reperfusion in the Rat  
Myocardial I/R was carried out in collaboration with Dr. Ahila Sivarajah at the Center for 
Experimental Medicine, The William Harvey Research Institute, Queen Mary, University of 
London. Male Wister rats (255-285g) were anaesthetised with thiopentone sodium (Intraval
 
120 mg/kg
  i.p.).  Anesthesia was maintained by supplementary injections of thiopentone 
sodium as required.  The trachea was cannulated and the animals were ventilated with a 
Harvard ventilator (inspiratory oxygen concentration: 30%; 70 strokes/min, tidal volume: 8-
10 ml/kg).  Body temperature was maintained at 37±1 
 
  and the right carotid artery was 
cannulated and connected to a pressure transducer (Senso-Nor 840, Senso-Nor, Horten, 
Norway) in order to monitor mean arterial pressure (MAP) and heart rate (HR), which was 
displayed on a data acquisition system (MacLab 8e, ADI Instruments, Hastings, UK). The 
right jugular vein was then cannulated for the administration of drugs.  A para-sternal 
thoracotomy was then performed, using an electrosurgery device to cauterize the intercostals 
arteries before cutting through three ribs. The chest was retracted and pericardium dissected 
from the heart. The left anterior descending (LAD) coronary artery was isolated and a snare 
occluder was placed around the LAD. The retractor was then removed and the animal 
allowed to stabilize for 15 min. The occluder was tightened at time 0.  After 25 min of LAD-
occlusion, the occluder was released to allow reperfusion for the indicated times. At the end 
of the reperfusion period, the LAD was re-occluded and 1 ml of Evans Blue dye (2% w/v) 
was injected into the animal, via the jugular vein. Evans Blue dye binds albumin and stains 
the tissue through which it is able to circulate, so that the non-perfused vascular (occluded) 
tissue remains un-colored. Each animal was killed with an over-dose of anesthetic, the heart 
excised, and excess dye washed off. The heart was then sectioned into slices of 3-4 mm, the 
right ventricle wall was removed, and the risk area (the non-perfused and, hence, non-stained 
myocardium) was separated from the non-ischemic (blue) tissue and immediately snap-frozen 
in liquid nitrogen. For ROS inhibition experiments, animals were subjected to (i) Sham 
operation, (ii) LAD coronary artery occlusion (25 min) and reperfusion (30 min) treated with 
saline 5 min prior to the onset of reperfusion, or (iii) LAD coronary artery occlusion (25 min) 
and reperfusion (30 min) treated with 100 mg/kg tempol 5 min prior to the onset of 
reperfusion (n=4 in all cases). Tissue was either snap frozen in liquid nitrogen for subsequent 
protein extraction or fixed in 10% formalin. 85 
 
2.3.2 Endotoxic shock 
Toxic shock occurs as a result of bacterial overload and is a useful model to examine in vivo 
responses to pro-inflammatory insult. Age and sex-matched wild-type (WT) and MKP-1
-/-
 
 
mice were challenged with 10 mg/kg or 2.5 mg/kg of LPS by intraperitoneal (i.p.) injection 
and survival of mice was monitored up to 50 hr. The incidence of mouse lethality was 
compared and analyzed using the log rank test, performed by GraphPad Prism version 3.0. 
2.3.3 Listeria Infection 
L. monocytogenes (strain 43251) was inoculated into trypsicase soy broth (Becton Dickinson, 
MD) and incubated overnight with shaking at 37°C. Following
  this, the bacteria were 
harvested by centrifugation, resuspended
  in trypsicase soy broth broth containing 20% 
glycerol, and stored at -70°C
  as 1-ml aliquots. Before each experiment, an aliquot was 
thawed,
 inoculated into 50 ml of trypsicase soy broth, and incubated at 37°C
 with shaking 
until mid-log-phase growth was reached. The optical
 density of the bacterial suspension was 
read with a spectrophotometer,
  and the numbers of CFU of L. monocytogenes  were 
extrapolated
 from a standard growth curve. To prepare the inoculum for the
 mice, appropriate 
dilutions were made in sterile endotoxin-free phosphate-buffered
 saline to achieve the desired 
bacterial concentration. The actual
 number of CFU in the inoculum was verified by plating on 
agar plates of tyrsicated casein.
 MKP-1
+/+ and MKP-1
-/- mice were injected i.v with 1.0 x 
 cfu 
of L. monocytogenes, 72 hr later, spleens and livers were harvested into 0.1% Triton in PBS 
and homogenized. The number of viable L. monocytogenes  in the spleen and liver was 
assessed by plating serial 10-fold dilutions of tissue homogenates onto agar plates of 
tyrsicated casein. Plates were cultured at 
 
  and colony number was counted after 24  hr.  
Bacterial load data is expressed as colony forming units (cfu) per organ. 
2.3.4 Experimental Autoimmune Encephalomyelitis (EAE) 
EAE is a mouse model of the human inflammatory disease multiple sclerosis and is used to 
test immune defects in vivo. EAE was induced by s.c. flank injections of 50 µg of myelin
 
oligodendrocyte glycoprotein (MOG)35–55 peptide (synthesized
 in the Keck Facility at Yale 
University) emulsified in complete Freund's adjuvant (CFA; Difco) supplemented with heat-
killed Mycobacterium tuberculosis (500 µg per mouse; Difco). Mice received i.p. injections 
of 200 ng of B. pertussis toxin (List Biological, Campbell, California, USA) immediately 
after the first immunization and again 72 hr later. The mice were observed daily for clinical 86 
 
signs and scored
 on a scale of 0–5: 0, no clinical signs; 1, flaccid tail;
 2, wobbly gait; 3, 
partial hindlimb paralysis; 4, complete hindlimb
 paralysis; 5, complete hindlimb paralysis and 
forelimb weakness
 
 
or paralysis. 
2.3.5 Dextran Sulphate Sodium (DSS) Induced Colitis 
In patients, colitis is comprised of two related disorders; Crohn’s disease and ulcerative 
colitis. To model these conditions in vivo, DSS administration is used. DSS induces colitis by 
damaging the epithelial lining of the digestive tract, thus allowing access of the commensal 
flora to the gut which initiates an immune response. MKP-1
+/+ and MKP-1
-/-
 
 mice were given 
2.5% DSS ad libitum in drinking water for 7 days followed by replacement with regular 
drinking water. Body weight was measured daily over a 3 week period. 
2.3.6 Middle Cerebral Artery Occlusion (MCAO) 
MCAO is an in vivo rat model of human stroke. MCAO and magnetic resonance imaging 
(MRI) was carried out in collaboration with Dr. Romina Badin at the biophysics unit, ICH, 
University College London. Rats were anesthetized with 3% isoflurane in 100%   and 
maintained at 2% isoflurane in a 70:30 :
 
  mix delivered by a nose cone. The common, 
internal, and external carotid arteries were exposed by a cervical midline incision. A 290 µm 
monofilament suture was introduced into the lumen of the common carotid artery and 
advanced approximately 17 mm to occlude the MCA. After 30 mins, the suture was removed 
and rats were reperfused for the indicated times. Rectal temperature was maintained at 37°C
1°C via a heating blanket controlled by a thermocouple and physiological monitoring 
included electrocardiography (ECG) recordings and rectal temperature recordings. MRI scans 
were performed using a 2.35-T horizontal bore magnet (Oxford Instruments, Oxford, UK) 
interfaced to a SMIS console (Guildford, UK). Images were acquired using a volume 
transmitter coil and a separate decoupled surface receiver coil. A multislice T2-weighted spin 
echo (SE) sequence (TR=1500 ms, TE=120 ms, 8 averages, 9 slices) with a 1-mm-slice 
thickness was also run to determine the lesion volume. Total scan time was 35 mins. All 
images were reconstructed with IDL Software Version 5.2.  
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2.4 Cell Culture 
 
2.4.1 Freezing and Recovery of Cell Lines 
1 x  cells were centrifuged at 300 x g for 5 min and resuspended in FBS containing 10% 
DMSO and placed in cotton wool overnight at -, the following day cells were placed in liquid 
nitrogen for long term storage. Cells were recovered by thawing liquid nitrogen stocks 
rapidly at  and transferring to a 25 
 
 flask. The medium was changed and cells were passaged 
as required using 2.5% trypsin (Gibco). All cell lines were grown in dulbeccos modified 
eagles medium (DMEM) containing 10% foetal bovine serum (FBS, Hyclone) with 40 
units/ml penicillin (Gibco) and 40µg/ml streptomycin (Gibco). All cell culture plastics were 
from Nunc. 
2.4.2 Preparation of Neonatal Rat Ventricular Cardiac Myocytes 
Neonatal rat ventricular cardiac myocytes (NRVM) were isolated from the hearts of 1-3 day 
old Sprague Dawley rats. Hearts were removed and placed in oxygenated ADS buffer (116 
mM NaCl, 5.4 mM KCl, 20 mM HEPES, 0.8 mM  , 405.7 µM  , 5.5 mM glucose, pH 7.35). 
Heart tissue was digested in 10  ml oxygenated ADS buffer supplemented with 0.1% 
collagenase and 0.025% pancreatin for 15 min, liberated cells were pelleted at 300g for 5 min 
and resuspended in FBS. This digestion procedure was repeated 7 times after which cells 
were plated at  for 1 hr to allow adherence of fibroblasts. Myocytes were plated at a density 
of 2.5 x 
 
/ml in DMEM with penicillin, streptomycin and 15% FBS on plates pre-coated for 1 
hr with 1% gelatin. Cells were allowed to attach overnight and the media was replaced with 
DMEM 1% FBS. This yielded typical cultures of >95% cardiac myocytes as assessed by 
desmin staining. 
2.4.3 Hypoxia/Reoxygenation of NRVM 
To model myocardial infarction in  vitro, cardiac myocytes were subjected to 
hypoxia/reoxygenation injury. Cells were incubated for 4 hours in ischaemic buffer (137mM 
NaCl, 12mM KCL, 0.49mM  , 0.9 mM  , 4 mM HEPES, 20mM sodium lactate, 10 mM 
deoxyglucose, pH 6.2) in a  hypoxic chamber with 5% , 95% argon. Following hypoxia, 
medium was replaced with DMEM 1% FBS and cells were reoxygenated in 5%   in a  
incubator. For experimental controls, cells were incubated for four hours in Esumi control 88 
 
buffer (137 mM NaCl, 3.8 mM KCl, 0.49 mM  , 0.9 mM 
 
, 4 mM HEPES, 10 mM glucose, 
pH 7.4) then in DMEM 1% FBS. 
2.4.4 Isolation of Bone Marrow Derived Macrophages 
The femur and tibia of 6-10 week old mice were removed and the bone marrow was extracted 
into 10% DMEM by flushing with a 25 gauge needle. Cells were spun at 300 x g and 
resuspended in ACK buffer (150 mM , 10 mM , 0.1
 mM EDTA, pH 7.2) for 5 min to remove 
red blood cells. Cells were filtered through a cell strainer and washed twice in 50 ml 10% 
DMEM and resuspended in DMEM with 20% FBS and 30% L929 supernatant (source of M-
CSF). Bone marrow cells were cultured at an initial density of approximately  cells/ml for 5-6 
days and fresh medium was added at day 3.  Cells were harvested in cold 0.2% EDTA 
(Invitrogen) and plated at a density of 2-4 x 
 
 cells/ml in DMEM with 10% FBS. Macrophages 
were cultured for at least 12 hr before stimulation.  
2.4.5 Isolation of Bone Marrow Derived Dendritic Cells 
The femur and tibia were removed from 6-10 week old mice and the bone marrow was 
extracted into RPMI 1640 supplemented with 5% FBS, 50 units/ml penicillin, 50 units/ml 
streptomycin and 50µM beta mercaptoethaol by flushing with a 25 gauge needle. Cells were 
spun at 300 x g and resuspended in ACK buffer for 5 min to remove red blood cells. Cells 
were filtered through a cell strainer and washed twice in RPMI 1640. Lymphocytes were 
killed with a cocktail of 50 µg/ml mAbs and rabbit complement for 60 min at 
 
. The antibodies 
used were B220 (anti CD145), GK1.5 (anti-CD4), TIB120 (anti- Ia), TIB 211 (anti – lyt2) 
and were obtained from Pharmingen or as hybridomas from American Type Tissue Culture 
Collection (ATCC), Manassas Virginia. Cells were then washed twice and resuspended at a 
final concentration of 1 x 106/ml in RPMI suplimented with 5% FBS, 50 units/ml penicillin, 
50 units/ml streptomycin, 50µM beta mercaptoethaol and 1% GM-CSF, fresh media was 
added every two days and cells were treated on day 6. 
2.4.6 T Cell Isolation from Mouse Spleen and Lymph Node 
Superficial cervical, mediastenial, axillary, mesenteric and inguinal lymph nodes as well as 
spleen were removed from 6–10-week-old mice, ground and placed through a cell strainer. 
Cells were washed in 50 ml 10% DMEM and then resuspended in ACK buffer for 5 min to 89 
 
remove red blood cells. CD4 and CD8 T cells were enriched by immunomagnetic selection 
using antibodies against CD4 and CD8 and magnetic beads conjugated with goat anti-mouse 
and anti-rat Ig (Miltenyi Biotec). Cells were cultured in Bruff's medium (10% FCS, 
penicillin, streptomycin and L-glutamine). 
 
2.4.7 T cell Differentiation 
CD4 T cells form distinct effector subsets in vivo  following antigenic stimulation, these 
subsets can e recapitulated in vitro  using distinct combinations of cytokines. For  T cell 
differentiation, the purified CD4 T cells were stimulated with 5 µg/ml anti-CD3 (145-2C11), 
2 µg/ml anti-CD28 (37.5.1), 10 U/ml recombinant mouse IL-2,  30 U/ml, irradiated 
splenocytes (2000 Gray, 5 fold APC per T cell) and for Th1 cell; 2 ng/ml rIL-12 (a gift from 
Wyeth Research), and 10 µg/ml anti-IL-4 (clone 11B11) or Th2 cells; 500 U/ml rIL-4 and 10 
µg/ml anti-•IFN (clone XMG2.1), antibodies were from ATCC, Manassas, Virginia. After 5 
days of T cell differentiation, live effector cells were obtained by Ficoll centrifugation 
(LSMOL Lymphocyte Separation Medium, Cappel) and restimulated at 1 × 
 
 cells per well 
(96 well flat bottom plate, Falcon) with plate bound anti-CD3 or with 1 µg/ml PMA and 1 
µM ionomycin. 
2.4.8 Preparation of High Titre Adenoviral Stocks 
In order to maximise gene expression in cardiac myocytes adenovirus was used. Adenoviral 
stocks of Ad-GFP and Ad-DN ST3 (dominant negative STAT3) were kind gifts from Prof. 
Brian Foxwell, Imperial College London and the Ad-STAT3C (constitutively active STAT3) 
was a kind gift from Michitaka Ozaki,  Okayama University. The adenovirus vector is a type 
five adenovirus with deletion of the E1A region necessary for viral replication. High titre 
adenoviral stocks were prepared by infecting one well of a 6 well plate of 293 cells at 80% 
confluency for 2 days or until full cytopathic effect (CPE) was seen. Cells and lysate were 
removed, freeze-thawed three times and added to a T75 flask of 80% confluent 293 cells until 
full CPE was reached. This procedure was repeated and 10 large flasks (T175) of 80% 
confluent 293 cells were infected for 32 hr. Cells were harvested, pelleted at 300 x g for 5 
min and then resuspended in 10 ml of 0.1M Tris pH 8.0. Cells were freeze-thawed three 
times and passed through a blunt needle four times to shear chromatin. Cellular debris was 
pelleted by centrifugation at 600 x g for 5 min. The supernatant was removed and made up to 
11.4 ml with 0.1M Tris pH 8.0, 6.6 ml of saturated CsCl solution was added to a final volume 90 
 
of 18 ml.  The suspension was centrifuged at 180,000 x g for 16 hr. The virus band was 
removed by piercing with a needle and cleaned using a PD10 column. The virus was eluted 
from the column in PBS, filter sterilized and stored at -
 
. Adenoviral titre was determined by 
plaque assay on 293 cells. For experimental infections, cells were infected at the indicated 
multiplicity of infection (MOI) for 24 hr, after which time the medium was changed and cells 
were left for a further 24 hr before treatment.  
 
2.5 Analysis of Protein Levels 
 
2.5.1 Western Blotting 
Western blotting was used to detect the expression levels of total proteins or their 
phosphorylated forms in cell lysates. Cardiac tissue was snap frozen in liquid nitrogen and 
ground to a fine powder using a pestle and mortar and lysed in RIPA buffer (0.75 M NaCl, 
5% (
v/v) NP40, 2.5% (
w/v) deoxycholate, 0.5% (
w/v) SDS, 0.25 M Tris-HCl pH 8.0, 
containing protease inhibitor cocktail) or cells were lysed directly in RIPA. After lysis, the 
lysates were centrifuged at 13,000 x g to pellet cell debris.  Protein concentration from the 
supernatant was determined using the  BCA protein assay kit (Pierce, Rockford, USA). 
Laemmli laoding buffer (50 mM Tris-Cl, pH 6.8, 2% SDS, 10% glycerol 0.1% bromophenol 
blue) and dithiothreitol to a final concentration of 10 mM were added to protein lysate and 
the solution was boiled for 5 min. 20 µg of protein was electrophoresed on polyacrylamide 
gels, transferred to Hybond-C nitrocellulose membranes (Amersham Biosciences, Bucks, 
UK) and blocked for 30 minutes in 4% non-fat dry milk in TBS.  Membranes were incubated 
with primary antibody (1:1000 dilution, see Appendix 1) at 
 
 overnight in 4% non-fat dry 
milk. Horse radish peroxidase (HRP) conjugated secondary antibodies (DAKO, Glostrup, 
Denmark) were applied at 1:2000 dilution and incubated at room temperature for one hour. 
Membranes were washed in tris buffered saline (TBS) containing 0.05% Tween 20 and 
proteins visualised by enhanced chemiluminescence (ECL, Amersham Biosciences, Bucks, 
UK) and exposed to light sensitive film (Kodak, New Haven, USA). 
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2.5.2 ELISA 
ELISA was used as a method to measure cytokine secretion from macrophages in culture. 96 
well plates were coated overnight at 
 
 with 1 µg/µl of appropriate capture antibody diluted in 
PBS. Plates were washed 3 times with PBST then incubated with blocking buffer (1% BSA, 
5% sucrose, 0.05% sodium azide in PBS) for 1 hr at room temperature. Plates were then 
washed 3 times with PBST and 50 µl of cytokine standard or culture supernatant at the 
appropriate dilution was added and incubated at room temperature for 2  hr. Plates were 
washed 5 times with PBST and incubated with 1µg/µl of biotin-conjugated detection 
antibody for 2 hr, followed by incubation with avadin-HRP for 30min. The HRP substrate 
3,3',5,5'-tetramethylbenzidine (TMB) was used for chromogenic detection at 450 nm in a 
spectrophotometer. Serum levels of cytokines were also measured using Beadlyte (Upstate) 
mouse multi-cytokine detection system which utilises  beads conjugated to monoclonal 
antibodies specific for a target cytokine. Antibody-coupled beads were incubated with plasma 
samples for 30  min followed by washing and 30  min incubation with biotin-conjugated 
detection antibody. Samples were washed and incubated with sterptavadin-PE for 10 min and 
finally analysed on a Bio-plex Instrument (Biorad) per manufacturer’s protocols. 
2.5.3 Immunohistochemistry 
Immunohistochemistry was used to detect protein expression in tissue sections. Following 
indicated treatments; the myocardial risk area was separated, cut transversely into 4 slices, 
fixed in 10% formalin and embedded in paraffin. 4  µm sections were deparaphinised in 
xylene followed by serial rehydration, antigen retrieval was carried out by microwaving in 10 
mM sodium citrate buffer pH 6.0 for 5 min. Sections were incubated in 1%  to quench 
endogenous peroxidase activity and non-specific binding was blocked using 5% normal goat 
serum. Individual sections were incubated overnight with 1:50 dilution of anti-phospho 
STAT Y701(Zymed) or anti-phospho STAT3 Y705 (Cell Signalling Technology). In control 
sections, the corresponding serum was used in place of primary antibody. After washing in 
PSB the sections were incubated for 1 hr with 1:100 dilution of biotin-conjugated secondary 
antibody (Vector Laboratories) followed by streptavadin-biotin peroxidase complex solution 
(DAKO) for 30min. After a further PBS wash, the colour reaction was developed by 
incubating sections with 3’3-diaminobenzidine (Sigma) for 5  min. The sections were 
rehydrated through an ethanol series into xylene and mounted using DPX mounting media. 
Images were captured on a Zeiss Axioscop 2 plus microscope. 92 
 
2.5.4 Intracellular staining 
Intracellular staining was used to measure cytokine expression in vitro using fluorescently 
conjugated cytokine antibodies. Monensin (GolgiStop from Pharmingen) was added in the 
final 4 hr of T cell activation. Cells were harvested and washed twice in staining buffer 
(1%FBS in PBS). Cells were fixed in 4% paraformaldehyde on ice for 10 min, washed twice 
and permeabilised by 0.1% saponin. Cells were stained with appropriate fluorophor-
conjugated antibodies at 
 
 for 30 min and then analysed by flow cytometry. 
2.5.6 Determination of tissue malondialdehyde concentration 
Levels of malondialdehyde (MDA) serve as a marker for oxidative stress. MDA in heart 
tissue was measured by high-performance liquid chromatography (HPLC). Tissue was 
homogenized using an Ultra-Turrax homogeniser in 2 ml 50 mM potassium phosphate buffer 
(pH 6.0) containing 0.5% (
w/v) hexadecyltrimethylammonium bromide. 25 µl of homogenate 
were incubated with 2.5 µl 0.2% (
w/v) butylated hydroxytoluene in ethanol and 375 µl 1% 
(
v/v) phosphoric acid, and then derivatised with 345 µl 15 mM 2-thiobarbituric acid at 100ºC 
for 60 min. 200 µl of the derivatised solution were collected and mixed with 200 µl methanol. 
After addition of 15 µl 1 M  and 4 µl 2M KOH/2.4 M  samples were centrifuged (13000rpm 
for 10 min at 4ºC). HPLC was performed on a Hypersil 5 µm ODS column at a flow rate of 1 
ml/min, isocratically with an eluant of 65% 50 mM 
 
 (pH 7.0)/35% methanol. Fluorescence 
was monitored by a Jasco FP-1520 detector (excitation wavelength 515  nm; emission 
wavelength 553 nm) and values of molar concentration were calculated by comparison with 
reference solutions of MDA-tetrabutylammonium salt (Sigma-Aldrich, Poole Dorset, UK) 
derivatised and analysed in parallel. Protein concentration in the homogenate was measured 
by the method of Peterson (Peterson, 1977), and MDA was expressed as nmol/mg protein. 
2.5.7 Nuclear Extract 
To measure the levels of transcription factor binding by ELISA, nuclear proteins were first 
extracted from cells. Cells were removed into ice-cold PBS and pelleted at 300 x g for 15 
min. 400 µl of buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM 
EGTA and protease/phosphatase inhibitors; 100 mM DTT, 100 mM PMSF, 50 mM NaVO4, 
0.5 M NaF, 5 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mg/ml pepstatin) was added and cells 
were allowed to swell on ice for 15 min. 25 µl of 5% NP40 was added, followed by vortexing 
and centrifugation at 13000 x g for 30 seconds. 50 µl buffer C (20 mM HEPES pH 7.9, 400 93 
 
mM NaCl, 1 mM EDTA, 1 mM EGTA and protease/phosphatase inhibitors as per buffer A) 
was added to the pellet and was incubated at  for 15 min with shaking. The extract was spun 
at 13000 x g for 5 min and the supernatant was stored at -
 
.  
2.5.8 Electromobility Shift Assay (EMSA) 
EMSA is a method of measuring transcription factor binding in nuclear lysates using 
readiolabelled oligonucleotide probes corresponding to the consensus binding site  of the 
transcription factor of interest. Complimentary oligonucleotides were annealed in STE buffer 
(10 mM Tris, 50 mM NaCl, 1 mM EDTA) by heating to  for 5 min, then allowing to cool to 
room temperature. 100 ng of annealed oligo were labeled with 30 µCi  dCTP using 200 U 
MMLV reverse transcriptase. 10  µg nuclear extract was added to 500  pg probe, 1  µg 
polydIdC and diluted in binding buffer (10 mM HEPES, 50 mM KCL, 50 mM NaCl, 25 mM 
KPO4, 5 mM  , 2 mM DTT, 1 mM EDTA and 10% glycerol) followed by incubation at rt for 
15 min.  Samples were electrophoresed on polyacylamide gels, dried for 1hr at  and exposed 
to autorad film at -
 
. 
2.6 Gene Expression Analysis 
 
2.6.1 RNA Extraction 
For RNA extraction from cells, 0.5-1 ml Trizol (Invitrogen) was added directly to the tissue 
culture dish, tissue was ground to a fine powder under liquid nitrogen and homogenized in 1 
ml Trizol using a dounce homogenizer. Samples were incubated at rt for 5 min and 200 µl 
chloroform was added per 1 ml Trizol, samples were mixed vigorously and incubated at rt for 
3 min. Samples were centrifuged at 12,000 x g for 15 min at . The upper aqueous phase was 
transferred to a new tube and RNA was precipitated with 0.5 ml propan-2-ol for 15 min at rt. 
Samples were centrifuged at 12,000 x g for 20 min at  and the pellet was washed in 1ml 70% 
ethanol. RNA was centrifuged at 7,500 x g for 5 min at , residual ethanol was removed and 
the pellet was allowed to air dry for 15 min. The pellet was resuspended in 25  µl of 
diethylpyrocarbonate (DEPC) treated water and concentration was measured 
spectrophotometrically at . A / of ~ 1.8 was considered free of protein contaminants and an / 
of ~ 2.0 was considered free of phenol contamination. For qPCR and gene array applications, 
RNA purity was examined using the Bioanalyser 2100 (Agilent Technologies, Palo Alto, 
CA).    94 
 
 
2.6.2 cDNA Synthesis 
1 µg total RNA was DNase treated at rt for 15 min, the reaction was stopped by heating to  
for 10 min with 25 mM EDTA. 200 ng random hexamer primer and 1 µl of 10 mM dNTP 
was added, heated to  for 5 min and cooled on ice. 4 µl first strand buffer (Invitrogen), 2 µl of 
0.1  M DTT and 1  µl superscript II reverse transcriptase (Invitrogen) were added to the 
sample, followed by thermal cycling of  for 10 min,  for 50 min and 
 
 for 15 min. cDNA was 
diluted to 100 µl final volume. 
2.6.3 Quantitative Real Time PCR (qPCR) 
qPCR was used to accurate measure the mRNA levels of genes using Sybr Green which 
binds to the minor groove of DNA causing it to fluoresce. Following each round of PCR the 
total fluorescence in the sample is measured which corresponds to the amount of DNA 
present after each cycle. In chapters 3-5, qPCR was carried out using Platinum SYBR Green 
(Invitrogen,  Paisley, U.K.) on the DNA Engine Opticon system (MJ Research,Waltham, 
MA). For PCR reactions, 5 µl SYBR Green was added to 5 µl cDNA with 500 nM primers in 
a 20 µl reaction and the PCR conditions were  for 3 min followed by 45 cycles of  for 30 sec,  
for 30 sec,  for 30 sec. A melt-curve was performed from  to , reading every 0.
GeneAmp® Fast PCR 2x master mix
 with a 1 sec 
hold between reads. Specific primers were designed with the aid of CloneWorks and the 
Ensembl database and are listed in Appendix 2, where possible primers were intron-spanning. 
For single-exon genes, a control cDNA reaction without reverse transcriptase was included to 
confirm the absence of genomic DNA. qPCR data presented in chapter 6 was performed on 
the applied biosystems ABI 7500 Real-time PCR system using TaqMan® TAMRA™ 
primer/probe sets purchased from ABI. 5  µl cDNA was used with 200  nM primer and 
 with ROX passive reference. Thermal cycling was 
carried out as follows:  for 2 min,  for 10 min and 40 cycles of  for 15 sec and  for 1 min. All 
PCR reactions were visualised on agarose gels to ensure the presence of a single product. 
HPRT, •-Actin and •2-microglobulin were used together as normalizing genes and for each 
experiment both target and normalizing gene PCR efficiency was firstly determined to ensure 
normalizing genes were acceptable. Expression changes were calculated using the 2
-••C t
 
 
method and expressed as fold change over control. 
2.6.4 Luciferase Promoter Assay  95 
 
 
To measure gene promoter regulation in vitro, promoter sequences are cloned into a plasmid 
vector upstream of the luciferase gene. Promoter activity therefore results in luciferase 
expression which can be measured by luminometry. Cells were seeded in 24 or 96 well plates 
at the indicated densities. After 24 hr fresh media was added and transfections were carried 
out using the fugene-6 liposomal reagent according to the manufacturers instructions. 50 ng 
luciferase reporter and 50 ng CMV-renilla plasmid were used for each transfection. Fresh 
media was added 24 hr after transfection. After indicated treatments cells were washed with 
PBS and lysed in 100 µl of promega passive lysis buffer. Luciferase activity was measured 
using a Teaconic luminometer, 25 µl luciferase reagent was added to 50 µl cell lysate and 
luciferase activity was measured for 10 seconds, 25 µl of stop and glow reagent was then 
added and renilla activity was measured for a further 10 sec. Relative luciferase activity was 
calculated as luciferase activity/renilla activity and normalised to untreated controls. 
 
2.7 Affymetrix Microarray Analysis 
 
Microarray analysis allows one to measure the expression of thousands of transcripts 
simultaneously. Target RNAs from cells or tissue samples are converted into double stranded 
biotinylated RNA probes. These probes are hybridized to target oligonucleotides deposited on 
the surface of the microarray chip surface. After washing away unbound targets, the 
microarray is stained with phycoerythrin labeled streptavadin and read with a scanner. The 
levels of expression of each individual gene can then be compared against control samples to 
get a measurement of differential expression. 
 
2.7.1 cDNA Preparation 
1µl of 100 ng/µl T7 Oligo(dT) primer was added to 1 µg RNA in 11 µl of nuclease-free water 
and incubated at  for 10 min. This was added to 1 µl of 10 mM dNTP, 4 µl first strand buffer, 
1 µl RNase inhibitor, 2 µl of 0.1 M DTT and 1 µl Supercript II (all from Invitrogen) and 
heated to  for 10 min,  for 50 min and  for 10 min. Second strand synthesis was performed in 
a final volume of 15 0µl with 30 µl reaction buffer (100 mM Tris-Cl pH 6.9, 23 mM  , 450 
mM KCl, 0.75 mM •-NAD
+, 50 mM (), 3µl of 10 mM dNTP, 4 µl E. coli DNA polymerase I 
(10 units/µl), 1 µl E. coli DNA Ligase (10 units/µl),1 µl E. coli RNase H (2 units/µl) and 
incubated  at    for 2  hr. To fill in the 3’ overhangs of the first strand, 2  µl of T4 DNA 
polymerase (5 units/µl) was then added and incubated for 5 min at , followed by addition of 96 
 
10 µl of 0.5M EDTA to stop the reaction. The second strand DNA synthesis reaction was 
cleaned by adding equal volume of (25:24:1) phenol:chloroform:isoamylalcohol and 
centrifuging at 12,000 x g for 2 min. The aqueous layer was transferred to a new tube and 
DNA was precipitated with 0.5 volumes of 7.5 M ammonium acetate and 2.5 volumes of pre-
cooled ethanol. Samples were centrifuged at 12,000 x g for 15 min and DNA pellets were 
washed twice with 500 µl of 80% ethanol and resuspended in a final volume of 12 µl in 
RNase free water. 
 
2.7.2 Preparation of Biotinylated cRNA Target by In Vitro Transcription 
12 µl of phenol/chloroform precipitated double standed cDNA was used per 40 µl reaction 
with 4µl biotin labeled ribonucleotides, 2 µl T7 RNA polymerase, 4 µl 10X DTT, 4 µl 10X 
RNase inhibitor and 4 µl 10X IVT reaction buffer (Enzo Life Sciences, Farmingdale, NY). 
Reaction was incubated at 
 
 for 16 hr. Contaminants were removed using RNeasy clean-up kit 
(Quiagen, USA) according to the manufacturer’s instructions. cRNA was made up to 100 µl 
with RNase-free water and added to 350 µl of buffer RLT. 250 µl ethanol was added and the 
sample was added to the RNeasy spin column. Samples were centrifuged at 13,000 x g for 15 
sec, 500 µl of RPE buffer was then added followed by centrifugation at 13,000 x g for 15 sec. 
Next, 500 µl of 80% ethanol was added and samples were centrifuged at 13,000 x g for 5 min 
and eluted in 30µl RNase-free water by centrifugation at 13,000 x g for 1 min. The quality of 
biotinylated aRNA was assessed using a Bioanalyser 2100.  
2.7.3 Target cRNA Fragmentation and Hybridisation 
Probe arrays were from Affymetrix (Rat expression  230)  and contain 25-mer probe sets 
interrogating 15,000 mRNA transcripts and EST clusters from the UniGene database. These 
arrays contain maintenance genes (GAPDH, beta-Actin, hexokinase 1), which facilitate 
expression normalization between each sample. The also contain hybridization controls of 
eukaryotic origin (bioB, bioC, bioD, Cre), to provide alignment signals for the image analysis 
software as well as 100 probe sets for normalistaion controls to allow for fluorescence 
differences between chips due to the procedure  alone. 15  µg biotinylated aRNA was 
hydrolysed into 60-200 nt fragments in a 30 µl reaction with 6 µl cRNA fragmentation buffer 
(200 mM Tris-acetate, pH 8.1, 500 mM KOAc, 150 mM MgOAc), heated to  for 35 min then 
placed on ice. 15 µg fragmented cRNA was added to 3 nM control olignonucleotide, 15 µl 
hybridization controls, 30 µg herring sperm DNA, 150 µg BSA, 150 µl 2X hybridization 97 
 
buffer (200 mM MES buffer, 2 M NaCl, 40 mM EDTA, 0.02% Tween-20), 30 µl DMSO in 
300 µl   and heated to  for 5 min,  for 5 min and centrifuged at 13,000 x g to remove any 
insoluble material. The probe array was filled with 1X hybridization buffer and incubated at  
for 10 min, this solution was then removed, replaced with 200 µl hybridization solution (10 
µg RNA probe) and rotated at 60 rpm for 16 hr at 
 
. 
2.7.4 Fluidics Protocol for Microarray Staining 
Microarray signals are generated by binding of phycoerythrin labeled streptavadin (SAPE) to 
the biotinylated cRNA targets which are hybridized to the RNA probes on the chip. An 
amplification step is also included in which an anti-streptavadin goat antibody binds to 
SAPE, this is followed by a biotinylated anti-goat antibody and then a further SAPE binding. 
Microarrays were washed with buffer A (900 mM NaCl, 60 mM  , 6 mM EDTA, 0.01% 
Tween-20) with 10 cycles of 2 mixes/cycle at  followed by 4 cycles of 15 mixes/cycle with 
buffer B (90 mM NaCl, 6 mM  , 0.6 mM EDTA, 0.01% Tween-20) at . The probe array was 
stained for 10 min in a solution containing 10 µg/ml SAPE in stain buffer (900 mM NaCl, 6 
0mM  , 6  mM EDTA, 0.01% Tween-20, 0.2  µg/ml BSA, 0.2  µg/ml Ficoll, 0.2  µg/ml 
polyvinylpyrolidone) at  and washed with buffer A for 10 cycles, 4 mixes/cycle at . The probe 
was then stained for 10 min in antibody solution (5 µg/ml biotinylated antibody in stain 
buffer) at , then stained for a further 10 min with SAPE solution at . The final wash consisted 
of 15 cycles, 4 mixes/cycle with buffer A at  and the array was kept at 
 
 in holding buffer (100 
mM MES, 1 M NaCl, 0.01% Tween-20). Microarrays were scanned using an Affymetrix 
GeneChip scanner. 
2.7.5 Microarray Data Analysis 
Quality control was carried out using Affymetrix GCOS software. Downstream analysis was 
conducted with Bioconductor and Genespring 7.3.1. The R 2.8 programmes affylmGUI and 
OneChannelGUI were downloaded from the Bioconductor resource in conjunction with the 
required  BioC 2.3 software packages and used to read CEL files and prepare intensity box-
plots and RNA degradation plots. Background correction, normalization and summarization 
of the probe-level data into probe-set expression values were carried out using Robust Multi-
array Analysis (RMA) and GC-RMA. Differential expression was calculated using limma 
and outputs included the log2-fold change, the moderated t-statistic, P-value and the posterior 
log-odds of differential expression with Benjamini and Hochberg false discovery rate (FDR). 98 
 
Using Genespring 7.3.1, signal values were calculated using MAS 5.0, scaled to 100 and 
normalised to the median. Statistical analysis was carried out using a two-tailed students t-test 
with Welsh correction and Benjamini and Hochberg FDR. Genes were considered to be 
differentially expressed where there was a fold change  •2 with a P value  <0.05. Gene 
ontology analysis was carried out using a combination of Affymetrix GO terms and manual 
Pubmed searches and with the Ingenuity package.  
 
2.7.6 Ingenuity Pathway Analysis 
To uncover function groupings and putative interaction networks, lists of differentially 
expressed genes were analysed using Ingenuity Pathway Analysis (IPA) software (Ingenuity 
Systems, Redwood City, CA). Datasets containing gene identifiers and expression values 
were mapped to the corresponding identifier in the Ingenuity Pathway Knowledge Base 
(IPKB) which ascribes functional groupings and known interactions from the published 
literature. The Fischer’s test is used to calculate a p-value which determines whether the 
biological function assigned to the gene signature is due to chance alone. Therefore 
functional analysis describes biological functions that are most significant to the genes in 
each list. The IPA algorithm applies a score to rank networks based on the number of focus 
genes and the network size. Networks are related graphically where each gene is represented 
as a node, links between nodes denote biological relationships between genes and are 
supported by at least one peer reviewed publication.  Colour intensity signifies levels of 
differential regulation and uncoloured nodes are integrated by the IPA algorithm being 
relevant to the network but not differentially regulated in the input gene signature. 
 
2.8 Propagation and Purification of Plasmid DNA 
2.8.1 Preparation of Competent JM109 
The E.Coli strain JM109 was used for the propagation of plasmid DNA. E.Coli was streaked 
on a Luria Bertani (LB) agar plate (1% NaCl, 1% tryptone, 0.5% yeast extract, 2% agar) for 
16 hr, a single colony was picked and bacteria were grown overnight in 10 ml LB medium in 
an orbital shaker at . 1 ml of overnight culture was inoculated into 99 ml LB and grown at  in 
an orbital shaker until an optical density of 0.3-0.4 at 600 nm had been reached. Cells were 
centrifuged at 3000 x g for 5 min at  and resuspended in 10 ml of MR buffer (10 mM RbCl, 
10 mM MOPS, pH 7). Cells were centrifuged at 3000 x g for 5 min at  and 8 ml MRC buffer 99 
 
was added (10 mM RbCl, 50 mM , 100 mM MOPS, pH 6.5), cells were incubated on ice for 
30 min. Bacteria were then centrifuged at 3000 x g for 5 min at , resuspended in 5 ml MRC 
buffer containing 15% glycerol, snap frozen in liquid nitrogen and stored at -
 
. 
2.8.2 Transformation of JM109 
500 ng plasmid was added to 50 µl competent JM109 E.Coli and left on ice for 30 min. Cells 
were then heat shocked to  for 45 seconds and placed in ice for 2 min. The E.Coli were then 
added to 1ml LB medium in a 1.5 ml ependorff tube and incubated in an orbital shaker at  for 
90 min. 500 µl of transformed E.Coli was then added to an LB agar plate containing 0.1 
mg/ml ampicillin or 0.05mg/ml kanamycin, incubated at  overnight and stored at 
 
. 
2.8.3 Large Scale plasmid DNA Extraction from E.Coli 
A single colony of transformed E.Coli was inoculated into 500 ml LB medium with the 
appropriate selection antibiotic and incubated overnight in an orbital shaker at . The 
following day, cells were centrifuged at 6000 x g for 15 min at  and resuspended in 10 ml P1 
buffer (10 mM EDTA, 50 mM Tris-HCl, pH 8.0, 100 µg/ml RNase A). 10 ml P2 buffer was 
added (0.2 M NaOH, 1%SDS) and cells were incubated at rt for 5 min. 10 ml chilled P3 
buffer was added (3 M potassium acetate, pH 5.5) and incubated on ice for 20 min followed 
by centrifugation at 20,000 x g for 30 min at . The supernatant was added to an equilibrated 
anion exchange Quiagen-tip  and the resin was washed twice with QC buffer (1.0M NaCl, 50 
mM MOPS, pH 7.0, 15% isopropanol). The plasmid DNA was eluted in buffer QF (1.25 M 
NaCl, 50  mM Tris-Cl pH 8.5, 15% isopropanol) and precipitated in 0.7 volumes of 
isopropanol. DNA was centrifuged at 15,000 x g for 30 min at  and the DNA pellet was 
washed with 70% ethanol. After centrifuging for 10 min at 15,000 x g, the DNA pellet was 
allowed to air dry for 10 min and was resuspended in TE buffer (10mM Tris-Cl, 1 mM 
EDTA, pH 8.0). DNA concentration was determined by reading absorbance at 260 nm in a 
spectrophotometer, where an OD of 1 is equal to 50  µg/ml of double stranded DNA. /
 
readings indicate levels of protein contamination, only plasmid preparations with an / 
2.8.4 DNA Restriction Digest and Agarose Gel Electrophoresis 
of <1.8 
were used. Typical yields from 500 ml culture were 0.5-1 mg plasmid DNA. 
All plasmid  DNA preparations were examined by restriction endonuclease digestion to 
ensure that the insert was correct. 0.3 µg plasmid DNA was incubated with 10 U recombinant 100 
 
DNA endonucleases from NEB in the appropriate buffer as recommended by NEB and 
incubated for 16 hr at 
 
. Agarose gel electrophoresis was used to determine the size of digested 
products. 1% agarose was dissolved in TAE (0.04 M Tris-HCl, 0.02 M sodium acetate, 1 mM 
EDTA), for small DNA products of ~ <300 base pairs TBE buffer was used (45 mM Tris 
base, 45 mM boric acid, 1 mM EDTA pH 8.0) as it has a better resolving capacity for small 
DNA fragments. 0.5 µg/µl ethidium bromide was added to the gel to allow visualization of 
DNA under UV light. DNA loading dye was added from a 6 x stock (0.25% bromophenol 
blue, 0.25% xylene cyanol, 30% glycerol) and DNA was electrophoresed for 1 hr at 100V. 
2.8.5 DNA Transfection 
A complete list of the constructs used in these studie sis presented in Appendix 1B. NRVM 
were transfected using the calcium phosphate method.   was added dropwise to a solution 
containing plasmid DNA with 50% HBS (280 mM NaCl, 50 mM HEPES) and 70 mM   to 
give a final  concentration of 0.125 M. The DNA/
 
 mix was incubated at room temperature 
for 20 min and then added to cells. Fresh DMEM 1% FBS was added after 16 hr. Typical 
transfection efficiencies were of the order of 5-15%. Cell lines were transfected using the 
liposomal reagent fugene-6, which was added to DNA at a ratio of 2:1 or 3:1 (µl fugene-6: µg 
DNA), incubated for 20 min then added to cells. Fresh DMEM 10% FBS was added after 16 
hr. Typical transfection efficiencies were of the order of 50-90%. 
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2.9 Cell Death Measurements 
2.9.1 TdT mediated dUTP nick end labbeling (TUNEL)  
TUNEL allows fluorescent labelling of new 3’-OH DNA ends generated by  DNA 
fragmentation, in this way terminal transferase (TdT) is used to catalyze  binding of 
rhodamine labelled dUTP to the end of DNA strand breaks produced during apoptosis 
(Gavrieli et al., 1992). It must be noted however, that as well as the double strand breaks 
generated during apoptosis, TUNEL may also label single strand breaks generated by 
necrosis (Charriaut-Marlangue et al., 1995). TUNEL was carried out using commercial kits 
purchased from Roche. Cells grown on coverslips in 24 well plates were washed in PBS and 
fixed in 4% paraformaldehyde for 10 min at rt. Cells were then washed twice with PBS and 
permeabilised using 0.5% Triton-X 100 for 10 min at rt, followed by two washes with PBS. 
250  µM dUTP, 10U dTdT and 250  µM CoCl2 in TdT reaction buffer (1  M potassium 
cacodylate, 125 mM Tris-HCl, 1.25 mg/ml BSA, pH 6.6) were added to cells in for 1 hr at 
     
. 
The reaction was stopped by incubating cells in 1 mM EDTA for 5 min. Hoecht reagent was 
added to stain nuclei and cells were washed 6 times in PBS. TUNEL positive cells were 
visualised by fluorescence microscopy using a rhodamine filter (550-580nm) and appeared as 
bright red nuclei.   
2.9.2 Exclusion of Trypan Blue 
Trypan blue is a stain which enters dead cells with disrupted outer membranes and thus the 
level of cell death can be assessed by counting the number of blue cells compared against 
cells which exclude the dye. Cells were added to 0.4% trypan blue solution (Sigma) at 
appropriate dilutions and incubated for 5 min at room temperature. Dead cells appear blue 
under light microscopy and the number of dead cells was counted using a haemocytometer. 
                         
2.9.3 Annexin V Staining 
Measurement of apoptosis using annexin V is based on the fact that once cells begin to 
undergo apoptosis, phosphatidlyserine (PS) flips from the inner to the outer leaflet of the cell 
membrane. Annexin V is a 
+-dependent
 phospholipid binding protein with a high affinity for 
PS (Meers et al., 1991). Fluorescently labelled annexin V can thus be used to quantify levels 
of exposed PS by flow cytometry and is therefore a sensitive marker of  apoptosis 
(Kooperman et al., 1994). Cells were washed once in PBS, trypsinised for three minutes and 102 
 
removed to polypropylene FACS tubes. Cells were centrifuged for 5min at 300 x g , washed 
once in PBS and resuspended in 300 µl of AnnexinV binding buffer (0.1 M HEPES pH 7.4, 
1.4 M NaCl, 25 mM 
 
) with 3 µl of AnnexinV-PE (BD biosciences) and 5 µl 7AAD (1 mg/ml 
Sigma). Annexin V and 7AAD fluorescence was measured after 30 min in the FL2 and FL4 
channels respectively of a Becton Dickinson flow cytometer. 
2.9.4 Quantification of Infarct Size in the Heart 
Following 25 min ischaemia and 2 hr reperfusion, the heart was removed, the left ventricle 
separated and the risk area was removed (assed by Evans Blue staining, section 2.3.1). The 
tissue from the risk area was cut into
 small pieces and incubated with 0.5
 mg/ml p-nitroblue 
tetrazolium for 30 min at 37°C. Dehydrogenase enzymes present in viable tissue catalyse 
conversion p-nitroblue tetrazolium to a formazan derivative and therefore infarcted tissue 
(nonviable) will exclude the stain. The
 stained tissue was separated from the infarcted tissue, 
weighed,
 
 
and the infarct size expressed as a percentage of the risk area. 
2.9.5 Statistical analysis 
All values are presented as mean ± standard error mean (SEM) of n obsevations. Where two 
values are being compared a student’s t test was used. Where groups of values were 
compared a Two-way analysis of variance (ANOVA) was used followed by either a Dunnet’s 
or Bonferroni post test. Micrarray data was anaysed using the modified Bayesian method 
linear models statistics (Limma) followed by Benjamini-Hochberg false discovery rate for 
multiple testing. Differences among groups were considered significant at p < 0.05. 
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Chapter 3: Investigating the 
Role of STAT3 in 
Ischaemia/Reperfusion 
Injury 
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3.1 Aims 
Molecular control of I/R injury is a highly organised and complex process. However, while 
our understanding of intracellular signalling pathways activated during reperfusion has grown 
considerably during the last decade, uncovering the precise signalling cascades which control 
cell death in the myocardium is highly desirable if we are to develop novel clinical 
interventions for I/R injury. Knowledge of transcription factors which regulate the expression 
of proteins involved in apoptosis should greatly improve our understanding of how cell death 
is orchestrated in cardiac cells following I/R damage. Thus transcription factors constitute 
appealing targets for therapy. It is now well appreciated that STAT1 serves as a pro-apoptotic 
transcription factor following I/R injury in the heart (Stephanou et al., 2000, 2002). Less is 
known however about the role of STAT3 in the myocardium during I/R injury.  STAT3 has 
been shown to function as an anti-apoptotic transcription factor in certain cell types and a 
pro-apoptotic factor in others (Bromberg et al., 1999, Chapman et al., 1999, Shen et al 2001). 
With this in mind, the aims of this chapter were as follows. 
•  In general, to ascertain whether STAT3 has a role in I/R mediated cell death in 
cardiac cells 
•  Characterise the expression and transcriptional activity of STAT3 in cardiac myocytes 
during I/R injury 
•  Identify the kinases responsible for STAT3 phosphorylation in cardiac myocytes 
•  Characterise the activity of STAT3 during I/R injury in vivo 
•  Disect the role of ROS in mediating STAT1 and STAT3 activity 
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3.2  Overexpression of STAT3 Protects Cardiac Myocytes from 
Ischaemia/Reperfusion Induced Cell Death 
 In order to ascertain if STAT3 has a role in cardiac myocyte cell death, transient transfection 
experiments were carried out using neonatal rat ventricular cardiac myocytes (NRVM). Since 
murine STAT3 expression constructs were more readily available, their activity in rat cardiac 
mycoytes was initially tested by dual-luciferase promoter assays since murine and rat STAT3 
are 99% identical at the protein level. Two well characterised STAT3 target promoters were 
used, p21 and Ly-6E. STAT3 has been shown to bind to the p21 promoter directly by ChIP 
assay and the  Ly-6E promoter contains an upstream GAS element responsive to STAT3 
(Khan et al., 1993, Giraud et al., 2004). Cells were transfected for 48 hr with reporter 
constructs and with either STAT3 or pcDNA3. Luciferase activity normalised to renilla 
demonstrated that STAT3 increased promoter activity of p21 by 3.1 ± 0.8 fold and Ly-6E by 
3.1 ± 0.2 fold  (Fig 3.1). This demonstrates that the murine STAT3 construct is indeed 
transcriptionally active in NRVMs.    
 
Fig 3.1. Murine STAT3 is transcriptionally active in neonatal rat ventricular myocytes. 0.5 µg of 
the p21 or Ly6E promoter construct and 100 ng CMV-renilla construct were transfected into cardiac 
myocytes in 6 well plates with 0.5 µg STAT3-pcDNA3 vector or pcDNA3 alone. Luciferase activity 
was measured after 48 hr and expressed as relative luciferase units (RLU) normalised to 1. * p<0.05, 
** p<0.01, students t-test, n=3, experiment repeated in triplicate.  
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An in vitro I/R system was used to measure I/R induced cell death in NRVMs using the 
method of Esumi  (Esumi et al., 1991). In this system  glycolysis is inhibited with 2-
deoxyglucose, while the addition of 12 mM potassium and 20 mM lactate at pH 6.5 leads to 
membrane depolarisation and increased hydrogen ion and 
+ concentration. Furthermore, the 
cells are deprived of oxygen by placing them in an ischaemic chamber (5% , 95% Argon); 
this in vitro system therefore mimics most of the conditions experienced by cardiac myocytes 
during ischaemic damage in vivo. Since true I/R injury can only be experienced in an in vivo 
context, this in vitro system is more correctly termed simulated I/R injury but for clarity’s 
sake it will herein be referred to simply as I/R injury. For control experiments, cells were 
placed in a buffer similar to the Esumi buffer but which importantly was at pH 7.4 and 
contained 3.8 mM KCL without 2-deoxyglucose or sodium lactate. The control cells were 
incubated in a standard 5% 
After the indicated times of reperfusion, the myocytes were fixed in 4% paraformaldehyde 
and levels of cell death were measured using the terminal transferase dUTP nick-end labeling 
(TUNEL) technique. Cell death is assessed by counting TUNEL positive cells (red) using 
fluorescent microscopy and expressed as the percentage of TUNEL positive cells per number 
of transfected cells (GFP positive cells). A representative example of a GFP and a TUNEL 
positive cell is shown in Fig 3.2a and the average increase in TUNEL positive cells following 
I/R injury is shown in Fig 3.2b. It should be noted that there is a level of 20% cell death in the 
control cells and there are several possible reasons for this; (1) a significant number of cells 
which die during the myocyte isolation can remain attached in culture and give a low level of 
false positives, (2) myocytes are maintained in 1% FCS and thus there is natural cell death 
over time in each culture and (3) there is also a low level of background staining inherent in 
the TUNEL technique. Notwithstanding these technical limitations, it is clear that in vitro I/R 
injury increases cell death in a time- dependent manner (Fig 3.2b).  
 chamber for the duration of the ischaemic episode. Following 
ischaemia, cells were reoxygenated by washing away the ischaemic buffer and replacing it 
with DMEM with 1% foetal calf serum (FCS); fresh buffer was also added to control cells. 
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Fig  3.2.  Transfection of STAT3 into cardiac myocytes confers protection from 
ischaemia/reperfusion injury. (A). GFP (460-480nm) and TUNEL (550-580nm) double positive 
cells were assessed by fluorescent microscopy. (B) Typical cell death observed following I/R injury 
by counting the number of TUNEL positive cells per total population of GFP positive. Statistical 
analysis was carried out with a one way ANOVA with Dunnett’s post test, * p<0.05 compared to con 
(C) Cardiac myocytes were transfected in 6 well plates with 0.5 µg GFP construct and 0.25 µg 
STAT3-pcDNA3 or pcDNA3 for 48 hr and subjected to I/R injury for the indicated times. Cell death 
was measured using TUNEL, a minimum of 200 GFP positive cells were counted per experiment. 
Experiments repeated in triplicate, statistical analysis was carried out using a 2-way ANOVA with a 
Bonferroni post test, * p<0.05. 
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To assess the effect of STAT3 overexpression on cell viability, NRVMs were co-transfected 
with GFP and either STAT3 or pcDNA3 empty vector. 48 hr after transfection, cells were 
exposed to 4 hours ischaemia, followed by either 4 hr or 16h reperfusion (I/R). As expected, 
I/R resulted in significant cell death, most notably after 16 hr reperfusion when 50.0 ± 4.5% 
of cells were TUNEL positive (Fig 3.2c). Importantly, transient expression of STAT3 
conferred significant protection from I/R mediated cell death after 16 hr reperfusion, reducing 
the number of TUNEL positive cells by 39.0 ± 8.1% (Fig 3.2c). This suggested that STAT3 
may function as an anti-apoptotic factor during I/R injury. 
 
3.3 Adenoviral Delivery of Dominant Negative STAT3 Increases I/R mediated 
Cell Death in Cardiac Myocytes 
To further clarify the role of STAT3 in myocardial apoptosis, a dominant-negative STAT3 
adenovirus (Ad ST3-DN) was employed. The Y705 phosphorylation site in the C-terminal 
domain of STAT3 is essential for STAT3 activation and a tyrosine-phenylalanine mutant 
(Y705F) functions in a dominant-negative manner (Kunisada et al., 1998, Williams et al., 
2004). To measure cell death in these experiments, annexin V/7-AAD staining was used as an 
alternative to TUNEL. 7-amino-actinomycin D (7-AAD) is a fluorescent dye (630-660nm) 
which interchelates DNA and can only enter cells which have disrupted cell membranes and 
as such can be used as a marker of necrosis. Using annexin V in combination with 7-AAD 
allows the distinction of apoptotic and necrotic cell populations, cell populations positive for 
both annexin V and 7-AAD are undergoing secondary necrosis, which occurs when apoptosis 
has reached an advanced stage in the absence of phagocytosis. For all experiments using this 
method, cell death is given as the total population of apoptotic and necrotic cells.  
 
Cardiac myocytes were initially transduced with a GFP control adenovirus (Ad GFP) or Ad 
ST3-DN for 48 hr at a multiplicity of infection (moi) of 10, 100 and 300. GFP expression was 
visualised by fluorescent microscopy and revealed that an moi of 100 was sufficient to give 
>90% transfection efficiency (Fig 3.3a). Cell lysates from transduced cardiac myocytes were 
examined for STAT3 expression and showed very high levels of overexpressed STAT3-DN, 
especially at an moi of 100 and 300 (Fig 3.3b). Next, cardiac myocytes were transduced with 
Ad GFP or Ad ST3-DN at moi=100 for 48 hr, cells were then subjected to I/R and levels of 109 
 
cell death were examined. Using this approach, adenoviral delivery of dominant negative 
STAT3 was found to increase I/R mediated cell death from 46.0 ± 3.1 % in the GFP control 
group to 81.2 ± 6.9 % in the STAT3 D/N group (Fig 3.4a), representative flow cytometry 
plots are shown in Fig 3.4b. Since dominant negative STAT3 blocks STAT3 mediated 
transcriptional activity (Williams et al., 2004), this data demonstrates that a fully 
transcriptionally active STAT3 is necessary to protect cardiac myocytes from I/R induced cell 
death, further verifying the cytoprotective role of STAT3 in cardiac myocytes.  
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Fig 3.3 Adenoviral transduction of cardiac myocytes. Cardiac myocytes were seeded in 12 well 
plates at a density of 6 x /cm2. Ad GFP or Ad ST3-DN with viral titres of 5 x  ifu/ml and 10 x 
   
 ifu/ml 
respectively were added at moi of 10, 100, 300. (A) 48 hr post transduction, GFP expression was 
visualised by fluorescent microscopy. (B) Lysates from transduced cells were examined for STAT3 
expression by western blot, GAPDH was used as a loading control. 
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Fig 3.4. Dominant negative STAT3 increases I/R induced cell death in cardiac myocytes. Cardiac 
myocytes were transduced in 6 well plates for 48 hr with control Ad GFP or Ad STAT3-DN at moi=100. 
Cells were then subjected to 4 ischaemia and 16 hr reperfusion and cell death was ascertained by annexin 
V and 7AAD staining measured by flow cytometry. (A) % annexin V / 7AAD positive cells, * p<0.05, ** 
p<0.01, one way ANOVA with Bonfferoni post test, n=3 per group, average of two experiments. (B) 
Representative flow cytometry plots for each group. 
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The preceding experiments addressed the question as to whether STAT3 protects myocytes 
from I/R injury. A significant amount of the cellular damage induced during I/R injury is due 
to oxidative stress and the production of toxic free radicals during both the ischaemic and 
reperfusion phases. To extend these findings the question was therefore asked whether 
STAT3 can also protect myocytes from oxidative stress. STAT3 or pcDNA3 were transfected 
into NRVMs for 48 hr at which time myocytes were treated with 0.1 mM 
 
 for a further 16 hr 
and assessed for cell death using Annexin V with 7AAD (Fig 3.5). STAT3 overexpression 
led to a 20.2 ± 5.4% reduction in TUNEL positive cells, showing that like its protective 
activity during I/R, STAT3 can also protect against oxidative stress. 
 
 
 
Fig 3.5. STAT3 Protects Cardiac Myocytes From Oxidative Stress.  Cardiac Myocytes were 
transfected in 6 well plates with GFP together with pcDNA3 control or with STAT3 expression 
construct. After 48 hr, myocytes were treated for 16 hr with 0.1 mM H2O2 and levels of cell death 
were measured by Annexin V/7AAD staining. Statistical analysis was carried out using a one way 
ANOVA with Bonferroni post test, *p<0.05, n=3 per group, representative experiment shown. 
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3.4 Deletion of STAT3 Sensitises Cells to Oxidative Stress and I/R Injury  
While overexpression is a very useful tool to examine the effects of increased transcription 
factor activity, it may lead to spurious results due to the non-physiological levels of 
expression. Mice with a floxed STAT3 allele do exist, however our lab was unable to attain 
them. However, mouse embryonic fibroblasts (MEFs) deficient in STAT3 were available and 
were used to further validate the protective role of STAT3 and to ascertain the  cellular 
response to I/R and oxidative damage in the context of STAT3 deficiency. The MEFs used 
for these studies were obtained from Valeria Poli’s group and have been immortalised by 
transformation with SV40 large T antigen (Alzoni et al., 2001). STAT3 deletion was carried 
out by Cre mediated deletion of a floxed STAT3 allele, which removes exons 12-14, the 
/fl 
MEFs used in these studies are thus herein referred to here as wild type (Costa-Pereira et al., 
2002). Western blotting confirmed total deletion of STAT3 (Fig 3.6a). It should be noted here 
that MEFs are more sensitive to I/R injury than neonatal cardiac myocytes. Subjecting MEFs 
to 2 hr ischaemia and 16 hr reperfusion revealed that STAT3
-/- MEFs were highly susceptible 
to I/R injury, indeed few STAT3
-/- cells remained attached to the culture dish following this 
stress (Fig 3.6b). To quantify the difference in cell death, STAT3
+/+ and STAT3
-/- MEFs were 
challenged with a less lethal dose of reperfusion injury of 2 hr. This resulted in a 2.8 ± 0.7 
fold increase in cell death in the STAT3
-/-  MEFs compared to STAT3
+/+ 
   
MEFs when 
quantified by both annexin V/7-AAD staining and a 2.8 ± 0.4 fold increase when quantified 
by trypan blue uptake (3.6 c,d). 114 
 
 
 
Fig 3.6. STAT3-/- MEFs are highly sensitive to I/R damage. (A) Western blot demonstrates that 
STAT3
-/- MEFs are completely deficient in STAT3 protein. (B) STAT3
+/+ and STAT3
-/-
   
 MEFs were 
subjected to 2 hr ischaemia and 16 hr reperfusion and visualised under light microscopy. (C) MEFs were  
subjected to 2 hr ischaemia followed by 2 hr  reperfusion and cell death was quantified by annexin V and 
7AAD staining (D) Cells were treated as in C and cell death was quantified by trypan blue uptake * 
p<0.05, student’s t-test, n=3 per group, average of three experiments 
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Next, wild type and STAT3 knockout MEFs were treated with three separate doses of   for 24 
hr and cell death was measured by flow cytometry (Fig 3.7a). At doses of 0.5, 1 and 5 mM , 
STAT3 deficient cells were significantly more susceptible to oxidative stress; 0.5 mM   
induced a 1.5 ± 0.1 fold increase in cell death in STAT3
-/- cells, 1 mM induced a 1.7 ± 0.2 
fold increase and 5 mM a 1.8 ± 0.1 fold increase (Fig 3.7a). A kinetic analysis, this time 
using trypan blue uptake, showed that at 8 hr of 0.5 mM   there was a 2.5 ± 0.6 fold increase 
in cell death in STAT3
-/- MEFs and at 24 hr of 0.5 mM 
Taken together, both the I/R and 
 treatment there was a 1.7 ± 0.6 fold 
increase (Fig 3.7b). This demonstrates that there is both a time and dose dependent increase 
in cell death in STAT3 deficient MEFs. 
  experiments clearly show that the absence of STAT3 
renders fibroblasts susceptible to the toxic effects of I/R injury and   
                                                                                                                                                          
mediated oxidative 
stress.  Furthermore, these experiments are consistent with the previous data showing that in 
cardiac cells, overexpression of STAT3 confers protection from, and inhibition of STAT3 
increases susceptibility to I/R injury.                    116 
 
 
Fig 3.7 STAT3
-/- MEFs undergo enhanced cell death following oxidative stress. (A) STAT3
+/+ and 
STAT3
-/- MEFs were treated with indicated concentrations of  for 24 hr and cell death was assessed 
by annexin V and 7AAD staining. (B) MEFs were treated with 0.5 mM   
 
for the indicated times and 
cell death was measured by trypan blue uptake. Statistical analysis was carried out using a 2-way 
ANOVA with Bonfferroni post test, * p<0.05, ** p <0.01, *** p<0.001 
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3.5  STAT3 becomes Phosphorylated and Transcriptionally Active Following 
Ischaemia/Reperfusion in vitro 
While the previous experiments demonstrate that exogenous STAT3 can protect myocytes 
from I/R damage, it is unclear whether endogenous STAT3 becomes activated during I/R 
injury. In resting conditions, the majority of STAT3 in cells is inactive and only becomes 
active once it is phosphorylated at either Y705 or S727 (Levy and Darnell, 2002). To assess 
the STAT3 phosphorylation status, myocytes were subjected to  either  4 hr ischaemia  or 
ischaemia plus 4 hr or 16 hr reperfusion, followed by western blotting with phospho-specific 
antibodies. Fig 3.8a shows that both STAT3 tyrosine and serine phosphorylation were 
induced during ischaemia, and stayed active up to 16 hr (Fig 3.8a). The levels of total STAT3 
remained constant, showing that this was specifically due to increased phosphorylation rather 
than an increase in total protein. This demonstrates that during I/R injury, myocytes increase 
the activity of STAT3 which may be important in initiating a cardioprotective programme. 
The levels of pro-apoptotic STAT1 phosphorylation was examined in order to compare with 
that of STAT3. STAT1 was phosphorylated at both Y701 and S727 during ischaemia,   
remained constant up to 16 hr reperfusion whereas the 
 
 levels were reduced over time in 
agreement with previous studies (Fig 3.8b) (Stephanou et al., 2000, 2002). Again, total 
protein levels remained unchanged. Caspase-9 cleavage was also examined as a positive 
control for I/R induced apoptosis. Fig 3.8b shows that in this system, ischaemia induced 
partial caspase-9 cleavage, whereas reperfusion led to significant cleavage after 16 hr; this is 
consistent with previously published results (Stephanou et al., 2001). 
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Fig 3.8. Activation of STAT3 and STAT1 following I/R Injury. NRVMs were subjected to 4 hr 
ischaemia or ischaemia plus the indicated times of reperfusion and lysates were subjected to western 
blots using antibodies for (A)Tyrosine and serine phosphorylated STAT3 or (B) Tyrosine and serine 
phosphorylated STAT1 and caspase-9. GAPDH was used as a loading control.  
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While STAT3 is phosphorylated at both sites, this does not prove per se that STAT3 
dependent transcriptional activity is increased during I/R. STAT3 transcriptional activity was 
therefore assessed by examining the expression of STAT3 target genes using qPCR. qPCR 
reactions were carried out with Sybr Green and PCR quantification was determined using the 
2
-••C t
When using the 2
 method (Livak and Schmittgen, 2001). Although the Livak and Schmittgen method is 
one of the most highly cited methods for normalising qPCR, it only suggests using a single 
normalising gene. There has been subsequent debate in the literature as to the merits and 
possible pitfalls of normalising to a single control gene, thus for these studies it was chosen to 
normalise to three separate genes, namely hprt, actin and •2 -microglobulin. This minimises 
the chance of spurious results due to differences in concentration of input RNA, differing 
RNA quality and unequal reverse transcription efficiency. All three normalising genes were 
used in qPCRs unless otherwise stated. 
-••C t
 
 method, it is necessary to first ensure that the PCR efficiency of the 
target is the same as that for the normalising genes. An example is given of two tested genes 
(STAT3 and c-Fos) and two normalizing genes (Actin and HPRT) (Fig 3.9). An example 
qPCR amplification plot for these 4 genes is shown in Fig 3.9a and the melt curves are shown 
in Fig 3.9b, there were 4 distinct peaks in the melt curves showing the presence of a single 
product for each primer pair. qPCR was carried out on a 2-fold dilution series from a pooled 
set of cDNA and the threshold Ct value was plotted (y axis) versus log cDNA dilution (x 
axis) (Fig 3.9c).  The PCR efficiency was calculated using the equation m = (-1/logE), where 
m is the slope of the line and E is the efficiency (Schmittgen and Livak, 2008). Schmittgen 
and Livak recommend that the PCR efficiency of the normalizing and control genes should 
be within 10% of each other and this approach was adopted for all qPCR studies (Schmittgen 
and Livak, 2008). Fig 3.9c shows the dilution series for HPRT, actin, STAT3 and c-fos and 
demonstrates that their efficiencies were within 10% of each other and thus HPRT and actin 
were acceptable as normalizing genes. This standard approach was adopted herein for all 
qPCR experiments. 
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Fig 3.9. Testing qPCR efficiency. (A) Standard amplification plots for actin, HPRT, STAT3 and c-
fos. (B) Standard melt curves for actin, HPRT, STAT3 and c-fos. (C) qPCR of a 2-fold series dilution 
of pooled cDNA samples was carried out using primer pairs for the indicated genes and the Ct values 
were plotted against the log DNA dilution n=3. Linear regression was carried out to give the  
 
values 
and the slope (m). The efficiency (E) was calculated from the equation m = (-1/logE) and at 100% 
efficiency should be equal to 2.  
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Two STAT3 target genes, SOCS3 and c-Fos, were chosen as they have previously  been 
shown to be targets of STAT3 in other cell types (Hou et al., 2008, Yang et al., 2003). 
However, since it has not been shown that they are induced by STAT3 in cardiac myocytes, it 
was necessary to first confirm this before measuring their expression during I/R injury. 
Therefore, NRVMs were transduced for 24 hr with a constitutively active STAT3 adenovirus 
(STAT3C) and the levels of SOCS3 and c-Fos were measured by qPCR. Initially STAT3C 
was transduced at a moi of 10, 100 and 300 and moi=100 was found to give significant 
STAT3 protein expression (Fig 3.10a). Both SOCS3 and c-Fos were significantly upregulated 
by 24 hr STAT3C transduction at moi=100, whereas the levels of a non-STAT3 target gene 
HSP70 remained constant, demonstrating that both SOCS3 and c-Fos are true STAT3 targets 
in cardiac myocytes (Fig 3.10b).  
 
 
Fig 3.10 Characterisation of STAT3 dependent gene expression in cardiac myocytes. (A) 
NRVMs  were transduced with STAT3C at moi of 10, 30 and 100 and STAT3 expression was 
assessed by western blot, GAPDH was used as a loading control. (B) NRMVs were transduced with 
STAT3C adenovirus at moi=100. After 24 hr, the expression of SOCS3, c-fos and HSP70 was 
examined by qPCR. ** p<0.01, students t-test, n=3 per group, repeated in duplicate.  
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Next, a time course of I/R injury was carried out in neonatal myocytes and the levels of 
STAT3 and the STAT3 target genes SOCS3 and c-fos were measured by qPCR. The fold 
changes for each time point of reperfusion were divided by the average of the corresponding 
time points for samples which had been incubated in Esumi control buffer without I/R and 
subsequently normalized to the control time point (4 hrs in Esumi control buffer) (Fig 3.11). 
Analysing in this way takes into account any background fluctuations which occur over time 
in culture. 
 STAT3 mRNA expression was found to be reduced by 39.8 ± 10.3% by 4 hr and remained 
reduced up to 24 hr (Fig 3.11a). The mechanism of reduced STAT3 mRNA expression by I/R 
is unknown but possibilities include decreased transcript stability or induction of STAT3 
specific miRNAs during I/R.  It is interesting that this reduced mRNA expression was not 
paralleled by a decrease in protein expression (see Fig 3.8), although more detailed kinetic 
analysis of STAT3 protein turnover would be necessary to verify this. Expression of both 
STAT3 target genes however was increased by I/R injury; after 4 hr reperfusion SOCS3 
expression was increased 5.5 ± 1.3 fold and c-fos expression increased 38.9 ± 12.7 fold (Fig 
3.11b,c). Expression of both genes was still elevated after 24 hr reperfusion but returned to 
baseline after 48 hr reperfusion. This data in conjunction with the phosphorylation data in Fig 
3.8 suggests that STAT3 transcriptional activity is at its highest in the first few hours after 
reperfusion.  
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Fig 3.11. STAT3 mRNA expression is decreased and STAT3-dependent gene expression is 
increased by I/R injury. NRVMs were subjected to a time course of I/R injury and the levels of 
STAT3, SOCS3 and c-Fos were measured by qPCR and normalized to control (con) levels. Statistical 
analysis was carried out using a one-way ANOVA with Dunnett’s post test, n=3 samples, experiments 
repeated in triplicate, * p<0.05, ** p<0.01 compared to con.  
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As an alternative to qPCR, the Ly6E reporter system was again employed, since Ly-6E was 
earlier shown to be a STAT3 target gene in cardiac myocytes (Fig 3.1). I/R injury (24 hr 
reperfusion) was found to induce a 46.5 ± 7.7 fold increase in Ly6E luciferase activity, 
confirming that I/R does indeed increase STAT3 mediated transcriptional activity (Fig 3.12). 
Taken together, these data suggest that STAT3 becomes active during reperfusion and 
instigates a transcriptional programme which attempts to rescue the cell from reperfusion 
mediated cell death.  
 
 
Fig 3.12. STAT3 dependent luciferase reporter activity is enhanced by I/R injury. 1 µg of Ly-6E 
luciferase reporter and 0.1 µg CMV-renilla were transfected into NRVMs in 6-well plates for 24 hr. 
Cells were then subjected to 4 hr ischaemia and 24 hr reperfusion (I/R) or control and luciferase 
activity was measured, the RLU of the control was set to 1. ***p<0.001, n=3, experiment repeated in 
duplicate.  
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3.6 Oxidative stress induces STAT3 serine phosphorylation through an ERK-
dependent pathway  
It is well appreciated that phosphorylation of STAT3 at Y705 is mediated by JAK kinases, 
most notably JAK1 and JAK2, indeed inhibition of JAK2 with AG490 abrogates tyrosine 
phosphorylation of STAT3 in cardiac myocytes  (Mascareno et al., 2005). It is unclear 
however what kinase is responsible for phosphorylating STAT3 at serine 727 in cardiac 
myocytes. Several reports have identified putative STAT3 serine kinases (see table 1.1), 
including MAP kinases, PKC and cyclin dependent kinases, however on careful analysis of 
the literature it is clear that STAT3 S727 phosphorylation is both cell - type and - stimulus 
dependent.  
In an effort to identify the serine kinase responsible for STAT3 phosphorylation in cardiac 
myocytes,  a time course was first carried out by treating NRVMs with 100 µM . Basal 
phosphorylation of STAT3 S727 could be detected in resting cells but this was increased 
significantly by 15 min   treatment and remained elevated up to 4 hr while   treatment had no 
affect on total STAT3 protein levels (Fig 3.13a). Next, myocytes were treated with 100 µM  
for 30 min in the presence of the MEK1/2 inhibitor U0126, the p38 MAPK inhibitor 
sb203580, the JNK inhibitor sp600125, or DMSO control and STAT3 phosphorylation was 
examined (Fig 3.13b). Inhibition of JNK or p38 MAPK had no effect on STAT3 serine 
phosphorylation, however U0126 treatment almost completely abolished STAT3 S727 
phosphorylation to a level below that of baseline, densitometric analysis showed a reduction 
of almost 90% in the U0126 treated cells compared to DMSO control (Fig 3.13c). As 
expected, inhibition of MEK1/2 reduced the levels of phosphorylated ERK1/2. To verify that 
inhibition of the MEK1/2-ERK1/2 pathway abrogated STAT3 S727 phosphorylation, a 
second unrelated MEK1/2 inhibitor, PD98059, was used. This likewise reduced the levels of 
 
 
phosphorylation, confirming that the reduction is not due to a non-specific effect of U0126 
(Fig 3.13d). This data clearly shows that STAT3 is phosphorylated at serine 727 in cardiac 
myocytes by oxidative stress and that the kinase responsible is likely to be either ERK itself 
or possibly a downstream ERK target. Crosstalk between the MEK1/2 – ERK 1/2 pathway 
and the STAT3 pathway may therefore represent an important point in cell fate decisions in 
cardiac myocytes. 126 
 
 
Fig 3.13. STAT3 serine 727 phosphorylation is ERK1/2 dependent. (A) NRVMs were treated with 
100 µM   for up to 4 hr and western blots were carried out using the indicated antibodies. (B) NRVMs 
were treated with 100 µM  for 30 min in the presence of the MEK1/2 inhibitor U0126, the p38 MAPK 
inhibitor SB200538, the JNK inhibitor SP600125 or DMSO control and western blots were carried 
out using the indicated antibodies (C) The levels of total and serine 727 phosphorylated STAT3 from 
B were quantified by densitometry and the ratio of /STAT3 was calculated, the samples which were 
not treated with 
 
 (con) were set at 100% with all other samples expressed relative to this, repeated in 
triplicate. (D) NRVMs were treated as in B with the addition of the MEK1/2 inhibitor PD98059. 
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3. 7 Activation of STAT1 and STAT3 following in vivo ischaemia/reperfusion 
injury 
Since STAT3 was shown to act as an anti-apoptotic factor during I/R injury in vitro (see 
above), and STAT1 has been demonstrated to increase cardiac myocyte apoptosis in vitro 
(Stephanou et al., 2000), the in vivo activation of STAT1 and 3 was examined. The left 
coronary artery is responsible for supplying the left ventricle with blood and has two main 
branches; the anterior descending (LAD) and the circum-flex. In this in vivo model of I/R 
injury, the anterior descending left coronary artery is constricted as this artery is the one most 
commonly obstructed in human pathology. This model was carried out in conjunction with 
Dr. Ahila Sivarajah at St. Bartholomew's and The Royal London School of Medicine and 
Dentistry.  
A time course of 25min LAD occlusion followed by up to 2 hr of reperfusion was carried out 
in male wistar rats.  In order to assure consistency between animals, mean arterial blood 
pressure (MAP) and heart rate were measured throughout the experiment (Fig 3.14a). MAP 
fell during ischaemia but remained constant throughout reperfusion, while heart rate 
remained constant during both ischaemia and reperfusion. At the end of reperfusion, Evans 
blue dye was infused to separate the risk from non-risk area of the left ventricle (Fig 3.14b), 
the risk area denotes the area of the heart most deprived of oxygen (causing it to exclude 
Evans dye) and therefore the area at risk of becoming infarcted. To ensure that the model was 
working consistently, the infarct size was measured in 8 animals. The infarct size is expressed 
as a percentage of the area at risk; 2 hr of reperfusion injury increased the infarct size from 8 
± 1% in the sham group to 56 ± 2% in the I/R group (Fig 3.14c).  
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Fig 3.14. Parameters of the in vivo ischaemia/reperfusion model. (A) Measurement of mean 
arterial pressure and heart rate. The right carotid artery was cannulated and connected to a pressure 
transducer in order to monitor mean arterial pressure  and heart rate throughout ischaemia and 
reperfusion (n=8 animals). (B)  Separation of left ventricle into risk and non-risk. Following 
reperfusion, the coronary artery was re-occluded and Evans Blue dye was injected into the left 
ventricle which allows separation of the ventricle into risk and non-risk. (C) Infarct measurement; the 
area at risk (AAR) was separated, and incubated with 0.5 mg/ml p-nitroblue tetrazolium for 30 min at  
 
C,  the non-stained tissue was weighed and expressed as a percentage of the total weight of the AAR.  
n=8 animals,  ***p<0.001. 
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Next, the extent of DNA damage and apoptosis was examined. DNA damage results in rapid 
phosphorylation of histone 2AX on serine 139 (known as •H2AX) which is a standard 
molecular marker for the induction of DNA damage (Rogakou et al., 1998). •H2AX was 
rapidly induced by reperfusion with maximum activity at 30 min, demonstrating  that 
reperfusion is a potent inducer of DNA damage (Fig 3.15). Similarly, cleavage of caspase-9 
occurred in a reperfusion dependent manner, showing that the apoptotic pathway is rapidly 
activated in this model of reperfusion injury (Fig 3.15). 
 
 
 
 
Fig 3.15. Reperfusion activates the DNA damage and apoptotic pathways. A time course of 
reperfusion was carried out in vivo, tissue  was isolated from the risk area and cell lysates were 
immunoblotted for •H2AX (S139), pro-caspase 9 and GAPDH, S = sham operated. 
 
Western blot analysis revealed activation of both STAT1 and 3 with distinct patterns of 
tyrosine and serine phosphorylation (Fig 3.16a). Importantly, only minimal activation of both 
STATs was seen in the non-risk area, demonstrating that STATs are only activated in areas of 
myocardial damage. STAT3 was  phosphorylated at tyrosine 705 during ischaemia  and 
reperfusion injury increased 
 activity, reaching a maximum at 30 min, followed by a decline 
thereafter. The kinetic pattern of serine phosphorylation in STAT3 differed in that although it 
was induced by ischaemia it did not increase during reperfusion, however similarly to Y705, 
serine phosphorylation declined after 1 hr. No consistent difference in total STAT3 levels 
was seen throughout the time course of reperfusion. In contrast to STAT3, 
S        0         5      15       30        60     120
GAPDH
Pro-Caspase-9
•H2AX
Min Reperfusion
 was not activated 
during ischaemia but similarly to STAT3, STAT1 tyrosine phosphorylation reached a 
maximum by  30  minutes of reperfusion (Fig 3.16b).  Fig 3.16c  illustrates the kinetics of 
STAT1 and STAT3 tyrosine phosphorylation using densitometric analysis. It is clear that 
tyrosine phosphorylation of both proteins followed a very similar pattern, peaking at 30 min 
and then rapidly declining by 1 hr. Indeed this profile suggests that proteins which control the 130 
 
negative regulation of STAT1 and STAT3 activity may be concomitantly activated during 
reperfusion injury which might account for this rapid dephosphorylation.  
Interestingly, STAT1 was phosphorylated at serine 727 during ischaemia but no serine 
phosphorylation was detected during reperfusion. This suggests that co-ordinate distinct 
pathways lead to STAT phosphorylation following I/R injury. Since STATs are intimately 
involved in apoptotic control (STAT3 can protect cardiac myocytes from I/R injury, while 
STAT1 promotes cardiac myocyte apoptosis) this in vivo phosphorylation of both tyrosine 
and serine residues may be important for  cardiac myocyte survival during myocardial 
infarction. 
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Fig 3.16. Time course of STAT1 and STAT3 activation following I/R injury. Tissue from the risk 
and non-risk areas was analysed by western blot for (A)  tyrosine phosphorylated, serine 
phosphorylated and total STAT1 and (B) tyrosine phosphorylated, serine phosphorylated and total 
STAT3. Equal loading was confirmed using GAPDH (C) Densitometric analysis was performed using 
a Biorad GS-800 detection system. Values are normalised to sham levels, n=3 animals.  
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3.8. Increased Expression of STAT3 Target Genes Following in vivo I/R injury  
STAT3 was found to be phosphorylated at both residues following I/R injury and this would 
suggest that I/R is a potent inducer of STAT3 transcriptional activity. To address this 
question, qPCR analysis was carried out on STAT3 target genes. The expression of SOCS3 
(8.8 ± 0.7 fold), c-Fos (64.1 ± 20.7 fold) and Bcl-2 (3.3 ± 0.1 fold) were all significantly 
upregulated after 2 hr of reperfusion (Fig 3.17). This fits well with the phosphorylation data 
where STAT3 reached maximal activity by 30 min, gene expression initiated at that time 
would be expected to peak 1-2 hr later. Importantly there was no increase in STAT3 mRNA 
expression which suggests that the increased expression of the STAT3 targets is more likely 
to be due to the increased phosphorylation per STAT3 molecule and not an overall increase 
in total STAT3 content.   
 
Fig 3.17. Expression of STAT3 target genes are increased following I/R injury in vivo. RNA was 
extracted from the left ventricles of rats subjected to I/R injury (2 hr reperfusion) or sham surgery and 
the levels of SOCS3, Bcl-2, c-Fos and STAT3 were measured by qPCR and normalized to sham. n=4 
animals, *p<0.05, ***p<0.001, students t-test.  
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3.9  I/R injury in the brain induces distinct kinetics of STAT activity 
In order to ascertain if the rapid activation of STAT1 and STAT3 in the heart is a general 
phenomenon of reperfusion injury or if it is specific to the myocardium, a time course of I/R 
injury in the brain was carried out. Technical aspects of this study were carried out in 
conjunction with Dr. Romina Badin of the Biophysics unit at the Institute of Child Health. 
This cerebral ischaemia/stroke model involves transient focal cerebral ischaemia via middle 
cerebral artery occlusion (MCAO) by insertion of suture 17 mm from carotid bifurcation for 
30 min followed by removal of the suture and reperfusion (Fig 3.18a). The MRI images in 
Fig 3.18b show T2-weighted proton density scans from 6 hr and 24 hr reperfusion; by 6 hr 
early infarction can be delineated while 24 hr after reperfusion the infarct lesion can clearly 
be seen.  
Following 30 min of ischaemia, the brain was reperfused for 10, 30, 60, 120 and 360 min. 
The basal ganglia and cortex were dissected out and separated into ipsilateral and 
contralateral areas. While no STAT activation was seen in the cortex in this model (not 
shown), both STAT1 and STAT3 became tyrosine phosphorylated at 6 hr post-reperfusion in 
the basal ganglia, on the ipsilateral but not contralateral side (Fig 3.18 C and D). Surprisingly, 
this is in contrast to the relatively quick effect of reperfusion on STAT activation in the 
myocardium. This suggests that the rapid (~15 min) reperfusion induced tyrosine 
phosphorylation of STAT1 and STAT3 in the myocardium may occur through a mechanism 
distinct from that of I/R induced activation in the brain.  
 
 134 
 
 
 
Fig 3.18. STAT activation following cerebral I/R injury. Middle cerebral artery occlusion (MCAO) 
was carried out in adult male Spague-Dawley rats for 30 min, followed by the indicated times of 
reperfusion. (A) Occlusion of MCA with suture. (B) Representative centre slice T2-weighted images 
of animals reperfused for 6 hr or 24 hr, infarct lesion appears as bright signal. (C and D) 
Representative western blots of tryrosine phosphorylated STAT1 and 3 from ipsilateral and 
contralateral basal ganglia, total STAT1 and 3 are shown as loading controls. n=3 animals.  
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3.10 Reperfusion Induced Myocardial STAT Tyrosine Phosphorylation is 
Mediated by ROS  
It is well appreciated that ROS are rapidly generated by reperfusion injury and indeed ROS 
have been shown to be capable of inducing both STAT Y705F activity in vitro (Simon et al., 
1998) and S727 activity in vitro (Fig 3.13). Therefore, the possibility that ROS production is 
a trigger of STAT phosphorylation during in vivo  I/R injury was examined. For these 
experiments, 30 min of reperfusion was chosen, as maximal STAT activation occurs at this 
time (Fig 3.16). Rats underwent 25 min ischaemia and were then infused with 100 mg/kg of 
the antioxidant tempol, followed by 30 min reperfusion. ROS inhibition was assessed by 
measuring tissue malondialdehyde (MDA) levels, a marker of lipid peroxidation (Hogberg et 
al, 1975). Tempol infusion lowered MDA levels to the levels of sham operated or non-risk 
tissue, suggesting that tempol is effective at abolishing the majority of ROS production by 
reperfusion (Fig 3.19a). Tempol infusion also reduced infarct size  by 57.1 ± 5.0 %, 
demonstrating that a large majority of tissue damage following reperfusion can be attributed 
to ROS production (Fig 3.19b)  
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Fig 3.19 Infusion of tempol inhibits ROS production and lowers infarct size. Rats underwent 
sham operation, 25 min ischaemia and either 30 min (A) or 2  hr (B) reperfusion with infusion of 
saline or 100 mg/kg tempol. (A) Tissue MDA levels were measured by HPLC from each of the 
indicated groups (B) Infarct size was measured using NBT staining. Statistical analysis was carried 
out using a one way ANOVA with Bonferoni post correction, *** p< 0.0001, n=6 animals  
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Tempol infusion before the onset of reperfusion led to a reduction in the levels of tyrosine 
phosphorylated STAT1 by 71 ± 5% and of STAT3 by 45 ± 15% (assessed by densitometry), 
there was also a reduction in S727 phosphorylation of STAT3 (41.4 ± 20.7) but this was not 
statistically significant over  three animals (Fig 3.20a,b). This suggests that following 
reperfusion injury, the rapid generation of ROS is a major contributor to STAT1 and STAT3 
activation. The levels of the STAT1/3 kinase JAK2 paralleled the tyrosine phosphorylation 
by I/R injury and reduction by tempol. Fig 3.20c Shows a 2–fold increase in pJAK2 levels 
during I/R, which were reduced back to sham levels by tempol infusion. This suggests that 
JAK2 is also activated by ROS and it is likely that this kinase lies upstream of STAT1/3 in 
ROS mediated STAT1 and STAT3 tyrosine phosphorylation.   
While JAK2 may be a major regulator of STAT phosphorylation status during I/R, it is likely 
to be one of many JAK/STAT regulating proteins active during I/R injury. With this in mind, 
the expression of the recently characterised STAT3 inhibitor GRIM-19 was measured (Lufei 
C et al., 2003). GRIM-19 levels were reduced by 68 ± 11.3 % during I/R injury and were 
increased back to almost 80% of sham levels by tempol infusion (Fig 3.20c). This is the first 
time that GRIM-19 has been shown to be regulated by I/R injury and the rapid reduction in 
protein levels (i.e. 30 min) is suggestive of protein degradation and thus may represent a 
novel mechanism of STAT3 regulation during I/R injury. 
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Fig 3.20. Tempol infusion reduces JAK/STAT activation and increases GRIM-19 expression. 
100 mg/kg tempol was infused prior to 30 min reperfusion, the risk area was separated, snap frozen in 
liquid nitrogen and lysed in RIPA buffer. Western blot analysis was carried out for (A)  and total 
STAT1 (B)  , 
 and (C) 
/1008
   
 and GRIM-19, equal loading was confirmed with GAPDH. For each 
western the corresponding densitometric analysis is shown, raw numbers were normalised by initially 
setting I/R to 100% and re-normalised to express as fold change over sham. n=4 for each group * 
p<0.05, *** p<0.001 analysed by one way ANOVA with Bonferroni post test. 
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In order to examine the tissue distribution of STAT1/3 tyrosine phosphorylation, 
immunohistochemistry  was carried out. Intense STAT1 and STAT3  phospho-tyrosine 
staining was noted in myocardial cross-sections after 30 min of reperfusion and this was 
found to be mainly localised to the nucleus (Fig 3.21). STAT1 and STAT3 tyrosine 
phosphorylation also appeared to be evident in endothelial cells surrounding vessels but 
endothelial cell-specific co-staining would need to be carried out to confirm this. Tempol 
infusion was found to dramatically lower STAT1 and STAT3 phopsho-tyrosine staining, thus 
confirming the results seen with western blot. Moreover, this staining pattern suggests that 
STAT1/3 tyrosine phosphorylation is not solely confined to the cardiac myocyte population 
of the heart and may also play a prominent role in endothelial cell apoptosis. 
 
 
 
Fig 3.21. Immunohistochemical staining of STAT phosphorylation following tempol infusion. 
Rats underwent sham operation, I/R (30 min reperfusion) or I/R with infusion of 100 mg/kg tempol. 
The risk area was separated from each sample and fixed in 10% formalin, 5µm tissue sections were 
stained with the indicated antibodies. 
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3.11 Increased 
 
The previous results showed that infusion of antioxidants during reperfusion lowered the 
levels of STAT1 and STAT3 phosphorylation. However, since STAT1 is pro-apoptotic in the 
myocardium and STAT3 is anti-apoptotic, it is unclear what the effects are of lowering both. 
Indeed the possibility exists that inhibition of both STAT1 and STAT3 might have no overall 
effect. Since tempol is clearly cardioprotective, the most likely scenario is that reducing pro-
apoptotic STAT1 activity may play a major role in anti-oxidant protection. To address this, 
rats underwent ischaemia with 2 hr reperfusion and were infused with the potent STAT1 
agonist IFN-•, tempol or tempol and IFN-• in combination prior to reperfusion. This two hour 
time-point was chosen as previous experiments have shown this to be the optimal time-point for 
conducting infarct measurements (McDonald et al., 1999). The mean arterial pressure (MAP) and 
pressure rate index (PRI) fell during ischaemia, while heart rate was slightly increased, these 
indices returned to near baseline levels during reperfusion (Fig 3.22). Importantly, none of the 
drug treatments significantly altered any of the heart function readouts, showing that any effect 
was not due to global changes in blood pressure (Fig 3.22). 
Phosphorylation Following IFN-•  Treatment Increases Infarct 
Size and Reduces the Protective Effect of Tempol 
When compared to sham-operated animals, 2 hr of reperfusion caused a significant increase in 
infarct size  to 56 ± 2 % (Fig 3.23a).  Administration of IFN-γ  (25  µg/kg) 5 min prior to 
reperfusion upregulated STAT1 activity and caused a 30 ± 1 % increase in myocardial infarct 
size when compared with I/R alone, indicating that increased STAT1 activity is associated with 
increased myocardial damage in vivo (Fig 3.23). Importantly, IFN-• reduced the cardioprotective 
effect of tempol. Tempol infusion alone reduced the infarct size by 57.1%, whereas tempol + 
IFN-• together lead to a reduction in infarct size by 21.9% compared to IFN-• treatment alone. 
This is mirrored in the western blot which shows that the decrease in 
   
 phosphorylation caused by 
tempol was completely blocked by IFN-• (Fig 3.23b). This strongly implicates STAT1 activation 
as a main target in tempol-mediated cardioprotection and together with previous work (Townsend 
et al., 2004)  suggests that the inhibition of proapoptotic STAT1 activity may be a general 
mechanism of antioxidant protection during I/R injury. 141 
 
 
 
Fig 3.22. Effect of I/R and drug infusion on blood pressure, heart rate and pressure rate index. 
The rat carotid artery was cannulated and connected to a pressure transducer to measure MAP and 
heart rate, the pressure rate index was calculated as the product of MAP and HR. Animals (n=4) were 
monitored throughout the 30 min ischaemia and 120 min reperfusion in each of the indicated groups.  
 142 
 
 
 
Fig 3.23. IFN-• induced STAT1 increases infarct size and abrogates the protective effect of 
tempol. (A) Infarct size was measured in rats subjected to sham operation or 25 min LAD occlusion 
and 2 hr reperfusion with infusion (5 min prior to reperfusion) of either saline (I/R n=7), 100 mg/kg 
tempol (n=7), 25 µg/kg IFN-• (n=6) or both tempol and IFN-• together (n=6), statistics were carried 
out with a one-way ANOVA with a Bonferoni post test, *** p<0.001, ** p<0.01.  (B) Western blot 
analysis of STAT1 phosphorylation from heart tissue from the indicated treatment groups, n=3. 
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3.12 Discussion 
 
STAT transcription factors have been shown to play a prominent role in cell fate following 
various stresses. The work presented here demonstrates that STAT3 plays an important role 
in protection from I/R injury in cardiac myocytes. Transient overexpression of STAT3 and 
transduction with a dominant negative STAT3 virus both revealed that STAT3 functions as 
an anti-apoptotic transcription factor in cardiac myocytes. Likewise, experiments in STAT3-
deficient cells revealed that in the absence of STAT3 signalling, oxidative stress mediated 
cell death is greatly exacerbated. In support of this, transient overexpression of STAT3 also 
increased survival in NRVMs exposed to 
 
.  
Both STAT1 and STAT3 were phosphorylated at tyrosine 701/705 and serine 727 following 
I/R injury in vitro. Both tyrosine and serine phosphorylation peaked at 1 hr,  levels stayed 
elevated up to 20 hr while 
 levels tapered off. The differential effects of phosphorylation on 
individual tyrosine or serine residues are unknown. The current dogma posits that Y705 
phosphorylation is obligatory for DNA binding and nuclear retention but that S727 
phosphorylation is necessary for a fully fledged transcriptional response (Levy and Darnell, 
2002). It is likely that S727 phosphorylation serves as a rheostat for STAT3 activity and may 
influence promoter choice, chromatin on/off rates as well as the duration and level of 
transcript production. STAT1 phosphorylation in vitro displayed a broadly similar pattern, 
the exception being that 
 
 phosphorylation is more pronounced during ischaemia.  In support 
of these phosphorylation studies, qPCR analysis of STAT3 target genes confirmed the 
increased transcriptional activity of STAT3 during I/R. Both SOCS3 and c-Fos were 
maximally expressed between 2 and 4 hr of reperfusion which follows closely after the time 
of maximal STAT3 phosphorylation. Taken together, the in vitro studies show that STAT3 is 
rapidly induced during I/R injury and oxidative stress and show that this activity is important 
in allowing cardiac myocytes to minimise the deleterious effects of I/R injury.  
It is interesting to observe that the MEK-ERK pathway feeds into the STAT3 pathway during 
oxidative stress.  treatment led to STAT3 Y705 and S727 phosphorylation within 15 min and 
S727 phosphorylation was shown to be ERK1/2 dependent, while the MAPKs appeared to 
have no affect on Y705 phosphorylation. ERK1/2 has previously been shown to confer 
protection from oxidative stress and I/R injury (Yue et al., 2000, Adderlay and Fitzgerald, 
1999), therefore this ERK1/2-STAT3 crosstalk may represent a novel cardioprotective 144 
 
pathway whereby oxidative stress promotes ERK mediated STAT3 serine phosphorylation 
and subsequent cardioprotection. It would be interesting to examine if increased ERK activity 
can still confer cardioprotection in mice where the STAT3 S727 residue has been mutated to 
an alanine.  
 
As with the evidence from NRVMs in vitro, phosphorylation of 
 and  were induced during 
ischaemia in vivo.  phosphorylation was enhanced during reperfusion, while 
 
 phosphorylation 
did not increase over the levels observed in ischaemia as seen in vitro. STAT1 was also 
activated by I/R but showed distinct kinetics to STAT3. Interestingly both STAT1 and 
STAT3 tyrosine phosphorylation peak after 30 min of reperfusion and are then 
dephosphorylated, demonstrating that rapid activation of both STATs is an important feature 
of I/R injury.  In support of this, the STAT3 target genes SOCS3, Bcl-2 and c-Fos were all 
upregulated by I/R in vivo. Analysis of STAT activity in a regional model of I/R injury in the 
brain suggest that a different STAT signalling pathway may exist in the cerebellum. 
Temporal analysis revealed that STAT1 and STAT3 tyrosine phosphorylation was delayed 
with respect to myocardial I/R. No STAT phosphorylation was seen until 6 hr of reperfusion. 
Although these are distinct models of I/R, it nonetheless highlights that reperfusion may not 
activate the same set of signalling pathways in all tissues damaged by I/R and cautions 
against generalisations made about I/R injury in different contexts.  
Importantly, very little STAT phosphorylation was observed in the non-risk area of the heart 
following I/R which suggests that the activation of STAT1 and STAT3 is confined largely to 
the area of most cellular damage. By measuring MDA levels it was shown ROS are generated 
solely in the risk area, which is supported by the finding that phosphorylation of histone 
2AX, a marker for DNA damage occurs rapidly in the risk area following I/R injury. 
Inhibition of ROS with the free radical scavenger tempol, reduced infarct size following I/R 
injury in vivo. Furthermore, inhibition of ROS reduced both STAT1 and STAT3 tyrosine 
phosphorylation, suggesting that ROS production following I/R injury is one of the main 
instigators of STAT activation during I/R injury.  
 
 
 
Precisely which kinases are responsible for ROS-induced STAT  activity are currently 
unknown but the finding that pJAK2 levels were also reduced by tempol suggests that JAK2 145 
 
may be involved. JAK2 activity has been shown to be induced within 5 min of 
 
 treatment and 
indeed ROS production in vivo has been shown to occur within minutes after restoration of 
blood flow following ischaemia (Abe and Berk, 1999, Zhao, 2004). The activity of non-
receptor tyrosine kinases was not examined in this study but Src, Fyn, Lck and Abl have all 
been shown to be activated by oxidative stress and therefore may also play a role in STAT 
phosphorylation during I/R injury (Harwick and Sefton, 1995, Aikawa et al., 1997, Abe et al., 
2000, Sun et al., 2000) 
Expression of the STAT3 inhibitor GRIM-19 was also found to be reduced during I/R and its 
levels were restored by tempol treatment. GRIM-19 has been shown to bind to STAT3 
following IL-6 or IFN-• treatment and STAT3 S727 phosphorylation was shown to be 
obligatory for this interaction (Zhang et al., 2003). Overexpression of GRIM-19 inhibited 
STAT3 dependent transcriptional activity (Zhang et al., 2003, Lufei et al., 2003), and it is 
noteworthy therefore that levels of GRIM-19 and active STAT3 were inversely related during 
I/R.  Free radical mediated transcriptional inhibition or protein degradation of GRIM-19 
levels may constitute one pathway in which STAT3 transcriptional activity is elevated during 
I/R. 
 
It seems therefore that JAK/STAT activation following cardiac stress may be modular in 
nature. In the first instance, intracellular ROS generation following the restoration of ATP 
synthesis may directly activates STAT1 and STAT3, possibly through activation of JAK1/2, 
non-receptor tyrosine kinases or reduction of GRIM-19  as well as through STAT serine 
kinases such as ERK1/2. This early response may set the stage for early upregulation of pro- 
and anti-apoptotic genes which are instrumental in the early decision to commit to apoptosis 
and the formation of infarct. This is borne out by the finding that mice deficient in cardiac 
STAT3 have reduced infarct sizes, whereas hearts overexpressing a constitutively active form 
of STAT1 suffer more severe infarction following I/R  (Stephanou et al., 2002, Hilfiker-
Kleiner et al., 2004). A second temporal level of JAK/STAT control might come from the 
later release of a variety  of cytokines, hormones and growth factors which  leads to the 
upregulation of genes involved in maintenance of cardiac integrity,  the release of angiogenic 
factors, development of compensatory hypertrophy and control of the remodelling 
programme.  
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Tempol was found to dramatically lower STAT1 tyrosine phosphorylation, suggesting that 
some of the protective effects of tempol might be attributable to inhibition of this 
proapoptotic transcription factor. In the presence of IFN-•,  tempol no longer showed a 
STAT1 inhibitory effect and this was associated with a reduction in tempol’s infarct sparing 
activity. Taken together these data suggests that inhibition of STAT1 activity may play a 
prominent role in the cardioprotective action of tempol, although of course it must be noted 
that IFN-• promotes many effects other that STAT1 activation. Previously it has been shown 
that the green tea polyphenol epigallocatechin-3-gallate (EGCG), could reduce infarct size 
following I/R injury in rats (Townsend et al., 2004). This was associated with a reduction in 
STAT1 activity and suggests that other antioxidants may also function through inhibition of 
the proapoptotic activity of STAT1.  
 
In the course of this work several studies have been published which support the 
aforementioned data. Oshima and colleagues demonstrated that mice engineered to express 
cardiac-specific constitutively active STAT3 showed a 60% reduction in infarct size 
following I/R injury  (Oshima et al., 2005). This infarct sparing effect was attributed to 
STAT3 mediated induction of the antioxidant proteins metallothionein 1 and 2, as crossing 
the STAT3 overexpressing mice onto a metallothionein negative background abolished the 
cardioprotective effect of STAT3. Although total deletion of STAT3 is embryonically lethal 
(Takeda et al., 1997), further evidence for the role of STAT3 as a cardioprotective 
transcription factor is highlighted in studies using cardiac myocyte-specific STAT3 knockout 
mice  (Hilfiker-Kleiner et al., 2004). These mice suffer from decreased left ventricular 
capillary density and show symptoms of heart failure after 12 months, including cardiac 
fibrosis, impaired contractile function and a decrease in systolic function over time. Cardiac-
specific STAT3 deficient  mice are also more susceptible to I/R-  induced cardiac injury, 
displaying larger infarct sizes and a greater number of caspase-3 and TUNEL positive cells 
following reperfusion when compared with wild type controls (Hilfiker-Kleiner et al., 2004). 
 
Granulocyte-colony stimulating factor (G-CSF) has recently been shown to confer protection 
from myocardial and cerebral ischaemia through STAT3 upregulation, with G-CSF failing to 
illicit protection in mice overexpressing dominant negative STAT3 (Harada et al., 2005, 
Komine-kobayashi et al., 2006). STAT3 has also been shown to play a role in endothelial cell 
apoptosis in response to I/R by inhibiting FAS and caspase-3 expression (Zhang et al., 2005). 
While this is the first study to show STAT3 serine phosphorylation by I/R injury, some recent 147 
 
studies have begun to address the role of STAT3 serine phosphorylation in the myocardium. 
Mice in which serine 727 has been mutated to an alanine show enhanced susceptibility to 
doxorubicin-induced heart failure (Shen et al., 2004). Upregulation of ICAM has been shown 
to increase neutrophil recruitment during I/R injury while its expression is associated with 
cardiac pathology  (Palazzo et al., 1998). Following  I/R  in endothelial cells, serine 
phosphorylated STAT3 was shown to bind to the GAS element in the ICAM-1 promoter in 
association with Sp1 and enhance ICAM-1 expression following reperfusion (Yang et al., 
2005). These studies are all in agreement with the data presented in this thesis and reaffirm 
the central finding that STAT3 activity is enhanced during I/R injury and is part of an anti-
apoptotic programme which rescues myocytes from I/R damage. 
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Chapter 4: Investigating Gene 
Expression changes in 
Myocardial Infarction using 
Microarray Analysis 
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4.1 Aims 
In the previous chapter, the STAT3 dependent genes c-fos  and  socs3  were shown to be 
induced during I/R injury in the in vivo rat heart, an effect which could be blocked by free 
radical scavenging with tempol. In order to ascertain if other STAT3 target genes are 
upregulated during I/R injury, global gene expression analysis was carried out on rat hearts 
using Affymetrix gene arrays. These arrays allow examination of 15,866 individual 
transcripts simultaneously and thus give an indication of total transcriptional changes brought 
about by I/R in vivo when compared to the hearts of sham operated rats. In addition to the 
effect on STAT3 target genes, the transcriptional profile of I/R injured hearts can be used to 
identify changes in the expression of genes which may not have been previously documented 
as having a role in I/R injury and thus potentially identify novel physiological changes. To 
extend these studies, the effects of free radical inhibition on global gene expression was also 
examined by infusing with the anti-oxidant tempol before reperfusion.  
In addition to the first aim, a second set of experiments was carried out to examine the 
transcriptional effects of two other novel cardioprotective peptides. Both the CRF family 
members urocortin1 and urocortin2 (stresscopin-related peptide) have been shown to be 
beneficial in experimental MI (Rademaker  et al., 2005, 2008). Urocortins work through 
binding G-protein coupled receptors; Ucn1 binds to both the corticotropin-releasing factor 
(CRF) receptors CRFR1 and CRF2, whereas Ucn2 binds specifically to CRFR2 (Kuperman 
et al. 2008). Although Ucn1 is clearly beneficial in preventing ischaemic damage, its effect 
on CRF1 may limit its usefulness as a therapeutic peptide since it stimulates the hypothalamic 
pituitary axis (HPA) (Tsatsanis et al., 2007). Moreover, administration of Ucn1 to healthy 
adults led to increases in plasma levels of corticotrophin (ACTH), cortisol and atrial 
natriuretic peptide (ANP) and decreases ghrelin levels (Davis et al., 2004). For this reason, 
long term Ucn1 treatment in patients may have significant drawbacks. 
Ucn2 may avoid some of the potential side effects of Ucn1 as it is specific for the CRF2 
receptor. Intravenous infusion of Ucn2 in patients with heart failure increased cardiac output 
and decreased blood pressure but had no effect on hormone responses (David et al., 2007).  It 
is currently unknown how the responses to Unc1 and Ucn2 differ at the transcriptional level 
and to address this question rats were infused with Ucn1 or Ucn2 before reperfusion and the 
effect on global gene expression was examined. The rationale for these experiments is to 
better understand the similarities and differences in the transcriptional effects of Ucn1 and 150 
 
Ucn2 in experimental MI and to compare them to anti-oxidant treatment.  Analysis of 
downstream transcriptional effects might reveal a common subset of targets between the two 
peptides which could potentially be exploited as targets for therapeutic intervention through 
the rational design of more selective peptides.  
 
4.2 Drug Infusion, Gene Array Procedure and Quality Control 
These experiments were carried out in conjunction with Dr. Ahila Sivarajah at St. 
Bartholomew's and The Royal London School of Medicine and Dentistry.  Rats were 
randomly separated into 5 groups with 3 rats in each group; group 1: sham surgery, group 2: 
I/R with saline infusion, group 3: I/R with infusion of 100 mg/kg tempol, group 4: I/R with 
infusion of 15 µg/kg urocortin and group 5: I/R with infusion of 15 µg/kg urocortin 2. The 
hearts were removed and the right atrium and ventricle were separated and discarded. RNA 
was extracted from the left ventricular tissue, quality assessed on an Agilent 2100 array and 
processed into cRNA as outlined in the materials and methods. The cRNA was also run on an 
Agilent 2100 to ensure that the RNA from each sample had a similar size distribution. cRNA 
was hybridised overnight to Affymetrix RAE230A gene arrays and scanned on an Affymetrix 
scanner 3000. After scanning, each microarray image was manually inspected to look for any 
misalignment features. 
Microarrays were subjected to quality control to test the data set for differences in chip 
quality, variance in sample hybridisation and quality of RNA. Quality control was initially 
carried out using Affymetrix GCOS software.  An important control with microarray 
experiments is to ensure that the fluorescence is similar across all the arrays used in the study. 
The RawQ value, which is a measure of total fluorescence of each array, had a mean value of 
2.54 ± 0.51 which is within accepted normal range of 1.5-3.0 (Heber and Sick, 2006) (Table 
4.1a). Background fluorescence values for Affymetrix arrays normally range between 10 and 
100, average background fluorescence across the 15 tested arrays was 68.86 ± 11.25 which 
was within accepted limits (Heber and Sick, 2006)(Table 4.1a). The scaling factor is used to 
set the same median intensity across all arrays i.e. more intensely stained arrays have a low 
scaling factor while weakly stained arrays have a larger scaling factor. Affymetrix sets a 
maximum threshold of 3 standard deviations away from the mean for a sample to be included 
in the data set. The scaling factor standard deviation across the 15 arrays was 0.90, allowing 151 
 
all 15 arrays to be included in downstream analysis (Table 4.1a). The percentage present is a 
measure of the total number of possible transcripts expressed. The average percent present 
call was 50.5% ± 6.3 (Table 4.1b) which fits well with published rat myocardial data sets 
(http://www.affymetrix.com/support/technotes/expression).  
 
 
Table 4.1. Quality control statistics for microarrays. Quality control statistics were obtained using 
Affymetrix GCOS software for all 15 microarrays used in the study. (A) RawQ score, background 
fluorescence and scaling factor (SF). (B) % calls for all probe sets. (C) 3’/5’ scores for GAPDH and 
•-Actin probes  
 
RNA target quality was examined in each array to ensure that any differential expression was 
not simply due to RNA degradation in some of the arrays. Since RNA becomes degraded in a 
RawQ Background SF
SH1 2.46 71 0.79
SH2 2.91 73.7 0.39
SH3 2.37 65.9 0.60
IR1 2.13 63.4 3.32
IR2 1.9 59.3 2.07
IR3 2.11 63.3 1.99
Tem1 2.17 60.3 0.66
Tem2 2.5 72.6 0.72
Tem3 2.05 56 0.67
Ucn1 3.52 93.3 0.73
Ucn2 3.1 81.4 0.54
Ucn3 3.34 81.5 0.51
UcnII1 2.73 82 0.75
UcnII2 2.02 53 0.95
UcnII3 2.85 71.2 0.43
Present  Absent  Marginal
SH1 50.1 47.9 2.0
SH2 58.3 40.1 1.6
SH3 56.6 41.7 1.7
IR1 38.2 59.9 1.8
IR2 42.6 55.5 1.9
IR3 41.0 57.0 2.0
Tem1 57.1 41.4 1.5
Tem2 48.9 49.0 2.1
Tem3 58.6 39.8 1.6
Ucn1 47.7 50.3 2.0
Ucn2 52.4 45.8 1.8
Ucn3 53.2 45.2 1.6
UcnII1 47.6 50.5 1.9
UcnII2 51.2 46.8 1.9
UcnII3 54.6 43.6 1.8
GAPDH Beta-Actin
SH1 1.14 0.96
SH2 1.42 1.29
SH3 1.36 0.95
IR1 2.57 2.37
IR2 1.9 3.3
IR3 1.27 0.99
Tem1 1.53 1.46
Tem2 1.52 1.22
Tem3 2.04 1.92
Ucn1 1.19 1.19
Ucn2 1.3 1.23
Ucn3 1.3 1.43
UcnII1 1.31 1.19
UcnII2 1.21 1.44
UcnII3 1.33 1.15
A B
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5’-3’ manner, examination of the number of probes hybridising to the 3’ end compared to the 
5’ end of the transcript gives an indicator of potential RNA degradation and 3’-5’ ratios of 
greater than 3 are regarded to be indicative of poor target quality (Archer et al., 2006). The 
average 3’/5’ ratios over the 15 arrays was 1.49  ± 0.39 for GAPDH and 1.47 ± 0.63 for •-
Actin, allowing them all to be included in further analysis (Table 4.1c). Since rRNA does not 
contain polyadenylated 3’ ends, the oligo(dT) primer should not produce any rRNA product 
unless the rRNA has been degraded, thus exposing polyadenylated sequences within the 
rRNA primary structure (Archer et al., 2006). Therefore, a positive signal for 5S rRNA 
represents another indicator of poor RNA quality, the 5S rRNA signal was absent from all 15 
arrays. 
Further analysis was carried out in Bioconductor using linear models statistics (Limma); two 
software packages, AffylmGui and OneChannelGui, were used for this analysis (Wettenhall 
et al., 2006, Sanges et al., 2007)
To ensure that all the arrays had similar quality of hybridised RNA and similar second strand 
synthesis efficiencies, RNA degradation plots were produced in which the probe number on 
the x-axis is plotted against the mean intensity on the y-axis. It is important to note that since 
RNA degradation occurs in a 5’ to 3’ and an oligo d(T) primer is used during amplification, 
Affymetrix chips have a greater number of probes designed to the 3’ end of transcripts and 
thus one would expect a positive slope in the degradation plot.  Fig 4.1d shows that all the 
arrays produced a similar profile with the average slope being 2.36 ± 0.55. Importantly the 
I/R group did not have significantly different slope values from the other groups which 
suggests that the reduced probe intensity seen in Fig 4.1c was not due to poor RNA target 
quality.  
.  Expression values were normalised using GCRMA (GC-
Robust Multichip Average) (Qin et al., 2006) and box-plots of the raw and normalised data 
were generated showing the median and inter-quartile range (Fig 4.1a,b). The intensity varied 
within the groups with the I/R group being the lowest, however GCRMA normalisation was 
sufficient to normalise across all groups (Fig 4.1b). Similarly a perfect patch (PM) intensity 
distribution showed that the I/R group displayed less intensity (Fig 4.1c). This is also 
reflected in the fact that the scaling factor was higher in this group (Table 4.1a). While taking 
this into account, it is still clear that the GCRMA method gives a similar profile after 
normalisation (Fig 4.1b) and thus all arrays were included for further analysis.  
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Fig 4.1. GCRMA normalisation, probe intensity and RNA degradation plots. (A) Intensity Box 
Plot of the fluorescence from the 15 microarrays. (B) Box Plot following GCRMA normalisation. (C) 
Perfect matched (PM) probe intensity distribution from the 15 microarrays. (D) RNA degradation plot 
with slopes and corresponding p values.  
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4.3 Parameters for Differential Expression 
Since the 15 arrays passed all quality control checks, differential expression between the 
groups was examined. Genes were considered differentially expressed between two groups if 
there was a fold change greater than 2 with a t-test p value of <0.05. In addition, the false 
discovery rate (FDR) cut-off was set to 0.05 using the Benjamini and Hochberg equation 
(Benjamini and Hochberg, 1995). The Volcano plots in Fig 4.2a graphically highlight in red 
those genes fulfilling these selection criteria, log fold change is shown on the x axis and the p 
value is shown on the y axis. As well as assigning p values, Limma also assigns a log odds 
(LOD) score for each differentially expressed gene known as the B value, which is based on 
Bayes log posterior odds (Smyth, 2004). For each B value the % chance of differential 
expression is given as [exp(B)/(1 + exp(B))] x 100 and a positive B value is a good indicator 
of differential expression (Lönnstedt and Speed, 2002). 
The breakdown of differential expression is indicated in Fig 4.2b. In total, I/R was found to 
upregulate 480 genes and downregulate 553 genes when compared to the sham group. Each 
of the drug treatment groups was compared to the I/R group in order to assess the effect of 
the drugs on I/R dependent gene expression. Tempol was found to upregulate 52 genes and 
down regulated 14 genes, the Ucn1 group had 38 upregulated genes and 27 downregulated 
genes and Ucn2 upregulated 104 genes and downregulated 37. The entire set of differentially 
regulated genes is shown in Appendix 3. Not all differential expression induced by the three 
drug treatments were reversal of expression changes during I/R. Fig 4.2c lists the numbers of 
genes changed which by tempol, Ucn1 and Ucn2 which were not affected by I/R. 
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Fig 4.2. Volcano plots and numbers of differentially expressed genes. (A) Volcano plots for I/R vs. 
Sham and tempol, Ucn1 and Ucn2 vs. I/R, fold change and p value cut-off lines are shown, 
differentially expressed genes are highlighted in red. (B) Numbers of probe sets and annotated genes 
upregulated or downregulated in each group. (C)  Numbers of annotated genes changed by drug 
treatments which were also regulated by I/R. 
 
 
Probe Sets Annotated Genes  Upregulated Downregulated
IR Vs Sham 1109 798 480 553
Tem Vs IR 67 38 52 14
Ucn1 Vs IR 67 47 38 27
Ucn2 Vs IR 142 90 104 37
A
I/R Tem
Ucn1 Ucn2
B
Regulated by I/R Not Regulated by I/R
Tem 31 16
Ucn1 27 22
Ucn2 65 39
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4.4 Gene Ontology Analysis of Genes Differentially Expressed by I/R Injury 
The top 20 most differentially expressed genes following I/R are shown in table 4.2 and 
include chaperones, transcription factors and immune regulators. Since there are over 1000 
differentially expressed transcripts, functional classification was carried out to group the 
transcripts into distinct biological processes using gene ontology (GO) terms. This was done 
in two ways; firstly GO terms were assigned manually using literature searches to define the 
most common function for each gene. With this method, each gene is assigned to a single 
group and thus avoids the drawback of having several GO terms designated to a single gene. 
Using this approach it was clear that the majority of changes were either transcripts without 
an assigned identity or annotated genes of unknown function (Fig 4.3). The next major 
grouping comprised genes involved in metabolic regulation, which is not surprising since 
perturbed metabolic function is a hallmark of I/R injury (Lopaschuk et al., 2000). Along with 
the genes involved in metabolism, there are changes in expression of large numbers of genes 
involved in mitochondrial regulation and ion transport. Interestingly, the next two major 
categories were genes involved in transcriptional control and genes involved in the regulation 
of RNA and DNA. Thus it seems that the expression of almost 200 genes involved in the 
maintenance of DNA stability and transcription/translation of mRNA are altered and suggests 
that a large transcriptional regulatory network is activated by reperfusion injury. A cursory 
examination of transcriptional regulators showed that several transcription factors were 
among the most highly differentially expressed genes, for example all the components of 
heterodimeric transcription factor AP-1 were induced; Fos (40.8 ± 1.5 fold), Fosl1 (30.2 ± 1.6 
fold) c-Jun (4.8 ± 0.4 fold) and JunB (4.0 ± 0.7 fold), other highly differentially regulated 
transcription factors include Atf3 (23.9 ± 2.8 fold), Klf15 (-21.6 ± 1.9 fold), Erg1 (17.2 ± 1.3 
fold),  Erg2 (16.6 ± 0.6 fold) and Klf6 (9.3 ± 0.6 fold).  
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Fig 4.3. Manual Gene Ontology analysis of genes differentially expressed by I/R compared to 
sham. GO terms were assigned to the 1109 probe sets based on manual searching of the literature to 
define the most common function of each gene.  
   
Table 4.2. The 20 geneswiththe highest rate ofdifferential expressionbetweenthe sham and I/R groups.
Symbol Gene Title FC P value B value
Hspa1a /Hspa1b heat shock 70kD protein 1A /1B (mapped) 41.5 2.2E-05 9.6
Fos FBJ osteosarcoma oncogene 40.8 4.3E-05 8.7
Hspa1b heat shock 70kD protein 1B (mapped) 39.3 9.1E-06 11.2
Fosl1 fos-like antigen 1 30.2 1.1E-04 6.7
Npy neuropeptide Y 28.9 1.2E-04 6.6
Cxcl2 chemokine (C-X-C motif) ligand 2 27.7 2.5E-03 1.6
Plaur plasminogen activator, urokinase receptor 25.5 1.7E-05 10.1
Il1r2 interleukin 1 receptor, type II 24.7 7.3E-04 3.6
Atf3 activating transcription factor 3 23.9 9.6E-05 7.0
Nr4a3 nuclear receptor subfamily 4, group A, member 3 23.2 1.2E-05 10.6
Klf15 Kruppel-like factor 15 -21.6 1.6E-04 6.1
Dnajb1_predicted DnaJ (Hsp40) homolog, subfamily B, member 1 20.9 4.4E-05 8.7
Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 20.2 1.0E-05 10.8
Pf4 platelet factor 4 18.6 9.1E-04 3.3
Pglyrp1 peptidoglycan recognition protein 1 17.9 4.3E-04 4.4
Sphk1 sphingosine kinase 1 17.3 4.5E-06 12.0
Egr1 early growth response 1 17.2 1.6E-05 10.2
Homer1 homer homolog 1 (Drosophila) 16.9 3.9E-03 1.0
Serpine1 serine (or cysteine) peptidase inhibitor,member1 16.9 2.3E-04 5.5
Egr2 early growth response 2 16.6 9.1E-05 7.1
I/R  Vs Sham
Unknown Function
No Identity
Metabolism
Transcription
Mitochondrial Regulation
Cell migration/Growth & prolif
DNA/RNA Regulation
Kinases & Phosphatases
Immune Regulation/Inflammation
Channels/Ion transport
Trafficking
Signal transduction 
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Cell Cycle
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Since manual designation of GO terms may be subject to bias, a second alternative method 
was used. The list of differentially regulated genes was functionally annotated using the 
Ingenuity package. Genes were firstly assigned into groups based on significant p values 
using a right tailed Fischer Exact Test. This takes into account the number of genes 
associated with a pathway in the input list compared to the total number of genes associated 
with that pathway in the Ingenuity database. It is therefore a measure of functional groups 
which are over represented in the data set. This analysis revealed that the most significant 
functional groups were cell death, growth and proliferation and similarly to the manually 
assigned list, metabolism and DNA regulation were highly overrepresented (Fig 4.4a).  
The Ingenuity package also provides delineation of genes into separate pathways and Fig 
4.4b shows the most significant pathways from the I/R data set. The left y-axis represents the 
proportion of genes in the data set divided by the total number of genes known to be involved 
in a particular pathway; the right y-axis denotes the negative log of the p value. Surprisingly, 
the highest scoring pathway was ketone body metabolism with 20% of genes involved in this 
pathway differentially expressed during I/R, all of the genes in this list were downregulated. 
Ketone bodies are known to provide protection from oxidative stress, possibly by acting as 
anti-oxidants (Hacles., 2008) and administration of the ketone body acetoacetate was shown 
to increase cardiac contractile performance and restore GSH/GSSG levels in the stunned 
myocardium (Squires., 2003, Mallet., 2003). Downregulation of genes involved in ketone 
body metabolism may therefore be damaging to the heart. Unsurprisingly 15% of genes 
involved in cardiovascular hypoxic signaling were differentially regulated. Cytokine 
responses were also prevalent, including IL-6, IL-10, TGF-• and acute phase signaling, 
highlighting the important role of inflammation in I/R injury. 
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Fig 4.4. Ingenuity analysis of genes differentially expressed by I/R. (A) Functional annotation of 
1109 probe sets identified as being differentially expressed by I/R. Groups are ranked according to p 
value significance, the p<0.05 threshold is shown, on top are the number of genes in each grouping. 
(B) Pathway analysis; pathways are ranked by ratio (x axis) which represents the number of molecules 
in a given pathway that meet cutoff criteria (fold change  > 2, p<0.05) divided by total number of 
molecules that make up that pathway. The orange line denotes the p value as given on the y axis.  
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Next, network analysis was carried out using the Ingenuity package, this uses a right-tailed 
Fisher’s Exact Test and takes into account the number of molecules in the input list (which 
have a fold change > 2 and p<0.05) and the total number of molecules eligible to be included 
in the network. Upregulated genes are colored red and downregulated genes are colored 
green. Network interactions are generated from published associations and include protein 
binding and transcriptional regulation between two molecules. There were 5 networks 
identified, all of which had a p value of less than 10
-36
The second network (Fig 4.5b) is a transcriptional regulatory network with the transcription 
factor Myc (c-Myc) at its centre which was upregulated 6.5 ± 0.1 fold by I/R. c-Myc is a 
highly pleiotropic transcriptional regulator and exerts its effects through recruitment of 
histone acetylase, basal transcription machinery, DNA methytransferases and chromatin 
modifiers (Dang et al., 2006). Indeed c-Myc is thought to regulate as much as 15% of the 
genome, predominantly genes involved in cell cycle regulation, ribosome biogenesis, 
metabolism and cell adhesion (Dang et al., 2006). Therefore the c-Myc regulatory network 
depicted in Fig 4.5b may represent only a fraction of the total number of genes which are 
differentially regulated during I/R as a result of increased c-Myc expression. 
.  The first network (Fig 4.5a) is split 
into two main nodes consisting of Casein Kinase 2 with ubiquitin/proteasome related genes 
and a transcriptional network centered around RNA Polymerase II, subunit J (PolR2J).  
The third network involves AP-1 regulation (Fig 4.5c); all the proteins which constitute the 
AP-1 complex are present (Fos, FosL1, cJun and JunB) and include other upregulated 
transcription factors such as Atf3, Erg1, and Ets2. The fourth network comprises several heat 
shock proteins including, HSP70 (HSPA1), HSP90 and HSP27 (HSPB1) as well as other 
chaperones including several members of the DNAJ family of chaperones which modulate 
HSP70 function (Fig 4.5d). HSPs and chaperones have well documented roles in protection 
from I/R injury (Robison et al., 1995, Li G et al., 2008).  
The final network found was composed of the members of the IL-1 family and several CC 
and CXC chemokines which are induced by IL-1 (Fig 4.5e). An IL-1• inflammatory cascade 
has recently been observed in a model of renal I/R injury and indeed blockade of IL-1• 
secretion has been proposed as a therapeutic strategy in myocardial I/R injury (Furuichi et al., 
2006, Wanderer, 2008) 
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Fig 4.5. Ingenuity network analysis of genes differentially expressed during I/R. Five significant 
regulatory networks were identified from the 1109 probe sets identified as being differentially 
expressed by I/R (A-E). Interactions are defined from the curated Ingenuity database and comprise 
referenced published protein-protein interactions and transcriptional regulation. Upregulated genes are 
shown in red and downregulated genes are shown in green.  
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4.5 Differential Expression mediated by Tempol Infusion During I/R 
Gene ontology analysis of the tempol group, i.e. differential expression between tempol and 
saline infusion during I/R, demonstrated that like the I/R group, the majority of differentially 
expressed genes in the tempol group were either unidentified transcripts or genes with no 
known function (Fig 4.6). Similarly to the I/R dataset, genes involved in transcription and 
translation were the most prominent grouping. The list of the 20 most differentially expressed 
genes is shown in Table 4.3. Of the most highly expressed genes, several are involved in 
cytoskeletal control and myocardial contraction. For example, radixin (2.74 ± 0.1 fold 
increase) and vinculin (59.6 ± 1.6% decrease) both anchor actin to the cell membrane 
(Humphries et. al, 2007), tropomyosin (60.2 ± 0.1% decrease) forms part of the thin filament 
of the sarcomere and controls actin-myosin interaction and ATP2a2 (2.5 ± 0.2 fold increase) 
and the ryanodine receptor (3.5 ± 0.4 fold increase) control myocardial contraction by 
regulating the release of 
+
   
 from the sarcoplamic reticulum. This suggests that restoration of 
calcium homeostasis and myocyte contractility may be central to tempol mediated 
cardioprotection. Ingenuity functional group analysis is shown in Fig 4.7a and placed genes 
in several distinct groups including cell signalling, molecular transport and cell death. 
Ingenuity pathway analysis was not informative due to the low numbers of genes in each 
pathway. One significant network was found and is shown in Fig 4.7b. This network centres 
around two main nodes, the sarcomeric proteins Ryr/ATP2a2 and the apoptosis regulating 
transcription factor p53. Although p53 itself did not pass the significance test, p53 expression 
was found to be reduced 37.8 ± 6.8% by tempol with a p value of 0.06, suggesting the 
possibility that p53 regulation may play a role in tempol mediated cardioprotection. This also 
highlights the usefulness of the network analysis approach in uncovering potential regulatory 
interactions.  165 
 
 
Fig 4.6. Manual GO analysis differentially expressed genes between tempol and I/R. GO terms 
were assigned to the 67 probe sets based on manual searching of the literature to define the most 
common function of each gene.  
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Table 4.3. Top 20 differentially expressed genes between tempol and I/R
Symbol Gene Title FC P value B value
Nfe2l1_predicted nuclear factor, erythroid derived 2,-like 1 (predicted) 6.2 0.02 1.1
Rpl7 Ribosomal protein L7 -5.2 0.01 4.3
Gbas glioblastoma amplified sequence 4.3 0.01 2.3
Dut deoxyuridine triphosphatase 3.7 0.00 6.3
Ryr2 ryanodine receptor 2, cardiac 3.5 0.04 0.2
Tm9sf1 transmembrane 9 superfamily member 1 3.5 0.02 1.7
Orc4 origin recognition complex, subunit 4 3.2 0.01 2.4
Rdx Radixin 2.7 0.03 0.8
Qk /// Qki quaking homolog, KH domain RNA binding / quaking 2.6 0.01 2.7
Tpm3 tropomyosin 3, gamma -2.5 0.02 1.3
Atp2a2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 2.5 0.04 0.2
Vcl_predicted Vinculin (predicted) -2.5 0.02 1.9
Abcc1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 2.5 0.03 0.7
Hspa4 heat shock protein 4 2.4 0.02 1.0
Pja2 praja 2, RING-H2 motif containing 2.4 0.01 3.5
Ppp3ca protein phosphatase 3, catalytic subunit, alpha isoform 2.4 0.03 0.8
Pdia4 protein disulfide isomerase associated 4 2.4 0.04 0.1
Tmem98 transmembrane protein 98 2.4 0.04 0.1
Gramd3 GRAM domain containing  3 2.3 0.04 0.2
Hmgb1 high mobility group box 1 2.3 0.02 1.6166 
 
 
 
Fig 4.7. Ingenuity analysis of differential expression between tempol and I/R. (A) Functional 
analysis of 67 probe sets identified as being differentially regulated by tempol. Groups are ranked 
according to p value significance, the p<0.05 threshold is shown, on top are the number of genes in 
each grouping. (B)  Network analysis, a single  network was identified from the 67 probe sets. 
Interactions are defined from the curated Ingenuity database and comprise referenced published 
protein-protein interactions and transcriptional regulation. Upregulated genes are shown in red and 
downregulated genes are shown in green.  
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4.6 Differential Expression mediated by Ucn1 and Ucn2 Infusion During I/R 
Ucn2 infusion during I/R injury resulted in twice as many (142) significantly differentially 
expressed genes as Ucn1 (67). This may not be biologically relevant however since an 
examination of the number of genes passing the 2-fold cut-off without applying a significant 
p value filter revealed that there were 234 genes differentially expressed in the Ucn1 group 
and 241 in the Ucn2. Therefore the lower number of significantly differentially expressed 
genes in the Ucn1 group is due to greater heterogeneity between the three urocortin 
microarrays resulting in fewer genes passing the significance filter. The top 20 most 
differentially expressed genes between Ucn1, Ucn2 and saline treatment during I/R is shown 
in Table 4.4. Of the 67 and 142 genes differentially expressed by Ucn1 and Ucn2 
respectively, 30 of them were common to both. This suggests that although both hormones 
signal through CRF receptors, they have distinct effects on gene expression patterns. Manual 
gene ontology analysis showed that transcription, translation and proteolysis were prominent 
subgroups in both the Ucn1 and Ucn2 dataset (Fig 4.8). Ingenuity functional group analysis 
of both hormones showed that all the groups assigned to Ucn2 were present in Ucn1, with 
genes involved in cell death or cell growth being the largest set (Fig 4.9). Therefore, although 
Ucn1 and Ucn2 regulate distinct genes, gene ontology analysis suggests that their 
transcriptional programmes may exert similar biological effects.  
Network analysis identified one significant network for each hormone (Fig 4.10). Most of the 
genes shown in the Ucn1 network are on the periphery of the network, the central molecules 
are p53, CREB, IFN-• and glucose. There was no signal for CREB1 or IFN-• found on the 
microarray so differential expression could not be calculated but qPCR analysis showed that 
Ucn1 did indeed lower the expression of IFN-• (Fig 4.13b). In addition, Ucn1 has previously 
been shown to regulate glucose utilization (Keperman et al., 2008) and p53 and CREB might 
well be regulated at the level of phosphorylation. The Ucn2 network is centred on the kinases 
ERK, JNK and Akt, although Ucn2 has no effect on the expression of these kinases, Ucn2 
has previously been shown to phosphorylate ERK and Akt in cardiac myocytes and 
phosphorylate JNK in intestinal cells (Chanalaris, 2003, 2005). This network suggests that 
likewise, Ucn2 may alter gene expression through MAPK or Akt pathways in I/R injury.    168 
 
 
Table 4.4. Top 20 differentially expressed genes between Ucn1, Ucn2 and  I/R.  
 
 
 
Ucn1
Symbol Gene Title FC P value B value
Ssr3 signal sequence receptor, gamma 6.3 0.02 1.0
Cap2 CAP, adenylate cyclase-associated protein, 2 (yeast) 5.2 0.05 -1.0
Nfe2l1_predicted nuclear factor, erythroid derived 2,-like 1 (predicted) 5.2 0.03 0.3
Gbas glioblastoma amplified sequence 4.6 0.01 2.7
C1qr1 complementcomponent 1, q subcomponent, receptor1 -4.1 0.05 -0.9
Rabgap1 RAB GTPase activating  protein 1 -3.8 0.03 0.1
Orc4 origin recognition complex, subunit 4 3.7 0.01 3.5
Pdia4 protein disulfide isomerase associated 4 3.7 0.01 3.3
Ralgds ral guanine nucleotide dissociation stimulator -3.5 0.04 -0.6
Mt1a metallothionein 1a -3.4 0.03 -0.1
Rpl7 Ribosomal protein L7 -3.3 0.02 1.5
Limd1_predicted LIM domains containing 1 (predicted) -3.3 0.02 1.2
Timp3 tissue inhibitor of metalloproteinase 3 -3.3 0.03 -0.2
Dut deoxyuridine triphosphatase 3.2 0.00 5.2
Srp72 signal recognition particle 72 -3.2 0.02 1.3
Them4 thioesterase superfamily member 4 3.1 0.03 0.0
Tm9sf1 transmembrane 9 superfamily member 1 3.1 0.02 0.8
Eif2c2 eukaryotic  translation initiation factor 2C, 2 3.0 0.05 -0.9
Ap2s1 adaptor-related protein complex 2, sigma 1 subunit 3.0 0.03 0.2
Sparc secreted acidic cysteine rich glycoprotein -2.9 0.05 -1.0
Symbol Gene Title FC P value B value
Rpl7 Ribosomal protein L7 -10.3 0.00 7.4
Slc34a1 solute carrier family 34  (sodium phosphate), member 1 -7.0 0.01 4.2
Birc4 baculoviral IAP repeat-containing 4 4.8 0.03 1.0
Cap2 CAP, adenylate cyclase-associated protein, 2 (yeast) 4.6 0.04 0.2
Clu clusterin -4.4 0.01 3.7
Ccdc58_predicted coiled-coil domain containing 58 (predicted) -4.2 0.00 5.6
Nrarp Notch-regulated ankyrin repeat protein 4.1 0.01 2.8
Nfe2l1_predicted nuclear factor, erythroid derived 2,-like 1 (predicted) 4.0 0.05 0.0
Lsm12 LSM12 homolog (S. cerevisiae) 3.6 0.02 1.8
Gnb1 guanine nucleotide binding protein, beta 1 -3.3 0.00 5.0
Dut deoxyuridine triphosphatase 3.1 0.00 5.0
Napsa napsin A aspartic peptidase -2.9 0.05 -0.2
Igf1 insulin-like growth factor 1 -2.8 0.03 0.7
Arf2 ADP-ribosylation factor 2 2.7 0.02 1.3
Tmem98 transmembrane protein 98 2.6 0.03 1.0
Rac2 RAS-related C3 botulinum substrate 2 -2.6 0.02 1.4
Kcnj8 potassium inwardly-rectifying channel, subfamily J8 -2.5 0.04 0.2
Cdh2 cadherin 2 2.4 0.05 -0.2
Mccc2 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 2.4 0.01 2.4
Ppp6c protein phosphatase 6, catalytic subunit 2.4 0.04 0.0
Ucn1169 
 
 
 
Fig 4.8. Manual GO analysis of differential expression by Ucn1 and Ucn2 compared to I/R. GO 
terms were assigned to the 67 probe sets for Ucn1 and 142 probe sets for Ucn2 and based on manual 
searching of the literature to define the most common function of each gene.  
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Fig 4.9. Ingenuity analysis of differential expression by induced by Ucn1 and Ucn2. Functional 
annotation of the 67 probe sets in the Ucn1 group and 142 probe sets in the Ucn2 group identified as 
being differentially expressed when compared to saline infusion during I/R. Groups are ranked 
according to p value significance, the p<0.05 threshold is shown, on top are the number of genes in 
each grouping.  
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Fig 4.10 Network analysis of the Ucn1 and Ucn2 groups. A single network was identified from the 
67 probe sets in the Ucn1 group and the 142 probe sets from the Ucn2 group. Interactions are defined 
from the curated Ingenuity database and comprise referenced published protein-protein interactions 
and transcriptional regulation. Upregulated genes are shown in red and downregulated genes are 
shown in green.  
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4.7 Validation of Microarray Data by qPCR 
Before making any general inferences on regulation of specific genes, qPCR analysis was 
carried out in order to confirm some of the gene changes seen on the microarray. Fig 4.11a 
shows a list of 23 genes which were tested for differential expression between sham and I/R. 
With this data at hand, the effect of three common algorithms were examined to ensure that 
GCRMA was indeed the best method of normalization to choose for this dataset. Both 
GCRMA and RMA normalizations were carried out in Bioconductor and MAS5.0 
normalization was carried out using Genespring 7.3. The log of the microarray fold change 
between sham and I/R was plotted on the x-axis versus the log qPCR fold change on the y-
axis. Nonlinear regression analysis was used to test the correlation between the microarray 
data and qPCR levels (Fig 4.11b,c,d). Taking all 23 genes into account, the 
 
 value was 
highest for GCRMA at 0.947, followed by RMA at 0.943 and MAS 5.0 at 0.857. With a few 
exceptions (Bcl-2, XIAP), the qPCR data verifies the microarray results and thus some 
general conclusions can be drawn from the dataset as a whole. The following sections 
therefore will deal with regulation of specific genes and what effects they may have on I/R 
injury. It must be noted here that due to sample problems, it was not possible to confirm the 
gene expression changes seen with Ucn2 by qPCR. 173 
 
 
Fig 4.11. Fold changes obtained by three separate normalisation methods compared with qPCR. 
(A) Fold changes between I/R and sham were obtained using MAS5.0 in Genespring and RMA or 
GCRMA in Bioconductor and compared against qPCR data. (B, C and D) Linear regression analysis 
was carried out between qPCR data and microarray data and the   correlation co-efficient was 
calculated.
 
   
MAS5.0 RMA GCRMA qPCR
HSP70 16.6 19.8 40.4 316.0
c-Fos 13.4 23.3 40.8 64.1
IL-1B 5.1 6.1 12.8 21.1
iNos 15.9 4.2 11.8 18.0
MMP8 4.6 4.1 8.5 17.1
MMP9 14.7 2.8 10.2 11.7
IL-6 4.1 5.5 9.4 10.6
Socs3 - 2.5 6.4 8.8
DUSP1 3.7 2.5 4.9 4.7
IL-17 R 3.5 3.6 7.0 4.6
Bcl-2 - - - 3.3
Icos 2.2 1.2 1.2 1.9
Map4k2 -3.0 -1.7 -1.8 -1.4
Tim23 -2.2 -1.6 -1.6 -1.6
Scn5a -2.3 -1.4 -1.5 -1.7
Tom20 - -1.4 - -1.9
Timm8a -2.3 -1.8 -1.7 -1.9
BNip3 -3.1 -2.0 -2.1 -2.0
Timm44 -9.6 -2.5 -2.9 -2.0
Xiap - -1.5 - -2.1
Dut -4.2 -2.7 -4.7 -2.4
Timm13 -3.3 -2.4 -2.6 -2.7
Timm8b -2.5 -2.0 -1.9 -3.0
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4.8 Activation of a STAT3 Transcriptional Programme Following I/R Injury  
Ingenuity pathway analysis identified the IL-6 and IL-10 pathways as being highly 
represented in the I/R dataset (Fig 4.4b) with approximately 15% of the genes in these 
pathways being upregulated by I/R. Both IL-6 and IL-10 have a commonality in requiring 
STAT3 to mediate their cellular effects (Murray, 2007) and therefore an analysis of STAT3 
target genes differentially regulated by I/R injury was conducted. The list of 796 
differentially expressed annotated genes was manually cross-referenced against genes which 
have been shown to be targets of STAT3 in the literature. This identified 46 STAT3 target 
transcripts comprising 5.8% of the differentially expressed annotated genes (Table 4.5), it is 
likely however that this is an underrepresentation of the true figure, since additional STAT3 
target genes are being continually characterised.  In the previous chapter it was shown that 
STAT3 was phosphorylated and transcriptionaly active following I/R injury, this genomic 
expression data therefore extends these findings in identifying a large set of STAT3 
dependent genes upregulated by I/R injury. While the genes identified in table 4.5 can be 
upregulated or repressed by STAT3, other transcription factors may be involved in their 
regulation, and individual chromatin immunoprecitpitation would need to be conducted on 
each individual target to verify STAT3 binding to their promoter regions during I/R. 
Nonetheless the data suggest that during I/R injury STAT3 has a large impact on the resulting 
transcriptional programme. 
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Symbol Gene Name FC p value Referenece
Alox15 arachidonate 15-lipoxygenase 12.9 0.00 Xu B et al., 2003
Angpt2 angiopoietin 2 4.6 0.01 Synder et al., 2008
Bmp4 bone morphogenetic protein 4 2.3 0.01 Synder et al., 2008
Calm3 calmodulin 3 -2.4 0.00 Synder et al., 2008
Ccl2 (MCP-1) chemokine (C-C motif) ligand  2 4.9 0.00 Burysek et al., 2002
Ccng2_predicted cyclin G2 (predicted) -2.1 0.01 Paz et al., 2004
Ccr1 chemokine (C-C motif) receptor 1 7.2 0.00 D'Amico et al., 2000
Cd44 CD44 antigen 4.0 0.00 Synder et al., 2008
Cdh2 cadherin 2 -2.0 0.03 Synder et al., 2008
Cox-2 (Ptgs2) prostaglandin-endoperoxide synthase 2 2.7 0.02 Xuan et al., 2005
Dusp1 dual specificity phosphatase 1 5.0 0.00 Lam et al., 2007
Egr1 early growth response 1  17.2 0.00 Ng et al., 2006
Fgfr1 Fibroblast growth factor receptor 1 3.9 0.02 Synder et al., 2008
Fgl2 fibrinogen-like 2 7.6 0.00 Synder et al., 2008
Fos FBJ murine osteosarcoma viral oncogene homolog  40.7 0.00 Joo et al., 2004
Fosl1 fos-like antigen 1 30.2 0.00 Paz et al., 2004
Ftl1 ferritin light chain 1 2.6 0.00 Minami et al., 1996
Gadd45g growth arrest and DNA-damage-inducible 45 gamma 4.5 0.00 Nakayama et al., 1999
Gata6 GATA binding protein 6 -2.3 0.01 Synder et al., 2008
H2a histone 2a 2.1 0.00 Paz et al., 2004
Hif1a hypoxia inducible factor 1, alpha subunit 2.0 0.01 Xu et al., 2005
Ifrd1 interferon-related developmental regulator 1 3.8 0.00 Synder et al., 2008
Il4ra interleukin 4 receptor, alpha 3.9 0.00 Lang et al., 2002
Jak2 Janus kinase 2 2.2 0.02 Synder et al., 2008
Jun Jun oncogene  4.8 0.00 Alvarez et al., 2005
Junb Jun-B oncogene 4.0 0.00 Ng et al., 2006
Lbp lipopolysaccharide binding protein 3.2 0.01 Schumann et al., 1995
Lyz lysozyme 2.5 0.00 Minami et al., 1996
Mcl1 myeloid cell leukemia sequence 1 2.6 0.00 Niu et al., 2002
Mmp9 matrix metallopeptidase 9 10.2 0.00 Landen et al., 2007
Myc myelocytomatosis viral oncogene homolog (avian) 6.5 0.00 Bownman et al., 2001
Nfil3 nuclear factor, interleukin 3 regulated 3.8 0.01 Alvarez et al., 2005
Nfkb1 Nfkblight polypeptide gene enhancer in B-cells 1, p105 2.0 0.02 Synder et al., 2008
Oasl1 2'-5' oligoadenylate synthetase-like 1 2.2 0.04 Dauer et al., 2005
Phlda1 pleckstrin homology-like domain, family A, member 1 9.4 0.00 Li et al., 2002
Plaur plasminogen activator, urokinase receptor 25.5 0.00 Dauer et al., 2005
Plscr1 phospholipid scramblase 1 3.5 0.00 Lang et al., 2002
Ralgds ral guanine nucleotide dissociation stimulator 4.8 0.00 Senga et al., 2001
S100a9 S100 calcium binding protein A9  8.0 0.00 Li et al., 2004
Slpi secretory leukocyte peptidase inhibito 9.0 0.00 Clarkson et al., 2006
Smad1 MAD homolog 1 (Drosophila) 2.0 0.01 Synder et al., 2008
Socs3 suppressor of cytokine signaling  3 6.4 0.05 Synder et al., 2008
Stat3 signal transducer and activator of transcription 3 2.3 0.00 Synder et al., 2008
Tfpi2 tissue factor pathway inhibitor 2 7.7 0.00 Dauer et al., 2005
Timp1 tissue inhibitor of metalloproteinase 1 6.4 0.00 Dien et al., 2006
Tnfrsf12a tumornecrosis factor receptor superfamily, member 12a 7.2 0.00 Synderet al., 2008
Table 4.5.Genesdifferentiallyregulatedby I/Rpreviouslybeenshowntobe targetsofSTAT3176 
 
Microarray analysis showed that IL-6 (9.6 ± 1.4), the IL-6 receptor (1.9 ± 0.0) and gp130 (3.0 
± 0.3) were all upregulated by I/R as was the IL-6 signaling antagonist SOCS3 (6.4 ± 1.9). 
qPCR showed that IL-6 was upregulated 7.6 ± 1.3 fold by I/R and significantly reduced by 
tempol treatment (Fig 4.12a). Upregulation of IL-6 during I/R injury may be therefore br 
involved in STAT3 phosphorylation and inhibition of IL-6 expression by tempol may 
contribute to its ability to inhibit STAT3 phosphorylation.  IL-6 has previously been shown to 
have beneficial effects in I/R injury and is also required for preconditioning (Mastsushita et 
al., 2005, Dawn et al., 2004). Interestingly, the I/R mediated increase in IL-6 expression was 
paralleled by an increase in SOCS3 expression, this suggests that similarly to inflammation, 
I/R leads to concomitant upregulation of stimulators and inhibitors to the JAK/STAT 
pathway. 
Ucn1 increased IL-6 expression 1.8 fold over and above the levels in the saline treated 
samples and also repressed SOCS3 expression by I/R (Fig 4.12b). Since IL-6 induces STAT3 
phosphorylation and SOCS3 inhibits it, the effect of Ucn1 on STAT3 phosphorylation was 
tested. Fig 4.12d shows that as previously demonstrated, I/R injury increased STAT3 tyrosine 
and serine phosphorylation; surprisingly however, the addition of Ucn1 had no consistent 
effect on  or 
 
 levels. Ucn1 treatment did increase STAT3 mRNA levels compared to the sham 
or I/R groups (Fig 4.12c) but this was not reflected by increased STAT3 protein levels 
(Fig4.12d). While Ucn1 had no effect on STAT3 phosphorylation or protein levels in the 2 hr 
reperfusion samples, it may increase both STAT3 protein expression and phosphorylation if 
examined over a longer period.  
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Fig 4.12. The IL-6/STAT3/SOCS3 axis is induced by I/R and enhanced by Ucn1. (A, and C) IL-
6, SOCS3 and STAT3 expression was measured by qPCR and normalised to sham levels. Statistical 
analysis was carried out using a one-way ANOVA with Dunnett’s post test, n=3 samples, * p<0.05, 
** p<0.01, *** p<0.001 compared to I/R + Sal. (D) The expression of , 
 
 and total STAT3 was 
measured by western blot.  
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Recently nitric oxide has come to the fore as a potent cardioprotective agent (Bolli, 2001). 
Nitric oxide synthase (NOS) is the enzyme responsible for producing nitric oxide and exists 
in three isoforms; NOS1 (nNOS), NOS2 (iNOS) and NOS3 (eNOS). Both eNOS and iNOS 
were upregulated on the microarray by 11.8 ± 1.1 and 3.3 ± 0.8 fold respectively. In epithelial 
and smooth muscle cells, IFN-• and IL-1• have been shown to have a synergistic effect on 
iNOS expression and in addition, STAT1 and c-Fos interact with one another and bind to the 
iNOS promoter, thereby increasing iNOS expression (Tang et al., 2002, Xu et al., 2003). 
STAT1 activity was shown to be enhanced by I/R (see Fig 3.16b) and qPCR analysis found 
that IFN-•, IL-1•, c-Fos and iNOS were markedly upregulated by I/R (Fig 4.13), thus 
confirming microarray data. During I/R, IL-1• and IFN-• together with STAT1 and c-Fos 
may therefore co-operate to enhance iNOS expression. Cardioprotection by iNOS lies 
upstream of COX-2 (Li, 2007) and indeed COX-2 expression was also found to be 
upregulated by 2.7 ± 0.2 fold on the microarray. In addition, tempol-mediated inhibition of 
IFN-• expression may contribute to the reduction in STAT1 phosphorylation by tempol. 
The data therefore suggests that the JAK/STAT-iNOS/COX2 axis, one of the major 
cardioprotective pathways is induced by oxidative stress. It may seem counter-intuitive that 
tempol should inhibit a cardioprotective pathway such as this, however tempol treatment is 
expected to affect all pathways which are responsive to oxidative stress and therefore will 
reduce the activity of many cardioprotective molecules, on balance however it is expected to 
block the activity of more of the damaging pathways. 
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Fig 4.13. Regulation of the Nitric Oxide pathway by I/R injury. (A-D) The expression of 
the indicated genes was measured by qPCR and normalised to sham levels. Statistical 
analysis was carried out using a one-way ANOVA with Dunnett’s post test, n=3 samples, * 
p<0.05, ** p<0.01, compared to I/R + Sal.  
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4.9 IL-17 Regulation in I/R injury  
The IL-17 receptor was found to be upregulated by I/R (microarray 7.0 ± 1.1) and regulation 
of the IL-17 axis in I/R injury has not previously been reported. Huge interest has recently 
been generated in the newly identified subset of IL-17 producing T cells (termed Th17 cells) 
which are crucial to inflammatory responses and autoimmune disease. Differentiation of 
Th17 cells is controlled by TGF-• and IL-6 and stabilized and reinforced by IL-21 and IL-23 
(Dong, 2008). STAT3 has been shown to be necessary for both the differentiation and 
stabilization of Th17 cells via transactivation of the Th17 specific transcription factors 
retinoic acid receptor-related orphan receptor gamma (ROR•) and ROR• (Yang et al., 2007, 
2008, Nurieva et al., 2007). Moreover, STAT3 is necessary for the subsequent production of 
IL-17A and IL-17F which mediate Th17 cell’s biological effects (Chen et al., 2006). This is 
evidenced by the recurrent infections which occur in patients with hyper IgM syndrome, 
these patients harbor dominant negative mutations in the STAT3 DNA binding domain 
resulting in impaired IL-17 production and inability to clear infections (Ma et al., 2008).
Upregulation of the IL-17R was verified by PCR (4.6 ± 0.8) Fig 4.14a. There were no probes 
present for IL-17A or IL-17F on the RAE 230A microarrays, but their expression was 
measured by qPCR. Fig 4.14 b and c show that both IL-17A and IL-17F were upregulated by 
I/R injury 8.3 ± 3.2 fold and 4.3 ± 1.3 fold respectively. A search for downstream IL-17 
targets revealed upregulation of a host of IL-17 mediators upregulated by I/R injury on the 
microarray, including; Cxcl1, Cxcl2, Cxcl3, Ccl2, IL-1•, iNOS, IL-6, S100a8, S100a9, Ccr1, 
P-selectin, ICAM-1,  MMP-9, Ptgs2, Timp1,  lcn2, Cotl1 and Spsb1 (
 
Little is known about IL-17 pathway regulation in the cardiovascular system, however one 
report has demonstrated upregulation of IL-17A following middle cerebral artery occlusion in 
rats and in ischaemic lesions in human brain (Li et al., 2005). 
Huang  et al., 2007, 
Jovanovic et al., 1998, Hwang et al., 2004, Fossiez et al., 1996, Lubberts et al., 2005, Shen et 
al., 2005, Albanesi et al., 1999 McAllister et al., 2005). 
To examine the kinetic expression of the IL-17 axis during I/R injury, their expression was 
measured following I/R injury in vitro. The mRNA expression of the IL-17R was time-
dependently increased during I/R injury in NRVMs, reaching a maximum at 4 hr (Fig 4.14d). 
Analysis of IL-17A and IL-17F mRNA levels could not be accurately and consistently 
determined since the Ct threshold for these PCRs was in the range 38-40 cycles. IL-17A and 
IL-17F mRNA have been shown to be regulated by STAT3 (Yang et al., 2007), therefore in 181 
 
order to examine if neonatal cardiac mycoytes are capable of expressing IL-17A and IL-17F 
mRNA, NRVMs were transduced for 24 hr with a constitutively active STAT3 adenovirus 
(STAT3C). STAT3C transduction allowed for consistent measurements by qPCR (Fig 4.17 e, 
f), IL-17A was upregulated 3.5 ± 0.5 fold, IL-17F was upregulated 9.5 ± 1.3 fold and 
STAT3C had no effect on the IL-17R (Fig 4.14 e-g). This qPCR data shows that cardiac 
myocytes, although they express low constitutive levels, can still produce IL-17A and IL-17F 
mRNA when their transcriptional regulator is overexpressed. In the future, analysis of IL-17 
levels using flow cytometry will allow more careful examination of the effect of in vitro I/R 
injury on IL-17 levels.  
Taken together this data shows that the IL-17 axis is upregulated during IR injury in vivo, 
cardiac mycoytes express IL-17A, IL-17F and the IL-17R and upregulate the receptor 
following I/R injury. What effect this has on cardiovascular biology is currently unknown. 
Likewise it is unknown what are the major cell types affected by IL-17 in the heart. 
Endothelial cells and fibroblasts have been shown to express a functional receptor and one 
report has shown that conditioned medium from cardiac fibroblasts contains IL-17 (Honorati 
et al., 2000, La Framboise  et al., 2007, Chang et al., 2006). Since cardiac myocytes 
upregulate the receptor in vitro and in vivo following reperfusion injury, it is likely that IL-17 
does affect cardiac myocyte physiology. Detailed examination of IL-17 production by flow 
cytometry and analysis of the effect of IL-17A and IL-17F production on cardiac myocyte 
survival following I/R  injury should greatly add to the understanding of the role of this 
cytokine family in I/R injury.  
 
 182 
 
 
Fig 4.14. The IL-17 axis is regulated by I/R injury. (A-C) The expression of IL-17R, IL-17A and 
IL-17F was measured by qPCR and normalized to sham. (D)  IL-17R expression was measured 
following a time course of in vitro  I/R injury in NRVMs. (E-G)  NRVMs were transduced with 
STAT3C at moi=100 for 24 hr and the expression IL-17A, IL-17F and IL-17R.   
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4.10 Differential Regulation of MAPKs and MKP-1 during I/R Injury 
MAPK phosphatases (MKPs also known as dual-specificity phosphatases -DUSPs) are 
endogenous inhibitors of JNK, p38 MAPK and ERK activity. p38 MAPK and JNK have both 
been shown to be pro-apoptotic factors in the myocardium and mice deficient in MKP-1 had 
increased infarct sizes after I/R injury due to excessive p38 MAPK activity (Kaiser et al., 
2004). Although, the activity of MAPKs in I/R injury has been addressed previously, there is 
little published information regarding the expression of MKP/DUSPs during I/R. The 
microarray results showed that the expression of 4 DUSPs was elevated by I/R; 
DUSP1/MKP-1 (4.9 ± 0.5), Dusp5 (16.6 ± 0.9), Dusp6/MKP-3 (5.3 ± 0.9) and Dusp16/MKP-
7 (2.8 ± 0.5). Each phosphatase has a distinct specificity for each of the MAPKs, DUSP1 
preferentially dephosphorylates p38 and JNK (Franklin et al., 1997), DUSP 5 and DUSP6 are 
selective for ERK (Camps et al., 1998, Mandl et al., 2005) and DUSP16 interacts with p38-• 
and JNK1 but not ERK (Tanoue et al., 2001). The expression of DUSP1/MKP-1 was 
examined by qPCR, which showed a 4.7 ± 0.6 fold induction during I/R, this was 
significantly inhibited by tempol but not Ucn1 (Fig 4.15a). 
The phosphorylation status of ERK and p38 MAPK was also examined. Fig 4.15b shows that 
ERK was maximally phosphorylated within 15 min of reperfusion and by 30 min 
dephosphorylation had started to occur. Phosphorylation of p38 MAPK was found to be 
regulated in a more complex fashion; p38 MAPK was phosphorylated during ischaemia then 
rapidly dephosphorylated within 5 min of reperfusion. During reperfusion, phospho-p38 
MAPK levels increased up to 60 min and were once again reduced by 2 hr, with total p38 
MAPK levels remaining constant. Thus both ERK and p38 MAPK phosphorylation was 
reduced by 2 hr reperfusion, coinciding with increased DUSP expression. Upregulation of 4 
separate DUSPs highlights the complex regulation of the MAPK cascade in I/R and shows 
that during I/R injury, the heart induces both activators and inhibitors to precisely control the 
temporal activation of MAPKs.  
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Fig 4.15 MAPK activity during I/R injury. (A) The expression of MKP-1 was analysed by qPCR 
and normalised to sham levels. Statistical analysis was carried out using a one-way ANOVA with 
Dunnett’s post test, n=3 samples, ** p<0.01 compared to I/R + Sal.  (B) Rats were subjected to a time 
course of I/R injury up to 2 hr. The indicated antibodies were used to measure the levels of MAPKs, 
GAPDH was used as a loading control.  
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4.11 Uracil Metabolism is Altered by I/R Injury 
Although the effect of purines on myocardial physiology has been extensively studied, less is 
known about the effect on heart function of pyrimidines such as uridine triphosphate (UTP) 
and uridine diphosphate (UDP).  Extracellular pyrimidines activate the membrane bound P2Y 
G-protein coupled purinoceptors leading to increases in adenylyl cyclase and phospholipase 
C activity (Mazzola et al., 2008). UTP acts through the  and   receptors while UDP is an 
agonist for the  receptor. Both UTP and UDP have been shown to have positive ionotropic 
effects on cardiac myocytes and measurements of plasma levels of UTP showed an increase 
of 57% in patients with myocardial infarction (Wihlborg  et al., 2006). UTP influences 
vascular tone and blood pressure through its effects on smooth muscle and endothelial cells 
and also promotes hypertrophy of cardiac myocytes (Pham et al., 2003). In addition, UTP has 
been shown to protect cardiac myocytes from hypoxic cell death by acting on the  receptor 
(Yitzhaki et al., 2005). UTP also reduces infarct size in vivo when administered both before 
and after I/R, preserving ATP levels and maintaining mitochondrial function. (Yitzhaki et al., 
2006). In the I/R group,  was upregulated by 4.3 ± 0.3 fold and  was upregulated 3.4 ± 1.2 
fold, there was no change in  levels. Since pharmacological inhibition of P2Y receptors 
during  in vivo  I/R injury  increased contractile dysfunction and UDP and UTP are 
cardioprotective (Wee et al., 2007, Mazzola et al., 2008), it is possible that upregulation of  
and 
Deoxyuridine triphosphatase (Dut), also known as dUTPase, hydrolyses dUTP to give dUMP 
and pyrophosphate and is essential to cell survival by maintaining a constant dUTP/dTTP 
balance (Tooth et al., 2007). dUTPase prevents excess uracil from getting incorporated into 
newly synthesized DNA, which would cause DNA fragmentation and cell death (Curtin et al., 
1991). Although dUTPase is necessary to maintain genomic stability, very little is known 
about its transcriptional regulation. It is known that alternative splicing produces distinct 
nuclear and mitochondrial isoforms but how their expression is controlled has not been 
ascertained (Ladner et al., 1997). Likewise, the role of dUTPase in the myocardium or its 
regulation by I/R injury has never been addressed. I/R injury was found to decrease the 
expression of dUTPase by 78.3 ± 2.5%, suggesting that dUTP  levels are likely to be elevated 
in the myocardium during I/R injury. Alignment analysis of the affymetrix probe sets for 
dUTPase showed that the probes are not specific to either isoform and therefore this figure 
represents a reduction in total dUTPase RNA levels.  By microarray, tempol, Ucn1 and Ucn2 
 represents a novel endogenous cardioprotective mechanism initiated during I/R injury. 186 
 
increased the expression of dUTPase by 3.8 ± 0.3, 3.2 ± 0.2 and 3.3 ± 0.4 fold respectively. 
qPCR analysis confirmed repression of dUTP by I/R and increased expression by tempol, 
however qPCR did not show elevated levels of dUTPase after Ucn1 treatment (Fig 4.16). The 
reasons for this are unknown; the qPCR primers were designed to an area of the dUTPase 
gene common to both isoforms. It is clear however that dUTPase mRNA expression is 
lowered during I/R, the reasons for this reduction and the resulting physiological outcome are 
unknown but it is likely that persistent inhibition of dUTPase would result in significant DNA 
damage. Increased dUTPase expression by tempol may be a novel effect of antioxidant 
treatment during I/R injury. It is of course necessary to measure dUTP levels directly in the 
myocardium following I/R injury to formally show that this is the case, nonetheless it may 
represent a previously unappreciated role for dUTPase in cardiac pathology.  
 
 
Fig 4.16. dUTPase levels are reduced by I/R and partially restored by tempol.    dUTPase 
expression was measured by qPCR and normalised to sham levels. Statistical analysis was carried out 
using a one-way ANOVA with Dunnett’s post test, n=3 samples, * p<0.05, *** p<0.001 compared to 
I/R + Sal.  
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4.12  Reduced Expression of Mitochondrial Translation Genes Following I/R 
Injury  
Mitochondrial dysfunction during I/R injury results in reduced ATP synthesis and initiation 
of apoptosis, thus recovery of mitochondrial function is necessary to restore contractility after 
an ischemic episode (Solaini  et al., 2005)
 
. The majority of mitochondrial proteins are 
encoded in the nucleus while the mitochondrial genome encodes 13 proteins, 22 tRNAs and 2 
rRNAs. Mitochondrial mRNAs are translated by the 12 S and 16 S mitochondrial rRNAs and 
approximately 80 nuclear encoded mitochondrial ribosomal proteins (MRPs) which must be 
imported into the mitochondria (Wang et al., 2007). Mitochondrial encoded proteins form an 
essential part of the mitochondrial respiratory chain (Emdadul Haque et al., 2008) and require 
a specialized mitochondrial translation system. Mitochondrial genes were the third highest 
differentially expressed annotated group following I/R injury (Fig 4.3) and examination of 
genes in this group suggested that mitochondrial translation may be  reduced during I/R 
injury. There are 68 MRPs represented on the RAE230A arrays and of these, 47 had reduced 
expression following I/R. The expression of MRPs L1, L3, L4, L9, L11, L12, L13, L14, L15, 
L16, L18, L20, L21, L22, L23, L27, L28, L30, L32, L35,  L36, L37, L40, L41, L42, L43, 
L44, L46, L50, L53, L54, S9. S14, S16, S17, S18A, S21, S23, S24, S25, S27, S30, S33, S35, 
S36 and MRP63 were downregulated on average 51.3 ± 1.7 % by I/R injury. With such a 
large number of mitochondrial ribosomal proteins having reduced mRNA levels, it is likely 
that this results in a global reduction in the availability of mitochondrial proteins. In addition 
to MRPs, mitochondrial translational requires the elongation factors EF-Tu (TUFM), EF-Ts 
(TSFM) and EF-G (GFM1). Following I/R, EF-Tu expression was reduced by 51.3 ± 5.4% 
and EF-G expression was reduced by 55.6 ± 10.7 %; however there are no probes for EFTs 
present on the Affymetrix RAE 230A arrays. This suggests that the entire mitochondrial 
translational machinery is transcriptionally downregulated following I/R injury and may 
represent a heretofore unrecognized facet of mitochondrial dysfunction during I/R.  
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4.13  Reduced Expression of Mitochondrial and Respiratory Chain Genes 
Following I/R Injury  
During I/R injury, mitochondrial respiration is compromised, superoxide production is 
increased and the MPT pore opens, leading to cytochrome c release and dysregulation of 
calcium homeostasis (Di Lisa et al., 2007). The mitochondrial respiratory chain is the main 
source of ROS generation in the cell and at the same time is a major target of ROS damage 
(Ott et al., 2007). Approximately 1-2% of molecular oxygen used during normal 
mitochondrial respiration is converted to free radicals; this is increased during I/R injury and 
can contribute significantly  to cardiac damage (Ott et al., 2007). Oxidative phosphorylation 
occurs through the mitochondrial respiratory chain which consists of five enzymatic 
complexes (I to V) embedded in the inner mitochondrial membrane (Fontanesi et al., 2006). 
It is widely accepted that mitochondrial respiration and oxidative phosphorylation are 
compromised during ischaemia and all five of the respiratory complexes have been shown to 
be affected by ischemic damage (Paradies et al., 2004, Petrosillo et al., 2003).  
NADH-ubiquinone oxidoreductase (complex I) reduces ubiquinone using NADH as the 
electron donor. A significant reduction in complex I activity has been demonstrated in vitro 
and in vivo, for example Maklashina et al. demonstrated a 40% reduction in Complex I 
activity following 30 min of ischaemia (Maklashina et al., 2002). Currently the exact cause 
for this reduction is unknown but it has been attributed to both ROS production and damage 
from peroxynitrite intermediates (Paradies et al., 2002, Jekabsone et al., 2003). I/R injury was 
found to significantly downregulate 19 out of the 33 complex I genes represented on the RAE 
230A microarrays by an average of 45.1 ± 1.7% (Table 4.6). Out of the three cardioprotective 
agents, only Ucn2 changed the expression of any of these genes significantly; Ndufb6 by 2.0 
±0.1 fold and Ndufs8 by 1.9 ± 0.4 fold. This suggests that a facet of complex I functional 
inhibition during I/R may be attributable to transcriptional downregulation of a large number 
of NADH dehydrogenase genes. 
Complex II (succinate dehydrogenase) oxidizes succinate to fumarate, releasing two electrons 
which are used to reduce ubiquinone to ubiquinol. There have been conflicting reports as to 
the effect of I/R injury  on complex II activity but a study by Abe et al. demonstrated a 
reduction in activity following I/R injury in rats (Abe et al., 1999). One component of 
complex II, succinate dehydrogenase complex D (Sdhd), was found to be downregulated 47.5 
± 6.6% by I/R injury. 189 
 
 
 
 
 
 
Gene  Gene Title FC p value
Nqo2 NAD(P)H dehydrogenase, quinone2 -2.56 0.02
Ndufa2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2 (predicted) -1.51 0.00
Ndufa6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 (B14) (predicted) -1.65 0.04
Ndufa7 NADH dehydrogenase(ubiquinone) 1 alpha subcomplex, 7 (B14.5a) (predicted) -1.53 0.09
Ndufa9 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9 -2.07 0.01
Ndufa11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11 -1.78 0.04
Complex I Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 (predicted) -1.57 0.01
Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 (predicted) -2.12 0.00
Ndufb7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7 (predicted) -1.79 0.01
Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11 (predicted) -1.74 0.03
Ndufc2 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2 -1.55 0.04
Ndufs1 NADH dehydrogenase (ubiquinone) Fe-S protein 1 -1.82 0.04
Ndufs2 NADH dehydrogenase (ubiquinone) Fe-S protein 2 -1.65 0.01
Ndufs3 NADH dehydrogenase (ubiquinone) Fe-S protein 3 (predicted) -2.00 0.02
Ndufs5 NADH dehydrogenase (ubiquinone) Fe-S protein 5 -1.76 0.02
Ndufs7 NADH dehydrogenase (ubiquinone) Fe-S protein 7 -1.98 0.00
Ndufs8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 (predicted) -2.32 0.00
Ndufv1 NADH dehydrogenase (ubiquinone) flavoprotein 1 -1.67 0.01
Ndufv3l NADH dehydrogenase (ubiquinone) flavoprotein 3-like  -2.28 0.00
Complex II Sdhd succinate dehydrogenase complex, subunit D, integral  membrane protein -1.94 0.05
Coq3 coenzyme Q3 homolog, methyltransferase (yeast) -2.82 0.01
Coq6 coenzyme Q6 homolog (yeast) -1.69 0.03
Complex III Coq10a coenzyme Q10 homolog A (yeast) (predicted) -1.98 0.04
Uqcr ubiquinol-cytochrome c reductase, 6.4kDa subunit -1.61 0.00
Uqcrq ubiquinol-cytochrome c reductase, complex III subunit VII -1.80 0.00
Cox6b1 cytochrome c oxidase, subunit VIb polypeptide 1 -1.89 0.00
Cox15 COX15 homolog, cytochrome c oxidase assembly protein (yeast) -2.66 0.00
Complex IV Cox17 cytochrome c oxidase, subunit XVII assembly protein homolog (yeast) -1.75 0.00
Cox18 COX18 cytochrome c oxidase assembly homolog (S. cerevisiae) -1.45 0.04
Cox19 COX19 cytochrome c oxidase assembly homolog (S. cerevisiae) -2.05 0.04
Atpaf1 ATP synthasemitochondrial  F1 complex assembly factor 1 (predicted) -2.49 0.00
F1/F0 ATP   Atpaf2 ATP synthase mitochondrial  F1 complex assembly factor 2 (predicted) -2.16 0.01
Synthase Atp5s ATP synthase, H+ transporting, mitochondrial F0 complex, subunit s -2.03 0.03
Atp5d ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit -1.84 0.01
Table 4.6 Mitochondrial respiratory complex genes differentially expressed during I/R injury. 190 
 
Complex III (coenzyme Q: cytochrome c -  oxidoreductase)  uses  ubiquinol to reduce 
cytochrome c, thereby pumping 4   from the mitochondrial matrix to the intermembrane 
space, resulting in the production of a proton gradient across the membrane. Veitch et al. 
recorded a 34% reduction in complex III activity after 1 hr ischaemia and 5 min reperfusion 
(Veitch et al
Complex IV consists of the 13 subunits of the cytochrome c oxidase (COX) enzyme which is 
the rate limiting enzyme in mitochondrial respiration. Complex IV transfers electrons from 
cytochrome c to oxygen, reducing oxygen to 
., 1992). Reduction in complex III activity has been attributed to a decreased 
content of mitochondrial cardiolipin which is necessary for complex III function (Petrosillo G 
et al., 2003). I/R injury was found to decrease the expression of 5 of the 13 subunits of 
complex III by an average of 50.0 ± 2.0% (Table 4.6), showing that reduced complex III 
activity may be in part due to decreased subunit expression. In addition, there is a slight 
reduction (41.1 ± 15.4 %) in cardiolipin synthase expression following I/R which may 
account for some of the reduced abundance of cardiolipin and hence reduced complex III 
activity following I/R injury. Cardiolipin is also important in retaining cytochrome c within 
the mitochondrial intermembrane space (Paradies et al., 2000) and therefore reduced 
cardiolipin synthase expression might also contribute to cytochrome c release from the 
mitochondria and subsequent apoptosis. 
 in the process. The energy generated by this 
electron flux is used to pump protons from the mitochondrial matrix into the inter-membrane 
space and the resulting proton gradient is used by complex V to catalyze the conversion of 
ADP and inorganic phosphate into ATP (Fontanesi et al., 2006). Some studies have shown 
that COX activity remains unaltered after ischaemia (Lesnefsky et al. 1997) although there is 
loss of cytochrome c which mediates electron transfer between complexes III and IV (Solaini 
2005). Other studies have on the other hand demonstrated a reduction in complex IV activity 
after I/R (Sadek et al., 2002). 
The final step of the mitochondrial respiratory chain involves 
Following I/R injury, 5 of the 13 COX subunits was found to be 
significantly downregulated including Cox15 (61.9 ± 4.6%), Cox17 (41.9 ± 6.7%), Cox19 
(48.6 ± 10.4%) Cox6b1 (47.0 ± 2.2%) and Oxa1L (54.1 ± 4.7%).   
  -ATPase which is responsible 
for the production of over 90% of the ATP needs of the myocardium (Solaini et al. 2005). I/R 
injury reduced expression of subunits of both the  and  ATPase by an average of 54.2 ± 2.9% 
(Table 4.7). It is currently unclear what effect reduced expression of the 4 ATPase genes has 
on cardiac function after I/R injury. During ischaemia, the  -ATPase reverses and hydrolyses 191 
 
ATP thus allowing protons to be pumped from the mitochondria. (Solaini et al. 2005). While 
total inhibition of the -ATPase slows the rate of ATP depletion during ischaemia, it also 
inhibits ATP recovery after reperfusion (Grover et al., 2008.) Selective inhibition of the -
ATP hydrolase activity however allows the heart to restore ATP levels at a faster rate during 
reperfusion and leads to a reduction in cell death following I/R. (Gary et al., 2004).  Reduced 
expression of 
  
-ATP may therefore reduce the level of ATP hydrolysis during ischaemia; on 
the other hand it may also decrease the production of ATP following the onset of reperfusion. 
Thus it appears that the transcriptional regulation of genes vital to the activity of the electron 
transport chain is affected by I/R injury. The reduced expression of 37 genes which are 
integral to all stages of mitochondrial respiration may contribute significantly to the 
documented decreases in activity. 
4.14 Reduced Expression of Mitochondrial Import Machinery Genes Following 
I/R Injury 
The Tim Tom and SAM family of genes are mitochondrial pore proteins which facilitate 
mitochondrial biogenesis by controlling the import and assembly of proteins into the 
mitochondria. Thirteen members of the mitochondrial transport machinery were found to be 
downregulated by I/R injury (Table 4.7). qPCR analysis confirmed the microarray data, 
showing significant repression of Tim8a, Tim8b, Tim13, Tim23, Tim44 and Tom20 (Fig 
4.17). There was a trend towards reduced repression of the Tim proteins in the tempol group, 
however this only reached significance with Tim44, Ucn1 also increased the expression of 
Tim23 and Tim44 compared to saline infusion. The repression of  Tim23 and Tim44 by was 
confirmed in a second ex vivo model of I/R injury using the Langendorf perfusion system 
(samples obtained from Dr Naushaad Suleman ICH). In these experiments mice hearts were 
subjected to 30 min of ischaemia and 45 min of reperfusion. Although the period of 
reperfusion was much less than the in vivo model, the expression of Tim23 and Tim44 was 
still reduced by 30.2 ± 6.6% and 47.7 ± 4.7% respectively (Fig 4.18).  
The voltage-dependent anion channel (VDAC) is central in the transport of metabolites and 
ions across the outer mitochondrial membrane, has important roles in apoptosis and may be a 
component of the mitochondrial permeability transition pore (Shoshan-Barmatz et al. 2003). 
VDAC1 was downregulated 64.5 ± 13.9% by I/R; in addition the SAM complex proteins 192 
 
Sam50, metaxin1 and metaxin2 were also downregulated (Table 4.7) and these have been 
shown to be necessary for import and assembly of VDAC into the mitochondria (Kozjak-
Pavlovic et al., 2007). Reduced VDAC1 expression and insertion into the mitochondria may 
therefore affect MPT opening and release of apoptogenic factors from the mitochondria 
during I/R injury.  
These data show that a large portion of the mitochondrial import machinery is repressed 
during I/R injury. This is likely to have significant effects on mitochondrial function since the 
Tim/Tom/SAM complexes control  entry of almost all proteins into the mitochondria. 
Therefore reduced mitochondrial function during I/R may actually stem from a reduction in 
the availability of necessary components of the respiratory transport chain since they cannot 
be inserted into the mitochondria at the normal rate. 
 
  
 
 
Table 4.7. Mitochondrial import genes are 
differentially regulated during I/R injury. 
 
                
 
FC  p value 
Tim8a  -1.68  0.020 
Tim8b  -1.94  0.004 
Tim9  -1.80  0.230 
Tim10  -1.55  0.089 
Tim13  -2.60  0.000 
Tim17a  -1.79  0.016 
Tim22  -1.95  0.003 
Tim23   -1.58  0.086 
Tim44  -2.93  0.000 
Tom7  -1.57  0.010 
Metaxin1  -4.22  0.007 
Metaxin2  -1.81  0.074 
Oxa1l  -2.20  0.001 
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Fig 4.17. I/R injury represses the expression of mitochondrial transport genes. The expression of 
indicated genes was analysed by qPCR and normalised to sham levels. Statistical analysis was carried 
out using a one-way ANOVA with Dunnett’s post test, n=3 samples, * p<0.05, ** p<0.01, *** 
p<0.001 compared to I/R + S. 
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Fig 4.18. Tim23 and Tim44 are repressed in an ex vivo model of I/R injury. Mouse hearts were 
subjected to 30 min of ischaemia and 45 min of reperfusion using the Langendorf perfusion system. 
The mRNA levels of Tim23 and Tim44  were then examined  by qPCR and normalised to sham 
levels. Statistical analysis was carried out using a student’s t-test, n=5 animals, * p<0. 
 
 
4.15 Cardioprotective Genes Induced by Ucn1 and Ucn2 
Out of the list of potential cardio-protective genes differentially regulated by Ucn1 and Ucn2, 
several have not been previously shown to have a role in I/R injury and were examined in 
greater detail. One of the highest differentially expressed genes in the Ucn1 group is Birc4 
(4.8 ± 0.3 fold) also known as X-linked inhibitor of apoptosis protein (XIAP), one of a family 
of 6 inhibitors of apoptosis (IAP) proteins. XIAP functions by inhibiting the effector 
caspases-3, -7 and -9 through ubiquitin mediated degradation (Martins et al., 2002)
Sham I/R
0.00
0.25
0.50
0.75
1.00
1.25
F
o
l
d
 
C
h
a
n
g
e
Sham I/R
0.00
0.25
0.50
0.75
1.00
1.25
F
o
l
d
 
C
h
a
n
g
e
* *
Tim23 Tim44
. There are 
few studies addressing the role of XIAP in the myocardium, however Scarabelli et al. 
demonstrated that cardioprotection by minocycline was associated with increased expression 
of XIAP (Scarabelli et al. 2004). XIAP has also been shown to function as an anti-apoptotic 
factor in cerebral I/R (Zhu C et al., 2007, Guegan et al., 2006). Although XIAP expression 
was not reduced by I/R on the microarray, qPCR data showed that XIAP expression was 
reduced 51.3 ± 8.5% by I/R and increased 1.8 ± 0.2 fold by tempol and 1.6 ± 0.1 fold by 
Ucn1 which represents a restoration of XIAP expression to near sham levels (Fig 4.19). 
Urocortin administration has previously been shown to lower the number of caspase-3 
positive endothelial cells and cardiac myocytes following I/R injury in vivo (Scarabelli et al., 
2002) and it is therefore tempting to speculate that some of the anti-apoptotic effects of 
tempol and Ucn1 may be mediated through reduced executioner caspase activity via XIAP 
upregulation. 195 
 
                                          
Fig 4.19. Tempol and Ucn1 upregulate XIAP expression.  XIAP expression was measured by 
qPCR and normalised to sham levels. Statistical analysis was carried out using a one-way ANOVA 
with Dunnett’s post test, n=3 samples, * p<0.05, ** p<0.01 compared to I/R + Sal.  
 
AMP-activated protein kinase (AMPK) is responsible for promoting fatty acid oxidation and 
increasing glucose uptake and glycolysis (Dyck et al. 2006). AMPK-•2 (Prkaa2), which is 
the main cardiac isoform, was upregulated 2.3 ± 0.2 fold by Ucn1 and 1.9 ± 0.1 fold by Ucn2. 
Several reports have demonstrated that AMPK-•2 can protect the myocardium from I/R 
injury. Carvajal et al. found that AMPK-•2 deficiency resulted in reduced myocardial 
glucose uptake and glycogen content during I/R, leading to accelerated contracture (Carvajal 
et al., 2007). Mice expressing a kinase dead form of AMPK-•2 had exacerbated contractile 
dysfunction following I/R, accompanied with elevated TUNEL positivity and caspase-3 
activity (Russell et al. 2004). Scarabelli et al. previously reported improved myocardial 
energetics when administering Ucn1 before reperfusion (Scarabelli et al., 2002) and this 
energetic recovery of the ischaemic myocardium might therefore be linked to increased 
AMPK levels.  
Nuclear factor erythroid 2-related factor 1 (Nfe2l1), also known as Nrf1, is a member of the 
CNC (cap 'n' collar)-basic leucine zipper family of transcription factors. Nrf1 is a crucial 
mediator of oxidative stress and is required for free radical scavenging and maintenance of 
redox potential. It achieves this through binding to the antioxidant response element (ARE) in 
a number of oxidative stress regulated gene promoters, including NAD(P)H:quinone 
oxidoreductase, glutathione-S-transferase, haem oxygenase-1, glutathione peroxidise, 
thioredoxin reductase 1 and aldo-keto reductases (Mathers et al., 2004
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pertaining to the role of Nrf1 in I/R injury; however the related transcription factor Nrf2 has 
been shown to protect rats from cerebral I/R injury in a stroke model (Shih et al., 2005). I/R 
injury reduced the levels of Nrf1 by 84.5 ± 6.1% (-7.6 ± 1.2 fold) while tempol (6.2 ± 0.8), 
Ucn1 (4.0 ± 0.83) and Ucn2 (5.2 ± 0.8) all increased it and this was confirmed by qPCR (Fig 
4.20a). The physiological  effect of such a large reduction in Nrf1 levels during I/R is 
unknown but some conclusions can be drawn from studies of Nrf1 deficiency. Nrf1 knockout 
mice die mid gestation; however Nrf1
-/- fibroblasts display increased levels of cell death 
when treated with oxidants such as paraquat and cadmium chloride (Kwong et al., 1999). 
Likewise Nrf1
-/-
Since Nrf1 is a major regulator of anti-oxidant proteins and both Ucn1 and Ucn2 upregulated 
Nrf1 to nearly the same level as tempol, the question was asked whether Ucn1 and Ucn2 
could also afford some level of protection from oxidative stress. To address this question the 
levels of MDA in the left ventricle were measured in each group. Fig 4.20b shows that I/R 
injury increased MDA levels form 0.46 ± 0.05 to 0.91 ± 0.08 µmol MDA/g protein. As 
expected, tempol lowered the MDA concentration back to sham levels (0.44 ± 0.03 µmol/g); 
surprisingly though, Ucn1 lowered MDA levels to 0.52 ± 0.13 and Ucn2 to 0.38 ± 0.08. This 
data shows that Ucn1 and Ucn2 are as efficient at inhibiting free radical formation as the 
SOD mimetic tempol and this previously unappreciated activity of urocortins may be central 
to their cardioprotective effects. It is likely that urocortins inhibit oxidative stress via an 
intermediary rather than possessing antioxidant activity per se and upregulation of Nrf1 may 
be a likely candidate for this effect. Therefore it would be of interest to examine the anti-
oxidant capacity of Ucn1 in Nrf1 deficient cells. 
 foetal lever cells have been shown to be extremely sensitive to oxidative 
stress (Chen et al., 2003). Taken together this suggests that during I/R, transcriptional 
repression of Nrf1 leads to reduced levels of anti-oxidants which may sensitize cardiac 
myocytes to oxidative stress. In this setting, upregulation of Nrf1 levels by tempol, Ucn1 or 
Ucn2 may be important in aiding free radical scavenging and protecting from I/R injury. 
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Fig 4.20. Ucn1 and Ucn2 inhibit free radical formation following I/R injury. (A) Nrf-1 levels 
were measured by qPCR and normalized to Sham. (B) Saline, tempol, Ucn1 or Ucn2 were infused 
after 25min ischaemia and was followed by 30min reperfusion. Tissue MDA levels were measured by 
HPLC from each of the indicated treatment groups n=5 animals. Statistical analysis was carried out 
using a one way ANOVA with Dunnet’s post test, * p< 0.05, *** p<0.001 compared to I/R + saline. 
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4.16 Discussion 
 
Affymetrix microarray analysis was used to examine the change in MI induced gene 
expression in left ventricular tissue from rats. Detailed discussion of all differentially 
expressed genes is not possible due to the numbers involved, therefore I will discuss 
differential expression which is both novel and of interest to the pathogenesis of I/R injury. 
From the outset it must be acknowledged that the conclusions of this work are based on 
mRNA data which may not necessarily be mirrored by changes in protein expression. Being 
that as it may, novel transcriptional changes will be discussed with a view to confirming 
many of these changes by other means in the future.  
 
One of the initial goals of the study was to ascertain if STAT3 target genes were induced 
during  I/R injury and altogether a total of 46 known STAT3 targets were found to be 
differentially regulated by I/R. Therefore the increased phosphorylation of STAT3 described 
in chapter 3 was accompanied by induction of a STAT3 transcriptional programme. IL-6 and 
SOCS3 were highly upregulated by I/R injury, demonstrating that both activators and 
inhibitors of STAT3 activity are induced at the same time. The IL-6/SOCS3 balance may be 
in part responsible for controlling the levels of STAT3 phosphorylation shown in Fig 3.16a 
and a detailed kinetic analysis of IL-6 and SOCS3 levels during I/R injury would aid in 
understanding the dynamics of STAT3 activity. Tempol lowered the levels of both IL-6 and 
SOCS3 and this may impact on tempol mediated reduction in STAT3 phosphorylation. In 
contrast, Ucn1 increased mRNA levels of STAT3 and IL-6 while decreasing levels of SOCS3 
and although there was no effect on STAT3 phosphorylation by 2 hr of reperfusion, 
examination of STAT3 activity over an extended time period might reveal novel effects of 
Unc1 on STAT3 functionality. Recently Ucn1 has been shown to increase expression from a 
STAT3 dependent luciferase reporter in HEK293 cells suggesting that Ucn1 can indeed 
augment STAT3 activity (Pan et al., 2007).  
 
The IL-17 receptor, IL-17A and IL-17F were all found to upregulated at the mRNA level in 
vivo. IL-17R was also found to be time-dependently increased by reperfusion in an in vitro 
model of I/R injury in NRVMs, however detailed examination of IL-17A and IL-17F 
expression by qPCR in this model proved to be problematic. These cells were shown to be 
capable of expressing both cytokines when using forced expression of STAT3. The effects of 
IL-17 on cardiac physiology are currently unknown. One recent report demonstrated that 199 
 
exogenously added IL-17 could induce upregulation of MMP-1in human cardiac fibroblasts, 
suggesting that it may play a role in cardiac remodeling (Cortez et al., 2007). IL-17 may also 
play a role in growth of vascular endothelial cells (Takahashi et al., 2005) and has also been 
implicated in the pathology of auto-immune myocarditis (Rangachari et al., 2006). Studies 
aimed at understanding the role of IL-17 in cardiac physiology and pathophysiology should 
give a greater insight into immunological responses during I/R. Experiments such as 
administering IL-17 or an IL-17 receptor antagonist during I/R injury in vivo or ex vivo will 
clarify if this cytokine is protective or detrimental to I/R-mediated pathology. Analysis of IL-
17 plasma levels in patients suffering from myocardial infarction would also be of help to 
clarify if IL-17 is secreted during cardiac pathology in humans. It is not yet clear what are the 
major cell types which produce IL-17 during I/R injury. It is therefore of interest to address in 
more detail if cardiac myocytes can truly express IL-17A and IL-17F and to examine if IL-
17A and IL-17F work in an autocrine or paracrine manner in the myocardium during I/R 
injury. Increased activity of STAT3 in the myocardium may also contribute to increased IL-
17A and IL-17F levels, this could be tested directly by inhibiting STAT3 in vivo during I/R 
injury and measuring both serum levels and intracellular levels of these cytokines by flow 
cytometry. 
 
One of the main gene ontology groupings in I/R mediated differential expression 
encompassed genes involved in mitochondrial regulation. Three main families of genes were 
affected; those involved in mitochondrial translation, the respiratory chain, and mitochondrial 
import; together totaling 95 separate gene expression changes. Although there is a large body 
of literature addressing general mitochondrial dysfunction during I/R injury, there is little 
information regarding changes in mRNA levels of genes involved in these three processes. In 
all three groups, the expression of genes was reduced and while the physiological effects of 
this reduction are currently unclear, it is likely that a decrease in components of the 
respiratory chain, translation and transport would all contribute to mitochondrial dysfunction. 
Again, this would need to be confirmed by western blot to make more definitive conclusions.  
 
A large number of mitochondrial ribosomal proteins were downregulated by I/R. MRPs are 
thought to form a regulatory network and may all be coordinately regulated (Hi et al. 2007), 
suggesting the possibility that the reduced expression of 47  MRP genes may be due to 
alterations in one or a few MRP transcriptional regulators. The outcome of decreased MRP 
expression is unclear, but since MRPs are necessary for correct translation of mitochondrial 200 
 
proteins, it is highly likely that this may slow or block mitochondrial biogenesis and thus 
contribute to reduced mitochondrial function during I/R injury. The biology of the MRP 
proteins is poorly understood at present and although their main function lies in regulation of 
mitochondrial gene translation, other functions have recently been ascribed to them. For 
example, MRPL41 increases p53 stability and enhances its translocation to the mitochondria 
where it promotes p53 mediated apoptosis (Yoo et al., 2005). MRPS36 plays a role in cycle 
progression by promoting increased expression of p21 (Chen et al., 2007). MRPL12, in 
addition to its role in translation, regulates mitochondrial transcription through binding 
bacteriophage-related RNA polymerase (POLRMT) (Wang Z 2007). Since MRPL12 is 
involved in both mitochondrial gene transcription and ribosome biogenesis, its reduction 
during I/R may play a key role in inhibiting mitochondrial protein synthesis. In humans, a 
mutation in MRP22 causes respiratory chain dysfunction, manifesting in hypotonia, 
cardiomyopathy and tubulopathy (Miller et al., 2004). A mutation in MRPS16 likewise 
damages the respiratory chain and leads to fatal neonatal lactic acidosis (Saada et al., 2007). 
These defects highlight the important role of MRPs in maintaining a functional respiratory 
chain and thus the I/R mediated repression of MRPs is suggested to compromise 
mitochondrial energetics and have direct effects on apoptosis and the cell cycle. 
 
A total of 34 genes from all five of the mitochondrial respiratory chain complexes were 
repressed during I/R injury; none of these genes have been previously shown to be 
transcriptionally regulated by ischaemic injury in the myocardium. Reduced activity of the 
mitochondrial respiratory system has been well documented; however mitochondrial 
dysfunction has never been attributed to decreased mRNA levels of complex I-V 
components. At present it is not known what effect reduced expression of individual 
components of the respiratory complex has on mitochondrial energetics; reduced availability 
of 34 components in combination however would clearly be expected to perturb normal 
mitochondrial function. To fully understand the role of these individual genes it would be 
necessary to inhibit their expression (through RNAi for example) individually or in 
combination and then assess the state of mitochondrial respiration during I/R.  It is also worth 
considering that although mitochondrial respiration is obligatory for maintaining cell 
viability, it can also contribute to ischaemic damage. For example, inhibition of complex I 
with rotenone reduces the production of ROS from complex I substrates, thereby protecting 
the heart from ischaemic damage (Lefensky et al., 2004). This suggests that the mitochondrial 
electron transport chain can contribute to the deleterious effects of ischemic damage.  201 
 
 
The subunits that comprise the mitochondrial electron transport chain (ETC) are encoded by 
both the nuclear and mitochondrial genomes. Correct 1:1 stoichiometry is necessary to form 
functional complexes and this is governed by coordinated transcription from both genomes. 
Recently it has become clear that genes involved in oxidative phosphorylation are co-
coordinately regulated. The transcription factors Nrf1, EREF, YY1F, PGC1 and CREB all 
correlate significantly with oxidative phosphorylation  gene expression pattern  and are 
thought to be the main regulators of this coordinated expression (van Waveren et al., 2008). 
Of these genes, only Nrf1 gave a signal on the microarray, mRNA levels being highly 
repressed by I/R. Nrf1 and the related transcription factor Nrf2 have previously been 
suggested to control the coordinated transcription of respiratory chain factors encoded by 
both the mitochondrial and nuclear genomes (Evans et al., 1990).  Moreover, Nrf1 is known 
to play a pivotal role in regulating the expression of transcription and mitochondrial DNA 
maintenance factor (TFAM) and transcription specificity factors (TFB1M and TFB2M), both 
of which control mitochondrial gene expression (Dhar et al., 2008). Nrf1 has been shown to 
regulate all ten nuclear encoded COX subunits in neurons and Nrf1 binding sites have been 
found in Complex I, complex II and cytochrome C genes (Dhar et al., 2008, Elbehti-Green et 
al., 1998, De Sury et al., 1998, Xia et al., 1998, Venugopal et al., 1996). Nrf1 knock-out mice 
are not viable but analysis of Nrf1
 
 
deficient foetal livers demonstrated exuberant oxidative 
stress due to insufficient expression of the antioxidant genes GHS and GSSG (Chen et al., 
2003). These studies all underscore the concept that Nrf1 is a master regulator of 
mitochondrial biogenesis and the novel finding that its expression is reduced during I/R may 
account in a large part for the reduced expression of oxidative phosphorylation genes. Nrf1 
may also play a role in controlling the expression of mitochondrial transport proteins, for 
example the 5’ flanking region of the Tom20 gene contains an Nrf1 binding site that controls 
its expression in conjunction with Nrf2 (Blesa et al., 2007).  
I/R injury was found to downregulate several genes involved in controlling entry of proteins 
into the mitochondria. The TOM complex sits in the mitochondrial outer membrane and 
regulates protein transport into the intermembrane space. Two TOM components were 
downregulated by I/R, Tom7 and Tom20. Tom20 binds to mitochondrial presequences and 
Tom7 stabilises the main Tom40 translocase channel. Increasing or reducing levels of Tom20 
in C2C12 skeletal muscle cells lead to a corresponding increase or decrease in malate 
dehydrogenase import into the mitochondria (Grey et al., 2000). At present there is only one 202 
 
publication addressing the mitochondrial transport channel function during I/R. Boengler and 
colleagues showed that following 90 min of low-flow ischaemia in minipigs, the 
mitochondrial protein content of Tom20 was reduced and this effect was reversed by 
preconditioning. (Boengler et al., 2006). In skeletal muscle, contractile activity is associated 
with increased levels of Tom20 and inhibiting Tom20 expression reduced protein transport 
into the mitochondria (Grey et al., 2000). This lends weight to the argument that reduced 
Tom20 levels during I/R would result in a slower rate of mitochondrial import. 
 
Proteins destined for the inner membrane and the matrix are transported by the TIM22 and 
TIM23 complexes respectively. Both the Tim23 channel and it regulatory subunit Tim17 
were repressed by I/R. Tim44 which binds the mtHSP70 ATPase necessary to supply the 
energy for transport through the TIM23 complex was likewise downregulated by I/R. 
Interestingly, inhibition of Tim44 in human proximal tubular cells lead to a reduction in the 
mitochondrial import of SOD and glutathione peroxidise (Zhang et al., 2006). In addition, 
viral delivery of Tim44 reduced ROS production in vivo in both the balloon injury model of 
diabetic rats and in streptozotocin-induced diabetic CD-1 mice (Zhang et al., 2006, Matsuoka 
et al., 2005). Five components of the TIM22 complex also had reduced mRNA levels 
including the main Tim22 pore and the so called Tiny Tim accessory proteins Tim8a, Tim8b, 
Tim10 and Tim13 which aid in guiding proteins across the intermembrane space. Therefore, 
not only is there reduced availability of outer membrane pore components, correct trafficking 
of proteins inside the mitochondria is also likely to be disrupted during I/R injury. 
 
The SAM complex controls the insertion of •-barrel proteins into the outer membrane and the 
three main components of this pore, Sam50, metaxin-1 and metaxin-2 were all reduced in 
expression. The SAM complex controls insertion of MPT pore proteins such as VDAC into 
the outer membrane; closure of VDAC is associated with reduced ATP exchange with the 
cytosol and the antiapoptotic Bcl-xL can maintain metabolite exchange across the outer 
membrane by maintaining VDAC in an open configuration (Vander Heiden et al., 2000, 
2001), although this has recently been disputed (Baines et al., 2007). It is clear that reduced 
levels of the SAM complex will affect the constituents of the mitochondrial outer membrane 
and therefore may have a significant impact on the intrinsic pathway of apoptosis through the 
opening of the MPT pore. 
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Taken together, these observations all point to the fact that transport of proteins into the 
mitochondria may be reduced during I/R injury. Reduced availability of Tim, Tom and SAM 
proteins may represent a fundamental cause of decreased mitochondrial biogenesis during 
I/R. Further experiments aimed at addressing the role of mitochondrial import in I/R injury 
are likely to aid our understanding of mitochondrial biology and I/R injury. For example, 
GFP linked to mitochondrial pre-sequences could be used to measure the effect of ischaemic 
damage on the rate of import into the mitochondria. Likewise, inhibiting individual 
components of the import pathway could be used to assess the effects of TIM, TOM and 
SAM complex subunits on mitochondrial biogenesis, energy usage and ROS production. 
Since ischaemic preconditioning (IPC) is associated with increased rates of mitochondrial 
biogenesis (McLeod et al., 2005) it would also be informative to examine the expression of 
TOM, TIM and SAM complex components following IPC. Increased mitochondrial 
biogenesis during IPC might be linked to the expression of the mitochondrial transport 
apparatus and strategies aimed at restoring the mitochondrial import apparatus may prove to 
be cardioprotective.  Reduced levels of mitochondrial transport proteins in conjunction with 
decreases in electron transport chain proteins and inhibition of the mitochondrial translation 
apparatus all represent previously unappreciated causes of mitochondrial dysfunction during 
I/R injury. Elucidation of the signalling pathways involved in these three processes will 
greatly add to our understanding of mitochondrial dysfunction and altered energy usage in 
myocardial infarction.  
 
 
Although tempol is thought to exert its anti-oxidant properties by acting as a SOD mimetic, 
its affect on global gene expression has never been examined. Tempol was found to affect 
several genes of the contractile apparatus and genes involved in 
+  regulation.  In cardiac 
mycoytes, myofilament contraction occurs via sarcolemal membrane depolarisation and 
release of 
+ from the sarcoplasmic reticulum stores through the ryanodine receptor (RyR). 
During diastole, ATP2a2 also known as Sarcoplasmic Reticulum Ca(2+)-ATPase 2 
(SERCA2) is responsible for pumping 
+ from the cytosol back to the sarcoplasmic reticulum 
to maintain intracellular 
+  homeostasis  (Vangheluwe  et al., 2006).  Tempol was found to 
restore the expression of both SERCA2 and RyR. This is in agreement with a previous study 
where infusion of the antioxidants superoxide dismutase and catylase restored the levels of 
both RyR and SERCA2 after I/R injury (Temsah et al., 1999).  Moreover, this underscores 204 
 
the concept that a main focal point for anti-oxidant treatment is maintaining calcium 
homeostasis and restoring normal contractility to the heart. 
 
Interestingly p53 was present as a central node in the single statistically significant networks 
identified in both the tempol and Ucn1 group. Neither tempol nor Ucn1 had any direct effects 
on p53 expression, however tempol has previously been shown to phosphorylate p53 on 
serine 18 in thymocytes, thereby stabilising its expression (Erker et al., 2005). Although 
phosphorylation of p53 by tempol or Ucn1 in the myocardium has not been demonstrated, its 
appearance in a central network is nonetheless intriguing. While p53 is undoubtedly central to 
apoptosis, it is also necessary for maintaining mitochondrial respiration via upregulation of 
Synthesis of Cytochrome c Oxidase 2 (SCO2) and in the absence of p53, SCO2 levels are 
reduced and cells switch their energy production from oxidative phosphorylation to 
glycolysis (Matoba et al., 2006). Therefore, examination of the effects of tempol and Ucn1 on 
p53 function in the myocardium warrant further investigation. 
 
Both Ucn1 and Ucn2 lowered MDA concentration to near sham levels, demonstrating that 
urocortin administration  significantly reduces free radical damage during I/R injury. The 
exact mechanism for this is unknown at the present time.  Of the 67 genes which were 
differentially regulated in the tempol group, 21 were also changed by Ucn1 and 40 by Ucn2, 
demonstrating significant overlap between the groups. There was a total of 18 genes common 
to all three and of these, only 9 are currently annotated; Rpl7, H2A, Nfe2l1, Gbe1, Actr6, 
Orc4, Tmem98, Pja2 and Dut. From this list, Nfe2l1 (Nrf1) represents the most likely 
candidate gene common to all three which might be responsible for inhibiting free radical 
formation. In addition to its effects on mitochondrial gene expression, Nrf1 is a regulator of 
several anti-oxidant enzymes and the finding that tempol, Ucn1 and Ucn2 all increase its 
expression point to the fact that Nrf1 may represent a common mediator of anti-oxidant 
effects.  Ucn1 treatment has recently been shown to prevent MPTP opening during I/R injury 
(Townsend et al., 2007) and upregulation of Nrf1 could conceivable contribute to this effect 
by increasing mitochondrial biogenesis and upregulating antioxidant levels in the heart. It 
would therefore be of great interest to examine the extent of urocortin mediated free radical 
inhibition in Nrf1-deficient cells. Thus it could be determined if urocortins are still capable of 
reducing free radical damage in the absence of Nrf1 and also if Nrf1 deficiency has any 
impact on urocortin mediated cardioprotection. If Nrf1 did indeed represent a common 205 
 
mediator of Ucn1 and Ucn2 cardioprotection it could represent a novel downstream 
therapeutic target. 
 
Taken together these observations identify novel transcriptional changes which occur during 
I/R injury. The documented changes in mitochondrial genes, uracil metabolism and the IL-17 
pathway represent fruitful avenues of future research. The identification of a common 
transcription factor regulated by tempol, Ucn1 and Ucn2 may hold promise for future 
therapeutic intervention and the identification of a STAT3 transcriptional programme 
supports the findings of the previous chapter. In the future it will be necessary to also confirm 
the Ucn2 microarray changes by qPCR and confirm mRNA expression by western blot. 
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Chapter 5: Regulation of the 
DNA Damage Response by 
STAT3 
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5.1 Aims 
In chapter 3 it was shown that STAT3 deficient MEFs were more sensitive to oxidative stress 
than wild type cells. A key feature of oxidative stress involves DNA damage and repair; 
following strand breaks, the DNA damage pathway is rapidly activated and generates signals 
to initiate both DNA repair and apoptosis. Although several studies have addressed the role 
of STAT3 in apoptosis, its contribution to the DNA damage response and DNA repair has 
never been investigated. This chapter addresses this by examining the DNA damage response 
pathway in STAT3 deficient MEFs. 
5.2 STAT3
-/-
In order to ascertain what effect STAT3 has on the DNA repair pathway, the host-cell 
reactivation assay (HCR) was used (Qiao et al., 2002). The HCR assay involves introducing 
strand breaks in luciferase plasmids followed by transfection into cells. The damaged 
plasmids are repaired by the cell’s DNA repair machinery and only fully repaired plasmids 
will be transcribed correctly to generate active luciferase. The resulting luciferase activity is 
then compared against an undamaged control plasmid (set to 100%) to calculate a % of repair 
(known as % HCR). Initially a dose response of UVB irradiation was carried out; plasmids 
were irradiated with 25-1000 J/
 MEFs Repair DNA Less Efficiently That Wild Type Cells 
 UVB, transfected into wild type MEFs for 24 hr and the % 
HCR was calculated.  Fig 5.1 shows that there was a dose dependent decrease in HCR with 
increasing UV irradiation; at the highest dose, 1000 J/
 
 reduced the HCR to 3.4%.  
 
 
 
 
 
Fig 5.1. Rate of HCR in MEF cells with a dose response of UV irradiation. A luciferase plasmid 
was irradiated with the indicated dose of UV and transfected into MEF cells; 50 ng of luciferase 
plasmid and 20 ng renilla plasmid were used per well and values were measured 24 hr later with a 
luminometer. All values are relative to the non-irradiated control which was set to 100%.  
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Next the dose response was repeated and plasmids were transfected into both STAT3
+/+ and 
STAT3
-/- MEFs for 16-48 hr. Fig 5.2 shows that at 16 hr and 24 hr there are no differences 
between cell types. However as the time for DNA repair increased between 32 hr and 48 hr, it 
was apparent that STAT3
-/-
 
 MEFs had a lower %HCR, indicating a reduced efficiency of 
DNA repair. This data shows that STAT3 deficient MEFs, although they are capable of 
repairing damaged DNA, do so at a slower rate and may be defective in the late phase of 
DNA repair. Accumulation of damaged DNA in STAT3 deficient cells may therefore have 
effects on the rate of apoptosis in these cells. 
Fig 5.2. STAT3
-/- MEFs have reduced capacity to repair damaged DNA. STAT3
+/+ and STAT3
-/-
 
 
MEFs were transfected for 16-48 hr with 50 ng luciferase plasmids which were irradiated with the 
indicated doses of UV and 20 ng renilla plasmid in 96 well plates. Luciferase values were read with a 
luminometer, normalized to renilla and expressed as a percentage of un-irradiated control. A 
representative experiment is shown, n=6 per experiment, repeated in triplicate. Error bars represent 
mean ± SEM, statistical analysis was carried out using a Two-way ANOVA with Bonfferoni post test, 
* p<0.05, ** p<0.01, *** P<0.005.   
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To show that reduced DNA repair in the STAT3
-/- cells was directly attributable to reduced 
STAT3 levels, STAT3
-/- MEFs were transfected with increasing concentration of STAT3 and 
a luciferase plasmid irradiated with 500 J/ UV; the HCR assay was carried out after 48 hr. 
Transfection of 100 ng STAT3 increased the % HCR from 31.8% to 43.5% and 300 ng 
STAT3 significantly increased the HCR to 74.4%, showing that STAT3 directly contributes 
to DNA repair (Fig 5.3). These results are consistent with the previous data (Fig 5.2) which 
showed that at 500 J/ after 48 hr, the  % HCR in STAT3
+/+ MEFs was 67.1%  and  in STAT3
-
/-
 
 MEFs was 27.7%. Importantly this experiments shows for the first time that the level of 
STAT3 directly correlates with the level of DNA repair. This data thus predicts that cells 
which increase their expression of STAT3 (such as certain cancer cells) should repair 
damaged DNA more efficiently. 
 
 
 
 
 
 
Fig 5.3. STAT3 increases the rate of DNA repair. Luciferase plasmids were treated with 500 J/ UV 
and transfected into STAT3
-/-
 
 MEFS with 10, 100 or 300 ng STAT3-pcDNA3 or pcDNA3 along with 
20 ng renilla  plasmid  in 96 well plates. After 48 hr luciferase activity was measured with a 
luminometer, normalized to renilla and expressed as a percentage of non-irradiated control plasmid. 
The values were further normalized against pcDNA3 control values. Error bars represent mean ± 
SEM, statistical analysis was carried out using a One-way ANOVA with Dunnett’s post test. n=4 per 
experiment, repeated in duplicate. *** p<0.001.  
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5.3. STAT3
-/-
Following DNA strand breaks, the DNA damage response pathway is quickly activated. The 
apical kinase in this pathway is ATM which phosphorylates several key proteins involved in 
DNA repair and apoptosis. Since STAT3 deficient cells repair DNA at a slower rate, the 
levels of activated ATM were examined in STAT3
 MEFs Show Reduced Activity of the ATM/H2AX Pathway 
-/- MEFs to ascertain whether this key 
DNA damage kinase is altered in these cells. STAT3
+/+ and STAT3
-/- MEFs were treated for 
up to 4 hr with 10 µM etoposide, a topoisomerase II inhibitor which induces DNA strand 
breaks. Etoposide treatment resulted in a time dependent increase in ATM phosphorylation in 
both STAT3 WT and knock-out cells; however the levels of phosphoryled ATM (pATM) 
were far lower at each time point in the STAT3
-/-
The histone 2AX is a major ATM substrate which becomes phosphorylated at serine 139 
following strand breaks (known as •H2AX) and serves as a molecular beacon for the 
accumulation of DNA repair factors around the site of the break (Lowndes et al., 2005). 
Similarly to ATM, •H2AX was activated by etoposide in a time dependent manner, and again 
the levels were reduced in STAT3
 cells (Fig 5.4a). Densitometric analysis for 
three separate experiment revealed that on average, pATM levels were 2.5 times higher in 
wild type cells (Fig 5.4b). 
-/-
Two other downstream targets of ATM are Chk1 which is involved in blocking the cell cycle 
following DNA damage and p53 which mediates both cell cycle arrest and  apoptosis. 
Phosphorylation of Chk1 was seen within 30 min of etoposide treatment in WT MEFs and 
was dephosphorylated by 2 hr (Fig 5.5). The levels of 
 cells (Fig 5.4c). Densitometry showed that •H2AX levels 
were on average 3.5 times higher in wild type cells when examined over three experiments 
(Fig 5.4d).  
 in STAT3
-/- MEFs however were far 
lower at 0.5 hr and 1 hr, suggesting that like •H2AX, ATM mediated Chk1 phosphorylation 
may be reduced in the absence of STAT3. ATM phosphorylates p53 on serine 15; 
examination of  levels in STAT3
-/- 
 
MEFs however revealed no difference to wild type cells 
(Fig 5.5). Taken together this shows that reduced activity of ATM in STAT3 deficient MEFs 
may result in lower levels of phosphorylated H2AX and Chk1 but not p53, underscoring a 
complex regulation of the DNA damage response pathway in these cells. 
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Fig 5.4. Phosphorylation of ATM and H2AX are reduced in STAT3
-/-  MEFs.  STAT3
+/+  and 
STAT3
-/- MEFs were treated with DMSO (0 hr) or 10 µM etoposide for 1, 2 or 4 hr and western blots 
were carried out on cell lysates using antibodies for the phosphorylated forms of (A) ATM (
 
) and (C) 
H2AX (•H2AX), equal loading was confirmed using GAPDH. (B and D) Densitometry was carried 
out on three separate experiments by firstly normalizing to GAPDH levels and normalizing again to 
the band intensity at 1 hr which was arbitrarily set to 100. Error bars represent mean ± SEM, 
statistical analysis was carried out using a Two-way ANOVA with Bonfferoni post test. * p<0.05, ** 
p<0.01, *** p<0.001 
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Fig 5.5. Phosphorylation of Chk1 but not p53 is  reduced in STAT3
-/-  MEFs.  STAT3
+/+  and 
STAT3
-/- MEFs were treated with DMSO (0 hr) or 10µM etoposide for 0.5, 1, 2 or 4 hr and western 
blots were carried out on cell lysates using antibodies for the phosphorylated forms of Chk1 (), p53 (
 
) 
and  total STAT3, equal loading was confirmed with GAPDH. The experiment was repeated in 
duplicate.  
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5.4. STAT3 Facilitates DNA Damage Mediated Upregulation of MDC1  
The previous sections have demonstrated that activation of ATM and  its  downstream 
substrates are reduced in STAT3 deficient MEFs.  MDC1 functions to amplify DNA damage 
signals by binding to •H2AX through its BRCT domain and to ATM via its FHA domain 
(Lou et al., 2006). This allows further recruitment of ATM to the sites of strand breaks and 
enhances the ATM mediated DNA damage response by facilitating ATM dependent 
phosphorylation of Nbs1, 53BP1 and BRCA1 (Stucki et al., 2005). Although MDC1 has no 
effect on the initial activation of ATM and H2AX, it is required to maintain the DNA damage 
response past the initial activation phase (Lou et al., 2006). Since several other mediators of 
the DNA damage response were dysregulated in STAT3
-/-
The mRNA levels of MDC1 were measured in STAT3
  MEFs, it was of interest to 
examine the regulation of MDC1 in these cells. 
+/+ and STAT3
-/- MEFs by qPCR and 
no difference was seen between cell types (Fig 5.6a). Next, the regulation of MDC1 levels by 
STAT3 following DNA damage was assessed. It is unknown whether the expression of 
MDC1 is altered by DNA damage, therefore WT MEFs were treated with 10 µM etoposide 
for up to 24 hr and MDC1 mRNA levels were measured. Fig 5.6b shows that MDC1 levels 
increased over time following DNA damage with etoposide, and a significant increase could 
be seen by 12 hr. STAT3
-/- MEFs were then treated with 10 µM etoposide for 12 hr and 
compared to wild type cells (Fig 5.6c). In contrast to the 2 fold increase in MDC1 levels in 
WT cells, STAT3
-/- MEFs did not show any increase in MDC1 levels at 12 hr. To ascertain if 
increased MDC1 levels is a general feature of DNA damage, WT MEFs were irradiated with 
10 Gy •-IR and allowed to recover for 2, 8 and 24 hr (Fig 5.6d). At 8 hr and 24 hr after 
irradiation, MDC1 levels were significantly increased. Comparison of •-IR mediated MDC1 
upregulation showed that MDC1 failed to be upregulated in STAT3
-/-
 
 MEFs which supports 
the findings with etoposide (Fig 5.6e). 
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Fig 5.6. DNA damage mediated increase in MDC1 expression is compromised in STAT3
-/-   
MEFs. (A) Basal MDC1 expression was measured in STAT3
+/+ and STAT3
-/- MEFs by qPCR. (B) 
Wild type MEFs were treated with 10µM etoposide for the indicated times and MDC1 levels were 
measured by qPCR. (C) STAT3
+/+ and STAT3
-/- MEFs were treated for 12 hr with 10µM etoposide 
and MDC1 levels were measured by qPCR. (D)  Wild type MEFs were treated with 10 Gy •-
irradiation for the indicated times and MDC1 levels were measured by qPCR. (E) STAT3
+/+ and 
STAT3
-/-
 
 MEFs were treated for 8 hr with 10 Gy •-irradiation and MDC1 levels were measured by 
qPCR. Error bars represent mean ± SEM, Statistical analysis was carried out using a student’s t-test 
(A), one-way ANOVA with Dunnett’s post test (B, D) or a two-way ANOVA with Bonfferoni post 
test (C,E), n=2 per experiment,  repeated in triplicate. * p<0.05, ** p<0.01.  
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The STAT3 dependent regulation of MDC1 expression was examined in greater detail using 
an MDC1 promoter luciferase construct (Townsend et al., 2005). The MDC1 luciferase 
reporter was co-transfected with pcDNA3, STAT1, STAT3• or STAT3• into four separate 
cell lines; Chinese hamster ovary cells (CHOs), MEFs and the fibrosarcoma cell lines 2ftgh 
and U3A (Fig 5.7a). Luciferase activity was measured after 24 hr and in each cell line tested, 
both STAT3• and STAT3• increased MDC1 promoter activity. In contrast, STAT1 had no 
effect on MDC1 promoter levels.  
Next, STAT3
-/-
 
  MEFs were co-transfected with 10, 50 or 300 ng of STAT3 expression 
plasmid  and the MDC1 reporter, treated with 10 Gy of •-IR and assessed for luciferase 
activity after 24 hr (Fig 5.7b). STAT3 dose dependently increased MDC1 promoter activity 
and this effect was enhanced by •-IR, reaching a maximum level of 5 fold over control levels 
when transfected with 300 ng STAT3. In order to see if both tyrosine 705 and serine 727 
were necessary for this STAT3 dependent effect, the MDC1 promoter construct was co-
transfected with STAT3 mutant plasmids; Y705F, S727A and a plasmid with both mutations 
(Y705F/S727A) (Fig 5.7c). Mutation of the Y705 site had no effect when compared to wild 
type STAT3, both enhanced MDC1 promoter activity by 2.5 fold. This suggests that 
phosphorylation at Y705 may not be necessary for STAT3 mediated upregulation of MDC1. 
Surprisingly, mutation of the serine 727 site or mutation of both sites led to a 40% increase 
over WT STAT3 levels, suggesting that phosphorylation of STAT3 at serine 727 reduces 
STAT3 mediated upregulation of the MDC1 promoter.   
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Fig 5.7. STAT3 regulates the MDC1 promoter. (A) CHO, MEF, 2FTGH or U3A cells were 
transfected with 50 ng pcDNA3, STAT1, STAT3 or STAT3• expression plasmids together with 50 ng 
of MDC1 reporter and 20 ng of renilla plasmid. Luciferase activity was measured after 24 hr. (B) 
STAT3
-/- MEFs were transfected with 50 ng MDC1 expression plasmid, 20 ng renilla plasmid and 10, 
50 or 300 ng STAT3 expression plasmid or the corresponding amount of pcDNA3 for 24 hr and then 
left untreated (con) or treated with 10 Gy •-IR, luciferase activity was measured after 48 hr. (C) 
STAT3
-/-
 
 MEFS were transfected with 50 ng MDC1 reporter, 20 ng renilla and 50 ng of pcDNA3, 
STAT3, Y705F, S727A or Y705F/S727A in 96 well plates and luciferase activity was measured after 
24 hr. Experiments were repeated in triplicate, n=6 per experiment, luciferase values were normalized 
to renilla levels and then re-normalised to appropriate pcDNA3 controls and expressed as relative 
luciferase units (RLU). Statistical analysis was carried out using a student’s t –test (A and C) or a 
Two-way ANOVA with Bonfferoni post correction. * p<0.05, ** p<0.01. In B, * is compared to 
pcDNA3 control and # is compared to pcDNA3 •-IR.
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5.5 Discussion
 
Efficient repair of damaged DNA is essential to maintain genomic stability and cell survival. 
Although STAT3 has been shown to function as an anti-apoptotic transcription factor, there is 
little published data regarding its role in the DNA damage response. STAT3 deficient MEF 
cells were found to be less efficient at repairing damaged DNA from a transfected reporter 
construct, suggesting that STAT3 is necessary for optimum DNA repair.  Since STAT3
-/-
 
 
MEFS are less efficient at repairing damaged DNA, it is possible that DNA breaks may 
persist for longer in STAT3 deficient cells. In addition, artificially increasing the levels of 
STAT3 correlated with increased ability to repair DNA and restored the repair defect 
phenotype of knock-out cells.  
Several cancers are associated with elevated STAT3 levels, including multiple myelomas, 
lymphomas, breast, head and neck, lung, pancreatic and prostate cancers (Yu and Jove, 
2004). Moreover, elevated STAT3 activity is thought to contribute to chemoresistance in 
these malignancies (Barre et al., 2007) and targeting of STAT3 has been shown to restore 
sensitivity to chemotherapeutic drugs (Gariboldi et al., 2007, Alas et al., 2003). Thus over the 
past 5 years, STAT3 has emerged as a major new target for anti-cancer therapy (Yu and Jove, 
2004). STAT3 mediated chemonresistance has been attributed to upregulation of anti-
apoptotic STAT3 target genes such as cyclin D1, Bcl- 
 
and survivin (Gritsko et al., 2006, 
Turkson et al., 2005) and the data presented here now add to the understanding of how 
STAT3 may contribute to chemoresistance. Although the experiments were done in mouse 
embryonic fibroblasts, speculation can be made as to how these results elucidate the 
contribution of STAT3 to chemoresistance. Expression of STAT3 was associated with an 
enhanced ability to repair damaged DNA. By inference this suggests that cancer cells which 
overexpress STAT3 may be resistant to chemotherapeutics through their increased efficiency 
of DNA repair and greater resistance to genotoxic stress. It would therefore be of interest to 
examine the rate of DNA repair following treatment with chemotherapeutic drugs in tumor 
cells with elevated STAT3 expression.  Thus the HCR assay could be conducted on cancer 
cell lines which have varying expression of STAT3 to  examine the correlation between 
STAT3 expression and DNA repair. If the conjecture that elevated STAT3 levels in cancer 
contribute to increased efficiency of DNA repair, it would offer an alternative explanation for 
chemonresistance in these tumors.  218 
 
Molecular analysis of the DNA damage response pathway in STAT3
-/-  MEFS revealed 
several possible explanations for the reduced repair efficiency. The apical kinase in the DNA 
damage response is ATM which undergoes autophosphorylation after DNA damage, 
followed by dimer dissociation and activation (Bakkenist and Kastan, 2003).  ATM is 
responsible for phosphorylation of a host of proteins involved in DNA repair and cell cycle 
arrest and skin fibroblasts from Ataxia-telangiectasia patients have a reduced capacity to 
repair damaged DNA in conjunction with decreased HCR levels (Hannan et al., 2002). The 
reduced activity of ATM in STAT3
-/-
The activity of several downstream proteins in the ATM pathway were analysed in STAT3
 MEFs may therefore lead to dysregulation of repair 
proteins resulting in sub-optimal efficiency of DNA repair. 
-/- 
MEFs. Phosphorylation of both H2AX and Chk1 was decreased in the absence of STAT3; 
however there was no effect on phosphorylation of p53. Phosphorylation of H2AX by ATM 
is a key event in the DNA damage response; it leads to the recruitment of repair factors 
directly to the site of strand breakage (Celeste et al., 2002). Thus H2AX deficient cells are 
sensitive to radiation and have a reduced capacity to repair double strand breaks (Bassing et 
al., 2002). The level of both •H2AX and pATM activity after 1 hr etoposide treatment in wild 
type cells was only reached after 4 hr in STAT3
-/- cells (Fig  5.4b,d), suggesting that DNA 
damage signaling occurs at a slower rate in STAT3 deficient cells. This  reduced 
phosphorylation of H2AX in STAT3
-/- MEFS following etoposide treatment in conjunction 
with reduced active ATM might in part account for the slower rate of DNA repair in these 
cells. Reduced activity of H2AX would be expected to slow the rate of accumulation of DNA 
repair factors around the site of strand breakage, thereby hampering the DNA repair process. 
One caveat to this observation however is that since plasmid DNA does not contain histones 
it is unclear whether transfection of a plasmid with double strand breaks activates 
endogenous •H2AX. It would therefore be of interest to examine the rate of endogenous 
DNA repair in STAT3
-/-
Chk1 phosphorylation at seine 345 was also shown to be reduced in STAT3
 MEFs to confirm that the decreased activity of ATM and H2AX 
does indeed lead to decreased repair efficiency, this could be achieved using the comet assay 
for example (Singh et al., 1998). 
-/- MEFs. Chk1 
phosphorylation leads to its release from chromatin where it in turn phosphorylated the 
CDC25 phosphatases and targets them for destruction by ubiquitin-mediated proteolysis 
(Cimprich  and Cortez, 2008). This promotes CDK activation and cell cycle checkpoint block 219 
 
(Cimprich and Cortez, 2008). Chk1 can be phosphorylated by both ATM and ATR and 
although ATR phosphorylation was not examined in STAT3
-/- MEFs, it has been shown to lie 
downstream of ATM following DSB formation (Jazayeri et al., 2006). The importance of 
serine 345 phosphorylation in Chk1 is underscored by the finding that mutation of this site on 
Chk1 dysregulates checkpoint control and leads to mitotic catastrophe (Niida et al., 2007). 
Reduced phosphorylation of Chk1 in STAT3
-/-
 
 cells would be expected to abrogate cell cycle 
arrest through the checkpoint system and examination of cell cycle profiles from STAT3 
deficient cells could be used to address this. 
Active ATM phosphorylates p53 on serine 15 following ionizing radiation or radiomimetic 
drug treatment and this appears to be necessary for fully fledged activation of p53 (Banin et 
al., 1998, Fiscella et al., 1993). p53 serine 15 phosphorylation  proceeded with equivalent 
kinetics following etoposide treatment in both WT and knock-out STAT3 cells. This finding 
demonstrates that not all aspects of the ATM pathway are affected. Why •H2AX and Chk1 
phosphorylation is reduced but p53 phosphorylation is unaltered in STAT3
-/-  MEFs is 
currently unknown. Other p53 kinases may be involved in regulating p53 activity in STAT3 
deficient cells, for example both ERK and p38 MAPK have been shown to be capable of 
phosphorylating 
 
 (She et al., 2000) 
STAT3 was also shown to be capable of modulating MDC1 expression. Although MDC1 
levels were not increased over the time frame in which pATM and •H2AX activity were 
examined (1-4 hr), the increased expression of MDC1 by 12 hr is expected to promote further 
recruitment of DNA repair factors to the site of strand breakage. STAT3 deficient MEFs 
failed to upregulate MDC1 expression in response to etoposide and •-IR. Furthermore, 
STAT3 but not STAT1 upregulated the activity of an MDC1 promoter construct and 
transfection of STAT3 enhanced •-IR mediated MDC1 upregulation. It is not yet clear 
whether STAT3 directly regulates  the MDC1 promoter of if it does so through an 
intermediate STAT3 dependent protein. This could be addressed in two ways, firstly though 
the use of chromatin immunoprecipitation to ascertain if STAT3 can bind directly to the 
MDC1 promoter. In addition transfection of constitutively active STAT3 in the presence of 
transcriptional inhibitors would reveal whether MDC1 upregulation occurs through STAT3 
mediated transactivation of an MDC1 regulator. Recently Sp1 has been identified as a direct 
transcriptional activator of the MDC1 promoter (Bu et al., 2008). STAT3 might therefore co-220 
 
operate with Sp1 at the MDC1 promoter, indeed STAT3 has previously been shown to bind 
to Sp1, thereby enhancing Sp1 mediated upregulation of VEGF (Loeffler et al., 2005). 
Surprisingly neither the Y705 or S7272 sites of STAT3 appeared to be necessary for MDC1 
upregulation. Indeed mutating the S727 site to an alanine actually enhanced STAT3 mediated 
MDC1 upregulation (Fig 5.7c) suggesting that phosphorylation at this site may reduce the 
transactivation capacity of STAT3. It has previously been demonstrated that phosphorylation 
of STAT3 may not be necessary to induce transcriptional upregulation (Chatterjee-kishore et 
al., 2000, Yang et al., 2005). Indeed if STAT3 does prove to upregulate MDC1 indirectly, it 
may be through protein-protein binding which might not require Y705 phosphorylation. 
Taken together, this shows that STAT3 is necessary for the upregulation of MDC1 levels 
following DNA damage and impaired MDC1 expression may contribute to the reduced 
efficiency of DNA repair in STAT3
-/- 
 Although these studies were limited to mouse embryonic fibroblasts and DNA damage was 
induced predominantly with etoposide; some general conclusions can still be made. These 
studies have demonstrated that STAT3 is necessary for efficient repair of damaged DNA. 
Several candidate proteins which could mediate this affect have been highlighted, including 
ATM, H2AX, Chk1 and MDC1. Increased expression and/or activity of STAT3 in tumors is 
suggested to contribute to chemoresistance through the possibility of increasing the activity 
of ATM and its downstream targets and upregulating MDC1 expression, allowing more 
efficient localization of repair proteins to sites of damaged DNA. In future studies, direct 
imaging of DNA damage response factors at the sites of DNA breaks in tumor cells with 
varying levels of STAT3 will highlight any differences in duration of chromatin occupancy 
which might be influenced by STAT3. 
MEFs. In addition, it can be speculated that cancer cells 
overexpressing STAT3 might also have elevated MDC1 levels, allowing more efficient DNA 
repair and thus contributing to chemo-resistance. However analysis using both the Cancer 
Genome Anatomy Project and Oncomime cancer expression databases revealed few MDC1 
overexpressing cancers and none of these was associated with increased STAT3 expression. 
More detailed analysis of cancer cells from patients with chemoresistance may prove more 
informative. 
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Chapter 6: Regulation of the 
MAPK Pathway in 
Inflammation 
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6.1 Aims 
During the course of doctoral work the opportunity arose to carry out research at the lab of 
Prof Richard Flavell at Yale University. The experiments described in this chapter were all 
carried out in the Flavell lab and thus represent a separate body of work from the previous 
chapters. In chapter 4, MAPK phosphatase-1 (MKP-1) was found to be upregulated by I/R 
injury and inhibited by antioxidant treatment. MKP-1 upregulation coincided with reduced 
phosphorylation of p38 MAPK and ERK. In this chapter, the effect of MKP-1 deletion on 
MAPK activity is explored. The aims were to characterise the immune phenotype of MKP-1 
deficient mice and explore the relationship between altered MAPK responses and 
inflammation. In addition, the effect of MKP-1 on acquired immunity was also examined.  
 
 
6.2  MKP-1 Deficient Mice have Elevated Cytokine Production, are Hyper-
responsive to Endotoxic Shock and are Less Susceptible to Listeria 
Monocytogenes Infection in vivo. 
 
The reaction to bacterial LPS is a well characterised innate immune response which can lead 
to endotoxic shock due to systemic overproduction of pro-inflammatory cytokines. Cytokine 
production by LPS is dependent on activation of MAPKs which in turn are suppressed by the 
activity of MKPs. In order to further characterise the role of MAPK in cytokine production, 
MKP-1 deficient mice were used, Fig 6.1 shows genotyping of MKP-1
+/+, MKP-1
+/- and 
MKP-1
-/- mice. Age and sex matched MKP-1
+/+ and MKP-1
-/- mice were  treated with 10 
mg/kg LPS and serum cytokine levels were measured after 3 hours (Fig 6.2). MKP-1
-/- mice 
showed 8 fold and 4 fold higher levels of TNF-• and IL-6 respectively. Although less 
pronounced, there were significant increases in IL-1•, IL-12, IL-10, IL-4 and GM-CSF in 
MKP-1
-/- mice while no significant difference was observed in the levels of IL-2, IL-5 and 
IFN-•. Thus the absence of MKP-1 has a dramatic effect on the cytokine profile following 
LPS challenge and the results clearly demonstrate that MKP-1 negatively regulates cytokine 
production in vivo. Interestingly, although the majority of cytokines that were enhanced in 
MKP-1
-/-
 
 
mice were pro-inflammatory, the levels of the anti-inflammatory IL-10 were 
elevated 8 fold, this suggests that MKP-1 does not simply function to inhibit pro-
inflammatory mediators, rather it may have a more complex regulatory role in controlling the 
response of the innate immune system. 223 
 
 
 
 
Fig 6.1 MKP-1 genotyping. Genotyping was carried out as described in methods, wild type mice had 
a PCR product of 450bp, MKP-1 deficient mice had a PCR product of 700 bp and heterozygote DNA 
contained both bands 
 
 
 
 
 
 
 
Fig 6.2 MKP-1
-/-
 
  mice show enhanced cytokine production following LPS challenge. Serum 
cytokine levels were measured by Bioplex assay following 3 hr challenge with 10 mg/kg LPS. Data 
show mean ± SD for 5 mice per group, *p<0.05 determined using students t-test. 
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In order to ensure that the results obtained were not due to differences in generation of the 
myeloid and dendritic cell lineages in MKP-1
-/- 
 
mice, total spleen and lymph node were 
stained with CD11b and CD11c. No difference in cell numbers were seen in CD11b+ 
myeloid cells, and CD11b-CD11c+ and CD11b+CD11c+ dendritic cell populations between 
genotypes (Fig 6.3). Therefore the increase in cytokine levels are in fact due to elevated 
cytokine production and not due to increased cell numbers. 
 
 
 
 
 
 
Fig 6.3 Flow cytometry analysis of myeloid cells markers in MKP-1
+/+ and MKP-1
-/- mice. Total 
spleen and lymph nodes were harvested from MKP-1
+/+ and MKP-1
-/-
 
 mice, digested with collagenase, 
stained with CD11b and CD11c antibodies and analysed by flow cytometry. Percentages of CD11b+ 
myeloid cells, and CD11b-CD11c+ and CD11b+CD11c+ dendritic cell populations are shown. 
Representative flow cytometry plot from 3 mice. 
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The pathological consequences of endotoxic shock are attributed to the damaging effects of 
high levels of TNF-•, IL-6 and IL-1• induced by LPS. Since these three cytokines were 
elevated in MKP-1
-/- mice, the question was asked whether MKP-1 has a role to play in the 
mortality induced by toxic shock.  MKP-1
+/+ and MKP-1
-/- mice were injected i.v with two 
doses of LPS and survival was monitored over 48 hours. Administration of 10 mg/kg  LPS 
resulted in 100% mortality in MKP-1
-/- by 18 hr, whereas wild type mice died between 24 
and 48 hr. At the lower dose of 2.5 mg/kg LPS, all the MKP-1
-/-
  
 died within 24 hr whereas 
wild type mice survived significantly longer (Fig 6.4). This suggests that MKP-1 plays a 
distinct role in controlling the innate inflammatory response following endotoxic shock and 
in the absence of MKP-1, elevated levels of pro-inflammatory cytokines have significant 
detrimental effects on mortality. 
 
 
 
 
 
Fig 6.4. MKP-1
-/- mice are hyper-responsive to endotoxic shock in vivo.  MKP-1
+/+ (solid line) and 
MKP-1
-/-
 
 mice (dotted line) were injected i.p with either 10 mg/kg or 2.5mg/kg LPS and survival was 
monitored up to 50 hours. Both treatments resulted in significant differences between groups, p=0.008 
and p=0.004 for 10 mg/kg and 2.5 mg/kg respectively, log-rank (Mantel-Cox) test, n=5. 
 
 
 
 
 
 
 
 
 
 
 
Time After LPS Injection (Hours)
0 18 24 32 44 50
0
20
40
60
80
100
%
S
u
r
v
i
v
a
l
Time After LPS Injection (Hours)
0 4 7 18 26 32 48
0
20
40
60
80
100
%
S
u
r
v
i
v
a
l
10mg/kg 2.5mg/kg
MKP-1 +/+
MKP-1 -/-
MKP-1 +/+
MKP-1 -/-
Time After LPS Injection (Hours)
0 18 24 32 44 50
0
20
40
60
80
100
%
S
u
r
v
i
v
a
l
Time After LPS Injection (Hours)
0 4 7 18 26 32 48
0
20
40
60
80
100
%
S
u
r
v
i
v
a
l
10mg/kg 2.5mg/kg
MKP-1 +/+
MKP-1 -/-
MKP-1 +/+
MKP-1 -/-
MKP-1 +/+
MKP-1 -/-
MKP-1 +/+
MKP-1 -/-226 
 
To determine if overproduction of pro-inflammatory cytokines in MKP-1
-/-  affects the 
outcome of bacterial infection, MKP-1
-/- and wild type mice were inoculated with 1.0 x 
 
particles of Listeria monocytogens. Although the natural route of L. monocytogenes infection 
is through mucosal surfaces following ingestion, for experimental purposes i.v injection is 
used. This facilitates uptake of bacteria from the bloodstream by splenic and hepatic 
macrophages (Pamer, 2004). Examination of bacterial burden in the spleen and liver revealed 
that MKP-1
-/-  mice had a reduced bacterial load following 72 hours of infection. This 
suggests that elevated levels of pro-inflammatory cytokines in MKP-1
-/-
 
  mice  may be 
effective in slowing the progress of bacterial infection through enhanced bacterial killing and 
clearance. 
 
 
 
 
 
 
 
 
Fig 6.5. MKP-1
-/- mice are less susceptible to Listeria infection. Mice were injected i.v with 1.0 x  
particles of Listeria monocytogenes. 72 hr later, animals were sacrificed and the spleen and liver 
removed and homogenised. Serial dilutions of tissue homogenates were plated on brain-heart infusion 
agar plates and cultured at 
 
, colony numbers were counted following 24 hours of incubation, the 
results are expresses as cfu per organ.  
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6.3  MKP-1 Negatively Regulates p38 MAPK, JNK and AP-1 Activity and iNOS 
expression 
 
LPS is a potent activator of the MAPK family; including p38, ERK and JNK. Therefore, to 
determine if MKP-1 activity affects MAPK signalling following TLR stimulation, bone 
marrow derived macrophages (BMDM) from MKP-1
-/- and wild type mice were treated with 
10  ng/ml LPS and MAPK activity was determined using antibodies which recognise the 
active (phosphorylated) form of these proteins. No difference in the initial phase of MAPK 
activation (20 min) was seen between genotypes, however both p38 MAPK and JNK activity 
was prolonged in MKP-1
-/-  BMDM (Fig 6.6). By 2 hr LPS stimulation both active p38 and 
JNK levels had almost returned to beaseline, whereas in the MKP-1
-/-
 
 macrophages they were 
still elevated. In contrast, ERK activity was equivalent in wild type and knockout BMDM, 
suggesting that in macrophages, MKP-1 does not affect ERK activity in response to LPS. 
MKP-1 is therefore essential for the inactivation of p38 MAPK and JNK following LPS 
stimulation and as such provides an endogenous brake on prolonged MAPK signalling which 
would otherwise be deleterious by allowing overproduction of pro-inflammatory cytokines. 
 
 
 
Fig  6.6. Prolonged MAPK activity in MKP-1
-/-  BMDM in response to LPS. BMDM were 
harvested from MKP-1
+/+ and MKP-1
-/-
 
 mice and treated with 10  ng/ml LPS for the indicated times. 
Cells were lysed in RIPA buffer and western blot was carried out using the indicated antibodies. 
Representative gel from 3 separate experiments. 
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AP-1 is a well described transcription factor composed of c-jun and fos subunits, it is known 
to be strongly induced by MAPKs and is a potent transcription factor for several important 
cytokines (Hess et al., 2004). AP-1 activity was examined using a gel shift (EMSA) assay 
which revealed a substantial increase in AP-1 DNA binding at both 30 and 90 min LPS 
stimulation in MKP-1
-/- 
as AP-1. 
BMDM in comparison with wild type cells (Fig 6.7a). This suggests 
that MKP-1 controls cytokine expression through its effects on MAPKs and their downstream 
targets such  
 
JNK, p38 MAPK and AP-1 have all been shown to be necessary for iNOS upregulation in 
macrophages following LPS stimulation (Chan and Riches, 2001, Chen at al., 1999). iNOS 
levels were therefore measured in MKP-1 deficient macrophages by qPCR (Fig 6.7b). LPS 
stimulation resulted in significant overproduction of iNOS in MKP-1
-/-
 
 
  macrophages. 
Maximum iNOS levels were reached by 5 hr in wt cells, in MKP-1 deficient macrophages 
iNOS mRNA levels continued to rise until 12 hr at which time MKP-1 deficient cells 
produced 55 fold more iNOS mRNA than wt cells. Nitric oxide production is protective 
against listeria infection and iNOS deficient mice fail to restrain listeria growth (Boockvar et 
al., 1994, MacMicking et al., 1995). Therefore elevated iNOS levels in MKP-1 deficient mice 
may contribute to the reduced bacterial load of these mice following listeria infection. 
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Fig 6.7. Increased AP-1 DNA binding activity in MKP-1
-/- BMDM. (A) MKP-1
+/+ and MKP-1
-/- 
BMDM were treated for the indicated times with 10 ng/ml LPS, nuclear fractions were obtained and 
AP-1 binding activity was determined using a gel shift assay with a consensus AP-1 oligonucleotide. 
A representative gel is shown from 3 separate experiments. (B) MKP-1
+/+ and MKP-1
-/-
 
 macrophages 
were treated with LPS for up to 24 hr. iNOS mRNA levels were measured by qPCR and normalised to 
the levels of wt cells at 2 hr. Error bars represent mean ± SEM, statistical analysis was carried out 
using a Two-way ANOVA with Bonfferoni post test, * p<0.05, ** p<0.01, *** p<0.001. 
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6.4 TLR Mediated MKP-1 Expression Proceeds Through TRIF and MyD88  
 
In order to understand the temporal regulation of MKP-1, BMDM were treated with 10 ng/ml 
LPS over 24 hr, followed by qPCR analysis of MKP-1 expression. MKP-1 expression peaked 
following 1  hr  of LPS stimulation with a 15 fold induction in mRNA levels, this was 
followed by rapid downregulation and return to basal levels 3-4 hr post LPS treatment (Fig 
6.8a). MKP-1 protein showed a similar pattern of strong induction followed by rapid 
downregulation (Fig 6.8b). Such rapid induction of MKP-1 has presumably evolved to 
effectively limit prolonged MAPK activation which could lead to aberrant cytokine 
overproduction. Interestingly a second smaller peak of expression was consistently seen 5 hr 
following LPS treatment which may be associated with secondary cytokine release, possibly 
IL-10 which has recently been shown to induce MKP-1 expression (Hammer et al., 2005) 
 
TLRs can transduce their signals through the use of two adaptor proteins, MyD88 in the case 
of TLRs 2, 5, 6 and 9 or through Trif in the case of TLR3, while LPS can induce signal 
transduction through either adaptor (Fig 1.4). It was therefore of interest to examine which 
adaptor molecules are required for TLR induced upregulation of MKP-1.  To examine this 
aspect of TLR signalling, two mouse lines were employed; MyD88
-/- mice and the TRIF null 
mutant line . Treatment of BMDM from wild type, MyD88
-/- and 
 
 mice with LPS revealed 
that both pathways are required for maximal MKP-1 induction (Fig 6.8b). MKP-1 expression 
was reduced in both MyD88 and TRIF deficient cells by 1 hr post LPS treatment and by 2 hr 
MKP-1 expression was almost completely inhibited. 
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Fig 6.8. MKP-1 Expression can be Stimulated Through both the MyD88 Dependent and 
Independent Pathways. (A) BMDM were treated with 10 ng/ml LPS for the indicated times and 
MKP-1 expression was determined by qPCR.  (B)  Wild type, MyD88
-/-  and    BMDM were left 
untreated (con) or stimulated for the indicated times with 10 ng/ml LPS followed by western blotting 
for MKP-1 (C,D) Wild type, MyD88
-/- and 
 
 BMDM were left untreated (con) or stimulated for 1 hr 
with 10 ng/ml LPS, 1 µM CpG, 50 µg/ml Poly(I:C) or 200 ng/ml PAM3CSK4 and MKP-1 expression 
was determined by western blot (C) or qPCR (D). For qPCR data, error bars represent mean ± SEM, 
statistical analysis was carried out using a student’s t-test, *p <0.05, ** P<0.01, n=3 per experiment, 
repeated in triplicate. 
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In order to ascertain if this mode of MKP-1 regulation is particular to LPS or is a facet of 
TLR signalling in general, wild type, MyD88
-/- and   BMDM were treated with the TLR 9 
agonist CpG, the TLR3 agonist poly(I:C) or the TLR2 agonist  . All three agonists potently 
upregulated MKP-1 expression within 1 hr (Fig 6.8c). This demonstrates that a variety of 
bacterial and viral TLR ligands are capable of inducing MKP-1 expression and therefore 
upregulation of MKP-1 is a general phenomenon of inflammatory responses in macrophages 
during innate immunity. As expected, no MKP-1 upregulation was seen in MyD88
-/- mice 
treated with CpG or   since they both require MyD88 to transduce their signal and similarly 
no upregulation was seen in 
 
 mice treated with CpG which requires TRIF as an adaptor 
protein. These results were also confirmed by qPCR (Fig 6.8d). Taken together these results 
indicate that MKP-1 can be induced through MyD88 and TRIF dependent pathways in 
response to TLR stimulation. 
Since it was established that both TRIF and MyD88 contribute to induction of MKP-1 
expression, downstream components of the signalling cascade were analysed for their 
contribution to MKP-1 expression. Thus BMDM were treated with LPS for 1 hr in the 
presence of SP600125 (a JNK inhibitor), SB203580 (a p38 MAPK inhibitor), U0126 (a 
MEK1/2 inhibitor) and Ro106-9920 (an NF-•B inhibitor) and MKP-1 expression was 
evaluated by western blot and qPCR (Fig 6.9). Inhibition of JNK was found to have little 
effect on MKP-1 expression, however inhibition of p38, ERK or NF-•B all reduced the 
expression of MKP-1 at both the protein and RNA level. p38 and ERK have previously been 
shown to be involved in MKP-1 upregulation in other cell types (Lin and Yang, 2006). This 
is the first report of NF-•B mediated MKP-1 expression and suggests a previously 
unappreciated level of cross-talk between the MAPK and NF-•B family and as such warrants 
further investigation.  
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Fig 6.9. MKP-1 upregulation by LPS is dependent on MAPKs and NF-• B. BMDM were pre-
treated for 30 min with 10 µM of indicated inhibitors or DMSO control, then stimulated for 1 hr with 
10 ng/ml LPS and the expression of MKP-1 was analysed by (A) western blot and (B) qPCR 
 
 
 
Since dendritic cells (DCs) are a vital part of the innate immune responses and serve as a 
bridge between innate and adaptive immunity, it was of interest to examine the regulation of 
MKP-1 in DCs. DCs were treated with 10 ng/ml LPS for up to 24 hr and MKP-1 expression 
was determined at the protein and RNA level. Interestingly, the temporal regulation of MKP-
1 mRNA in DCs was very distinct to that of macrophages, there was a modest 3 fold increase 
in MKP-1 expression at 1 hr but surprisingly a 15 fold increase was seen at 12 hr which was 
sustained up to 24 hr (Fig 6.10a). This is in contrast to macrophages, where MKP-1 
expression returns to baseline levels from 9 hr LPS stimulation (Fig 6.8a). Intriguingly, 
analysis of MKP-1 protein expression in DCs did not recapitulate the temporal expression 
seen at the mRNA level (Fig 6.10b). MKP-1 protein was still evident at 12 and 24 hr LPS 
stimulation but was greatly reduced in comparison to levels seen at 1 hr. Since increased 
mRNA levels are not reflected by increased protein levels it suggests that MKP-1 may be 
regulated post-translationaly in DCs. The functional significance of this is currently unknown 
but highlights the fact that the regulation of MKP-1 during inflammation may be distinct in 
different immune cell types.  
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Fig 6.10. LPS induced MKP-1 expression in dendritic cells. BMDC were treated for the indicated 
times with LPS and MKP-1 expression was analysed by (A) qPCR and (B) western blot. Error bars 
represent mean ± SEM, n=3. Statistical analysis of qPCR was carried out by ANOVA with Dunnett’s 
post test and at all time points MKP-1 was significantly upregulated (p<0.05) compared to the 0 hr 
control.   
 
6.5 Regulation of IL-10 by MKP-1 
 
LPS treatment in vivo revealed that MKP-1 controls the expression of both pro and anti-
inflammatory cytokines, it was therefore of interest to examine cytokine responses in MKP-1
-
/- mice in more detail. IL-10 is a potent anti-inflammatory cytokine released by macrophages 
and TH2 cells which serves to inhibit pro-inflammatory cytokine release from macrophages 
and attenuate TH1 cell function (Couper et al., 2008). IL-10 expression was increased 8 fold 
in serum from MKP-1
-/- mice compared to wild type mice. To further investigate the effect of 
MKP-1 on IL-10 expression in response to innate immune signalling, MKP-1
+/+ and MKP-1
-/- 
BMDM were treated with a panel of TLR agonists; activation of TLRs 2, 3, 4, 5, 7 and 9 was 
induced for 12 hr and IL-10 in the culture supernatants was measured by ELISA. All TLR 
agonists tested resulted in elevated expression of IL-10 in MKP-1
-/-  BMDM, the biggest 
increase was seen with LPS (6 fold) and flagellin (5 fold) (Fig 6.11a). Interestingly, there is a 
gene dosage effect of MKP-1 on IL-10 expression; treatment of MKP-1
+/-
 mice with LPS in 
vivo or treatment of MKP-1
+/- BMDM with LPS in vitro resulted in IL-10 levels which were 
intermediate between that of MKP-1
+/+ and MKP-1
-/-
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Fig 6.11. MKP-1 inhibits TLR induced IL-10 expression and has gene dosage effects.  (A) 
BMDM from MKP-1
+/+  and MKP-1
-/- mice were treated for 12 hr with 10 ng/ml LPS, 1 µM CpG, 50 
µg/ml Poly(I:C), 10 µg/ml petidoglycan (PGN), 200 ng/ml  , 100 ng/ml flagellin, 200 µM loxoribine 
or left untreated and   IL-10 in the culture supernatant was measured by ELISA. (B) Serum from 
MKP-1
+/+, MKP-1
+/- and MKP-1
-/- mice was collected 3 hr following 2.5 mg/kg LPS challenge and 
IL-10 measured by ELISA. (C) BMDM from MKP-1
+/+, MKP-1
+/- and MKP-1
-/-
 
 mice were treated 
with 10 ng/ml LPS for 12 hr and IL-10 in the culture supernatant was measured by ELISA. Error bars 
represent mean ± SEM, n=3. Statistical analysis was carried out using a student’s t-test (A) and an 
ANOVA with Bonferroni post test (B) * p<0.05, ** p<0.01. 
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A time course of LPS treatment in BMDMs revealed increased IL-10 protein levels in MKP-
1
-/- at all times examined, with an 8 fold increase by 5 hr (Fig 6.12a). Detailed analysis of IL-
10 mRNA levels were in agreement with the ELISA data, with the greatest difference (10-20 
fold) observed  5-9 hr following LPS treatment,  mRNA levels were equivalent between 
genotypes  by 18-24 hr LPS treatment (Fig 6.12b). Since MKP-1 deficient macrophages 
showed enhanced MAPK activity, it was of interest to determine if the increased MAPK 
activity was responsible for the elevated IL-10 levels in MKP-1
-/- macrophages. Therefore, 
MKP-1
-/- BMDM were treated with the p38 MAPK inhibitor SB203580, the JNK inhibitor 
SP600125 or the MEK inhibitor U0126 at doses ranging from 1-20 µM, followed by LPS 
challenge (Fig 6.13). All the MAPK inhibitors dose-dependently decreased IL-10 expression, 
however p38 inhibition had the largest effect. At the lowest dose tested (1 µM), inhibition of 
JNK and ERK reduced IL-10 expression in MKP-1
-/- 
 
macrophages by an average of 50% 
whereas inhibition of p38 MAPK reduced IL-10 levels to that of wild type cells. This 
suggests that the inhibitory effect of MKP-1 on IL-10 expression is mainly mediated through 
the inhibition of p38 MAPK by MKP-1, although there are contributory effects from JNK 
and ERK. 
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Fig 6.12. Temporal regulation of IL-10 by MKP-1. MKP-1
+/+ and MKP-1
-/-
 
 BMDM were treated 
for the indicated times with 10 ng/ml LPS and IL-10 was measured in the culture supernatant by 
ELISA  (A)  or by qPCR  (B). Error bars represent mean ± SEM, n=3, experiments repeated in 
triplicate. Statistical analysis was carried out using a two-way ANOVA with Bonfferoni post test, * 
p<0.05, ** p<0.01, *** p<0.001. 
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Fig 6.13. MKP-1 inhibition of IL-10 is controlled through MAPK. MKP-1
+/+ (hatched bar) or 
MKP-1
-/- 
 
(white, grey, black bars) BMDM were pretreated for 1hr with 1 µM, 3 µM, 8 µM or 20 µM 
SB203580, SP600125, U0126 or DMSO control, followed by 12 hr treatment with 10 ng/ml LPS and 
IL-10 levels in the culture supernatant was measured by ELISA. Error bars represent mean ± SEM, 
n=3, experiments repeated in triplicate. 
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6.6 Dynamic Regulation of TNF-•  is Mediated Through IL-10 in MKP-1
-/- 
 
 
TNF-• is a potent pro-inflammatory cytokine which leads to strong macrophage induction, 
activates the endothelium and can cause to septic shock when released systemically. Since it 
is such a potent cytokine, multiple levels of control are employed by cells to tightly control 
TNF-• expression, including stabilisation of its mRNA by the p38 MAPK dependent protein 
MK1, which stabilises TNF-• message by inhibiting 3’ AU-rich element (ARE) dependent 
mRNA degradation. Another method to control TNF-• expression is the release of IL-10 
from macrophages and TH2 cells which inhibits TNF-• production from macrophages. To 
further determine the regulation of TNF-• by MKP-1, MKP-1
+/+   MKP-1
-/- BMDM were 
treated for 2, 5 and 18 hr with 10 ng/ml LPS and TNF-• protein was measured (Fig 6.14a). At 
earlier time points there was  3 fold increased TNF-• expression in MKP-1
-/-  BMDM, 
however by 18 hr LPS treatment, TNF-• expression was equal between genotypes To further 
elucidate the temporal regulation of TNF-•, a time course of LPS treatment was carried out 
and TNF-• mRNA levels were measured b qPCR. Compared with ELISA which measures 
the accumulative amounts of protein secreted into the culture medium, RNA analysis can 
reveal additional kinetic information concerning cytokine expression. qPCR analysis showed 
a 2-fold increase in TNF-• expression in MKP-1
-/- cells 1 hr post LPS challenge which is 
reflected in the increased protein levels (Fig 6.14b). Interestingly by 2 hr post LPS challenge, 
levels were equal between genotypes and from 5 hr to 24 hr, MKP-1
-/- cells produced less 
TNF-• mRNA than wild type cells. Therefore there is dynamic regulation of TNF-• mRNA 
in MKP-1
-/-
 
 macrophages, with increased expression at earlier time points and decreased 
expression at later time points.  
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Fig 6.14. Temporal regulation of TNF-•  in MKP-1 deficient cells. (A) MKP-1
+/+ and MKP-1
-/- 
BMDM were treated for the indicated times with 10  ng/ml LPS and TNF-• protein levels were 
measured in the culture supernatant by ELISA. (B) MKP-1
+/+ and MKP-1
-/-
 
 BMDM were treated for 
the indicated times with 10 ng/ml LPS and TNF-• mRNA levels were measured by qPCR. Error bars 
represent mean ± SEM, n=3 per group, experiment was repeated in triplicate.  
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 macrophages secrete increased 
amounts of IL-10, it was thought that IL-10 may be responsible for the decline in TNF-• 241 
 
levels seen by 5 hr LPS challenge in MKP-1
-/-  macrophages. Overlaying the LPS time course 
of TNF-• and IL-10 mRNA expression was highly suggestive of a role for IL-10 in 
controlling TNF-• expression since  IL-10 levels start to increase 1-2  hr following LPS 
treatment as TNF-• levels start to decline (Fig 6.15a). To test this further, MKP-1
+/+ and 
MKP-1
-/- BMDM were pretreated with an IL-10 blocking antibody or control IgG followed 
by LPS challenge for 5 hr or 12 hr At both time points, blocking IL-10 resulted in a two fold 
increase in TNF-• levels and inhibition of IL-10 completely abrogated the reduction of TNF-
• mRNA in MKP-1
-/- cells (Fig 6.15b). These results show that in MKP-1
-/- macrophages, 
there is an early overproduction of TNF-• mRNA due to excessive MAPK activation, 
however by 5 hr LPS activation, IL-10 has started to be overproduced in MKP-1
-/-
 
 cells 
which leads to TNF-• mRNA inhibition. This highlights the complicated and dynamic nature 
of cytokine production in macrophages, which is subject to multiple levels of control.  
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Fig 6.15. TNF-•  expression in MKP-1
-/- macrophages is controlled through IL-10 upregulation. 
(A) Overlay of TNF-• and IL-10 mRNA expression profiles following LPS treatment. (B) MKP-1
+/+ 
and MKP-1
-/-
 
  BMDM were pretreated with 10  ng/ml anti-IL-10 antibody or with IgG for 1  hr 
followed by 5 hr or 12 hr LPS treatment, TNF-• mRNA levels were then measured by qPCR. Error 
bars represent mean ± SEM, n=3 per group, experiment was repeated in triplicate. 
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Previous studies have shown that IL-10 inhibits TNF-• activity through STAT3-mediated 
induction of the I•B family member Bcl-3 (Kuwata et al., 2003). Bcl-3 binds to the p50 
subunit of NF-•B on the TNF-• promoter and inhibits NF-•B induced TNF-• transcription 
(Fig 6.16a). Therefore, if increased IL-10 in MKP-1
-/- cells does indeed cause inhibition of 
TNF-•, Bcl-3 may also be increased in the absence of MKP-1. Bcl-3 mRNA levels were 
therefore measured in MKP-1
+/+ and MKP-1
-/- macrophages following LPS challenge; 5 hr 
after LPS treatment, MKP-1
-/- macrophages produced 2.5 fold higher levels of Bcl-3 mRNA 
and levels remained significantly higher in MKP-1
-/- cells for up to 24 hr  (Fig 6.16b). In 
MKP-1
-/-
 
 macrophages, between 2 hr and 5 hr after LPS treatment, IL-10 levels increase and 
TNF-• levels concomitantly decrease (Fig 6.15a); the finding that Bcl-3 levels are also 
increased between 2 hr and 5 hr strongly suggests that Bcl-3 is involved in IL-10 mediated 
TNF-• downregulation in these cells.  
STAT3 is the main transcriptional regulator of Bcl-3, suggesting that STAT3 activity might 
be altered in the absence of MKP-1. To address this, MKP-1
+/+ and MKP-1
-/- BMDM were 
treated with LPS and STAT3 activity was assessed with phospho-specific antibodies.  STAT3 
serine phosphorylation was induced within 30 min of LPS treatment and returned to baseline 
levels after 2 hr in wild type cells; however in the absence of MKP-1, S727 phosphorylation 
remained elevated at 2 hr (Fig 6.16c). In contrast, STAT3 Y705 phosphorylation showed a 
slower course of activity when compared to serine phosphorylation but at 2 hr LPS treatment 
Y705 levels were again enhanced in MKP-1
-/-
  macrophages compared to wild type cells. 
Thus as predicted STAT3 phosphorylation is enhanced in MKP-1 deficient macrophages. 
Dysregulated STAT3 phosphorylation was specific since neither STAT1 tyrosine nor serine 
phosphorylation was altered in MKP-1
-/-
 
 macrophages (Fig 6.16d).  
It is likely that elevated STAT3 serine and tyrosine phosphorylation is brought about by 
distinct mechanisms. Since MKP-1 is responsible for dephosphorylating tyrosine and 
threonine residues, this precludes a direct effect on STAT3 serine phosphorylation. Therefore 
this must occur indirectly, possibly through elevated expression of MAPKs which have been 
shown to phosphorylate STAT3 at S727 after LPS treatment (Chung et al., 1997, Xu et al., 
2003). Thus elevated levels of active JNK and p38 MAPK in MKP-1
-/- cells might account 
for increased STAT3 serine phosphorylation. In contrast, the elevated levels of STAT3 
tyrosine phosphorylation are likely to be due to the higher levels of IL-10 and possibly IL-6 
in MKP-1
-/- macrophages. This fits well with the IL-10 kinetic data in Fig 6.12 which showed 244 
 
that IL-10 begins to be secreted by 2 hr LPS treatment with elevated levels being secreted 
from MKP-1
-/- macrophages. Taken together enhanced STAT3 705 and 727 phosphorylation 
in MKP-1
-/-
 
  macrophages  may be involved in upregulation of Bcl-3 and subsequently 
inhibition of TNF-•.  
 
 
 
Fig 6.16. Increased IL-10 in MKP-1
-/- macrophages leads to overproduction of Bcl-3 through 
increased STAT3 activation.  (A) Diagram of inhibitory effect of Bcl-3 on the TNF-• promoter. Bcl-
3 is a STAT3 responsive gene, following IL-10 stimulation it binds to the TNF-• promoter where it 
inhibits p50 mediated transcription. (B) MKP-1
+/+ and MKP-1
-/- BMDM were treated for the indicated 
times with 10 ng/ml LPS and Bcl-3 mRNA levels were assessed by qPCR, results are expressed as 
fold change over control.  Error bars represent mean ± SEM, n=3 per group, experiment was repeated 
in triplicate. Statistical analysis was carried out using a Two-way ANOVA with Bonferroni post-test * 
p<0.001. (C and D)
 -1
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BMDM were treated with 10ng/ml LPS for the indicated times 
and western blots were carried out with the indicated antibodies. 
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6.7 MKP-1 Activity Promotes IL-12 Expression 
 
IL-12 is composed of two subunits; p35 and p40 which form a functional p70 heterodimer. 
IL-12 is a potent pro-inflammatory cytokine and a strong inducer of Th1 responses, indeed 
IL-12 receptor expression is confined largely to activated T cells and NK cells (Trinchieri, 
2003). It is expressed at low levels in resting T cells but is upregulated upon activation. Since 
IL-10 and IL-12 are often reciprocally regulated and MKP-1 deficient macrophages produce 
elevated levels of IL-10, IL-12 regulation was examined in MKP-1
-/- BMDM in response to 
TRL stimulation. MKP-1
-/- macrophages produced an average of 2-fold less IL-12p40 with 
all TLR ligands examined (Fig 6.17a). IL-12p70 levels were also interogated, LPS mediated 
IL-12p70 expression was below the limits of detection in MKP-1
-/-
 macrophages, therefore to 
increase the levels of IL-12p70, macrophages were primed for 1 hr with IFN-• and then 
stimulated with LPS. Under these conditions, MKP-1
-/- macrophages produced an average of 
3.5 fold less IL-12p70 compared to wild type (Fig 6.17b). Similarly to IL-10, there was also a 
gene dosage effect evident, with MKP-1
+/-
 macrophages producing intermediate levels of IL-
12 (Fig 6.17c). Temporal analysis of IL-12 levels revealed that MKP-1
-/- produced reduced 
amounts of IL-12p40 protein when treated with LPS for 5 hr and 12 hr (Fig 6.18a). In 
addition, IL-12p40 and IL-12p35 levels were measured from 1-24 hr after LPS treatment (Fig 
6.18b,c). The mRNA levels of both subunits were significantly lower over the entire course 
of LPS treatment. Interestingly, there was a second peak of IL-12p40 expression at 18 hr LPS 
stimulation which was not seen with IL-12p35. Since IL-23 also utilizes the IL-12p40 subunit 
there may also be distinct regulatory effects of this cytokine in MKP-1
-/-
 
 mice, however this 
has not yet been explored. 
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Fig 6.17. IL-12p40 expression is repressed in MKP-1
-/- mice following TLR stimulation. (A) 
BMDM from MKP-1
+/+  and MKP-1
-/- mice were treated for 12 hr with 10 ng/ml LPS, 1 µM CpG, 50 
µg/ml Poly(I:C), 10 µg/ml petidoglycan (PGN), 200 ng/ml  , 100 ng/ml flagellin, 200 µM loxoribine 
or left untreated,  IL-12p40 in the culture supernatant was measured by ELISA. (B) BMDM from 
MKP-1
+/+ and MKP-1
-/- mice were  treated with 10ng/ml LPS for 12 hr or pretreated for 1 hr with 10 
ng/ml IFN-• followed by 10 ng/ml LPS for 12 hr. IL-12p70 levels were then measured from the 
culture supernatant. (C) BMDM from MKP-1
+/+, MKP-1
+/- and MKP-1
-/-
 
 mice were treated with 10 
ng/ml LPS for 12 hr and IL-12p40 in the culture supernatant was measured by ELISA. Error bars 
represent mean ± SEM, n=3. Experiments repeated in triplicate. Statistical analysis was carried out 
with a One-way ANOVA with Bonfferoni post test, * p<0.05. 
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Fig 6.18. Time course of IL-12 expression in MKP-1
-/- mice. (A) BMDM from MKP-1
+/+ and MKP-
1
-/- mice were treated with 10 ng/ml LPS for 5 hr or 12 hr with LPS and IL-12p40 levels in the culture 
supernatant were measured by  ELISA.  (B)  MKP-1
+/+  and MKP-1
-/-
 
  BMDM were treated for the 
indicated times with 10 ng/ml LPS and IL-12p40 (left panel) or IL-12p35 (right panel) mRNA levels 
were measured by qPCR. Error bars represent mean ± SEM, n=3 per group, experiments were 
repeated in triplicate. Statistical analysis was carried out using (A) t-test and (B) Two-way ANOVA 
with Bonferroni post test, * p<0.05, ** p<0.01, *** p<0.001. 
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Similarly to the experiments aimed at understanding which MAPKs control differentially 
regulation of IL-10 in MKP-1 deficient cells, MAPK inhibitors were again used to ascertain 
if the reduced IL-12 expression in MKP-1
-/-
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 macrophages is linked to the elevated MAPK 
activity in these cells.  IL-12p40 expression was found to be partially dependent on JNK 
activity in both wild type and knock out macrophages (Fig 6.19). Inhibition of p38 MAPK 
activity with sb203580, revealed that p38 MAPK represses IL-12 expression in both 
genotypes, this is most likely due to the fact that blocking p38 MAPK activity inhibits IL-10 
expression, this reduction in IL-10 would then be expected to lead to a concomitant increase 
in IL-12 expression. As expected, inhibition of ERK activity with U0126 had no effect on IL-
12p40 expression. 
 
Fig 6.19. Effect of MAPK inhibition on IL-12p40 levels. MKP-1
+/+ and MKP-1
-/-
 
 BMDM were 
treated for 1 hr with 10 µM of the indicated inhibitors or DMSO control followed by LPS stimulation 
for 12 hr. IL-12p40 levels in the culture supernatant were assessed by ELISA. Experiment was 
repeated in triplicate. 
 
The reciprocal regulation of IL-10 and IL-12 in MKP-1
-/- cells suggested that the decreased 
IL-12 levels seen in MKP-1
-/- macrophages might be directly attributable to the increased 
expression of IL-10 in these cells. To address this, IL-10 was inhibited using a blocking 
antibody, and cells were then stimulated with LPS for 12 hr. Inhibition of IL-10 increased IL-
12p70 production 11-fold (Fig 6.20a left panel), however it did not lead to equivalent 
production of IL-12 from both genotypes as was the case for TNF-• (Fig 6.14b).  This result 
was recapitulated for IL-12p40 protein expression and IL-12p40 and IL-12p35 mRNA 
expression (Fig 6.12), suggesting that reduced IL-12 expression in MKP-1
-/-
 
 
macrophages is 
not directly related to elevated IL-10 and may be a primary effect of increased p38 MAPK 
activity. 249 
 
 
 
 
Fig 6.20 Reduced IL-10 expression in MKP-1
-/- macrophages may not be responsible for the 
increased levels of IL-12. MKP-1
+/+ and MKP-1
-/-
 
 BMDM were pretreated for 1 hr with 10 ng/ml 
anti-IL-10 or IgG control, followed by 12 hr stimulation with LPS. (A) IL-12p70 and IL-12p40 levels 
were measured by ELISA, (B) IL-12p40 and IL-12p35 expression was measured by qPCR. 
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6.8 MKP-1 Deficiency has no Effect on the Outcome of DSS Induced Colitis 
 
Inflammatory bowel disease (IBD) comprises two main disorders; Crohn’s disease and 
ulcerative colitis, both confer significant chronic morbidity on patients. IBD is characterised 
by chronic inflammation of the digestive tract, mainly the bowel and is thought to occur when 
tolerance to comensal flora breaks down, eliciting an inflammatory response. A central role 
for TNF-• and IL-10 has been demonstrated in IBD and indeed anti-TNF-• therapy is one of 
the main treatments in Crohn’s disease (Peyrin-Biroulet et  al., 2008). Since cytokine 
expression is dysregulated in MKP-1 null mice in response to inflammatory stimuli, it was 
hypothesised that clinical outcome of colitis might be affected in these animals.  
 
To address this question, MKP-1
+/+ and MKP-1
-/- mice were fed dextran sulphate (DSS) in 
their drinking water for 7 days. DSS induces colitis by damaging the epithelial lining of the 
digestive tract, thus allowing access of the comensal flora to the gut which initiates an 
immune response. This inflammatory response includes neutrophils, macrophages B and T 
cell and manifests itself clinically as weight loss, sometimes accompanied by bloody stool. 
DSS was administered for the first 7 days of the protocol and weight loss was monitored up 
to 18 days. Weight loss began to occur by day 5 and continued up until day 10 when the mice 
started to regain weight (Fig 6.21). Over the course of the protocol, no significant differences 
in weight loss were observed between genotypes. This is quite a surprising finding in light of 
the fact that IL-10 therapy reduces DSS induced weight loss in mice and IL-10 deficient mice 
are highly susceptible to colitis (Sasaki et al., 2005, Kühn et al., 1993). As such, increased IL-
10 levels in MKP-1
 
 
deficient mice would be expected to elicit a level of protection by 
inhibiting the inflammatory cascade during colitis. This suggests that there may be other 
unappreciated regulatory mechanisms at play which preclude any protection afforded by 
increased IL-10 levels in this colitis model.  
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Fig 6.21. Loss of MKP-1 does not affect outcome of DSS induced colitis.  MKP-1
+/+ and MKP-1
-/-
 
 
mice were given 2.5% DSS in drinking water for 7 days, weight loss was measured daily over 18 
days. Error bars represent mean ± SEM. n=5, experiment repeated in duplicate. 
 
6.9  MKP-1 Deficiency Impairs Recovery from Experimental Autoimmune 
Encephalomyelitis  
 
While MKP-1 was shown to have a significant role in innate immunity, it was of interest to 
examine what role if any MKP-1 might play in the adaptive immune response. To examine 
adaptive immunity in vivo, a mouse model of multiple sclerosis (MS) was used as this disease 
is characterised by dominant T cell responses. MS is a severely debilitating terminal disease 
which affects 85,000 individuals in the U.K alone.  MS is characterised by severe muscle 
wasting and loss of neuronal function and is thought to be due to the overproduction of 
autoreactive T cells which attack the myelin sheath of neurons causing progressive neuronal 
loss over time (McFarland and Martin, 2007). Since neurons are terminally differentiated and 
non-dividing, progressive loss is irreversible.  
 
Experimental autoimmune encephalomyelitis (EAE) is a mouse model of multiple sclerosis 
which closely resembles the human disease and is also characterised by muscle wasting and 
loss of motor function. Given the drastically altered cytokine profile in MKP-1
-/- mice, it was 
of interest to ascertain whether this might affect the pathology of EAE. Differences in 
cytokine production from the innate immune system would be expected to have an effect on 
the profile of effector T cells and thus possibly influence  T cell responses to myelin. 
Therefore wild type and MKP-1 deficient mice were immunised with 50 µg myelin 
oligodendrocyte glycoprotein ( -55
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with another 200 ng  pertussis toxin. Clinical score was measured daily over 35 days 252 
 
according to the criteria shown in table 6.1. Clinical score began to increase from day 9, 
reaching a maximum at day 16 (Fig 6.22). No difference was seen between genotypes during 
the initiation phase of the disease, with clinical score being equivalent up to day 15 at the 
height of disease progression. From day 15 onwards, wild type mice showed a reduction in 
clinical score which is characteristic of this disease model (Stenman and Zamvil, 2005). 
Interestingly however, MKP-1 null mice did not show any recovery in symptoms, the clinical 
score remained close to day 15 levels for the duration of the protocol. This strongly suggests 
that MKP-1 plays a role in recovery from EAE and by inference, prolonged activation of 
MAPKs leads to a more severe pathology in MS. More detailed understanding of how MKP-
1 contributes to MS may open up novel therapeutic avenues in the future. 
 
Table 6.1. EAE clinical score measurement 
0  No symptoms 
1  Flacid Tail 
2  One immobilised hind paw 
3  Two immobilised hind paws 
4  Upper body immobilisation 
5  Moribund 
6  Death 
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Fig 6.22. MKP-1 null mice show impaired recovery from EAE. MKP-1
+/+ and MKP-1
-/- mice were 
immunized with 50 µg MOG injected s.c above 4 lymph nodes, mice were also injected with 200 ng 
pertussis toxin on day 0 and day 3. Clinical score was measured daily for 35 days. Error bars represent 
mean ± SEM, n=7 per group, experiment repeated in duplicate. Statistical analysis was carried out 
using a Mann-Whitney U test * p=0.01.  253 
 
6.10 Loss of MKP-1 does not Effect T Cell Differentiation 
 
Since EAE is dominated by T cell responses, one explanation for the severe phenotype seen 
in MKP-1 deficient mice may be dysregulated T cell production. To address this, the absolute 
numbers of lymphocytes in wild type and knock-out mice were examined; spleen, lymph 
nodes and thymus were  stained with CD4 and CD8 antibodies and analysed by flow 
cytometry (Fig 6.23). No difference in single positive, double positive or double negative 
CD4 and CD8 cells was seen between genotypes demonstrating that MKP-1 does not affect 
CD4 or CD8 T cell generation. 
 
 
 
 
Fig 6.23. Flow Cytometry analysis of lymphoid cell Markers in MKP-1
+/+ and MKP-1
-/- mice.  
Spleen, lymph node and thymus were harvested from MKP-1
+/+ and MKP-1
-/-
 
 mice, digested with 
collagenase and cells were stained with CD4 and CD8 antibodies and analysed by flow cytometry. 
Respresentative plots are shown from 3 separate mice.  
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Although the generation of CD4
+ and CD8
+ T cells was not affected, MKP-1 might have a 
role to play in CD4
+  T cell differentiation. Both JNK and p38 MAPK expression are 
necessary for Th1 differentiation (Dong et al., 2000, Rincon et al., 1998), suggesting that the 
prolonged phosphorylation of JNK and p38 in MKP-1 deficient mice might therefore lead to 
altered differentiation of T cell subsets. Taking this into account, it was thought that skewed 
T cell lineages might account for the difference in clinical outcome to EAE in MKP-1
-/-
Previously MKP-1 was shown to have no effect on the total numbers of Th1 and Th2 cells 
generated  in vitro  (Hongbo Chi, personal communication), however cytokine production 
from Th1 and Th2 cells has not been examined. 
 mice.  
 
Initially the study was focused on IL-10 regulation, since IL-10 was shown to be highly 
elevated in MKP-1 deficient macrophages. To this end, MKP-1
-/- mice were crossed with the 
TIGER strain of IL-10 reporter mice (Kamanaka et al., 2006). TIGER mice have a GFP 
sequence fused to an internal ribosome entry site (IRES) inserted immediately before the 
polyadenylation site of the IL-10 gene, thereby allowing GFP fluorescence to be used as a 
marker of IL-10 expression. CD4
+ T cells from TIGER
+/MKP-1
+/+ or TIGER
+/MKP-1
-/-
 
 mice 
were separated using magnetic activated cell sorting (MACS) beads coated with anti-CD4 
antibodies and incubated with irradiated splenocytes as a source of APCs along with IL-2 and 
soluble antibodies for CD3 and CD28. To induce Th1 and Th2 differentiation, cells were also 
incubated with IL-12 and anti-IL4 (Th1) or IL-4 and anti-IFN• (Th2). After 5 days in culture, 
viable effector cells were isolated using ficoll centrifugation and re-stimulated with PMA and 
ionomycin for 24 hr. The expression of GFP was then measured by flow cytometry. Fig 6.24a 
shows that as expected, Th1 conditions resulted in no GFP expression when compared to 
cells stimulated solely with anti-CD3, anti-CD28 and IL-2 (Th0), Th2 polarisation resulted in 
robust GFP staining, however there was no difference in GFP levels between MKP-1 wild 
type and knock- out mice.  
To ensure that the results from the TIGER/MKP-1 mice were accurate, the experiment was 
repeated in MKP-1
+/+ and MKP-1
-/- mice, this time using intracellular staining to measure the 
expression of IL-10 (Fig 6.24b). Th2 cells increased expression of IL-10 but again no 
difference was seen between genotypes. Expression of the Th1 signature cytokine IFN-• was 
also measured; Th1 cells upregulated IFN-•, with equal amounts being produced by wild type 
and MKP-1 deficient cells (Fig 6.24c).  255 
 
Taken together, these results demonstrate that the macrophage IL-10 phenotype is not 
recapitulated in CD4
+ T cells. Moreover, it appears that Th1 and Th2 cells differentiation is 
unaffected in the absence of MKP-1. The EAE phenotype in MKP-1
-/- mice can therefore not 
be accounted for by differences in intrinsic T cell responses. In addition, since IL-10 
production from T cells is a major regulator of IBD pathology, the equivalent production of 
IL-10 from Th2 cells in both genotypes this may in part account for the unexpected lack of 
phenotype in MKP-1
-/- mice treated with DSS. Despite this, the TIGER/MKP-1
-/-
 
 mice will be 
extremely useful for future studies aimed at detailed understanding of the regulation of IL-10 
in MKP-1 deficient mice. 
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Fig 6.24. MKP-1 does not affect IL-10 expression from Th2 cells or IFN-• expression from Th1 
cells. (A) TIGER
+/MKP-1
+ or TIGER
+/MKP-1
-/- CD4
+ T cells were differentiated into Th0, Th1 or 
Th2 cells and GFP levels were measured by flow cytometry – left panel, the GFP expression from 
Th2 cells of both genotyoes is shown in the right panel (B and C) IL-10 and IFN-• levels were 
measured in wild type effector cells by intracellular staining –left panels,  the levels of IL-10 (Th2 
cells) and IFN-• (Th1 cells) was compared  between MKP-1
+/+  and MKP-1
-/-
 
 mice – right panels. T 
cells were taken from 3 separate mice of each genotype, representative plots are shown. MKP-1 
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Since loss of MKP-1 does not appear to affect the differentiation of Th1 or Th2 cells, it was 
of interest to examine MKP-1 expression over the course of T cell activation. To examine the 
regulation of MKP-1 in T cells, total CD4 T cells were harvested from lymph nodes and 
spleen of wild type mice and activated with plate bound anti-CD3 and anti-CD28 antibodies 
over 28 hr and MKP-1 expression was analysed by qPCR. MKP-1 was transiently activated 
over 2 hours then time-dependently downregulated, by 28 hr only negligible levels of MKP-1 
were expressed (Fig 6.25a). This suggests that MKP-1 may have a role to play in the early 
activation of T cells, however since expression is reduced over time it is unlikely that MKP-1 
plays a significant role in fully differentiated effector T cells. To examine this further, total 
CD4 and CD8 T cells were grown in culture with irradiated splenocytes as a source of APCs 
along with IL-2 and soluble antibodies to CD3 and CD28 for up to 5 days. Both CD4 and 
CD8 cells downregulated MKP-1 mRNA levels following APC stimulation, showing almost 
no expression of MKP-1 over 5 days (Fig 6.25b,c). This finding that MKP-1 is normally 
downregulated in effector T cells explains why no difference was found in Th1 and Th2 
differentiation i.e. MKP-1 deficient effector T cells are essentially the same as wild type T 
cells in terms of MKP-1 expression. 
 
Fig 6.25. MKP-1 expression in activated T cells. (A) CD4
+
 
 T cells were incubated with 5 µg/ml 
anti-CD3 and 2  µg/ml anti-CD28 for the indicated times. MKP-1 expression was determined by 
qPCR. (B) Total CD4 or (C) CD8 T cells were incubated with irradiated splenocytes as a source of 
APC for the indicated times, MKP-1 expression was assessed by qPCR. Error bars represent mean ± 
SEM, n=3 per group, experiment was repeated in triplicate. 
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6.11 Discussion 
 
The family of MAP kinases comprises p38 MAPK, ERK and JNK, which are an integral part 
of the innate immune system and are all induced by TLR signalling. MAPKs phosphorylate 
several transcription factors, including ELK-1, MK2, 3 and 5, STATs, ATF2 and AP-1 and 
activation of these transcription factors leads to cytokine upregulation, comprising the first 
line of defense following pathogen infection. Cytokine release is obviously necessary and 
desirable to control the initial infection; however the resulting inflammation needs to be 
tightly regulated since uncontrolled cytokine release can have severely deleterious 
consequences. This is evidenced in many immunological  diseases such as toxic shock, 
rheumatoid arthritis, IBD and multiple sclerosis, where prolonged cytokine release leads to 
severe pathology. Although the regulation of the NF-•B pathway by TLRs has been 
extensively studied, the precise molecular control and regulation of the MAPK pathway in 
innate immunity is not as well defined.  
 
Using knockout mice, it was found that following LPS challenge in macrophages, MKP-1 
specifically inhibits p38 MAPK and JNK phosphorylation  but had no effect on ERK 
phosphorylation. Increased activity of JNK and p38 MAPK in the absence of MKP-1 was 
accompanied by elevated DNA binding activity of the AP-1 transcription factor and enhanced 
production of several pro-inflammatory  cytokines both in vitro and  in vivo.  This 
overproduction of cytokines resulted in MKP-1
-/-
  mice experiencing increased mortality 
during toxic shock, most likely due high systemic levels of TNF-•, IL-12 and IL-1•. It is 
therefore suggested that during acute inflammation, the predominant role of MKP-1 is to 
serve as an endogenous brake on MAPK activation to suppress the production of pro-
inflammatory cytokines. Although MKP-1
-/-
 
  mice produced increased levels of the anti-
inflammatory cytokine IL-10, which has been previously shown to rescue mice from 
endotoxic shock, it may not be produced early enough or in sufficient amounts to counteract 
the effects of sustained release of several potent pro-inflammatory cytokines in these mice.  
During toxic shock, nitric oxide levels are enhanced  and  cause  a decrease in vascular 
resistance and hypotension, which along with activation of the procoagulation pathway can 
lead to ischaemia and multiple organ failure (Mackmicking et al., 1995). MKP-1
-/- mice had 
increased expression of iNOS, and although this study did not measure nitric oxide levels 
directly, two groups recently demonstrated that the increased iNOS expression in MKP-1
-/- 259 
 
mice leads increased NO levels (Zhao et al. 2006, Calvert et al., 2008). MKP-1 deficeint mice 
experienced increased hypotension during toxic shock compared to wild type mice and this 
was reversed by treating with nitric oxide inhibitors (Calvert et al., 2008). This suggests that 
in addition to elevated pro-inflammatory cytokine levels, increased NO may contribute to 
toxic shock mediated mortality in MKP-1
-/-
 
 mice.  
This excessive pro-inflammatory cytokine production was also  shown to have functional 
significance during  bacterial  infection, MKP-1 null mice suffered reduced bacterial load 
following Lysteria Monocytogenes infection compared with wild type controls. Clearance of 
L. monocytogenes  infection is highly dependent on TNF-•  and NO production from 
macrophages and DCs  (Pamer, 2004), both  of which are elevated in MKP-1
-/-
LPS challenge of macrophages showed that MKP-1 is upregulated within 1 hr and is then 
rapidly downregulated, suggesting tightly controlled temporal regulation of MAPK activity. 
It is interesting to note that LPS induced MKP-1 expression is dependent on both p38 and 
ERK.  Since ERK phosphorylation is not affected by MKP-1 in the context of LPS 
stimulation, ERK mediated induction of MKP-1 may serve to limit the activity of p38 and 
JNK, suggesting an unappreciated level of cross regulation between MAPKs. Furthermore, 
MKP-1 expression was blocked by an NF-•B inhibitor, suggesting cross-talk between the 
MAPK and NF-•B pathways. Based on this data a model is proposed whereby following 
TLR stimulation, NF-•B upregulates MKP-1  gene expression and p38 MAPK promotes 
transcript stabilization through the AREs located in the 3’ UTR of MKP-1. More experiments 
will be need to verify this postulate, most importantly, examination of MKP-1 in cells 
deficient for components of the NF-•B pathway as well as investigating MKP-1 transcript 
stability in cells which over- or under-express p38 MAPK. MKP-1 expression was found to 
be induced by all TLR ligands tested and this was dependent on the TLR signaling adaptors 
MyD88 and Trif. This demonstrates that MKP-1 induction occurs in response to a diverse 
range of pathogens and thus may be central to the inflammatory response. 
  mice. 
Therefore dysregulated cytokine release in the absence of MKP-1 can have both positive and 
negative effects. On the one hand, lack of MKP-1 can confer protection from infection, 
however if the infection is not efficiently cleared and spreads to the bloodstream, lack of 
MKP-1 will compound the deleterious effects of toxic shock. This may have important 
implications for MAPK modulating drugs which might be used to treat inflammatory 
conditions. 260 
 
 
TNF-• production in macrophages is dynamically regulated by MKP-1, in the early part of an 
inflammatory response, MKP-1
-/- macrophages had increased mRNA and protein levels of 
TNF-•, demonstrating that early expression of MKP-1 inhibits TNF-• production. However, 
by 5 hr LPS challenge, the levels of TNF-• mRNA produced by MKP-1
-/- macrophages was 
less than that of wild type cells. Analysis of TLR signalling showed that IL-10 was 
upregulated in MKP-1
-/- macrophages by all TLR ligands tested, again showing that this is a 
general feature of innate immunity and not confined to a single set of pathogens. Comparing 
expression profiles revealed that as the levels of IL-10 increased in MKP-1
-/- cells, the level 
of TNF-• started to decrease. Blocking IL-10 with a neutralising antibody inhibited the 
downregulation of TNF-•, clearly demonstrating that IL-10 was responsible for this effect. 
IL-10 inhibits TNF-• induction via STAT3 mediated upregulation of Bcl-3 and both STAT3 
tyrosine  and serine phosphorylation and Bcl-3 expression were increased in MKP-1
-/-
 
 
macrophages.  
Based on chemical inhibitor studies, all three MAPK were found to contribute to IL-10 
overproduction, however p38 MAPK appeared to be the main MAPK responsible. It should 
be noted however that MAPK inhibitors may sometimes have off target effects (Muniyappa 
and Das, 2008). However, drawing on the results of several experiments, a clear picture has 
emerged whereby MKP-1 influences cytokine production (Fig 6.26). Following TLR ligation, 
NF-•B and MAPK are rapidly activated and in turn upregulate pro-inflammatory cytokines 
such as TNF-•. By 1 hr post TRL ligation MKP-1 is upregulated, also by NF-•B and MAPK, 
and begins to dephosphorylate p38 MAPK and JNK. By 2 hr TLR stimulation MKP-1 begins 
to be downregulated, most likely through feedback inhibition routed through MAPK 
inactivation. At this time, although p38 and JNK activity are reduced by MKP-1 they still 
have activity over basal levels; this enables the remaining active MAPK to induce IL-10 
expression which can then limit TNF-• production. Through the use of MKP-1, this negative 
feedback mechanism allows tight control of TNF-• expression which is necessary to prevent 
the deleterious consequences of TNF-• overproduction such as toxic shock. 
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Fig 6.26.  Model of MKP-1 mediated temporal regulation  of cytokine production in TLR 
signaling. TLR signalling through the MAPK pathway induces two phases of cytokine production, an 
initial phase charactarised by rapid production of pro-inflammatory cytokines such as TNF-• and a 
second later phase involving IL-10 production. In the first phase p38 MAPK and JNK are rapidly 
activated (~20 min) leading to production of TNF-•. This is followed by production of MKP-1 (~60 
min) mediated through the MyD88 and TRIF pathways which serves as a negative feedback 
mechanism to downregulate MAPK signalling and TNF-• production. In the second phase p38 
MAPK and JNK activity  are reduced due to MKP-1 but are still higher than basal levels whereas 
MKP-1 is downregulated to allow the remaining active p38 MAPK and JNK to promote IL-10 
expression which in turn limits TNF-• production. 
 
There are at least four MKPs expressed in macrophages; MKP-1, MKP-2, PAC-1 and MKP-
5. Each phosphatase appears to have different substrate specificity, for example MKP-1 
prefers p38 and JNK as substrates whereas MKP-5 appears to be selective for JNK (Zhang et 
al., 2004). It is likely that induction of all the phosphatases co-coordinately regulates MAPK 
dephosphorylation, indeed in MKP-1
-/-  cells, JNK and p38 MAPK dephosphorylation is 
delayed but does occur eventually, presumably through one of the other phosphatases. It is 
interesting to note that knockout of MKP-5 resulted in only a two-fold increase in TNF-• 
serum levels following LPS challenge, whereas MKP-1
-/-
 
 mice produced 8 fold more. This 
may reflect the fact that MKP-5 only affects JNK activity, whereas MKP-1 affects both JNK 
and p38 MAPK, thereby effecting cytokine production more profoundly (Zhang et al., 2004). 
In the future, generation of double and triple knockouts will be of interest to tease apart the 
precise role of each and to get a better understanding of the level of redundancy within the 
MKP family. 262 
 
While serum from LPS challenged MKP-1
-/- mice showed a 2 fold increase in the levels of 
IL-12, detailed analysis of MKP-1
-/- macrophages revealed that they in fact produced less IL-
12 than wild type cells, a finding which has recently been confirmed by other investigators 
(Zhao et al., 2006). The source of the elevated levels of IL-12 in the serum is currently 
unknown, however CD8•
+ DCs are the first cells to synthesise IL-12 upon LPS stimulation 
(Trinchieri, 2003), this may account for the increased IL-12 production in MKP-1
-/- mice in 
vivo, more detailed analysis of MKP-1 deficient immune cell types is necessary to confirm 
this. Interestingly the reduction in IL-12 levels in MKP-1
-/-
 
 macrophages was not due to the 
concomitant increase in IL-10 levels; rather it may be a direct result of increased p38 MAPK 
and JNK activity. 
IBD is characterised by excessive production of pro-inflammatory cytokines, including TNF-
•, IL-12 and IFN-• which induce an enhanced, chronic Th1 response. Furthermore, IL-6 
promotes resistance to apoptosis in these T cells, exacerbating the chronic nature of the 
disease (Atreya et al., 2000). IL-10 has been shown to be beneficial in IBD, IL-10 deficient 
mice suffer from spontaneous colitis and IL-10 therapy has shown therapeutic promise in 
IBD (Kuhn et al., 1993, Steidler et al., 2000). STAT3 is indispensable for IL-10 signalling 
and mice where STAT3 is deleted in haematopetic cells also suffer from colitis, 
demonstrating the important role of IL-10 in restraining the inflammatory response in IBD 
(Welte et al., 2003).  
 
Since MKP-1
-/-  mice have dysregulated production of TNF-•, IL-12, IL-6 and IL-10, all 
important cytokines in the pathogenesis of IBD, it was hypothesised that the response to IBD 
might be affected in MKP-1
-/- mice. However, no difference in weight loss was seen in MKP-
1 deficient mice using a DSS model of colitis. This was especially surprising in light of the 
fact that JNK and p38 activation is enhanced in the colon of Crohn’s patients and targeted 
MAPK inhibition has been shown to be of clinical benefit and was associated with reduced 
levels of TNF-•, IL-6 and IL-1• (Hommes et al., 2002). There may be several explanations 
for this result. Firstly, there is overproduction of both pro- and anti- inflammatory cytokines 
in MKP-1
-/- mice and during colitis they may have they have the effect of balancing each 
other out.  Secondly, excessive cytokine production may be transient and not sustained 
sufficiently long enough to have an effect on effector T cell function. Generation of effector 
T cells generally takes up to 96 hr and it is currently unknown if increased cytokine 
production in MKP-1
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of DSS induced colitis. Other possibilities include effects of regulatory T cells or possibly a 
role for TGF-•.  
 
Although no difference was seen in this model of colitis, use of additional colitis/IBD models 
should allow greater clarification of this issue. For example, transfer of naïve CD4
+ /
 T cells 
into lymphocyte-deficient Rag1
-/-/Rag2
-/-recipients leads to the development of a progressive 
Th1 cell-mediated IBD. (Annacker et al., 2003). Thus transfer of naïve T cells from MKP-1
-/- 
mice into Rag deficient mice or transfer of wt naïve T cells into MKP-1
-/-/Rag1
-/-/Rag2
-/-
 
 mice 
would more efficiently demonstrate if MKP-1 deficiency in T cells can affect the outcome of 
IBD. 
Multiple sclerosis is a severely debilitating disease where autoreactive T cells attack the 
myelin sheaths of neurons. The EAE mouse model of multiple sclerosis is characterised by an 
initiation phase where the clinical symptoms worsen, followed by a period of remission 
where clinical symptoms improve but do not return to baseline. The clinical symptoms of 
EAE did not vary between genotypes in the early progression of the disease. There was a 
significant difference in the remission phase however, MKP-1
-/-  mice
 
 
did not show any 
amelioration of symptoms whereas wild type mice progressively improved over the course of 
35 days. This suggests that MKP-1 may play an important role in the control of remission in 
EAE.  
How MKP-1 controls EAE is currently unknown but several scenarios can be postulated. The 
number of infiltrating T cells into the spinal chord was not changed between
 MKP-1
+/+ and 
MKP-1
-/-  mice at day 35. However, it would be of interest to examine the number of 
infiltrating T cells earlier during the initiation phase, optimally at day 15, this might reveal 
increased T cell numbers in MKP-1
-/-  mice in the spinal chord. By measuring at the end of 
the experiment, many of the autoreactive T cells may have already been removed by 
apoptosis. IL-10 production by B cells has been shown to be important in ameliorating the 
symptoms of EAE. Using bone marrow chimeric mice where the B cell compartment was 
deficient in IL-10, Fillatreau et al. found that these mice failed to recover from EAE even 
though IL-10 was being produced by other cell types (Fillatreau et al., 2002). Although it has 
been demonstrated that MKP-1 controls IL-10 signalling in macrophages, the role of MKP-1 
in B cells has yet to be examined. Immunosupressive regulatory T cells  (Treg) are also 264 
 
important producers of IL-10 and expand in numbers during the resolution phase of EAE, 
while immuno-depletion of Tregs delays recovery (McGeachy et al., 2005).  
 
MKP-1 deficiency was not found to affect generation of naïve CD4
+ or CD8
+
 
 T cells, nor did 
it affect the differentiation of Th1 or Th2 cells; this was surprisingly given the slew of 
evidence which highlights prominent roles for p38 and JNK in T cell differentiation (Rincon 
and Pedraza-Alva, 2003). While no intrinsic differences were found between Th1 and Th2 
cells in the absence of MKP-1, differences in cytokine levels from macrophages and DCs 
may influence aspects of adaptive immunity. Using macrophages and DCs deficient in MKP-
1 to present antigen and prime naïve T cells in vitro will address this question further. 
Macrophage iNOS and NO play a prominent role in EAE, inhibition of NO reduces the 
severity of EAE and NO  production by macrophages and brain microglia inhibit T cell 
proliferation (Rincon et al., 2003). It has also been suggested that NO might block 
conductance on hypomethylated axons (Redford et al., 1997). MKP-1
-/- macrophages were 
found to produce elevated levels of iNOS, however the contribution of this to EAE is 
currently unknown. Other possibilities include a role for MKP-1 in Treg function or an effect 
on the IL-23/IL-17 axis which has recently been shown to be paramount in EAE progression 
(Cua et al., 2003). In direct contrast to the results in MKP-1 mice, MKP-5 deletion confers 
protection from the onset of EAE, with MKP-5 deficient mice showing reduced disease 
incidence and reduced clinical score upon MOG immunization (Zhang et al., 2005). This may 
be due to reduced proliferation seen in MKP-5
-/-
 
 CD4 T cells and serves as a prime example 
of the functional heterogeneity seen within the MKP family. 
Since this work was carried out, several publications have arisen concerning the 
immunological role of MKP-1. Three separate groups confirmed the findings that (i) MKP-1 
regulates p38 MAPK and JNK activity in macrophages, (ii) MKP-1
-/- mice have increased 
mortality following endotoxic shock and (iii) serum levels of TNF-•, IL-6, IL-12 and IL-10 
are elevated in MKP-1
-/- after LPS challenge (Zhao et al., 2006, Hammer et al., 2006, Salojin 
et al., 2006). In addition, MKP-1 was found to control the expression of the chemokines 
CCL3, CCL4 and CXCl2 and the cell surface markers CD40 and CD86 (Hammer et al., 
2006, Salojin et al., 2006). Another recent study has shown that shown that LPS induces p300 
mediated acetylation of MKP-1 which enhances MKP-1 association with p38 (Cao et al., 
2008). Interestingly, histone deacetylase inhibitors reduced inflammation and mortality in 265 
 
wild type mice but failed to do so in MKP-1
-/- mice. MKP-1 has also been shown to be 
involved in limiting inflammation in the endothelium at sites of high shear stress (Zahhar et 
al., 2008). MKP-1 has been shown to be central to the anti-inflammatory effects of 
glucocorticoids. Glucocorticoids have been shown to both upregulate MKP-1 expression and 
attenuate MKP-1 proteasomal degradation (Kassel et al., 2001). In MKP-1 deficient cells, 
dexamethasome failed to inhibit p38 MAPK and JNK phosphorylation and failed to attenuate 
the upregulation of TNF-•, IL-1• and Cox-2 in response to inflammatory stimuli (Abraham 
et al., 2006, Furst et al., 2007). Importantly, damethasone treatment did not protect MKP-1
-/-
 
 
mice from LPS induced mortality (Abraham et al., 2006, Wang et al., 2008). These studies 
thus confirm the data presented here and show further that MKP-1 may be central to the 
pharmacology of widely prescribed anti-inflammatory drugs.  
Taken together, these results implicate MKP-1 as a central player in the control of innate 
immune responses. MKP-1 activity influences the expression of a myriad of cytokines and its 
deficiency has profound implications in the setting of inflammatory pathology. To date no 
genetic study has reported an association between MKP-1 polymorphisms and inflammatory 
disease but in light of its new role as an immunoregulatory factor, it would be of great interest 
to examine if such polymorphisms exist. In the future it will be of great interest to develop 
MKP-1 modulating compounds as a therapeutic strategy for regulating MAPK signaling in 
inflammatory diseases such as RA and multiple sclerosis. The finding that MKP-1 plays a 
central role in two medically relevant conditions, multiple sclerosis and toxic shock suggests 
that targeting MKPs activity may be therapeutically beneficial. The recent finding that many 
of the anti-inflammatory actions of glucocorticoids are mediated through MKP-1 should also 
pave the way for further research into MKP-1 signalling to facilitate the rational design of 
next generation steroid drugs which are more specific with fewer side effects.  
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STAT3 was found to be active during I/R injury where in was responsible for limiting the 
extent of I/R mediated cell death. This adds to earlier work which had shown that the related 
transcription factor STAT1 is a pro-apoptotic mediator of I/R injury. Anti-oxidant treatment 
using tempol was found to limit the phosphorylation of STAT1 and STAT3 during I/R injury. 
This inhibition of STAT1 activity was shown to be physiologically relevant, since increased 
STAT1 phosphorylation following IFN-• treatment counteracted the cardio-protective 
activity of tempol. These studies add the  emerging body of work which places STAT 
transcription factors at the centre of apoptotic control during I/R injury. Although 
manipulation of STAT transcription factors during I/R injury might theoretically be of 
clinical benefit, the pleiotropic role of these proteins may preclude direct  modulation. 
Therefore it is of great interest to understand the downstream signaling whereby STAT3 
mediates its anti-apoptotic effect in the myocardium. This effect is unlikely to reside in a 
single STAT3 dependent target but rather may involve several factors working in concert. 
STAT3 is upregulated in several cancers and in these cases the anti-apoptotic effects have 
been attributed to STAT3 dependent genes such as Bcl-2, Mcl-1, Bcl-
 
 and SOD2. Expression 
of these genes could be inhibited in turn in cardiac myocytes using RNAi and then asses if 
overexpression of STAT3 could still confer cardioprotection. 
Several studies have shown that administration of green tea and amino acid supplements 
modulate STAT1 and STAT3 phosphorylation. To further clarify the contribution of STATs 
to these cardioprotective effects they could be administered to STAT1 and/or STAT3 
deficient mice and assessed for cardioprotective activity. The STAT3 antagonist GRIM-19 
was found to be downregulated by I/R injury, how this influences STAT3 activity is currently 
unknown. Overexpression of GRIM-19 may abrogate the protective effects of STAT3 and 
this could be tested directly in transfection experiments. Another unanswered question is to 
what extent is the serine 727 residue of STAT3 critical for cardio-protection. The recent 
generation of STAT3 S727A mice (Shen et al., 2004) would be ideal to examine infarct sizes 
following  in vivo  I/R injury. Another unresolved question is whether phosphorylation of 
STAT1 and STAT3 following I/R injury is mediated through growth factor/cytokine release 
and JAK phosphorylation or through intracellular mechanisms such as via non-receptor 
tyrosine kinases. This question could be approached by taking conditioned medium from 
cardiac myocytes following I/R injury, adding it to a separate culture of myocytes and 
assessing STAT phosphorylation. If cytokine release occurs rapidly after reperfusion, this 268 
 
conditioned medium should be capable of rapidly inducing STAT phosphorylation in a new 
culture.  
 
STAT3 also appears to be necessary for a fully fledged DNA damage response; the absence 
of STAT3 renders cells less efficient in DNA repair. Several possible mediators of this were 
identified and included ATM, H2AX and MDC1. It is unclear precisely how STAT3 controls 
the DNA damage response. STAT3 was found to be able to upregulate expression of MDC1, 
however it is unknown whether this is through direct binding or indirectly via another STAT3 
target gene. Direct  ChIP assay of the MKP-1 promoter region would allow further 
characterization of STAT3 dependent transactivation. Increased levels of STAT3 were found 
to promote more efficient DNA repair which has implications for chemoresistance in cancer. 
If STAT3 overexpressing tumors can more readily repair damaged DNA it follows that 
STAT3 overexpression might directly contribute to increased resistance to chemotherapeutic 
drugs. DNA repair capacity could be tested directly in STAT3 overexpressing cancers and 
compared to the level of repair after treatment with one of the new class of STAT3 inhibiting 
drugs. 
 
Microarray analysis identified several novel transcriptional changes which occurred during 
I/R injury in vivo. Further characterization of these effects may give novel insight to I/R 
injury. A major first step would be to asses if these gene expression changes are also seen at 
the protein level. The reduced expression of mitochondrial transport proteins is intriguing. It 
is currently unknown if mitochondrial transport is altered during I/R injury but the reduced 
expression of specific mitochondrial transport proteins would argue that transport into the 
mitochondria may be compromised during I/R injury. Experiments could be carried out to 
directly examine mitochondrial transport of proteins during I/R. This could be achieved using 
an immunofluoresence approach, transfecting a GFP construct tagged with a mitochondrial 
target sequence into cardiac myocytes, subjecting them to I/R injury and then examination of 
the subcellular localization of GFP. Another approach would be to load cells with a 
radioactively labeled mitochondrial bound protein. Following I/R injury, cardiac myocytes 
could be subjected to subcellular fractionation and levels of radioactivity in control 
mitochondrial fractions compared to that of I/R fractions. If indeed mitochondrial transport is 
reduced during I/R injury, it may affect mitochondrial respiration. This could be assessed by 
overexpressing components of the mitochondrial transport machinery and examining their 
effect on mitochondrial respiration during I/R. 269 
 
  
Both Ucn1 and Ucn2 were found to lower oxidative stress during I/R injury, however the 
exact mechanism is unknown. Ucn1 and Ucn2 were both found to upregulate expression of 
the anti-oxidant gene Nrf-1. Again, examination of Nrf-1 protein levels following urocortin 
administration would clarify if Nrf-1 is a true target of urocortins and examination of both the 
anti-oxidant and cardio-protective activity of Ucn1 and Ucn2 in the absence of Nrf-1 would 
determine to what extent it mediates these effects. Another potential mediator of urocortin 
cardioprotection is XIAP, which has previously been shown to be necessary for upregulation 
of anti-oxidants (Resch et al., 2008). Caspase activity and apoptosis levels could be examined 
following urocortin treatment during I/R in the absence of XIAP to ascertain if XIAP is an 
absolute requirement for Ucn-mediated cardioprotection. 
 
The finding that the IL-17 cytokines and the IL-17 receptor are upregulated during I/R may 
represent an important point of cross talk between the immune system and the cardiovascular 
system during I/R injury. Many questions remain to be answered concerning the regulation 
and biological effect of IL-17 during I/R injury. Firstly, IL-17 cytokine and receptor levels 
need to be measured directly by flow cytometry to show that increased mRNA levels are 
recapitulated by increased protein expression. Measurements of serum IL-17 levels following 
experimental I/R and in patients would strengthen these findings. Detailed examination of 
signalling pathways induced by IL-17 in cardiac myocytes both in the presence and absence 
of I/R injury could be conducted to tease apart the effect of IL-17 on cardiac myocyte 
physiology. Fundamentally it is still unknown whether elevated IL-17 signalling represents a 
deleterious or beneficial phenomenon in I/R injury. 
 
The finding that MKP-1 serves as a rheostat for inflammatory responses is an important 
addition to the growing body of literature concerning the resolution phase of inflammation. 
Traditionally, the major focus of inflammatory research has been centered on understanding 
the signals which induce the inflammatory response with less regard given  to how 
inflammation is switched off. Over the last five years however, there has been much greater 
scientific focus on this resolution phase of inflammation (Serhan et al., 2007). The findings 
presented here place MKP-1 as a central modulator of inflammatory resolution, in the 
absence of MKP-1, exuberant cytokine production ensues,  leading to deleterious 
consequences in the case of toxic shock. Increasing cellular availability of MKP-1 might 
represent a novel approach to limit pro-inflammatory cytokine production which lies at the 270 
 
heart of an abundance of human pathologies. Although direct administration of MKP-1 is not 
feasible, more detailed understanding of MKP-1 protein biochemistry might allow small 
molecule targeting of proteins which inhibit MKP-1 activity. Emerging evidence suggests 
that one aspect of glucocorticoid mediated inflammatory suppression lies in their ability to 
induce MKP-1 expression. Although glucocorticoids are a widely prescribed and highly 
efficacious drug class, one of the major drawbacks of treatment is the resulting side effects 
such as osteoporosis, stomach ulcers and poor skin healing. Dissecting out the molecular 
pathways of the MKP-1  -  dependent versus the MKP-1  -  independent activity of 
glucocoticoids might pave the way for rational design of next generation anti-inflammatory 
drugs which might have reduced side effects. 
 
Many questions still remain to be answered regarding the immune response and MKP-1. 
While this study focused exclusively on MKP-1, there are several other MKPs which may 
exert control over the immune system in a parallel manner to MKP-1. At the moment only 
single knockouts of each phosphatase exist, but in the future, generation of double and triple 
knockouts will allow a greater understanding of how each phosphatase in turn and in concert 
influence  inflammatory responses. The main cell types examined in these studies were 
macrophages, T cells and to a lesser extent dendritic cells. There are a range of other cell 
types central to immune function including B cells, neutrophils and mast cells. Examination 
of the role of MKP-1 in these additional cell types will provide a more holistic picture of its 
place in the immune system.  
 
An exciting finding of this study was that MKP-1 deficient mice fail to recover from a mouse 
model of multiple sclerosis and this may have direct implications in understanding MS 
pathology. The study did not address the mechanism whereby MKP-1 contributes to the EAE 
phenotype and it is yet unclear as to whether MKP-1 regulates pathological T cell function 
intrinsically or through its impact on the innate immune system. Since macrophages and DCs 
deficient in MKP-1 produce altered cytokine responses, there is a good possibility that these 
cells might contribute to the generation of altered T cell repertoires. 
 
This can be addressed in several ways. Firstly by using OT-II transgenic mice in which T 
cells express a V 2/V 5 TCR specific for an ovalbumin (Ova). MKP-1
+/+ and MKP-1
-/- DC 
would be incubated with –339 peptide in the presence and absence of LPS, and then mixed 
with OT-II CD4 T cells (TCR-transgenic T cells that recognize –339). T cell proliferation and 271 
 
cytokine production (IL-2, IL-4, IFN-•, and IL-17) would then be assayed by -proliferation 
and ELISA, respectively. Indeed initial studies have suggested that lack of MKP-1 in antigen 
presenting cells may lead to a skewed Th1 phenotype although the experiments were too 
preliminary to include in this thesis. An alternative in vivo approach would be to label OT-II 
CD4 T cells with CFSE and transfer them into MKP-1
+/+ and MKP-1
-/-
 
 mice. The mice would 
then  be immunized  with OVA emulsified in Complete Freud’s Adjuvant (CFA). CFSE 
dilution would then be used to measure T cell proliferation and production of T cell cytokines 
assayed by intracellular staining. These assays would reveal the effect of MKP-1 deficiency 
in DC on the control of T cell activity in vitro and in vivo.  
It has recently become clear that IL-17 producing cells are central to the pathogenesis of 
EAE, however this study did not examine the effect of MKP-1 on Th17 cell production. To 
address this, naïve T cells could be purified from the spleen and lymph nodes of MKP-1
+/+ 
and MKP-1
-/- mice and stimulated  with plate bound •-CD3, •-CD28, IL-6 and TGF-β for 
five days and the production of IL-17 measured by ELISA and qPCR. In addition, EAE could 
be induced in MKP-1
+/+ and MKP-1
-/-
 
 mice, and production of IL-17 by infiltrating T cells in 
the brain could be determined by intracellular staining. 
To address which cell type requires MKP-1 for the regulation of EAE in vivo, an adoptive 
transfer approach could be employed using MKP-1/RAG1 double knockout mice. WT CD4 T 
cells would be transferred into MKP-1
+/+/RAG1
-/- or MKP-1
-/-/RAG1
-/- mice before MOG 
immunization – this would reveal whether lack of MKP-1 in APC but not T cells regulates 
EAE. Conversely, WT CD4 T cells or MKP-1
-/- CD4 T cells could be transferred into MKP-
1
+/+/RAG1
-/-
 
 mice before immunization – this would determine whether lack of MKP-1 in T 
cells but not APC regulates EAE. Altogether, these three approaches will allow one to 
explicitly address whether the protective role of MKP-1 in EAE is mediated through intrinsic 
effects in the adaptive immune system or through crosstalk between the innate and adaptive 
immune compartments. 
Another important question in whether MKP-1 regulates T cell-dependent immune responses 
and autoimmune inflammation through negatively modulating JNK or p38 activity. In order 
to ascertain if the non-remitting phenotype seen in the MKP-1 deficient mice is due to overt 
activation of p38 or JNK,  EAE would  be induced  in the presence of pharmacological 
inhibitors of p38 and JNK. These compounds are in clinical trials for the treatment of arthritis 272 
 
but have yet to be tested in neuro-inflammatory conditions. Although MKP-1 preferentially 
inactivates p38 and JNK in cell culture, the physiologically relevant substrate in a disease 
model is unknown. One could pursue this line of inquiry further by generating JNK1/JNK2 or 
MKK3/MKK6 double knockouts which would definitively reveal the contribution of JNK 
and p38 to EAE pathology. 
 
Relatively few MKP-1 binding partners have been thus far identified; it would therefore be of 
potential interest to characterize MKP-1 interactors in cells following LPS treatment. This 
could be done using an in vitro  purification/immunopreciptiation and mass spectrometry 
approach.  Identification of novel MKP-1 binding partners would aid in developing novel 
MKP-1 modulatory agents. One final caveat to the data presented here is that the studies were 
all conducted in total MKP-1 knockout mice; however a clearer understanding of how MKP-
1 affects the innate and T cell compartments could be cleaned from macrophage and T cell 
specific knockouts.  
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Appendix 1 
(A) Table of Antibodies 
 
Antibody  Company  Species  Catalogue No. 
Actin  Santa Cruz  Mouse  Sc-8438 
p42/44 ERK  Cell Signaling  Rabbit  9102 
GAPDH  Chemicon  Mouse  374 
JNK  Cell Signaling  Rabbit  9252 
MKP-1  Actin  Rabbit  sc-370 
Upstate 
 
Rabbit  07-164 
pERK1/ Santa Cruz    Mouse  sc-7383 
Cell Signaling 
/Y185  Rabbit  9251 
p38 MAPK  Cell Signaling  Rabbit  9212 
pp38  Cell Signallng 
/Y182  Mouse  9216 
STAT1  Santa Cruz  Rabbit  sc-346 
STAT3  Santa Cruz  Rabbit  sc-482 
p- Zymed    Mouse  33-3400 
p- Upstate     Rabbit  07-714 
p- Cell Signalling    Rabbit  9135 
p- Cell Signalling    Rabbit  9134 
Caspase-9  Santa Cruz  Rabbit  sc8355 
p- Cell Signalling    Rabbit  2341 
p- Cell Signalling    Mouse  9286 
GRIM-19  Gift from Dhan Kalvakolanu  Mouse 
   
 
 (B) Table of constructs 
Construct  Vector backbone  Obtained From  Institute 
STAT3  pcDNA3  James Darnell  Rockefeller Institute  
STAT3β  pSG5  Betty Pace  University of Texas 
STAT3 Y705F  pRc/CMV  James Darnell  Rockefeller Institute  
STAT3 S727A  pRc/CMV  James Darnell  Rockefeller Institute  
STAT3 Y705F/S727A  pRc/CMV  Xinmin Cao  National University of Singapore  
STAT3C  pRc/CMV  James Darnell  Rockefeller Institute  
p21-Luc  pGL3  Wafik El-Deiry  University of Pennsylvania 
3 x Ly-6E  pZLuc  James Darnell  Rockefeller Institute  
pEGFP-C1  pUC  Clontech 
   
 
(c) Table of cell lines 
Cell Line  Obtained From  Institute 
Mouse embryonic fibroblasts  Valeria Poli  University of Turin 
2FTGH  George Stark  Cleveland Clinic Foundation 
U3A  George Stark  Cleveland Clinic Foundation 
Chinese Hampster Ovary Cells  American Tissue Culture Collection  Virginia 274 
 
 
                       Appendix 2: List of Primers 
  Actin-F  AGATGACCCAGATCATGTTTGAG 
Actin- R  AGGTCCAGACGCAGGATG 
    Beta2-micro-F  GTCTTTCTGGTGCTTGTCTCA 
Beta2-micro-R  GTGAGCCAGGATATAGAAAGA 
    Bcl-2_F  GGGAGATCGTGATGAAGTAC 
Bcl-2_R  ACATCTCTGCGAAGTCACGA 
    BNip3_F  GTTCCAGCTTCCGTCTCTAT 
BNip3_R  CGCTTGTGTTTCTCATGCTG 
    c-fos_F  GCCTTTCCTACTACCATTCC 
c-fos_R  CCGTTTCTCTTCCTCTTCAG 
    DUSP1_F  TACAGGAAGGACAGGATCTC 
DUSP1_R  AGTGCACAAACACCCTTCCT 
    DUT-F  TCTGGGTGCTATGGAAGAGT 
DUT-R  AAGCCTCCTGAGCCTCTCTC 
    HPRT_F  CTCATGGACTGATTATGGACAGGAC 
HPRT_R  GCAGGTCAGCAAAGAACTTATAGCC 
    HSP70_F  ACATGAAGCACTGGCCCTT 
HSP70_R  AAGATGAGCACGTTGCGCT 
    Icos_F  CGGTGTCCATCAAGAATCCA 
ICOS_R  ACGGGTAACCAAAGCTTCAG 
    IFNg_F  GTCTTGGTTTTGCAGCTCTG 
IFNg_R  TGGTGACAGCTGGTGAATCA 
    IL-1B_R  CGTTGCTTGGTTCTCCTTGT 
IL-1B_R  CGTTGCTTGTCTCTCCTTGT 
    IL-17A-F  AGGCCCTCAGACTACCTCA 
IL-17A-R  TCTCAGGCTCCCTCTTCAG 
    IL-17F-F  GGCATTTCTGTCCCACGTG 
IL-17F-R  CTCCAACCTGAAGGAATTAGA 
    IL-17R-F  GGGTGTATGGCCTCATCAC 
IL-17R-R  ACAGGCAGTGATCAGGAACT 
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IL-6_F  ACTGCCTTCCCTACTTCACA 
IL-6_R  GCTCTGAATGACTCTGGCTT 
    iNOS_F  AGCGGCTCCATGACTCTCA 
iNOS_R  TGCACCCAAACACCAAGGT 
    MAP4K2_F  CCGCTTGTGGATATGTATGG 
MAP4K2_R  ATTGTAGCCACCCTTGCGTT 
    Mdc1_F  AGGTGATTGACTGGGATGCT 
Mdc1_R  GATGGTACTGGCAGGGAAA 
    MMP8_F  ATCTGGAGTGTGCCATCAAC 
MMP8_R  GCTGGGTTCTCTGTAAGCAT 
    MMP9_F  GAAGACGACATAAAAGGCATCC 
MMP9_R  TCAGAAGGACCAGCAGTAG 
    Nfe2l1-F  AGAGCCCGAGCCATGAAGA 
Nfe2l1-R  TCAGTCACGGTCCTGTAAATT 
    SOCS3_F  TGGTCACCCACAGCAAGTTT 
SOCS3_R  ACCAGCTTGAGTACACAGTC 
    STAT3_F  TCCTCTATCAGCACAACCTG 
STAT3_R  CTCCTTGACTCTTGAGGGTT 
    Timm8a_F  CATTTCATCGAGGTGGAGAC 
Timm8a-R  CTTGTATCAATGAAGCGTTC 
    Timm8b_F  AAGCGGAGTTACAACGCCT 
Timm8b_R  GTGATGGCAAGAGTAGTGTC 
    Timm13-F  ATGACGGACAAGTGTTTCC 
Timm13-R  TCACATGTTGGCTCGTTCC 
    Timm23_F  GTCCCGCTGACTGGTATGAA 
Timm23_R  GAGCCTAGAGTATTAGCCCA 
    Timm44_F  TAGAAGAGTCGGATGCCCTT 
Timm44_R  CTCCTTCTTCACCGACTCTA 
    Tom20-F  CTTCAAGAACAGGCTTCGAG 
Tom20-R  CCAAGCTGTATCTCTTCAAGG 
    XIAP-F  GAGGGCTCACGGATTGGAA 
XIAP-R  ACTCACAAGATCTGCAATCAG 276 
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